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ABSTRACT 
 
Considerable interest has been focused on inducing RNA interference (RNAi) in neurons to 
study  gene  function  and  identify  new  targets  for  disease  intervention.  Although  small 
interfering RNAs (siRNAs) have been used to silence genes in neurons, in vivo delivery of 
RNAi to the central and peripheral nervous system remains a major challenge limiting its 
applications.  
This thesis describes the development of a highly efficient method for in vivo gene 
silencing in dorsal root ganglia (DRG) using replication-defective herpes simplex viral (HSV-
1) vectors by identifying and evaluating various approaches to induce RNAi, i.e. expression 
of  individual  short-hairpin  RNAs  (shRNAs),  artificial  microRNAs  (miRNAs)  and  multiple 
tandem miRNAs. Following the development of these systems, HSV-mediated delivery of 
shRNA or miRNA against reporter genes was shown to result in highly effective and specific 
silencing in neuronal and non-neuronal cells in culture and in the DRG of mice in vivo, 
including in a transgenic mouse model. Proof of concept was established by demonstrating 
in vivo silencing of the endogenous trpv1 gene, thought to be involved in nociception, by 
assessing both mRNA and protein levels. These data are the first to show silencing in DRG 
neurons  in  vivo  by  vector-mediated  delivery  of  shRNA  and  support  the  utility  of  HSV 
vectors  for  gene  silencing  in  peripheral  neurons  and  the  potential  application  of  this 
technology  to  the  study  of  nociceptive  processes  and  in  pain  gene  target  validation 
studies. 
Moreover,  a  disabled  HSV-1  vector  targeting  p75,  Lingo1  and  NgR2,  which  are 
involved in myelin inhibition of axonal regeneration, was developed and evaluated for its 
ability to promote regeneration of sensory axons into the spinal cord, following injury of 
the dorsal roots. This is the first time such an appoach to silencing multiple genes has 
been employed.  Although HSV-mediated delivery of multiple miRNAs  resulted in highly 
effective  silencing  of  these  genes  in  dividing  cells  in  culture,  while  highly  effective 
silencing of p75 was achieved, only modest silencing of Lingo1 and NgR2 was observed in 4 
 
DRG neurons in vivo. Preliminary regeneration experiments, which were largely outside 
the scope of this thesis, were inconclusive and require more extensive study as a stand-
alone project, if the in vivo potential of the approach developed for silencing multiple 
genes targeted at axonal regeneration is to be further explored. 
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AAV  Adeno-associated virus  miRNA  microRNA 
Ad  Adenovirus  MOI  Multiplicity of infection 
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IRES  Internal ribosome entry site  TGS  Transcriptional gene silencing 
L4- L6  Lumbar dorsal root ganglia  tncRNA  Tiny-noncoding RNA 
lacZ  Β-galactosidase  tRNA  Transfer RNA 
LAP  Latency active promoter  trpV1  Transient receptor potential vanilloid 
LAT  Latency associated transcript  UL  US  Unique short and long regions 
Lingo1  LRR and Ig domain–containing, Nogo 
receptor–interacting protein 
WCm  WHV mutated post-transcriptional 
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LV  Lentivirus  WHV  Woodchuck hepatitis virus 
MAG  Myelin associated glycoprotein  x-gal  Β-galactosidase stain  
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1.1 RNA INTERFERENCE 
RNA  interference  (RNAi)  is  an  evolutionarily  conserved,  sequence-specific,  post-
transcriptional gene silencing (PTGS) mechanism originally observed in C. elegans. Guo 
and Kemphues used antisense RNA to inhibit par-1 mRNA expression, when they discovered 
that the sense RNA strand also repressed expression of par-1 (Guo & Kemphues, 1995). 
Subsequently, Fire and Mello demonstrated in their Nobel Prize winning study that double-
stranded RNA (dsRNA) was the trigger of gene silencing (Fire et al., 1998). Thus, instead of 
antisense RNA passively initiating silencing by pairing with the target mRNA, the presence 
of low concentrations of both sense and antisense strands in the RNA preparation was 
proposed to result in small amounts of dsRNA. It is now clear that the RNAi pathway is one 
of  many  cellular  responses  to  RNA  induced  by  small  dsRNA  molecules,  including  small 
interfering  RNAs  (siRNAs)  and  microRNAs  (miRNAs).  Despite  the  field  of  RNAi  being 
relatively  young,  it  has  already  reshaped  our  understanding  of  gene  regulation  by 
revealing unsuspected layers of transcriptional and post-transcriptional gene regulatory 
mechanisms.  The  structure,  biogenesis  and  functions  of  siRNAs  and  miRNAs  and  the 
application of RNAi as an effective gene silencing strategy are discussed in the following 
sections of this introduction. 
 
1.1.1 Structure & biogenesis of small dsRNAs 
Small dsRNAs (table 1.1)  are generated through distinct biogenesis pathways. Although 
siRNAs  and  miRNAs  were  initially  categorised  in  terms  of  their  origin,  exogenous  or 
endogenous,  since  the  discovery  of  endogenous  siRNAs,  it  has  become  difficult  to 
distinguish between them. siRNAs originate from endogenous or exogenous dsRNA that may 
be  hundreds  or  thousands  of  base  pairs  long,  and  have  been  suggested  to  function  in 
antiviral defence, silencing of mRNAs that are overproduced or translationally aborted, 
and  guarding  the  genome  from  disruption  by  transgenes  and  transposons.  Exogenous 
siRNAs  are  virally  derived  or  experimentally  introduced  into  the  cytoplasm,  whereas 19 
 
endogenous  siRNAs  (esiRNAs)  are  derived  from  transcription  of  coding  or  non-coding 
genomic regions. Plant esiRNAs include natural antisense-siRNAs (natsiRNAs), trans-acting-
siRNAs
  (tasiRNAs)  and  heterochromatic-associated  siRNAs  (hcRNAs).  natsiRNAs  originate 
from  convergent  partially  overlapping  transcripts  (Borsani  et  al.,  2005).  tasiRNAs  are
 
generated  from  specific  non-coding  genomic  regions.  Their  biogenesis
  is  initiated  by 
miRNAs that cleave the
 single-stranded RNA transcript to produce fragments which serve 
as  templates
  for  dsRNA  synthesis  by  the  RNA-dependent  RNA  polymerase  (RdRP)  RDR6 
(Allen et al., 2005, Vazquez et al., 2004). hcRNAs, which have also been identified in the 
yeast S. pombe, derive from long dsRNA precursors that are transcribed from genomic 
repeat regions. esiRNAs in C. elegans include tiny-noncoding
 RNAs (tncRNA), which are 
derived from non-coding,
 non-conserved sequences (Ambros et al., 2003), and secondary 
siRNAs, which originate from unprimed
 RdRP synthesis of dsRNA (Pak & Fire, 2007, Sijen et 
al., 2007) and have been also identified in plants.  
Until recently, esiRNAs were not believed to exist in mammals and insects which lack 
RdRPs. Moreover, exposure of mammalian cells to long dsRNA results in the induction of 
the interferon (INF) response, which leads to the general inhibition of cellular translation 
and was widely perceived to preclude any roles for endogenous RNAi. However, recent 
studies have revealed diverse sources of esiRNAs in D. melanogaster (Chung et al., 2008, 
Czech et al., 2008, Ghildiyal et al., 2008, Kawamura et al., 2008, Okamura et al., 2008) 
and mouse oocytes (Tam et al., 2008, Watanabe et al., 2008). These esiRNAs are derived 
from  transposable  elements  (TE-siRNAs),  overlapping  RNAs  formed  by  convergent  or 
divergent transcription (cis-NAT-siRNAs), antisense transcribed pseudogenes pairing with 
homologous  mRNAs  (trans-NAT-siRNAs),  and  long  inverted  repeat  transcripts  (hpRNAs) 
(figure 1.1). Mammalian esiRNAs outside oocytes, where long dsRNA does induce the INF 
response, remain to be identified. 
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miRNAs are endogenous, regulatory non-coding RNA molecules involved in almost every 
developmental  and  cellular  process  investigated  so  far.  The  first  miRNA,  lin-4,  was 
identified during a genetic screen in C. elegans (Lee et al., 1993). Cloning of the locus 
revealed that lin-4 produces a non-coding RNA that represses expression of lin-14, which is 
involved  in  post-embryonic  development.  Mammalian  miRNAs  are  now  predicted  to 
regulate  approximately  30%  of  all  protein-coding  genes  (Lewis  et  al.,  2005).  Over  500 
miRNAs have been identified in humans (Landgraf et al., 2007), and miRNAs have been 
recently  implicated  in  the  pathogenesis  of  human  disease,  including  cancer  (Esquela-
Kerscher & Slack, 2006) and neurodegenerative disorders (Kim et al., 2007, Lukiw et al., 
2008).  
Almost half of all known mammalian miRNAs reside within the introns of protein-
coding genes or within either the introns or exons of non-coding genes (Rodriguez et al., 
2004). Rarely, miRNAs lie within the exons of protein-coding mRNAs. These transcripts are 
thought to produce either miRNA or protein from a single mRNA molecule (Cullen, 2004). 
Some  miRNAs  form  their  own  transcription  units,  whilst  others  are  clustered  and 
transcribed  as  polycistronic  transcripts  (Cai,  2004,  He  et  al.,  2005).  The  majority  of 
miRNAs are transcribed by RNA polymerase (pol) II; although a cluster of human miRNAs 
have been recently shown to utilize RNA pol III for their transcription (Cai, 2004). The long 
primary miRNA transcript (pri-miRNA) consists of a stem of approximately 33bp, a terminal 
loop and flanking regions. In collaboration with the dsRNA-binding protein Pasha in flies 
and DGCR8 in humans, the RNase III enzyme Drosha selectively cleaves the pri-miRNA at a 
position approximately one helical RNA turn into the stem to generate a 70-100nt hairpin 
precursor miRNA (pre-miRNA) (Denli et al., 2004, Gregory et al., 2004, Han et al., 2004). 
Some  spliced-out  introns  in  C.  elegans,  D.  melanogaster  and  mammals  correspond 
precisely  to  pre-miRNAs  (mirtrons),  thus  circumventing  the  requirement  for  Drosha-
Pasha/DGCR8 (Okamura et al., 2007, Ruby et al., 2007). The discovery of mitrons suggests 
that any RNA, with a size comparable to a pre-miRNA and all the structural features of a 22 
 
pre-miRNA, can be utilized by the miRNA processing machinery and potentially give rise to 
a functional miRNA. The pre-miRNA is subsequently exported to the cytoplasm by Exportin 
5/Ran-GTP (Lund et al., 2004). Silencing of Exportin 5 by siRNA results in a reduction in 
the levels of pre-miRNA not only in the cytoplasm but also in the nucleus, suggesting that 
Exportin 5 may also be important for stabilizing pre-miRNA in the nucleus (Yi et al., 2003). 
Both siRNAs and miRNAs are generated by Dicer, a cytoplasmic family of RNase III 
enzymes  that  cleave  long  dsRNA  or  pre-miRNA  into  21-23nt  dsRNA  molecules  with 
symmetric 2-3nt 3’ overhangs (Bernstein et al., 2001, Hutvagner et al., 2001, Zhang et al., 
2002).  In  vertebrates,  this  reaction  is  carried  out  together  with  TRBP  (transactivating 
region  (Tar)  RNA-binding  protein)  and  PACT  (interferon-inducible  dsRNA-dependent 
protein kinase activator), which are both co-factors for strand selection (Chendrimada et 
al., 2005, Lee et al., 2006). In S. pombe, C. elegans and vertebrates, only a single Dicer 
gene has been identified (Bernstein et al., 2001, Hutvagner et al., 2001, Knight & Bass, 
2001, Volpe et al., 2002). In addition to two RNase III domains, mammalian Dicer has a 
PAZ domain and a C-terminal dsRNA binding domain, which recognize the 2nt 3’overhang 
generated by Drosha and long dsRNA, respectively (Zhang et al., 2004a). Thus, the same 
Dicer that generates siRNA can also process pre-miRNA. Additional proteins may interact 
with Dicer to allow it to recognize different sources of dsRNA. In D. melanogaster, two 
Dicer paralogs have been identified. Dcr-1 partners with Loquacious and is required for 
miRNA processing, while Dcr-2 partners with R2D2 and is mainly involved in the processing 
of long dsRNA (Lee et al., 2004). Interestingly, flies mutant in Loquacious, rather than 
R2D2,  are  highly  depleted  in  esiRNAs,  suggesting  that  a  subpopulation  of  Dcr-2  that 
specifically  recruits  Loquacious  may  be  devoted  to  the  esiRNA  pathway  (Chung  et  al., 
2008, Czech et al., 2008, Okamura et al., 2008). It remains to be established whether 
processing  of  esiRNAs  by  Dicer  takes  place  in  the  cytoplasm  or  nucleus,  but  it  seems 
unlikely that the substrates for esiRNA production would be exported to the cytoplasm. In 
the plant A. thaliana, four Dicer paralogs have been identified. DCL1 processes miRNA 23 
 
precursors (Park et al., 2002, Reinhart et al., 2002), DCL2 is required for production of 
natsiRNAs and siRNAs, DCL3 is involved in the production of hcRNAs, and DCL4 is required 
for the production of tasiRNAs (Xie et al., 2005, Xie et al., 2004b). DCL1, DCL3 and DCL4 
are  localised  in  the  nucleus  (Hiraguri  et  al.,  2005,  Xie  et  al.,  2004a),  and  DCL1  is 
responsible for the processing of pri-miRNA to miRNA (Kurihara & Watanabe, 2004, Papp 
et al., 2003). DCL2 is localised in both the cytoplasm and nucleus (Dorokhov et al., 2006). 
Following  processing  by  Dicer,  the  3’end  of  plant  miRNAs  and  siRNAs  is  modified  by 
addition of a 2’-O-methyl group by the RNA methyltransferase HEN1 (Yang et al., 2006).  
Following  unwinding  of  the  siRNA  or  miRNA  duplex,  the  strand  with  the 
thermodynamically less stable 5’end (Khvorova et al., 2003, Schwarz et al., 2003), termed 
the guide strand, is incorporated into related RNA-induced silencing complexes (RISCs), 
while  the  other  strand,  termed  the  passenger  strand,  is  degraded.  Naturally  occurring 
miRNAs show a strong bias for accumulating only one strand into the RISC, and effective 
siRNA  or  miRNA  duplexes  show  reduced  thermodynamic  stability  at  the  5'  end  of  the 
antisense strand.  
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Class  Size 
(nt)  Precursor  Mechanism/ 
Function 
3’end 
modifications  Organism 
siRNA  20-23  dsRNA  mRNA cleavage  Unmodified  Mammals 
C. elegans 
      Antiviral response 
Transposon defence   2’-O-methylated  Plants 
D. melanogaster 
natsiRNA  21-22  dsRNA  mRNA cleavage  2’-O-methylated  Plants 
      Regulation of gene 
expression       
tasiRNA  21-22  dsRNA  mRNA cleavage  2’-O-methylated  Plants 
      Trans-acting cleavage 
of endogenous mRNAs     
hcRNA  24  dsRNA  Regulation of chromatin 
structure  2’-O-methylated  Plants 
      Transcriptional gene 
silencing  Unknown  S. Pombe 
tncRNA  22  dsRNA  Unknown  Unknown  C. elegans 
      Unknown     
Secondary 
siRNAs  20-25  dsRNA  mRNA cleavage  Unmodified  C. elegans 
      Enhancement of 
primary signal  2’-O-methylated  Plants 
miRNA  20-23  Imperfect 
hairpin 
Translational 
repression/mRNA 
cleavage 
Unmodified 
Mammals 
D. melanogaster 
C. elegans 
Viruses 
      Regulation of gene 
expression  2’-O-methylated  Plants 
piRNA  28-33  ssRNA  mRNA cleavage  2’-O-methylated  Mammals 
D. melanogaster 
      Transposon defence in 
the germ line     
rasiRNA  23-28  ssRNA  Regulation of chromatin 
structure  2’-O-methylated  D. melanogaster 
      Transcriptional gene 
silencing     
 
Table 1.1 Classes of small dsRNA molecules, their characteristics and functions. 
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1.1.2 Gene regulation by siRNAs and miRNAs 
Whilst  siRNAs  and  miRNAs  differ  in  their  biogenesis,  they  have  the  same  regulatory 
potential,  depending  upon  the  degree  of  complementarity  to  their  target  mRNAs 
(Hutvagner & Zamore, 2002, Mourelatos et al., 2002). Endonucleolytic cleavage of mRNA is 
favoured by perfect complementarity and although some mismatches can be tolerated, it 
requires  base-pairing  between  bases  10  and  11  (Yekta  et  al.,  2004).  Nevertheless,  as 
explained in the following section, extensive base-pairing of a miRNA and its target mRNA 
is  not  always  sufficient  to  induce  mRNA  degradation.  siRNAs  generally  have  perfect 
complementarity to their mRNA targets and thus, mediate silencing by mRNA degradation. 
They can, however, repress the translation or reduce the stability of mRNAs to which they 
anneal with imperfect complementarity.  Moreover, esiRNAs have been shown to  direct 
transcriptional  gene  silencing  (TGS)  through  modulation  of  chromatin  structure.  Plant 
miRNAs generally base pair to their mRNA targets with nearly perfect complementarity 
and thus, trigger mRNA cleavage (Llave et al., 2002, Tang et al., 2003). Rarely, a similar 
mechanism is used by vertebrate and viral miRNAs (Davis et al., 2005, Pfeffer et al., 2004, 
Sullivan et al., 2005, Yekta et al., 2004). Unlike plants, animal miRNAs generally have 
imperfect complementarity to their target mRNAs, are present in multiple copies, bind to 
sites  in  the  3’UTR,  and  direct  silencing  by  repressing  translation  or  reducing  mRNA 
stability. Finally, some plant miRNAs may act directly in promoting DNA methylation (Bao 
et al., 2004), and recent studies describe a role for promoter-directed human miRNAs in 
facilitating repressive chromatin modifications and TGS (Gonzalez et al., 2008, Kim et al., 
2008a). The main mechanisms of gene regulation by siRNAs and miRNAs are described in 
detail in sections 1.1.4 and 1.1.5. 
 
1.1.3 RISC complexes and Argonautes 
siRNAs  and  miRNAs  function  as  components  of  RISCs  (Hammond  et  al.,  2001)  and 
ribonucleoprotein complexes (miRNPs) or miRISCs (Mourelatos et al., 2002), respectively. 26 
 
The key and best characterized components of the RISCs are Argonaute proteins. Other 
RISC-associated proteins include the VIG protein, the Tudor-SN protein, Fragile X-related 
protein and several RNA helicases, whose precise role in RNAi is still largely unknown. In 
humans, miRNPs reside in cytoplasmic foci, called processing bodies (P-bodies). Assembly 
of miRNPs is accomplished by a multiprotein  complex termed the miRNA RISC Loading 
Complex (miRLC), whose core components are Argonaute and Dicer. The miRLC processes 
pre-miRNA into miRNA, unwinds the miRNA duplex and after loading of the mature miRNAs 
to  Argonaute  proteins,  it  disassembles  resulting  in  the  formation  of  the  core  miRNP 
(Maniataki & Mourelatos, 2005).  
Argonautes is a diverse family of proteins that can be phylogenetically divided into 
AGO and PIWI based on similarities to Arabidopsis AGO1 and D. melanogaster PIWI proteins 
respectively, and WAGO (worm-specific Argonaute). There are eight Argonaute genes in 
humans:  four  AGO  (AGO1-4)  that  are  expressed  in  various  adult  tissues,  including  the 
nervous system, and four PIWI (PIWI1-4) that are mainly expressed in the testis (Sasaki et 
al.,  2003).  AGO  proteins  interact  with  miRNAs/siRNAs,  whereas  PIWI  bind  a  newly 
discovered class of small RNAs, known as piwi-interacting RNAs (piRNAs), which are found 
almost exclusively in the germline of mammals and insects. piRNAs, which include repeat-
associated siRNAs (rasiRNAs) discovered in D. melanogaster, are 28-33nt long and 2’-O-
methylated at their 3’end. piRNAs and rasiRNAs are believed to be processed from single-
stranded  RNA  derived  from  defined  genomic  regions  and  retrotransposons  or  other 
repetitive elements, respectively, by a Dicer-independent mechanism that remains largely 
unknown (Aravin et al., 2006, Aravin et al., 2003, Girard et al., 2006, Saito et al., 2006, 
Vagin et al., 2006). Mammalian piRNAs are believed to play a role in spermatogenesis and 
transposon regulation by mediating mRNA cleavage (Aravin et al., 2007, Carmell et al., 
2007), whereas rasiRNAs have been suggested to regulate heterochromatin formation (Pal-
Bhadra et al., 2004, Yin & Lin, 2007).  27 
 
Argonautes consist of a central PAZ domain and a C-terminal PIWI domain. The PAZ 
domain  recognizes  the  single-stranded  2nt  3’overhangs  characteristic  of  small  RNAs 
processed by Dicer and binds to them with low affinity in a sequence-dependent manner 
(Lingel et al., 2004, Ma et al., 2004). The PIWI domain has an RNaseH-like fold and binds 
to the 5’end of small RNAs (Parker et al., 2004, Song et al., 2004a). Recent studies have 
revealed  the  presence  of  a  middle  domain  similar  to  the  cap-binding  domain  of  the 
eukaryotic initiation factor eIF4E (Kiriakidou et al., 2007), whose function is discussed in 
section 1.1.4.1. 
Structural  and  biochemical  studies  have  confirmed  that  Argonaute  is  the 
endonuclease of the RISC (Liu et al., 2004, Rand et al., 2004, Rivas et al., 2005). In D. 
melanogaster  and  human  cell  lysates,  Argonaute  catalyses  multiple  rounds  of  mRNA 
cleavage,  resulting  in  each  siRNA
  directing  the  degradation  of  hundreds  of  target 
molecules (Haley & Zamore, 2004, Hutvagner & Zamore, 2002). Efficient release of the 
fragments  resulting  from  mRNA  cleavage  requires  adenosine  triphosphate  (ATP). 
Additional proteins are likely to be involved, as AGO2 alone can only direct a single round 
of mRNA cleavage (Rivas et al., 2005). Following release of the fragments,
 the 3’ fragment 
is degraded in the cytoplasm by 5’-3’ exonuclease
 Xrn1, whilst the 5’ fragment is degraded 
by the exosome via 3’-5’ mRNA degradation. When miRNAs with perfect complementarity 
to their targets direct mRNA cleavage, a short
 poly(U) tail is added to the 3' end
 of the 5' 
cleavage fragment, suggesting decapping and 5’-3’ mRNA degradation as an alternative 
route of degradation (Shen & Goodman, 2004). Certain Argonaute proteins, however, do 
not retain all the amino acids required for catalytic activity (Asp-Asp-Asp/Glu/His/Lys), 
which  is  referred  to  as  slicer  activity,    and  thus,  are  unable  to  cleave  target  mRNA. 
Interestingly,  the  presence  of  an  intact  PIWI  domain  catalytic  centre  only  partially 
explains the cleavage activity of Argonaute proteins. The human AGO3, for instance, is 
incapable  of  mediating  mRNA  cleavage  despite  having  an  intact  active  site,  which 28 
 
indicates that additional cofactors may be required for catalytic activity (Meister et al., 
2004).   
Most organisms examined to date contain multiple Argonaute proteins, with different 
Argonautes having specialized functions. In humans, AGO2 is the only Argonaute protein 
with a PIWI catalytic domain that can mediate cleavage of target mRNA (Meister et al., 
2004,  Song  et  al.,  2004a).  However,  it  has  also  been  shown  to  direct  translational 
repression in an engineered system (Pillai et al., 2004). The function of AGO1 remains to 
be determined, but AGO3 and AGO4 are likely to mediate translational repression. In D. 
melanogaster, both Argonaute 1 and 2 are capable of cleavage (Okamura et al., 2004), but 
Argonaute 1 is dedicated to the miRNA pathway, whilst Argonaute 2 mainly directs mRNA 
cleavage  (Tolia  &  Joshua-Tor,  2007).  In  C.  elegans,  the  Argonaute  protein  RDE-1  is 
required for mRNA cleavage, but plays little or no role in miRNA function (Tabara et al., 
2002), whereas ALG1 and 2 do not cleave mRNA, but are essential for miRNA function. 
Although the molecular basis for the selective interaction of certain Argonaute proteins to 
specific types of small dsRNAs remains to be elucidated, the biogenesis of small dsRNAs 
has been linked to effector programming (Förstemann et al., 2007, Tomari et al., 2007). 
In D. melanogaster, the structure of small dsRNAs allows sorting of miRNAs and siRNAs into 
Argonaute  1  and  2  complexes  respectively,  through  Dicer-Argonaute  interactions. 
However, although Argonaute 1 favours binding to small dsRNAs with central mismatches, 
a large proportion of miRNA duplexes with perfect complementarity in their central region 
still enter Argonaute 1-containing RISCs (Kawamura et al., 2008). These studies indicate 
that a specific miRNA that preferentially interacts with a particular Argonaute may be 
unable to direct cleavage, even if it has perfect complementarity to its target mRNA. The 
elucidation  of  mammalian  small  dsRNA  sorting  rules  may  therefore  have  important 
implications for improving the efficacy of experimentally induced RNAi. Finally, different 
expression patterns and levels of Argonaute proteins may control the extent to which the 
different RNA silencing processes operate. 29 
 
1.1.4 Mechanisms of gene regulation by miRNAs 
Animal miRNAs, which generally have imperfect complementarity to their target mRNAs, 
bind to sites in the 3’UTR and direct silencing by repressing translation or reducing mRNA 
stability (figure 1.3). It is currently considered that the specificity of the miRNA for its 
target mRNA is primarily specified by the 5’end ‘seed’ region (nucleotides 2-8 of the guide 
strand). Due to the short length of this region, miRNAs are remarkably promiscuous and it 
has been suggested that some miRNAs can target hundreds of mRNAs (Lim et al., 2005, 
Stark et al., 2005). Strong base pairing within the 3’end of the miRNA and its target mRNA 
is not essential for repression, but may compensate for a weaker seed region or enhance 
repression (Brennecke et al., 2005). Bulges or mismatches must be present in the central 
region of the miRNA-mRNA duplex to prevent Argonaute-induced cleavage. Furthermore, 
efficient  translational  repression  often  utilizes  multiple  miRNA-binding  sites  (Bartel  & 
Chen, 2004) either because multiple RISCs act in an additive manner or to ensure at least 
one site will be occupied by RISC. Finally, sequences surrounding the miRNA-responsive 
elements contain certain features that could affect the effectiveness of silencing. AU-rich 
nucleotide  composition  and  the  relative  position  of  the  sites  in  the  3′UTR  all  have  an 
impact on miRNA function (Grimson et al., 2007).  
 
1.1.4.1 Translational Repression 
Although it is well documented that miRNAs mediate silencing by translational repression 
(Brennecke et al., 2003, Chen, 2004, Lee et al., 2003, Poy et al., 2004, Wightman et al., 
1993), whether repression occurs at the initiation or post-initiation step remains a matter 
of intense debate. 
There is substantial evidence to suggest that miRNAs repress translation initiation. It 
has  been  shown  that  the  miRNA–RISC  complex  associates  with  the  anti-translation 
initiation factor eIF6, which inhibits joining of the 60S to the 40S subunits (Chendrimada 
et  al.,  2007).  Depleting  eIF6  in  either  human  cells  or  C.  elegans  effectively  abolishes 30 
 
miRNA-mediated translational repression. However, in D. melanogaster cells, depletion of 
eIF6 did not relieve silencing, indicating that in a system where there is little redundancy 
of the miRNA repression machinery, eIF6 is not fully required (Eulalio et al., 2008). In cap-
dependent translation, which is the major mode of translation initiation, the 5’ m7G cap 
is recognized by the cap-binding protein eIF4E. Several studies have concluded that the 
m7G cap is essential for translational repression and that miRNAs may cause an m7G cap-
dependent impediment to the recruitment of the 80S ribosomes to mRNA (Humphreys et 
al., 2005, Mathonnet et al., 2007, Pillai et al., 2005, Thermann & Hentze, 2007, Wakiyama 
et al., 2007). Moreover, it has been demonstrated that mutations in the AGO2 central 
domain, which is similar to the cap-binding domain of eFI4E, abolishes the ability of AGO2 
to repress translation when tethered to the mRNA 3’UTR (Kiriakidou et al., 2007). It has 
been therefore proposed that AGO2 competes with eIF4E for m7G cap binding and thus, 
prevents  translation  of  capped  mRNAs,  which  accumulate  in  P-bodies  (figure  1.2c). 
Finally, let-7 miRNA-mediated translational repression was recapitulated in two different 
cell-free systems established with extracts prepared from mouse cells (Mathonnet et al., 
2007) or human HEK293F cells over-expressing miRNA pathway components (Wakiyama et 
al., 2007). In these systems, the polyA tail and 5'-cap were both required for translational 
repression,  suggesting  that  let-7  represses  translation  by  impairing  the  synergistic 
enhancement of translation by the 5'-cap and 3' polyA tail.  
Other  studies  have  suggested  that  translational  repression  occurs  at  the  post-
initiation step. In contrast to the study by Humphreys et al. (2005), which demonstrated 
that replacing the cap structure with an internal ribosome entry site (IRES) impairs miRNA-
mediated  repression,  Petersen  et  al.  demonstrated  that  cap-independent  translation 
initiated  through  an  IRES  was  repressed  by  miRNA  (Petersen  et  al.,  2006).  Moreover, 
sucrose gradient sedimentation analysis in C. elegans has revealed that lin-28 and lin-14 
mRNAs are associated with polyribosomes capable of elongation in vitro (Olsen & Ambros, 
1999, Seggerson et al., 2002). Consistent with these observations, several recent studies 31 
 
have reported similar findings that miRNAs and their targets co-sediment with polysomes 
engaged  in  active  translation  elongation  based  upon  their  sensitivity  to  puromycin 
treatment (Maroney et al., 2006, Nottrott et al., 2006, Petersen et al., 2006). In the study 
by  Nottrott  et  al.  (2006),  nascent  polypeptides  could  not  be  detected  by 
immunoprecipitation and the authors suggested the existence of a co-translational protein 
degradation  mechanism  (figure  1.2b).    This  would  resemble  the  situation  in  yeast,  in 
which  many  proteins  undergo  massive  co-translational  degradation  without  reaching  a 
mature size (Turner & Varshavsky, 2000).  However, targeting reporter proteins to the 
endoplasmic reticulum did not prevent repression mediated by either endogenous miRNAs 
or tethering of AGO2 to the mRNA 3′ UTR (Pillai et al., 2005). If nascent proteins were 
degraded in the cytosol, co-translational insertion into the endoplasmic reticulum lumen 
would  be  expected  to  protect  them,  at  least  in  part,  from  proteolysis.  Moreover, 
proteasome  inhibitors  had  no  effect  on  miRNA-mediated  repression  and  pulse-labelling 
experiments failed to detect either full-length or nascent polypeptides (Petersen et al., 
2006, Pillai et al., 2005). Instead, Petersen et al. proposed a ribosome drop-off model, in 
which  premature  termination  of  translation  accounts  for  the  absence  of  protein 
production (figure 1.2a). Alternatively, the lack of nascent polypeptides may be due to 
repression at translation initiation. Finally, although some studies have assumed that the 
co-sedimentation  of  miRNA  complexes  with  polysomes  indicates  that  these  complexes 
contain ribosomes, Thermann and Hentze (2007) have recently demonstrated that miRNA-
mRNPs co-sedimented with polysomes are not necessarily being translated. These heavy 
RNP particles, termed pseudo-polysomes, were found to be insensitive to puromycin and 
thus, not actively elongating ribosomes. 
Furthermore, recent studies have indicated that translational repression by miRNAs 
can be reversed in response to certain stimuli. When human hepatoma cells are subjected 
to amino acid starvation or other types of stress, CAT-1 mRNA that is repressed by miR-122 
is released from P-bodies and recruited to polysomes through a mechanism that involves 32 
 
binding  of  HuR  (an  AU-rich-element-binding  embryonic  lethal  abnormal  vision  (ELAV) 
family  protein)  to  the  3′  UTR  of  CAT-1  mRNA  (Bhattacharyya  et  al.,  2006).  Moreover, 
reporter genes controlled by let-7 miRNA and containing HuR-binding sites are upregulated 
in the same way in stressed HeLa cells. In cultured rat hippocampal neurons, miR-134, 
which is present at dendritic spines, negatively regulates translation of an mRNA encoding 
a protein kinase (Limk1) that is important for spine development (Schratt et al., 2006). 
Treatment  of  cells  with  brain-derived  neurotrophic  factor  (BDNF)  stimulates  Limk1 
synthesis by relieving the miR-134 inhibition of Lim1 mRNA. The above data indicate that P 
bodies can also act as storage sites for mRNAs inhibited by miRNAs. 
Finally,  perhaps  the  most  interesting  development  regarding  miRNA-mediated 
translational  regulation  has  been  the  finding  that  it  oscillates  between  repression  and 
activation in coordination with the cell cycle (Vasudevan & Steitz, 2008, Vasudevan et al., 
2007). Cell cycle arrest activates translation of mRNAs bearing AU-rich elements (AREs) in 
their  3′  UTR  (Wilusz  et  al.,  2001).  This  activation  was  found  to  be  mediated  by  the 
recruitment of AGO2 and the fragile X mental retardation-like protein 1 (FXR1P) to the 
AREs  (Vasudevan  &  Steitz,  2007).  Vasudevan  and  colleagues  (2007)  subsequently 
demonstrated that miRNA369-3, which contains two seed regions for the tumour necrosis 
factor-α  (TNF-α)  ARE,  is  specifically  increased  in  cells  following  cell  cycle  arrest  and 
recruits the AGO2-FXR1P complex to the TNF-α ARE to activate translation. Importantly, it 
was also demonstrated that let-7 induces translation upregulation of target mRNA on cell 
cycle arrest through miRNA target sites in the 3’UTR,  while it represses translation in 
proliferating  cells.  The  authors  proposed  that  protein  changes  within  the  miRNP  may 
result  in  this  dual  mode  of  regulation.  Thus,  the  oscillation  between  activation  and 
repression  does  not  appear  to  be  restricted  to  miRNAs  targeting  ARE  sites.  However, 
whether it applies to all miRNAs remains to be determined. 
Although the precise mechanism by which miRNAs affect translation remains to be 
elucidated,  it  would  appear  from  the  available  data  that  two  distinct  modes  of 33 
 
translational  repression  exist.  It  cannot  be  excluded  that  miRNAs  modulate  protein 
synthesis through many different routes, including repression at both the initiation and 
post-initiation steps of translation. The factors that determine the mechanisms by which 
miRNAs  silence  their  targets  remain  unclear.  The  choice  may  depend  on  the  specific 
miRNA, specific mRNA targets or specific tissue and cell types, as well as proteins that 
interact  with  miRNPs.  Recently,  Kong  et  al.  have  suggested  that  that  the  mode  of 
translational  repression  may  be  dependent  upon  the  promoter  from  which  the  target 
mRNA is transcribed (Kong et al., 2008). 
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1.1.4.2 miRNA-induced mRNA degradation 
Although early studies in C. elegans indicated that miRNAs reduce protein levels without 
affecting mRNA levels (Olsen & Ambros, 1999, Wightman et al., 1993), it has since been 
demonstrated that miRNAs can also induce degradation of their mRNA targets (Bagga et 
al., 2005, Behm-Ansmant et al., 2006, Giraldez et al., 2006, Jing et al., 2005, Lim et al., 
2005,  Wu et al.,  2006). Unlike mRNA degradation mediated by siRNAs or miRNAs with 
perfect complementarity to their target mRNAs, miRNA-induced mRNA degradation is not 
slicer-dependent. Most miRNA-mRNA sites required for endonucleolytic cleavage contain 
mismatches and none of the intermediates arising from slicer activity have been identified 
(Bagga et al., 2005, Jing et al., 2005)). Instead, it has been suggested that miRNAs induce 
mRNA degradation by promoting deadenylation, which is the gradual shortening of the 
polyA tail, followed by decapping, which is the removal of the mRNA cap structure.  
Bagga and colleagues (2005) demonstrated in C. elegans that knockdown of Xrn1p, 
the enzyme required for mRNA degradation following decapping, resulted in attenuated 
silencing caused by let-7 and lin-4 miRNAs, and detected intermediates consistent with 5’-
3’ exonucleolytic mRNA degradation. Moreover, recent studies in D. melanogaster (Behm-
Ansmant et al., 2006), zebrafish embryos (Giraldez et al., 2006) and human cells (Wu et 
al., 2006) have revealed that mRNAs targeted by miRNAs for degradation undergo prior 
deadenylation.  Importantly,  mammalian  Argonaute  proteins,  miRNAs  and  their  mRNA 
targets co-localize to P-bodies, which are sites for mRNA degradation and contain amongst 
other components, the decapping DCP1:DCP2 complex, the CAF1:CCR4:NOT deadenylase 
complex and GW182 (Jakymiw et al., 2005, Liu et al., 2004, Meister et al., 2004, Pillai et 
al., 2005, Sen & Blau, 2005). This evidence has led to a model in which miRNAs sequester 
targets mRNAs to P-bodies and GW182 interacts with Argonautes to recruit deadenylases 
and decapping enzymes, leading to mRNA degradation. Nevertheless,  P-bodies are not 
absolutely required for miRNA function, as depletion of Lsm1 or GW182 in human and D. 
melanogaster  cells,  which  causes  loss  of  P-bodies  and  disperses  Argonaute  proteins 36 
 
throughout the cell, does not affect miRNA function (Chu & Rana, 2006, Eulalio et al., 
2008).  
It would appear that miRNAs silence genes primarily by inhibiting protein synthesis 
and that mRNA degradation is a consequence of this primary event (Chendrimada et al., 
2007, Mathonnet et al., 2007). However, mRNAs that cannot be translated are still subject 
to  deadenylation  and  deadenylation  still  occurs  in  mRNAs  when  miRNA  translational 
repression has been blocked (Wakiyama et al., 2007, Wu et al., 2006). These studies have 
suggested that deadenylation is a cause rather than a consequence of miRNA-mediated 
translational repression, particularly at the initiation step. Although deadenylation does 
not  necessarily  lead  to  mRNA  decapping  and  degradation  and  may  represent  one 
mechanism  to  repress  translation  of  target  mRNAs,  it  does  not  fully  account  for 
translational  repression  (Behm-Ansmant  et  al.,  2006,  Wu  et  al.,  2006).  It  has  been 
suggested  that  when  deadenylation  is  impaired,  an  alternative  mechanism  which  may 
inhibit  translation  initiation,  such  as  decapping,  may  be  activated  to  bypass  the 
requirement  for  deadenylation  (Eulalio  et  al.,  2007).  Thus,  miRNAs  may  downregulate 
their targets by repressing translation, or inducing translation-dependent or independent 
mRNA degradation. The factors that determine the mechanism of miRNA silencing that 
occurs in individual cases remain to be determined. 
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1.1.5 Mechanisms of gene regulation by siRNAs 
tasiRNAs (figure 1.4), natsiRNAs and most viral-derived siRNAs (figure 1.6) guide mRNA 
degradation,  whereas  hcRNAs  play  a  role
  in  heterochromatin  regulation  (figure  1.5). 
Genetic  studies  suggest  that  tasiRNAs
  may  mediate  cleavage  of  target
  mRNAs  that  are 
different from the sequences from which the tasiRNAs
 originate, playing a crucial role in 
plant development (Adenot et al., 2006, Fahlgren et al., 2006). The function of tncRNAs in 
C. elegans remains to be determined, whereas secondary siRNAs are believed to support 
the  primary  siRNA  signal.  Although  the  functions  of  animal  esiRNAs  remain  largely 
unknown, they have been suggested to play a role analogous to piRNAs in suppressing the 
expression of mobile genetic elements in both germ and somatic cells (Chung et al., 2008, 
Watanabe et al., 2008). Moreover, they seem to regulate the expression of specific mRNAs 
and may also be involved in heterochromatin formation (Czech et al., 2008, Okamura et 
al., 2008, Tam et al., 2008).   
 
1.1.5.1 siRNA-mediated transcriptional gene silencing  
Studies in S. pombe and plants have revealed that siRNAs can direct both transcriptional 
and post-transcriptional gene silencing. In S. pombe, hcRNAs are incorporated into RITS, a 
RISC-like  complex  that  contains  amongst  other  proteins  Ago1  and  the  chromodomain 
protein  Chp1  (figure  1.5).  The  RITS  complex  pairs  with  the  nascent  transcript  repeat 
sequences and directs modification of histones to promote the formation of repressive 
heterochromatin on DNA by a mechanism that is largely unknown (Bühler et al., 2006, 
Noma et al., 2004, Verdel et al., 2004, Volpe et al., 2002). It has been demonstrated that 
DNA  methylation  in  plants  can  be  induced  by  miRNA  with  extensive  complementarity 
exclusively to the corresponding spliced transcript, suggesting that RNA–DNA base-pairing 
is not required (Bao et al., 2004). Plant hcRNAs, however, whose biogenesis requires RNA 
polymerase V, have been suggested to interact directly with the target enhancer region to 
induce RNA-directed DNA methylation (Daxinger et al., 2009).  39 
 
In S. pombe, hcRNAs correspond to repeat sequences that flank the centromeres, the 
sites of attachment of chromosomes to the spindle during cell division (Reinhart & Bartel, 
2002). These sequences are normally embedded in heterochromatin that is important for 
centromere  function.  Mutations  in  components  of  the  RNAi  pathway  disrupt  this 
heterochromatin and lead to defects in chromosome segregation (Hall et al., 2003, Volpe 
et  al.,  2002).  Chicken  and  mouse  cells  lacking  Dicer
  also  fail  to  assemble  silent 
heterochromatin at their centromeres
 (Fukagawa et al., 2004, Kanellopoulou et al., 2005). 
Thus, esiRNAs may have a conserved role in the maintenance of pericentromeric hetero-
chromatin. Moreover, they may be involved in the regulation of invasive genetic elements, 
such as retrotransposons, which are subject to RNAi-mediated transcriptional silencing in 
both fission yeast and plants (Hamilton et al., 2002, Schramke & Allshire, 2003), and in 
transcriptional control of endogenous gene expression. A role for siRNAs in transcriptional 
gene regulation is supported by the discovery in plants that endogenous miRNAs direct 
methylation of a family of genes involved in leaf development (Bao et al., 2004).  
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1.1.5.2 Secondary siRNAs 
Recent  studies  in  C.  elegans  and  plants  indicate  that  experimentally  induced  RNAi  by 
introducing either longer dsRNA (Pak & Fire, 2007) or a miRNA-like transgene (Sijen et al., 
2007) generates two distinct siRNA populations that form during primary and secondary 
phases (figure 1.6). Primary siRNAs arise directly from trigger RNA molecules, whereas 
secondary  siRNAs require  RdRPs.  Although  it  remains  to  be  determined  how  secondary 
siRNAs are formed, it is unlikely that RdRPs synthesizes them by priming off of primary 
siRNAs.  Strong  evidence  comes  from  the  fact  that  secondary  siRNAs  are  perfectly 
complementary to the target mRNA even when given a mismatched primary siRNA as a 
trigger (Sijen et al., 2007). The role of secondary siRNAs in endogenous regulation and 
exogenous RNAi-induced silencing remain to be elucidated. In plants, secondary siRNAs 
from exogenous siRNA or natsiRNA are believed to support the primary siRNA signal by 
inducing mRNA cleavage, whereas secondary siRNAs from hcRNA are believed to induce 
unidirectional spreading of DNA methylation (Daxinger et al., 2009). In C. elegans, primary 
siRNAs  interact  with  Argonaute  RDE-1,  whereas  secondary  siRNAs,  which  have  a  5’-
triphosphate,  have  been  suggested  to  associate  with  SAGO-1  and  SAGO-2  Argonautes, 
which  are  members  of  the  WAGO  family  and  lack  residues  essential  for  endonuclease 
activity (Pak & Fire, 2007, Yigit et al., 2006).  Secondary siRNAs may therefore induce 
indirect mRNA destabilization or transcriptional gene silencing, rather than direct target 
cleavage.  It  has  been  proposed  that  if  RDE-1  was  allowed  to  interact  with  secondary 
siRNAs, RdRP amplification of siRNA production could spread into non-targeted, essential 
genes  resulting  in  unwanted  off-target  effects.  Hence,  specialization  of  Argonaute 
proteins may allow C. elegans to restrict a potent, amplified RNAi response to specific 
target loci.  
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1.1.6 Silencing in mammalian cells 
The discovery that RNAi operates in mammalian cells (Elbashir et al., 2001) generated 
great  excitement  regarding  potential  applications  in  functional  genomics  and  target 
validation, as well as harnessing RNAi as a therapeutic strategy to silence disease-causing 
genes. Whereas effective silencing in C. elegans and D. melanogaster can be achieved 
using long dsRNAs (Caplen et al., 2000, Fire et al., 1998), in mammalian systems, dsRNA of 
>30bp induces the INF response, which leads to non-specific translational inhibition and 
RNA  degradation  (figure  1.7).  INF  induces  activation
  of  RNA-dependent  protein  kinase 
(PKR)  and  2’,  5’-oligoadenylate  synthetase,
  which  regulate  protein  synthesis  via 
phosphorylation of the
 α-subunit of the eukaryotic initiation factor 2α (eIF2α) and RNA 
degradation via activation of RNase L, respectively (Sledz & Williams, 2004, Stark et al., 
1998). Instead, RNAi in mammalian cells can be induced by the introduction of synthetic 
siRNAs and by plasmid or viral vector systems that express short-hairpin RNA (shRNA) or 
artificial miRNA. Target gene expression in culture can be reduced by as much as a ten-
fold and the high degree of RNAi specificity has enabled the silencing of mutant genes 
with  single  nucleotide  mutations,  without  affecting  the  expression  of  the  wild-type 
alleles. However, two main challenges remain for the successful and safe application of 
RNAi in vivo; the design of siRNA/shRNA molecules so as to achieve optimal silencing with 
minimal off-target effects, and efficient delivery to target tissues. 
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1.1.6.1 Silencing by synthetic siRNA 
Ever  since  Tuschl  and  colleagues  demonstrated  that  efficient  gene  silencing  can  be 
achieved  by  delivery  of  siRNAs  to  the  cytoplasm  of  mammalian  cells,  chemically  or 
enzymatically  synthesised  siRNAs  have  become  a  powerful  tool  for  modulating  gene 
expression. Enzymatically synthesised siRNAs are generated through processing of in vitro 
transcribed  dsRNA  into  a  pool  of  siRNAs  (d-siRNA)  by  a  recombinant  Dicer  (Myers  and 
Ferrell, 2005, Myers & Ferrell, 2005). This approach eliminates the need to identify an 
individual  effective  siRNAs  and  is  cost  effective  and  relatively  quick.  However, 
unprocessed long dsRNA may activate the INF response and thus, gel purification of 21–
23nt  long  siRNAs  from  unprocessed  long  dsRNAs  and  partially  processed  products  is 
required.  Moreover,  competition  from  less  effective  siRNAs  in  a  pool  may  reduce  the 
overall  silencing  efficacy  and  it  is  more  difficult  to  verify  phenotypes  arising  from 
knockdown  of  target  gene  expression  compared  to  when  one  optimal  siRNA  of  known 
sequence is used. 
Chemically synthesised siRNAs represent the gold standard for RNAi applications, but 
are  considerably  more  expensive  than  enzymatically  generated  siRNAs.  Provided  some 
basic design rules are adhered to, synthetic siRNAs are well tolerated both in vitro and in 
vivo.  Conventionally  designed  siRNAs  are  21nt  long  with  symmetric  2nt  3’overhangs 
(Elbashir et al., 2001). However, 21-25nt duplexes with 2nt 3’overhangs (Caplen et al., 
2001,  Elbashir  et  al.,  2002)  and  21-29nt  duplexes  with  blunt  ends,  symmetric  or 
asymmetric  2nt  overhangs  have  been  shown  to  induce  effective  silencing  (Kim  et  al., 
2005). Longer siRNAs are processed by Dicer that is believed to be important for efficient 
incorporation into the RISC, but may yield multiple 21nt long siRNAs with variable activity. 
Moreover, long siRNAs (>23nt) are more likely to induce the INF response, and different 
cell  types  have  been  shown  to  manifest  drastically  different  cell  viability  and  IFN 
responses to long siRNAs, suggesting that the dsRNA length threshold varies considerably 
amongst cell types (Reynolds et al., 2006). Moreover, 5′-UGUGU-3′ motifs can induce the 47 
 
INF response and the release of inflammatory cytokines through interaction with specific 
toll-like receptors (Judge et al., 2005) and are therefore avoided, unless activation of an 
immune response together with siRNA-mediated gene silencing is desirable, such as in the 
treatment of viral infections and tumours. Modifications, such as locked nucleic acid (LNA) 
modifications,  which  add  a  methylene  linkage  between  the  2′  and  4′  positions  of  the 
ribose, and 2′-O-methyl modifications into the sugar structure of selected nucleotides can 
abrogate the immunostimulatory activity of siRNAs (Hornung et al., 2005, Judge et al., 
2005).  However,  depending  on  their  extent  and  location,  these  modifications  can  also 
reduce  or  completely  block  the  gene  silencing  activity  of  siRNAs  and  thus,  extensive 
modifications are not desirable. 
Different siRNAs against a target gene often manifest a spectrum of potency and may 
non-specifically target unrelated genes to which they anneal with partial complementary, 
termed off-target effects (Jackson et al., 2003). Computational tools have been developed 
to increase the likelihood of selecting effective siRNAs and reduce potential off-target 
effects.  Alternatively,  validated  siRNAs  are  commercially  available  and  tested  siRNA 
sequences can be obtained from the literature. Nevertheless, experimental validation is 
necessary to confirm the potency and specificity of the selected siRNAs. Reporter-based 
assays, which allow the target gene to be fused to a reporter gene and expressed from a 
plasmid vector, have been developed for rapid validation of siRNA sequences. Although 
downregulation  of  reporter  activity  correlates  well  with  knockdown  of  target  gene 
expression,  it  is  necessary  to  test  pre-validated  siRNAs  for  their  ability  to  silence 
endogenous gene expression.  
Candidate siRNAs are often designed to target the coding sequence of the target 
gene that is generally better characterised than the 3’ or 5’ UTR. Moreover, siRNAs may 
be designed to target orthologs in more than one species or multiple splice variants of the 
target  gene.  Algorithms  select  candidate  siRNA  sequences  based  on  the  sequence  and 
thermodynamic properties of functional siRNAs and in most cases, a genome-wide BLAST 48 
 
search is automatically performed to identify potential similarities to other mRNAs that 
may be unintentionally targeted. Considerations in the design of siRNAs include strand bias 
(AU  rich  5’end  on  the  guide  strand  for  sequence  asymmetry),  siRNA  stability  (low  to 
medium GC content and low stability at positions 9-11 of the guide strand), absence of 
internal repeats, the accessibility of the mRNA target site, which requires prediction of 
mRNA secondary structure, and specificity (Chalk et al., 2004, Khvorova et al., 2003, Luo 
& Chang, 2004, Reynolds et al., 2004). In addition to siRNA design, the success of RNAi-
mediated gene silencing is also dependent on target gene expression and protein turnover. 
Off-target effects may be caused by perfect complementarity between the central 
region of over half of the siRNA sequence and anywhere within the mRNA sequence, or by 
perfect complementarity between 6-7nt in the siRNA guide strand seed region and the 
3’UTR of the mRNA (Birmingham et al., 2006, Jackson et al., 2003, Jackson et al., 2006b, 
Lim  et  al.,  2005)  (figure  1.8).  In  the  latter  case,  siRNAs  mimic  miRNAs  and  mediate 
silencing by repressing translational and/or reducing mRNA stability. Although specificity 
can be enhanced by sequence asymmetry, introducing mismatches in the guide strand to 
the 3’UTR of undesired target mRNAs, 2′-O-methyl modifications in the seed region, and 
asymmetric 5’-O-methylation of siRNA duplexes, off-target effects cannot be completely 
eliminated (Holen et al., 2005, Jackson et al., 2003, Jackson et al., 2006a, Jackson et al., 
2006b,  Lin  et  al.,  2005).  Delivery  of  a  low  dose  of  siRNA  (≤20nM)  and  co-delivery  of 
multiple  siRNAs  against  a  single  target  are  effective  strategies  to  minimise  off-target 
effects (Semizarov et al., 2003).    
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Silencing by synthetic siRNAs is transient lasting for 3-7 days in dividing cells and up to 
several  weeks  in  terminally  differentiated  cells,  such  as  macrophages  and  neurons 
(Bartlett & Davis, 2006). Eventually siRNAs are diluted or degraded and thus, repeated 
administration  is  necessary  to  achieve  a  persistent  effect.  This  is  due  to  mammalian 
systems lacking RdRPs, which use the guide strand of the siRNA as a template to generate 
more siRNA duplexes, thus amplifying the silencing effect (Dillin, 2003). Moreover, siRNA 
duplexes  are  polyanionic  macromolecules  and  their  uptake  by  mammalian  cells  is 
generally poor. Transfection or electroporation of synthetic siRNAs is currently the most 
convenient  method  for  silencing  genes  in  mammalian  cell  cultures,  where  long-term 
inhibition  of  gene  expression  is  not  generally  required.  The  most  commonly  used 
transfection  reagents  are  cationic  lipids,  although  cationic  polymers  and  cationic  cell 
penetrating peptides have also been used deliver siRNA in culture. A common property of 
these delivery agents, which aim to enhance cellular accumulation of siRNA molecules and 
facilitate release from endosomes, is their net positive charge that facilitates complex 
formation  with  the  siRNA  and  interaction  with  the  negatively  charged  cell  membrane. 
However, it has been demonstrated that transfection reagents induce changes in gene 
expression,  which  may  impact  on  siRNA  activity  and  specificity  (Hollins  et  al.,  2007). 
Toxicogenomic studies in A431 human epithelial cells revealed that the commonly used 
cationic lipids Lipofectin and Lipofectamine (Invitrogen) affect the expression of numerous 
genes  involved  in  cell  proliferation,  differentiation  and  apoptosis  thus,  altering  the 
expression profile of the cell and potentially interfering with the desired genotypes or 
phenotypes (Omidi et al., 2003). 
In  vivo,  the  main  challenge  is  efficient  delivery  of  siRNAs  to  target  tissues. 
Hydrodynamic delivery (high-pressure intravenous injection) is the most common method 
used for systemic siRNA delivery to organs such as liver and kidney, but is not appropriate 
for clinical applications (Song et al., 2003). Delivery to localised regions, such as local 
tumours,  eye,  brain,  spinal  cord  and  mucus  membranes,  can  be  achieved  by  topical 51 
 
delivery  or  direct  injection  of  siRNAs.  However,  many  tissues  can  only  be  reached  by 
systemic administration of siRNAs in the bloodstream. Naked siRNAs have a very short half-
life in blood (5-60min) due to rapid filtration by the kidney, uptake by phagocytes and 
degradation by serum nucleases. Moreover, egress from the bloodstream and across the 
vascular endothelium poses an additional challenge, as molecules larger than 5nm do not 
readily cross the endothelium. A variety of strategies have been employed to increase 
siRNA stability and facilitate siRNA delivery to specific cell types. Chemical modifications 
improve  resistance  to  nucleases,  coupling  siRNAs  to  peptides  or  cationic  polymers 
facilitate  transport  across  the  cell  membrane,  encasing  them  into  nanoparticles  or 
liposomes limit renal filtration, and linking them to cell surface receptor ligands target 
siRNAs to specific cell types. 
Chemical modifications of the phosphorothioate linkage (backbone phosphate group 
O  →  S)  or  the  boranophosphate  linkage  (backbone  phosphate  group  O  →  BH3)  are 
considered a simple and effective method to increase the nuclease resistance of siRNAs 
(Amarzguioui et al., 2003, Braasch et al., 2004, Hall et al., 2004). Modifications of the 2′-
hydroxyl group of the pentone sugar, such as 2′-O-methyl, 2′-O-(2-methoxyethyl) and 2′-
deoxy-2′floro,  and  LNA  modifications,  can  also  increase  stability  without  affecting  the 
silencing activity of siRNAs (Blidner, 2007, Dowler et al., 2006, Elmén et al., 2005, Prakash 
et al., 2005). Strand bias can be influenced by chemical modifications or conjugation of 
siRNA and thus, either the 3′- or 5′-terminus of the sense strand is generally used.  
Several small molecules and peptides have been linked to siRNAs. Most conjugates 
employ  acid-cleavable  and  reducible  bonds,  such  as  β-thio-propionate  and  disulfide 
linkages,  which  are  cleaved  in  the  acidic  endosome  compartments  and  the  reductive 
cytosolic  space,  respectively,  to  facilitate  release  of  intact  siRNAs  inside  the  cells. 
Cholesterol-conjugated siRNAs, which demonstrate improved stability compared to naked 
siRNAs, have been administered intravenously to silence apolipoprotein B (ApoB) in the 
mouse  liver  and  consequently  reduce  cholesterol  levels,  without  inducing  an  immune 52 
 
response  or  any  significant  off-target  effects  (Soutschek  et  al.,  2004).  Cholesterol-
conjugated siRNAs linked to high-density lipoprotein (HDL) demonstrated five times more 
effective silencing of ApoB compared to unbound cholesterol-conjugated siRNAs through 
binding to the HDL receptor in the liver (Wolfrum et al., 2007). Amongst cell penetrating 
peptides, the HIV-1 trans-activator protein (TAT), Penetratin and Transportan have been 
most commonly used to deliver siRNAs. Penetratin conjugated siRNAs were used to silence 
target genes, including superoxide dismutase, in primary neuronal cells without any signs 
of  toxicity  (Davidson  et  al.,  2004).  However,  a  recent  study  has  demonstrated  that 
intrathecal  delivery  of  siRNAs  conjugated  to  Penetratin,  unlike  delivery  of  siRNAs 
conjugated to TAT or cholesterol, induces an immune response in mice and that siRNAs 
conjugated to cell penetrating peptides exhibit similar stability to naked siRNAs (Moschos 
et al.,  2007). Finally,  cell-specific ligands, such as antibodies, aptamers, vitamins and 
hormones, have been linked to siRNAs and facilitate delivery to target tissues and cellular 
uptake by receptor-mediated endocytosis. Vitamin E-conjugated 27/29nt siRNAs with 2’-O-
methyl  and  phosphorothioate  linkage  modifications  reduced  ApoB  levels  in  the  liver 
without inducing the INF response. Release of Vitamin E is facilitated through processing 
of the 27/29nt siRNA into 21nt siRNAs by Dicer (Nishina et al., 2008). 
Cationic peptides with an Arginine stretch can also serve as siRNA delivery vehicles. 
Peptide-siRNA  complexes  are  formed  through  electrostatic  interactions  between  the 
positively  charged  peptide  and  negatively  charged  siRNA.  Delivery  of  siRNA  against 
vascular endothelial growth actor (VEGF) using a cholesteryl oligoarginine peptide (Chol-
9R)  effectively  inhibited  tumour  growth  in  colon  adenocarcinoma  (Kim  et  al.,  2006b). 
Moreover, the cationic polypeptide protamine, which was linked to the C-terminus of the 
antigen-binding region (Fab or scFv) of an antibody against the HIV-1 envelope protein 
gp160 or the hormone receptor ERBB2, has been used to target siRNAs to HIV-infected 
cells and breast cancer cells, respectively (Song et al., 2005).    53 
 
Cationic  polymers  bind  to  siRNAs  and  condense  them  into  nanoparticles,  which 
demonstrate reduced renal excretion and efficient delivery into cells. Amongst cationic 
polymers,  cyclodextrin,  polyethyleimine  (PEI)  and  atelocollagen  have  been  most 
commonly used to deliver siRNA (Ge et al., 2004, Urban-Klein et al., 2004). Intranasal 
administration of siRNAs complexed to PEI inhibited pulmonary influenza infection (Ge et 
al.,  2004)  and  atelocollagen  has  been  used  to  deliver  siRNAs  against  VEGF  to  various 
tumour models systemically and locally (Minakuchi et al., 2004, Takeshita et al., 2005). 
However, whilst cyclodextrin and atelocollagen are well tolerated (Heidel et al., 2007), 
the use of PEI in vivo is hindered by its non-specific toxicity.  
Polyethylene glycol (PEG) is a hydrophilic non-ionic polymer. PEG-siRNA conjugates 
can be complexed with cationic polymers or peptides to form colloidal nanoparticles (Kim 
et al., 2006a). PEG-siRNA complexed with a cationic polymer forms a neutralised core 
surrounded by the PEG hydrophilic segments, which improve solubility. PEG-conjugation 
also increases siRNA stability, controls particle size, and prevents particle aggregation in 
the  presence  of  serum.  Moreover,  PEG  reduces  the  immunogenicity  of  the  cationic 
polymer and uptake by phagocytes (Martina et al., 2007). PEG-siRNAs complexed with PEI 
or a cationic fusogenic peptide (KALA) have successfully silenced VEGF in tumour cells. 
PEG-siRNA/PEI has also reduced tumour size following local or intravenous administration 
in mice (Kim et al., 2008b, Lee et al., 2007).  
DOTAP  (N-[1-(2,3-dioleoyloxy)]-N,N,N-trimethyl  ammonium  propane)  and 
Oligofectamine (Invitrogen) were some of the first cationic lipid formulations to be used 
for in vivo delivery of siRNA and effective silencing of tumour necrosis factor receptor 
(TNF-R) and β-catenin in mice (Sørensen et al., 2003, Verma et al., 2003). More recently, 
intra-vaginal delivery of siRNA against herpes simplex virus 2 (HSV-2) using Oligofectamine 
protected against lethal infection for up to 9 days (Palliser et al., 2006). Liposomes consist 
of a lipid bilayer that forms a sphere with an aqueous core in which siRNAs are encased. 
Cationic liposomes (SNALPs) stabilised by PEG are a clinically approved delivery system 54 
 
and  have  been  successfully  used  to  deliver  siRNAs  to  mice  and  non-human  primates 
(Morrissey  et  al.,  2005,  Zimmermann  et  al.,  2006).  Moreover,  Geisbert  and  colleagues 
demonstrated that SNALP-mediated delivery of siRNA can protect guinea pigs against a 
lethal  Ebola  virus,  whereas  siRNAs  delivered  by  PEI  conferred  partial  protection  from 
death  (Geisbert  et  al.,  2006).  However, cationic  lipids  have  been  shown  to  induce  an 
immune  response,  in  addition  to  potentially  increasing  off-target  effects,  as  discussed 
earlier.  Injection  of  siRNAs  complexed  with  cationic  lipids  induced  a  potent  cytokine 
response in mice that was debilitating to the organism, whilst injection of naked siRNAs or 
siRNAs conjugated to cholesterol had no significant effect on immune system activation 
(Heidel et al., 2004, Hornung et al., 2005, Judge et al., 2005, Ma et al., 2005, Soutschek 
et al., 2004). Recently, PEG stabilised nanoparticles consisting of cationic lipids (DOTAP 
and cholesterol) and protamine, were used to deliver siRNAs without inducing an immune 
response. A ligand was attached to PEG to facilitate targeting to tumour cells (Li & Huang, 
2006). Moreover, Sato and colleagues used Vitamin A-coupled liposomes to deliver siRNA 
against gp46 to hepatic cells and prolong survival of rats with lethal liver cirrhosis without 
inducing an immune response or any significant off-target effects (Sato et al., 2008).  
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Material  Target  Target  Route  Animal  Ref 
siRNA conjugates         
Cholesterol  Liver  ApoB  Intravenous  Mouse  Soutschek et al., 2003 
HDL-Chol  Liver  ApoB  Intravenous  Mouse  Wolfrum et al., 2007 
Vitamin E  Liver  ApoB  Intravenous  Mouse  Nishina et al., 2008 
Cell-penetrating peptides       
TAT  Lung  p38 MAP kinase  Intrathecal  Mouse  Moschos et al., 2007 
Penetratin  Lung  p38 MAP kinase  Intrathecal  Mouse  Moschos et al., 2007 
Cationic peptides       
Chol-9R  Tumour  VEGF  Intravenous  Mouse  Kim at el., 2006 
Protamine-F105P  HIV- infected cells  gag  Intravenous  Mouse  Song et al., 2005 
Cationic polymers         
PEI  Lung  respiratory 
syncytial virus  Intranasal  Mouse  Ge et al., 2004 
PEI  Tumour  c-erbB2/neu  Intraperitoneal  Mouse 
Urban-Klein et al., 
2005 
Atelocollagen  Tumours  VEGF  Intravenous 
Intratumoural  Mouse 
Takeshita et al., 2005 
Minakuchi et al., 2004 
PEGylated PEI  Tumours  VEGF  Intravenous 
Intratumoural  Mouse 
Lee et al., 2007; Kim 
et al., 2008 
Cationic lipids and Liposomes         
Oligofectamine  Vagina  HSV-2  Intravaginal  Mouse  Palliser et al., 2006 
SNALP  Ebola-infected cells  Polymerase L  Intravenous  Guinea 
pig 
Geisbert et al., 2006 
SNALP  Liver  Hepatitis B 
virus  Intravenous  Mouse  Morrissey et al., 
2005  
SNALP  Liver  ApoB  Intravenous  Monkey 
Zimmermann et al., 
2006 
LipoTrust   Liver  gp46  Intravenous  Rat  Sato et al., 2008 
 
Table 1.2 In vivo delivery of synthetic siRNA 
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Despite  the  problems  associated  with  the  in  vivo  delivery  of  synthetic  siRNAs, 
several clinical trials are ongoing or planned for taking siRNA into the clinic. Advanced 
clinical trials for the treatment of age-related macular degeneration, which is a leading 
cause  of  blindness,  and  respiratory  syncytial  virus  (RSV),  which  is  a  major  cause  of 
respiratory illness in children and infants, involve local delivery of naked siRNAs against 
VEGF and RSV nucleocapsid N gene to the eye and lung, respectively. These trials have 
reported that the siRNA doses used were well tolerated, with no adverse systemic effects. 
Phase I clinical trials for the treatment of hepatitis B and solid tumours involve systemic 
delivery of siRNAs using a cationic lipid and cyclodextrin decorated with a tumour specific 
ligand respectively, but results from these trials await publication. It has to be noted that 
a recent study has called into question the siRNA anti-angiogenic effect reported in the 
clinical  trials  for  age-related  macular  degeneration  by  demonstrating  that  non-specific 
stimulation of Toll-like  receptor 3 can reduce angiogenesis by downregulation of VEGF 
(Kleinman et al., 2008).  
 
1.1.6.2 Silencing by expression of shRNA/miRNA 
In addition to introducing synthetic siRNA into the cytoplasm, silencing triggers can be 
expressed from vectors using either pol II or pol III promoters. The most commonly used 
approach involves transcription of sense and antisense 19-29bp long sequences connected 
by a loop of unpaired nucleotides (figure 1.9a).  Expression under the control of a pol III 
promoter, such as the U6 snRNA or the H1 RNase P RNA promoter, results in the formation 
of a stable hairpin with a 3-4nt 3’overhang from the RNA pol III transcription termination 
that resembles an endogenous pre-miRNA (Lee et al., 2002, Paul et al., 2002, Yu et al., 
2002).  Following  expression  in  the  nucleus,  shRNAs  are  exported  to  the  cytoplasm  by 
Exportin 5 and are processed by Dicer to generate functional siRNAs. A variation on this 
theme uses a  pol III-based tandem system  to  transcribe independently both sense and 
antisense strands, which following annealing of both strands, compose the siRNA duplex. 57 
 
Nevertheless, it has been shown that tandem-type vectors present less silencing activity 
than hairpin-type vectors (Miyagishi et al., 2004).  
The conversion of active siRNA sequences into shRNAs can be problematic, as siRNAs 
do  not  require  further  processing  and  transport.  As  with  the  design  of  siRNAs, 
computational tools have been developed to increase the likelihood of selecting effective 
shRNA sequences and reduce potential off-target effects. Considerations in the design of 
shRNAs include, in addition to those discussed for siRNAs, no more than three consecutive 
U nucleotides anywhere within the hairpin or loop sequence as RNA pol III terminates at 
four or more Ts, five Ts at the 3′ end for efficient termination, and a G or A at position 1 
of the hairpin for efficient RNA pol III transcription initiation. Another important factor is 
the size and sequence of the loop, which is important for successful export of pre-miRNA 
or  shRNA  from  the  nucleus  (Brummelkamp  et  al.,  2002,  Zeng  &  Cullen,  2003).  A  few 
artificial loops have been successfully tested, including the 5′-TTCAAGAGA-3’ loop (Pekarik 
et al., 2003). Loops derived from naturally occurring miRNAs, such as the human miR-30 
5′-CUGUGAAGCCACAGAUGGG-3′  and  human  miR-23  5′-CTTCCTGTCA-3′  loops,  have  been 
shown to further enhance the potency of shRNAs (Boden et al., 2004, Xia et al., 2004). 
Screening of multiple  shRNA  sequences is required in order  to identify constructs that 
produce effective knockdown. 
Pol  II  promoters,  such  as  the  cytomegalovirus  immediate  early  (CMV  IE)  gene 
promoter, have also been used to express shRNA (Gou et al., 2004, Xia et al., 2004, Xia et 
al.,  2002).  Some  of  the  restrictions  for  expression  of  a  functional  shRNA  include 
elimination of 5' overhang sequences and the use of a minimal polyA signal. There are 
several advantages to the use of pol II promoters, including tissue-specific and inducible 
transcription of shRNA. Although it is clear that functional siRNAs can be produced from 
pol II systems, given the requirement for a polyA signal at the 3' end of the transcriptional 
units, it remains unclear how the shRNAs are produced and which transport system is used 
to export them to the cytoplasm. More recently, Scherer and colleagues created tRNA–58 
 
shRNA chimeras that use the endogenous tRNA 3’-end processing endonuclease to release 
shRNAs that are subsequently processed into siRNAs. This system was shown to produce 
excellent strand selectivity (Scherer et al., 2007). 
As the understanding of miRNA biogenesis advanced, new generation RNAi triggers 
were developed (figure 1.9b). Artificial miRNAs, also known as shRNAmir, have been most 
commonly modelled on the well-characterised human miRNA, miR-30 (Boden et al., 2004, 
Zeng & Cullen, 2003, Zeng et al., 2002). However, vectors based on miR-155 and miR-26a, 
have also been described (Chung et al., 2006, McManus et al., 2002). The stem of the pri-
miRNA, which is expressed using either pol III or pol II promoters, can be replaced with 
shRNA  sequences  against  different  target  genes,  without  affecting  normal  miRNA 
maturation. The Drosha–DGCR8 complex excises the engineered stem–loops to generate 
intermediates that resemble endogenous pre-miRNAs, which are subsequently exported to 
the cytoplasm and processed by Dicer into functional miRNAs. These artificial miRNAs, 
which have perfect complementarity to their mRNA targets, have been demonstrated to 
mediate silencing by mRNA endonucleolytic cleavage rather than translational repression 
(Boden et al., 2004, Chung et al., 2006, Zeng et al., 2002). The use of artificial miRNAs 
has become a very attractive alternative to the expression of shRNA (Boudreau et al., 
2008a,  Silva  et  al.,  2005).  Artificial  miRNAs  are  amenable  to  pol  II  transcription  and 
polycistronic strategies, which allow delivery of multiple shRNA sequences simultaneously 
and co-expression of a reporter gene or a biologically active protein together with the 
shRNA (Chung et al., 2006). Expression of shRNA and artificial miRNA is discussed in more 
detail in chapter 3 of this thesis.  
Several  reversible  and  irreversible  conditional  systems  have  been  developed  for 
expression of shRNA from pol III or pol II promoters. Reversible inducible expression of 
shRNA has been most commonly achieved using deoxycycline-controlled cassettes (Chen et 
al., 2003, Hosono et al., 2004, Matsukura et al., 2003, van de Wetering et al., 2003). The 
E. coli Tet operator sequence (tetO), which is placed downstream of the TATA box, binds 59 
 
to the tetracycline repressor (TetR) and represses shRNA expression. In the presence of 
deoxycycline, TetR no longer binds to tetO and expression of shRNA is initiated. However, 
insertion of the  tetO sequence into the pol lll promoter results in weak expression of 
shRNA  in  the  presence  of  deoxycycline,  and  this  system  does  not  guarantee  complete 
repression of shRNA expression in the absence of the drug. To overcome these limitations, 
TetR has been fused to the Krüppel-associated box (KRAB) domain that is found in many 
zinc finger proteins and can silence promoters within 3kb of its binding site by inducing 
heterochromatin formation. This system, in which the tetO sequence was placed upstream 
of  the  H1  promoter,  has  allowed  silencing  of  target  genes  with  high  efficiency  in  the 
presence of deoxycycline and suppression of shRNA expression in the presence of TetR-
KRAB  without  any  significant  leakiness  (Wiznerowicz  &  Trono,  2003).  Conditional 
expression of artificial miRNA has also been achieved using a tetO-CMV pol II promoter 
(Dickins et al., 2005). Irreversible inducible expression of shRNA has been demonstrated 
using Cre-mediated recombination. The U6-shRNA cassette has been inserted between two 
LoxP sequences. Following Cre-mediated recombination, the shRNA expression cassette is 
excised  resulting  in  termination  of  knockdown.  Alternatively,  the  TATA  box  of  the  U6 
promoter has been replaced with a mutated LoxP-TATA site. The second LoxP-TATA site 
was inserted upstream of the shRNA. A sequence was inserted between the two LoxP sites 
to prevent transcription of shRNA. Following Cre-recombination, the inhibitory sequence is 
excised and the functional TATA box is restored (Tiscornia et al., 2004, Ventura et al., 
2004). 
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Off-target effects have not been reported in systematic studies using shRNA or artificial 
miRNA.  This  is  most  likely  due  to  shRNAs/miRNAs  being  dependent  on  endogenous 
processing by Drosha and Dicer, which are rate limiting steps in the generation of siRNAs 
and  may  therefore  limit  the  concentration-dependent  off-target  effects  observed  with 
synthetic siRNAs. However, expression of shRNA has been shown to cause retraction of 
synapses and dendritic  spines  in primary hippocampal neurons by triggering the innate 
immune response (Alvarez et al., 2006) and early embryonic lethality in zygotes that was 
associated  with  increased  expression  of  the  Oas1  interferon-induced  gene  (Cao  et  al., 
2005).  Moreover,  specific  sequences  capable  of  inducing  an  IFN  response  have  been 
identified around the transcription start site in pol III driven shRNA expression systems 
(Pebernard & Iggo, 2004). Induction of the INF response gene Oas1 in primary cortical 
cultures by expression of shRNA was abolished by the introduction of the target sequence 
into  a  miR-30  backbone  (Bauer  et  al.,  2008).  Moreover,  neurotoxicity  in  the  mouse 
striatum  caused  by  expression  of  shRNAs  was  significantly  attenuated  when  these 
sequences were inserted in miR-30-based vectors (McBride et al., 2008). This is most likely 
due to endogenous miRNAs having evolved to preclude the induction of dsRNA-triggered 
cellular  immune  response.  Furthermore,  high  levels  of  shRNA  expression,  commonly 
achieved  with  pol  III  promoters,  can  lead  to  competition  with  endogenous  miRNAs  for 
limiting  cellular  factors,  such  as  Exportin  5,  Dicer  and  RISC  (Castanotto  et  al.,  2007, 
Hutvágner, 2004, Yi et al., 2005). This can result in oversaturation of the endogenous 
miRNA pathway, which has been shown to cause lethality in animals (Grimm et al., 2006). 
Selection of potent shRNA sequences capable of effective silencing even when expressed 
at low levels and the use of promoters that mediate moderate levels of shRNA expression 
are an effective strategy to minimise toxicity. Unlike siRNAs and shRNAs, miRNAs, which 
are  expressed  in  moderate  levels  and  processed  more  efficiently  than  shRNAs,  do  not 
compete with the endogenous miRNA pathway and thus, have improved safety profiles 
(Boudreau et al., 2008a, Castanotto et al., 2007).   62 
 
Hydrodynamic delivery of shRNA-expressing plasmids was shown to inhibit hepatitis C 
viral replication in  the liver of mice  (McCaffrey et al.,  2002,  McCaffrey et al.,  2003). 
Moreover, transfection of a plasmid vector expressing shRNA into embryonic stem cells, 
followed by injection into blastocysts, has been used to generate transgenic mice (Kunath 
et  al.,  2003).  However,  non-viral  delivery  of  shRNA  or  artificial  miRNA  remains  highly 
inefficient  for  many  in  vitro  and  most  in  vivo  applications.  Viral  vectors  allow  highly 
efficient delivery of shRNA/miRNA to a wide range of mitotic and post-mitotic cells of 
different species origin, allow targeted delivery to specific cell types in vivo, and are 
versatile, as they allow transient transfection, stable integration, germline transmission 
and the creation of in vivo animal models. Delivery of shRNA/miRNA has been achieved 
using vectors based on adenovirus, adeno-associated virus, retrovirus/lentivirus and more 
recently, herpes simplex virus, which are discussed in detail in section 1.2 and 1.3.  
 
1.1.6.3 Other nucleic acid-based gene silencing approaches 
Interest in RNAi has rapidly overtaken interest in other nucleotide-based strategies for 
gene silencing, including those using antisense oligonucleotides and ribozymes. Antisense 
oligonucleotides are generally 20nt long and hybridize to pre-mRNA and mRNA to produce 
a substrate for ribonuclease H (RNase H), which specifically degrades the RNA strand of 
the RNA–DNA duplex. When modified in a way to prevent the action of RNase H, antisense 
oligonucleotides can inhibit translation of mRNA via steric hindrance, or splicing of pre-
mRNAs (Kurreck, 2003). Ribozymes degrade target RNA by catalysing the hydrolysis of the 
phosphodiester backbone (Doudna & Cech, 2002). The hammerhead ribozyme, which is 
most commonly used, forms a unique secondary structure when hybridized to its target 
mRNA, as its catalytic region is flanked by sequences complementary to the target RNA 
sequences that flank the cleavage site.   
Although  a  direct  comparison  between  antisense  oligonucleotides  and  siRNAs  is 
difficult owing to their different mechanisms of action, numerous studies have concluded 63 
 
that siRNAs are more potent than various types of antisense oligonucleotides (Bertrand et 
al., 2002, Grunweller et al., 2003, Kretschmer-Kazemi Far & Sczakiel, 2003, Miyagishi et 
al.,  2003).  It  has  been  estimated  that  antisense  suppression  of  gene  expression  is 
approximatelly  100–1000-fold  less  effective  than  suppression  by  siRNAs.  Moreover, 
antisense oligonucleotides can only be applied to downregulate the expression of certain 
genes. Although a systematic comparison of the gene silencing efficacy of ribozymes and 
siRNAs has not been performed, several experiments have indicated that siRNAs are also 
more effective than ribozymes (Yokota et al., 2004). 
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1.2 VIRAL VECTORS FOR DELIVERY OF RNAi 
The use of viral vectors to deliver genes and RNAi to the nervous system shows great 
promise for both basic research and therapeutic applications. Although many viral vectors 
are  in  common  use  for  mainly  pre-clinical  studies,  it  is  important  to  select  the  most 
suitable  vector  for  each  specific  application.  A  number  of  factors  must  be  considered 
when making this decision including the route of delivery, tropism, the duration of gene 
expression or silencing required, and the level of toxicity that can be tolerated.  
 
1.2.1 Adenoviral vectors 
Adenovirus (Ad) is a large (36kb), non-enveloped, double-stranded DNA virus that causes 
endemic and epidemic respiratory and intestinal infections in humans. Ad binds to the 
coxsackie adenovirus receptor and integrins on the plasma membrane and enters the cell 
by  receptor-mediated  endocytosis.  Upon  acidification  of  the  endosome,  the  viral 
nucleocapsid is released into the cytoplasm and the linear DNA enters the nucleus through 
the nuclear pore, where it remains in an episomal form. Gene expression proceeds in a 
cascade fashion, with activation of early genes (E1-E4) followed by the onset of viral DNA 
replication and subsequently expression of late genes (L1-L5), leading to the production of 
infectious viral particles. 
Recombinant  adenoviruses  infect  a  broad  range  of  cell  types,  including  neurons. 
Moreover, Ad vectors based on serotype 5 undergo retrograde transport from the nerve 
terminals  of  neurons  to  cell  bodies  in  vivo.  Deletion  of  essential  E  genes  leads  to 
replication-defective viruses, which can be propagated to high titres in producer cell lines 
that  complement  the  deleted  gene  products  in  trans.  First-generation  replication-
defective Ad vectors were constructed by deletion of the E1α and E1β genes and deletions 
of varying sizes in the non-essential E3 region to allow the cloning of larger transgene 
expression cassettes (Akli et al., 1993, Bajocchi et al., 1993). These vectors have proven 
to  have  limited  use  in  gene  therapy  applications  due  to  cytopathic  effects  at  high 65 
 
multiplicities of infection (MOIs), which have been related to the expression of cellular 
transactivators with E1-like activity and a strong host immune response to viral antigens 
(Byrnes et al., 1996, Yang et al., 1994a). Deletion of E2α/β in second-generation vectors 
and E4 in third-generation vectors resulted in decreased expression of viral proteins and a 
lower level of inflammatory response (Gao et al., 1996, Yang et al., 1994b). Retention of 
E3 also decreased vector antigenicity (Lee et al., 1995). Gutless Ad vectors, in which all 
Ad genomic  sequences have been deleted except for the non-coding inverted terminal 
repeats  and  packaging  signal,  have  an  increased  transgene  capacity  (up  to  30kb), 
diminished immune activation and the ability to confer long-term gene expression in vivo 
(Kumar-Singh & Farber, 1998, Thomas et al., 2000). Moreover, the use of a cre-lox-based 
recombinase  system  allows  propagation  of  Ad  vectors  to  very  high  titres  (up  to  10
13 
infectious units per ml) without the need for a contaminating helper Ad virus (Hardy et 
al.,  1997).  Although  Ad  vectors  have  distinctive  advantages  for  efficient  delivery  to 
neurons both in vivo and in vitro, the high antigenicity of the virion and toxicity of the 
virion penton protein remain the most significant limitations for their use in long-term 
applications. 
 
1.2.2 Adeno-associated viral vectors  
Adeno-associated virus (AAV) is a naturally defective, small (4.7kb), single-stranded DNA 
virus that is known to be non-pathogenic in humans. Upon entry into the cell and release 
of the viral genome into the nucleus, AAV is propagated either by lytic infection in the 
presence of co-infecting Ad, or as a provirus by integration into the host genome. The 
linear AAV genome contains two open reading frames flanked by inverted terminal repeats 
(ITRs), which contain the minimal required cis-acting elements for AAV DNA replication, 
packaging, integration and rescue. In natural AAV infections, the virus encodes a set of 
replication (Rep) proteins that mediate replication of the viral DNA and facilitate site-
specific integration into chromosome 19 of the host genome.  66 
 
AAV infects both dividing and non-dividing cells, including neurons. Moreover, AAV-
based vectors, in which all viral sequences are deleted except for the ITRs, are non-toxic, 
do  not  integrate  into  the  host  genome  and  facilitate  long-term  transgene  expression 
(Hernandez  et  al.,  1999,  McCown  et  al.,  1996).  The combination  of  the  ITRs  and  Rep 
proteins  is  particularly  attractive,  as  it  allows  efficient,  site-specific  integration  of 
inserted  sequences  (Balague  et  al.,  1997).  The  main  limitations  of  recombinant  AAV 
vectors are their small transgene capacity (4.5kb), which is not a critical limitation for 
RNAi, but may prevent expression of a biologically active protein together with shRNA, and 
the difficulty in propagating them to high titres. The replication and packaging of AAV-
based  vectors  previously  required  the  use  of  Ad  helper  virus,  which  was  later  heat-
inactivated or separated by density gradient centrifugation (Ferrari et al., 1996). Ad-free 
methods for producing high titre AAV stocks and new strategies for purification of AAV-
based vectors have been described (Grimm et al., 1998, Xiao et al., 1998). 
 
1.2.3 Retroviral & lentiviral vectors 
Retroviruses and lentiviruses are enveloped RNA viruses. Following entry into the cell, the 
viral RNA is reverse transcribed into linear double-stranded DNA and transported to the 
nucleus,  where  it  becomes  integrated  into  the  host  genome.  In  retroviral/lentiviral 
vectors, essential viral genes are replaced by the gene of interest, which is flanked by the 
virus  long  terminal  repeats  (LTR)  and  packaging  signal.  Vector  production  utilises 
packaging  cell  lines  that  express  the  deleted  viral  genes  from  separate  plasmids  to 
minimise the possibility of generating replication-competent virus through recombination. 
Retroviral  vectors  derived  from  Moloney  murine  leukemia  virus  (MoMLV)  have  limited 
applications as delivery vectors to the nervous system, due to their inability to deliver 
genes  to  non-dividing  cells  and  thus,  post-mitotic  neurons.  They  have,  however,  been 
extensively used for ex vivo transplantation strategies and delivery to neural precursors 67 
 
and tumour cells, due to their high efficiency of transduction and long-term expression 
following stable integration in the host cell genome.  
Lentiviral  (LV)  vectors,  which  are  most  commonly  based  on  the  human  immuno-
deficiency virus 1 (HIV-1), have a modest packaging capacity (8kb) and induce a minimal 
inflammatory response when introduced into the brain (Blomer et al., 1997, Brooks et al., 
2002). The main advantage of LV vectors is their ability to produce long-term transgene 
expression  by  integration  into  the  genome  of  both  dividing  and  non-dividing  cells, 
including neurons. Nevertheless, the consequence of stable delivery offered by LV vectors 
is the risk of insertional mutagenesis by activation of cellular proto-oncogenes. The risk of 
oncogenic transformation is less of a concern for neurons, but more for glial cells, which 
retain  a  mitotic  competence.  An  important  gain  in  viral  safety  could  be  achieved  by 
directing integration to specific target sites through the use of viral integrase fused with a 
sequence-specific  DNA-binding  protein  (Tan  et  al.,  2004b),  or  through  the  use  of 
integration-defective LV vectors (Saenz et al., 2004). The complex genome and replication 
cycle of lentiviruses have made the development of vectors and stable packaging cell lines 
difficult. Moreover, the restricted host range, low titres and pathogenic characteristics of 
HIV-1 have limited its use. Significant progress has, however, been made in generating 
safe and versatile vectors. HIV-based vectors pseudotyped with the vesicular stromatitus 
virus envelope G glycoprotein (VSV-G) show broad tropism. In addition, a three-plasmid 
expression system is used to minimize the possibility of generating replication-competent 
virus through recombination. This consists of a HIV-1 packaging plasmid, a vector plasmid 
containing viral integrase and promoter-driven transgenes and a plasmid expressing the 
surface VSV-G glycoprotein (Naldini et al., 1996).  
Most  LV  vectors  incorporate  the  shRNA  cassette  between  the  two  LTRs  and  also 
contain a pol II reporter or drug resistance gene cassette. However, LV vectors have also 
been developed by introducing the cassette into the 3’LTR of the viral genome, in which 
case  following  transcription  and  genomic  integration,  the  proviral  form  contains  two 68 
 
sources  of  shRNA  (Mangeot  et  al.,  2004,  Tiscornia  et  al.,  2003).  Knockdown  mice 
expressing a shRNA transgene in selected tissues or in all tissues can be generated in a few 
months  by  transducing  embryonic  stem  cells  or  embryos  with  shRNA  expressing  LV 
(Brummelkamp  et  al.,  2002,  Rubinson  et  al.,  2003).  This  compares  with  several  years 
often needed to generate knockout mice. The use of inducible promoters allows for the 
controlled  expression  of  shRNA  in  response  to  an  inducer,  such  as  tetracycline 
(Wiznerowicz & Trono, 2003), and mice with graded degrees of gene knockdown can be 
produced to study subtle effects of gene expression (Hemann et al., 2003). Furthermore, 
genome-wide libraries of retroviruses or LV
 expressing shRNA or artificial miRNA designed 
to target the complete human and mouse genomes have been generated to enable large 
scale  RNAi  screens  (Berns  et  al.,  2004,  Paddison  et  al.,  2004).  These  libraries  have 
provided mammalian
 biologists for the first time with a genetic screening tool
 similar to 
that which has been used in more primitive organisms. Finally, a Phase I clinical trial that 
uses autologous bone marrow transplantation to treat AIDS-related lymphomas utilises a 
pol III promoter-shRNA cassette targeting the HIV tat and rev shared exons. The shRNA has 
been incorporated into an HIV-based LV vector, which in turn has been used to insert the 
shRNA  along  with  two  other  RNA-based  anti-HIV  genes  into  blood  stem  cells  that  are 
subsequently infused into HIV-positive patients. 
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1.3 HERPES SIMPLEX VIRUS  
Herpes simplex virus (HSV) has many unique features that support its development as a 
vector for the delivery of genes and RNAi to the nervous system. It is a highly infectious, 
naturally neurotrophic virus that is able to establish life-long latency in neurons following 
retrograde transport to the cell bodies. The HSV genome can be easily manipulated, has a 
high capacity to accept foreign DNA and does not integrate into the host chromosome, 
thus eliminating the possibility of insertional activation or inactivation of cellular genes. 
Whilst these aspects of the virus biology have been viewed as promising for some time, 
two main issues were required to be resolved for long-term application; these were the 
development of a vector genome which was safe and non-toxic and the development of 
promoters which were able to achieve long-term expression during latency. The biology of 
HSV-1 and the progress being made in the generation of vectors to solve these problems 
for neuronal gene delivery are discussed in the following sections.  
 
1.3.1 The biology of HSV-1 
HSV-1 is a member of the alphaherpesvirus subfamily and one of the most common human 
pathogens, infecting 40-80% of the adult population worldwide. HSV types 1 and 2 cause 
cold  sores  and  genital  herpes,  respectively.  Recurrent  HSV-1  infection  in  the  eye  can 
result in corneal scarring and is one of the most common infectious causes of blindness in 
the  developed  world.  Very  rarely  (approximately  1-2  cases  per  million  per  year)  and 
primarily  in  immunocompromised  individuals,  HSV  can  spread  to  the  central  nervous 
system causing viral encephalitis.  
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1.3.1.1 Structure of the virion  
The  mature  HSV-1  virion  consists  of  a  DNA  core  contained  in  an  icosahedral  capsid 
surrounded by a matrix of proteins, referred to as the tegument, and a trilaminar lipid 
envelope, in which are embedded at least 10 virally encoded glycoproteins (figure 1.10a). 
The envelope glycoproteins are involved in various aspects of the virus life cycle including 
attachment and entry, cell-to-cell spread, and immune evasion. The tegument proteins 
are responsible for initiating viral gene expression and for shutdown of host cell protein 
synthesis, and assist in virion maturation and egress.  
  
1.3.1.2 The HSV-1 genome 
The large HSV-1 genome consists of 152kb of linear double-stranded DNA (dsDNA) arranged 
as a unique long (UL) and a unique short (US) region, each flanked by a pair of inverted 
repeats  (IR)  (figure  1.10b).  Approximately  half  of  the  84  viral  genes  expressed  are 
essential  for  viral  replication  in  vitro.  The  non-essential  genes,  which  are  involved  in 
functions  important  for  virus-host  interactions  in  vivo,  such  as  immune  evasion  and 
shutdown of host protein synthesis, can be deleted in the generation of vectors allowing 
insertion of large or multiple transgenes (approximately 30kb).  
 
1.3.1.3 HSV-1 life cycle 
The life cycle of HSV-1 in vivo begins in epithelial cells of the skin or mucous membrane. 
During primary infection, progeny virions enter sensory nerve terminals innervating the 
infection  site,  and  the  nucleocapsid  and  tegument  proteins  undergo  retrograde  axonal 
transport to the cell bodies in the sensory ganglia, where the viral genomes are retained in 
a latent state. Periodic reactivation from latency can occur spontaneously or in response 
to  a  variety  of  stimuli,  including  physical  and  emotional  stress,  hyperthermia,  and  UV 
irradiation (Sawtell & Thompson, 1992, Wagner et al., 1975) and results in the production 72 
 
of progeny virions that are anterogradely transported back to the nerve terminals (figure 
1.11).  
 
1.3.1.4 Viral attachment & entry    
Entry of HSV-1 is a complex process involving several envelope glycoproteins and a number 
of different cellular receptors, and can be divided into two distinct phases: Attachment of 
the viral particle to the cell surface and entry of the nucleocapsid into the cell cytoplasm. 
Figure 1.12 summarises these processes.   
Initial attachment of the viral particle to the host cell surface is mediated through 
binding of the envelope glycoproteins gC (Tal-Singer et al., 1995) and/or gB (Herold et al., 
1994) to cell surface glycosaminoglycans, primarily heparan sulphate (Shieh et al., 1992, 
WuDunn & Spear, 1989). These interactions significantly enhance infection efficiency, but 
are  neither  essential  for  infection,  at  least  in  culture,  nor  sufficient  for  viral  entry. 
Deletion of gC reduces infection efficiency as much as 10-fold depending on HSV serotype 
and possibly on HSV strain and cell type (Cheshenko & Herold, 2002, Herold et al., 1991). 
Deletion of both gB and gC severely reduces binding efficiency (Herold et al., 1994) and 
abolishes infectivity partially due to the role of gB in viral entry, as discussed below. Cells 
deficient in heparan sulphate demonstrate significantly reduced susceptibility to HSV-1 
infection, unless entry receptors are also absent, in which case susceptibility is abolished 
(Banfield  et  al.,  1995,  Gruenheid  et  al.,  1993,  Shieh  et  al.,  1992).  In  the  absence  of 
heparan sulphate, chondroitin sulphate may assist in viral attachment to the cell surface 
(Gruenheid et al., 1993, Mardberg et al., 2002). 
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Binding  of  the  virus  to  the  cell  surface  is  followed  by  attachment  of  the  envelope 
glycoprotein gD to an entry receptor. A number of such receptors have been identified 
including  the  herpes  virus  entry  mediator  A  (HveA)  and  nectin-1  (HveC),  which  are 
members of the TNFα p75 receptor family (Montgomery et al., 1996) and immunoglobulin 
superfamily  (Geraghty  et  al.,  1998),  respectively.  These  molecules  are  expressed  in  a 
variety of tissues and cell types, and account for the broad host range of the virus. HveC is 
expressed in epithelial cells and nearly all neurons in the peripheral and central nervous 
system (Haarr et al., 2001). In the absence of any other entry receptors, resistant cells 
expressing heparan sulphate can be rendered susceptible to HSV-1 by expression of 3-O-
sulphotransferases, which generate sites in heparan sulphate that can serve as receptors 
for gD (Shukla et al., 1999).  
Entry into the cell is mediated through pH-independent fusion of the viral envelope 
with the plasma membrane. At least four glycoproteins (gB, gD, gH and gL) are required 
for penetration (Cai et al., 1988, Fuller & Spear, 1985, Roop et al., 1993). Glycoprotein gL 
has been shown to form a heterodimer with gH (Hutchinson et al., 1992, Peng et al., 
1998). A lipid-raft-associated receptor has been proposed to interact with gB (Bender et 
al., 2005, Bender et al., 2003), and integrin αVβ3 has been shown to bind directly to gH-gL 
heterodimers  (Parry  et  al.,  2005).  Although  the  exact  mechanism  remains  to  be 
elucidated,  it  has  been  suggested  that  interaction  of  gD  with  cell  surface  receptors 
triggers the fusion machinery, and an activation signal is transmitted to gB and  gH-gL 
resulting in conformational changes in these proteins that lead to membrane fusion (Fuller 
& Lee, 1992). Fusion at the plasma membrane is observed in the majority of cell types 
including sensory neurons. Recent studies, however, have demonstrated that HSV entry 
into  cultured  cells  can  also  proceed  via  pH-independent  or  pH-dependent  endocytosis 
(Milne et al., 2005, Nicola et al., 2005). 
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Following entry into the cell, the nucleocapsid and tegument proteins are released into 
the cytoplasm, where the tegument protein UL41 (vhs) remains and mediates shutdown of 
host cell protein synthesis through degradation of host and viral mRNA (Kwong & Frenkel, 
1989). The nucleocapsid and some tegument proteins are transported to the nuclear pore 
and the genome is released into the nucleoplasm. Transport across the cytoplasm occurs 
in a microtubule-dependent manner. Nucleocapsids are retrogradely transported to the 
nucleus via a mechanism that involves interactions between the tegument protein UL34 
and  cellular  dynein  (Sodeik  et  al.,  1997,  Ye  et  al.,  2000)  and  are  anterogradely 
transported to the nerve terminals via a mechanism that involves interaction of US11 with 
kinesins (Diefenbach et al., 2002).  
 
1.3.1.5 Lytic Infection 
Viral gene expression during lytic infection proceeds in a tightly regulated, interdependent 
cascade, in which three classes of viral genes are temporally expressed: immediate early 
(IE), early (E) and late (L) genes (Honess & Roizman, 1974). Expression of IE genes begins 
shortly after the genome arrives in the nucleus in the absence of de novo viral protein 
synthesis.  This  is  followed  by  expression  of  E  genes,  which  mainly  encode  proteins 
involved  in  viral  DNA  synthesis  and  replication.  Expression  of  L  genes,  which  mainly 
encode structural proteins, follows the onset of DNA replication.  
Expression  of  IE  genes  is  initiated  by  the  tegument  protein  VP16  (also  called 
Vmw65), which is synthesized late in infection. VP16 has a well-characterized acidic C-
terminal  activator  domain  and  activates  transcription  by  binding  to  the  TAATGARAT 
elements present just upstream of the TATA box in all IE gene promoters (Sadowski et al., 
1988). VP16 forms a complex with the host cell factor (HCF) and localizes to the nucleus 
(La Boissière et al., 1999), where it binds to the host transcription factor octamer binding 
protein 1 (Oct-1). The POU domain of Oct-1 binds to the TAAT region, and VP16 binds to 
the GARAT region of the TAATGARAT element (where R is a purine) (figure 1.13). This 77 
 
enables the activator domain of VP16 to interact with the host transcription factor IID 
(TFIID) and assist in the recruitment of the host RNA pol II transcription machinery into the 
close proximity of IE promoters to initiate transcription of IE genes (Gerster & Roeder, 
1988, Klemm et al., 1995, O'Hare et al., 1988). Other studies suggest that VP16 interacts 
with TFIIA (Kobayashi et al., 1995, Kobayashi et al., 1998) or TFIIB (Lin and Green, 19991; 
Choy and Green, 1993) to enhance formation of transcription pre-initiation complexes.  
Whereas the transactivating function of VP16 is not essential for viral replication and 
assembly, certain mutations in VP16 prevent the production of infectious progeny virions, 
indicating  that  VP16  is  required  for  virus  assembly  and  egress  (Ace  et  al.,  1989, 
Weinheimer et al., 1992). Furthermore, there is evidence to suggest that VP16 binds to 
the  vhs  protein  and  downregulates  its  activity  at  intermediate  and  late  times  post-
infection, thereby allowing the maintenance of viral protein synthesis (Lam et al., 1996, 
Mossman et al., 2000). 
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The virus encodes five IE proteins, designated infected cell polypeptides (ICP) 0, 4, 22, 27 
and 47. With the exception of ICP47, these nuclear phosphoproteins are known to regulate 
the coordinated expression of the HSV genome. Only ICP4 and ICP27 are essential for virus 
replication (figure 1.14). 
The RL2 gene encoding ICP0 (Vmw110) is located in the IR sequences flanking the UL 
regions  and  is  therefore  present  in  two  copies  per  genome.  ICP0  is  a  promiscuous 
transactivator of all three classes of viral genes, non-viral genes in transient transfection 
assays (Everett, 1984, O'Hare & Hayward, 1985a), and a subset of cellular genes (Hobbs & 
DeLuca, 1999). ICP4 has been shown to interact with ICP0 to enhance this transactivation 
(Everett,  1984,  Gelman  &  Silverstein,  1985).  ICP0  enhances  viral  gene  expression  and 
growth both in vitro and in vivo (Cai & Schaffer, 1992, Chen & Silverstein, 1992) and thus, 
mutants lacking ICPO are replication competent, but grow very poorly at a low multiplicity 
of infection (Everett, 1989, Sacks & Schaffer, 1987, Stow & Stow, 1986). ICP0 does not 
bind DNA directly, but has been shown to interact with components of the translation 
(translation  elongation  factor  EF-1δ  (Kawaguchi  et  al.,  1997a)),  transcription 
(transcription factor BML1 (Kawaguchi et al., 2001)), cell cycle (cyclin D3  (Kawaguchi et 
al.,  1997b))  and  proteolytic  (ubiquitin-specific  protease  USP7  (Meredith  et  al.,  1995)) 
machinery. Newly synthesized ICP0 initially accumulates at nuclear structures known as 
ND10. ICP0 contains a short sequence similar to the N-terminus of CoREST, a co-repressor 
that forms complexes with the repressor REST and histone deacetylases (HDACs) 1 or 2 to 
repress cellular gene expression. It has been therefore proposed that co-localization
 of the 
virus genome and ICP0 at the ND10
 structures serves to dissociate the HDAC1/2 from the 
CoREST/REST repressor complex,
  thereby blocking silencing of gene  expression, and to 
disrupt ND10
 structures and degrade its components, thereby blocking the IFN-mediated
 
host  response  to  infection  (Gu  et  al.,  2005).  Finally,  ICP0  is  required  for  efficient 
reactivation from latency, which will be discussed in more detail in the following section.  80 
 
ICP4 is a major activator of E and L gene transcription (DeLuca and Schaffer, 1985), 
a repressor of ICP0 and its own transcription (O'Hare & Hayward, 1985b) and consequently 
necessary for the transition from the IE to the E phase of viral gene expression (Dixon & 
Schaffer,  1980).  ICP4  exists  as  a  homodimer  (Metzler  et  al,  1985)  and  possesses  two 
transactivation  regions  and  a  DNA-binding  domain,  which  recognizes  the  degenerate 
RTCGTCNNYNYSG consensus sequence (where R is purine, Y is pyrimidine, S is C or G, and 
N is any base) (DiDonato et al., 1991). While repression is mediated by high-affinity ICP4 
binding sites when specifically positioned (Gu et al., 1995, Kuddus et al., 1995, Michael & 
Roizman, 1993), activation does not require any single site or collection of sites (Gu & 
DeLuca, 1994, Smiley et al., 1992). ICP4 can form tripartite complexes on DNA with TFIIB 
and TFIID (Smith et al., 1993). It has been suggested that the C-terminal region of ICP4 
interacts with TFIID and TBP-associated factors to facilitate the binding of TFIID to the 
TATA box, which in turn facilitates the formation of transcription pre-initiation complexes 
(Carrozza & DeLuca, 1996, Grondin & DeLuca, 2000). 
ICP27  functions  primarily  at  the  post-transcriptional  level,  but  has  also  been 
proposed to have a role in translation initiation (Ellison et al., 2005, Fontaine-Rodriguez et 
al., 2004). ICP27 contributes to shutoff of host cell protein synthesis by inhibiting pre-
mRNA splicing at early stages of infection (Hardy & Sandri-Goldin, 1994). Although the 
exact mechanism has not been fully defined, it has been suggested that ICP27 interacts 
with several splicing factors and affects their phosphorylation, resulting in inhibition of 
spliceosome assembly (Bryant et al., 2001, Sciabica et al., 2003). Later in infection, ICP27 
begins to shuttle between the nucleus and cytoplasm and acts as a chaperone of viral 
mRNA across the nuclear membrane (Mears & Rice, 1998, Soliman et al., 1997). It has 
been suggested that ICP27,  which binds specifically to intronless mRNA  (Sandri-Goldin, 
1998), facilitates export of viral mRNA to the cytoplasm by interacting with the cellular 
adaptor protein Aly/REF and the cellular receptor TAP/NXF (Chen et al., 2005). ICP27 is 
required  for  efficient  DNA  replication  by  promoting  E  gene  expression  and  for  the 81 
 
transition from the E to the L phase of viral gene expression by activating L genes, whilst 
repressing IE and E gene expression (Rice & Lam, 1994, Uprichard & Knipe, 1996). It has 
also been suggested to modulate the activity of ICPO and ICP4, as well as the modification 
state of ICP4 (Sekulovich et al., 1988, Su & Knipe, 1989).  
ICP22 is not essential for growth in most cell types  (Post & Roizman, 1981),  but 
promotes efficient L gene expression in a cell-type specific manner (Sears et al., 1985). 
ICP22 enables optimal expression of a subset of L genes (γ2), which depends on viral DNA 
synthesis for its expression, by mediating the stabilization of cyclin-dependent kinase cdc2 
and  the  replacement  of  its  cellular  partner,  cyclin  B,  with  the  viral  DNA  polymerase 
processivity  factor  UL42  (Advani  et  al.,  2001).  The  cdc2-UL42  complex  recruits  and 
activates  topoisomerase  IIα,  which  is  one  of  the  key  enzymes  required  for  viral  DNA 
synthesis  (Advani  et  al.,  2003).  ICP22  is  also  involved  in  the  production  of  a  novel 
phosphorylated form of RNA polymerase II (Rice et al., 1995) and regulates the stability 
and splicing of ICP0 mRNA (Carter & Roizman, 1996). 
Finally,  ICP47  blocks  the  presentation  of  antigenic  peptides  on  the  surface  of 
infected  cells  to  CD8+  T  cells  (cytotoxic  T  cells)  and  thus,  helps  the  virus  to  escape 
immune  surveillance  (York  et  al.,  1994).  ICP47  binds  to  and  precludes  transporters  of 
antigen processing TAP1/TAP2 from transporting antigenic peptides into the endoplasmic 
reticulum, where they are loaded onto the major histocompatibility complex class I (MHC 
class I) for eventual presentation on the cell surface (Früh et al., 1995, Hill et al., 1995).  
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According  to  the  classical  model  of  HSV-1  replication,  circularization  of  viral  genomes 
occurs before the onset of productive infection and thus, HSV-1 genomes replicate initially 
by a theta mechanism. This model has been recently challenged by Jackson and DeLuca 
(2003),  who have demonstrated that circularization occurs during the establishment of 
latency, rather than early in productive infection. ICP0 inhibits the formation of circular 
genomes suggesting  a  mechanism for the establishment of latency  (Jackson & DeLuca, 
2003).  Viral DNA replication proceeds via a rolling circle mechanism that leads  to  the 
production of HSV-1 genome concatemers (Jacob et al., 1979). These are cleaved into 
genome-length  units  and  packaged  into  the  capsid  through  recognition  of  packaging 
sequences located in the IR. Nucleocapsids acquire tegument proteins and an envelope 
during budding through the inner nuclear membrane. Extracellular virions are produced by 
de-envelopment  at  the  outer  nuclear  membrane  followed  by  budding  into  the  Golgi 
apparatus (Granzow et al., 2001).  
 
1.3.1.6 HSV-1 Latency 
HSV latency is classically defined as the retention of a complete viral genome without the 
production of infectious virions. During latency, the viral genome is maintained in a stable 
episomal  form  and  persists  sometimes  for  the  lifetime  of  the  host  in  the  absence  of 
detectable infection.  
The popular concept that HSV-1 latency is characterized by a complete lack of lytic 
gene  expression  has  been  called  into  question  by  several  recent  studies  that  have 
detected limited expression of ICP4, ICP8 and TK in mouse sensory ganglia (Feldman et 
al., 2002, Kramer & Coen, 1995). It has been therefore suggested that the latent viral 
genome  may  exist  at  different  stages  of  reactivation,  but  the  factors  that  determine 
whether  initiation  of  reactivation  will  lead  to  virion  formation  and  emergence  from 
latency are largely unknown. 84 
 
During latency, whilst most viral gene expression is silenced, a single region within the 
long  repeat  remains  transcriptionally  active  generating  a  population  of  RNA  species 
designated latency-associated transcripts (LATs) (Stevens et al., 1987) (Figure 1.15). The 
8.3kb polyadenylated primary LAT transcribed from this region is spliced to give a non-
polyadenylated 2kb LAT, which can be further spliced to produce smaller LATs (Wechsler 
et al., 1988). The 2kb and 1.5kb LATs are abundant and accumulate in the nucleus as 
stable lariat introns  (Farrell et al.,  1991).  LAT expression is driven by two promoters, 
referred to as latency active promoters 1 (LAP1) and 2 (LAP2).  LAP1  is located 660bp 
upstream of the 2kb LAT and contains a TATA box (Zwaagstra et al., 1991). Although LAP1 
is active in most cell types, it shows enhanced activity in neurons (Batchelor & O'Hare, 
1992, Zwaagstra et al., 1990), and activating transcription factor (ATF)/ cAMP response 
element (CRE) sites have been suggested to play a role in conferring neuronal specificity 
(Kenny et al., 1994). LAP2 lies directly 3’ to LAP1 and 257-58bp upstream of the 2kb LAT, 
and lacks a TATA box, but is a GC-rich promoter homologous to mammalian housekeeping 
gene  promoters  (Goins  et  al.,  1994).  Deletion  analysis  suggests  that  LAP1  is  primarily 
responsible for LAT expression during latency, whereas LAP2 is primarily responsible for 
LAT expression during lytic infection (Chen et al., 1995). Although both promoters may be 
able to function independently, there is evidence to suggest that LAP2 contains elements 
required to drive long-term expression from LAP1 during latency (Lokensgard et al., 1997).  
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Although the functions of the LATs remain largely unknown, it is clear that they are not 
essential for the establishment and maintenance of latency, or reactivation from latency 
(Ho & Mocarski, 1989, Javier et al., 1988). Evidence suggests, however, that the LATs 
regulate the efficiency of each of these processes by aiding the prevention of apoptosis in 
infected  neurons,  regulating  IE  gene  expression  by  an  antisense  mechanism,  and  by 
encoding  a  protein  which  may  be  important  in  the  initiation  of  the  reactivation  from 
latency. A key problem for studies in each of these areas is the paucity of available animal 
models, none of which truly reflects the situation in humans. Thus, caution needs to be 
applied to the conclusions derived from any in vivo results, which are so far all generated 
in mice and rabbits. 
Several  studies  of  LAT-null  mutants  suggest  that  LATs  are  required  for  efficient 
reactivation  from  latency  (Bloom  et  al.,  1996,  Hill  et  al.,  1996,  Perng  et  al.,  1994, 
Trousdale et al., 1991). The region associated with decreased reactivation in these animal 
models has been mapped to a 385bp sequence in the 5’end of the 8.5kb LAT (Bloom et al., 
1996, Hill et al., 1996). Thompson and Sawtell, however, demonstrated that LATs increase 
the  percentage  of  neurons  in  which  latency  is  established  in  mice,  thereby  increasing 
reactivation by increasing the pool of latently infected neurons available for reactivation, 
while no direct role in reactivation could be demonstrated (Thompson & Sawtell, 1997). 
Thus,  LATs  may  function  directly  to  promote  reactivation  and/or  enhance  the 
establishment of latency. 
Since the primary LAT is transcribed antisense and complementary to ICP0, it has 
been  suggested  that  LATs  may  aid  the  establishment  and  maintenance  of  latency  by 
suppressing expression of ICP0. The 2kb LAT has been shown to inhibit transactivation of 
gene  expression  by  ICP0  in  transient  transfection  assays  (Farrell  et  al.,  1991),  and 
elevated levels of ICP0 mRNA were observed in cultures infected with mutants unable to 
produce 2kb LAT (Arthur et al., 1998). Furthermore, LATs have been shown to suppress 
viral replication in a neuronal cell line by reducing the mRNA levels of ICP0 and to a 87 
 
smaller  extent,  ICP4  and  ICP27  mRNA  levels,  possibly  due  to  reduced  ICP0  expression 
(Mador  et  al.,  1998).  Nevertheless,  the  1.5kb  region  required  for  wild  type  levels  of 
reactivation in rabbits does not overlap ICP0 (Perng et al., 1996), and insertion of poly(A) 
at various sites within the 3’end of LAT, which terminates transcription, has no effect on 
reactivation (Bloom et al., 1996). Thus, LATs appear to enhance reactivation, at least in 
the rabbit, by a mechanism that does not involve antisense regulation of ICP0.  
Evidence  from  studies  performed  in  our  laboratory  suggests  that  the  LAT  region 
encodes a protein product (Thomas et al., 1999a, Thomas et al., 2002). A large 2kb LAT-
contained  ORF,  which  is  conserved  between  different  strains  of  HSV-1,  was  shown  to 
encode a protein that can profoundly enhance wild-type virus growth and compensate for 
deficiencies in ICP0 expression when expressed in vitro. Thus, whilst LAT expression may 
function to provide an antisense
 effect to ICP0 during the establishment
 and maintenance 
of latency, during reactivation and in response to as yet unidentified stimuli, translation
 of 
the LAT ORF may become possible, thereby relieving the ICP0 antisense effect
 of the LATs 
during latency and aiding the reactivation process. 
Several studies have concluded that LAT repress ICP4 expression (Chen et al., 1997, 
Garber et al., 1997, Mador et al., 1998) and inhibit apoptosis (Branco & Fraser, 2005, Jin 
et al., 2003, Perng et al., 2000). It has been suggested that the LATs may function as non-
coding RNAs, as recent studies predict that HSV-1 encodes eight miRNAs, three of which 
are located in the 8.3kb LAT region (Pfeffer et al., 2004), and one miRNA is transcribed 
approximately 450bp upstream of the LAT transcription start site (Cui et al., 2006). A 
miRNA  encoded  from  exon  1  of  the  LAT  gene  was  reported  to  accumulate  in 
neuroblastoma  and  non-neuronal  cells  transfected  with  LAT  or  infected  with  wild-type 
HSV-1  (Gupta  et  al.,  2006).  The  authors  suggested  that  this  miRNA  (miR-LAT)  inhibits 
apoptosis by downregulation of transforming factor β 1 (TGFβ1). However, although it is 
clear  that  HSV-1  downregulates  TGFβ1,  the  study  by  Cupta  et  al.  was  retracted  from 
Nature  in  2008  (Gupta  et  al.,  2008),  as  further  experiments  from  several  other 88 
 
laboratories  failed  to  detect  miR-LAT,  but  detected  a  neuroblastoma  encoded  miRNA 
instead.  Finally,  two  small  RNAs  within  the  first  1.5kb  of  LAT  have  been  recently 
detected, and although they are not mature miRNAs, they have the potential to base pare 
with  ICP4  mRNA  and  may  play  role  in  latency  reactivation  by  inhibiting  apoptosis  or 
reducing ICP4 expression (Peng et al., 2008). It has to be noted  that no HSV-encoded 
miRNA has as yet been shown to be expressed during latency.  
When
 human fibroblasts are infected with mutants defective in IE gene expression, 
the majority
 of viral genomes are
 retained in a quiescent state that resembles latency 
(Preston et al., 1997, Samaniego et al., 1998). Furthermore, VP16 mutants (in814) that 
are unable to form a complex with HCF-1 and Oct-1 establish latency in mice as efficiently 
as wild-type virus (Ace et al., 1989, Steiner et al., 1990, Valyi-Nagy et al., 1991). These 
finding have lead to the hypothesis that the block to replication occurs before or at the 
level of IE gene expression and that establishment of latency in neurons may be caused by 
the absence of functional VP16-induced complex. Roizman and colleagues suggested that 
VP16 may not be capable of translocation to the cell body of sensory neurons. Expression 
of VP16 in neurons, however, failed to affect the ability of the virus to establish latency 
(Sears et al., 1991). It has also been hypothesized that splice variants of Oct-2, which are 
unable to interact with VP16, repress IE gene expression by binding to TAATGARAT sites 
and blocking Oct-1 binding (Kemp et al.,  1990,  Lillycrop et al.,  1991). Another study, 
however, failed to detect Oct-2 in sensory neurons, and overexpression of Oct-2 failed to 
suppress  activation  of  an  IE  gene  promoter  (Hagmann  et  al.,  1995).  It  has  also  been 
suggested that Oct-1 may not be expressed in sensory neurons (Valyi-Nagy et al., 1991). 
However, it was later demonstrated that Oct-1 is present at low levels (Hagmann et al., 
1995). Finally, it has been shown that HCF-1, which is localized to the nucleus in most cell 
types,  accumulates  in  the  cytoplasm  of  sensory  neurons  (Kristie  et  al.,  1999)  and 
consequently, although VP16 translocates to the cell body, it may fail to localize to the 
nucleus.   89 
 
Other  proposed  contributors  to  the  establishment  of  latency  are  the  partially 
overlapping ORF O and ORF P, which are located in the 3’end of the primary LAT, almost 
entirely antisense to ICP34.5. The transcription initiation site for both ORFs resides within 
a  high-affinity  ICP4  binding  site.  Hence,  they  are  only  expressed  in  the  absence  of 
functional ICP4 and their expression is completely repressed during productive infection 
(Lagunoff  &  Roizman,  1994,  Lagunoff  &  Roizman,  1995,  Randall  et  al.,  1997). 
Furthermore, ORF O and P interfere with the expression of multiple IE genes required for 
lytic  gene  expression  and  thus,  appear  to  be  ideal  candidates  for  the  regulation  of 
latency.  ORF  P  has  been  shown  to  inhibit  expression  of  ICP0  and  ICP22  by  binding  to 
splicing factors and interfering with mRNA splicing,  and its transcription precludes the 
expression  of  ICP34.5  resulting  in  an  attenuated  phenotype  (Bruni  &  Roizman,  1996, 
Randall & Roizman, 1997). ORF O interacts specifically with ICP4 and interferes in vitro 
with  the  binding  of  ICP4  to  its  cognate  site  (Randall  et  al.,  1997).  Nevertheless,  a 
recombinant virus expressing a truncated ORF P and mutated ORF O has been shown to 
reactivate from latency with similar efficiency to wild type virus (Lee & Schaffer, 1998). 
Moreover,  another  study,  in  which  the  start  codon  of  both  ORFs  was  replaced,  has 
concluded that their expression is not essential for the establishment of latency (Randall 
et al., 2000). It is however possible that ORF O and P play a role in the maintenance of 
latency, but such a role remains to be established. 
Several studies have demonstrated that ICP0 is required for reactivation in latently 
infected human fibroblasts (Harris et al., 1989, Hobbs et al., 2001, Thompson & Sawtell, 
2006). Investigation of latency in the mouse, however, has revealed that ICP0-null mutants 
reactivate less efficiently than wild-type virus, indicating that ICP0 has an important role 
in reactivation, but is not essential for reactivation (Halford & Schaffer, 2001, Thompson 
& Sawtell, 2006). As discussed above, the work of Thomas et al (1999, 2002) suggests that 
a protein encoded by the 2kb LAT may substitute for ICP0 at this time. It has also been 
suggested that although ICP0 is not required for the initiation of reactivation in vivo after 90 
 
hypothermic treatment of mice, has an important role for later events in virus replication 
(Thompson & Sawtell, 2006). Furthermore, studies in latently infected trigeminal ganglion 
(TG) cell cultures and PC12 cells have demonstrated that expression of ICP0, ICP4 or VP16 
is sufficient to induce reactivation, indicating that reactivation in neuronal cells can be 
induced in the absence of ICP0 (Halford et al., 2001, Miller et al., 2006). While VP16 is 
sufficient to induce reactivation in neuronal cells, it is unlikely that it contributes to the 
initiation of reactivation in vivo, since it is a L gene and its expression is dependent on IE 
and E gene expression. Moreover, VP16 is not necessary for efficient reactivation from TG 
explants (Steiner et al., 1990). Collectively, the above findings suggest that IE genes play 
an  important  role  in  reactivation  and  thus,  suppression  of  IE  gene  expression  may  be 
essential for the maintenance of latency.   
Recent  studies  suggest  that  regulation  of  the  chromatin  structure  on  viral  DNA 
determines whether HSV-1 enters latency or lytic infection (figure 1.16). Viral DNA is not 
associated with histones (Oh & Fraser, 2008) and upon arrival to the nucleus, host cell 
mechanisms attempt to silence viral gene expression by assembling chromatin. As latency 
is  established,  the  LAT  promoter  and  enhancer  are  associated  with  euchromatin  and 
therefore exist in a transcriptionally permissive state (Kubat et al., 2004), whereas lytic 
genes  are  progressively  associated  with  heterochromatin  and  therefore  exist  in  a 
transcriptionally non-permissive state (Wang et al., 2005). Insulator elements that contain 
CCCTC sites bound by the CCCTC-binding factor have been identified upstream of the LAT 
promoter and in the LAT introns, and they are suggested to keep euchromatin activity 
within the LAT region (Amelio et al., 2006b). Moreover, expression of LAT has been shown 
to promote heterochromatin and reduce euchromatin formation on lytic gene promoters 
by a mechanism that is yet to be defined (Wang et al., 2005). Upon reactivation, the 
histones associated with LAT become deacetylated and lytic genes become associated with 
acetylated histones (Amelio et al., 2006a). It has been hypothesized that in epithelial and 
other non-neuronal cells, VP16 promotes euchromatin formation on IE gene promoters. 91 
 
Expression of ICP0 and ICP8 has also been suggested to promote euchromatin formation on 
lytic  gene  promoters,  thereby  further  promoting  lytic  gene  expression  (Herrera  & 
Triezenberg,  2004,  Kent  et  al.,  2004).  The  mechanism  by  which  these  gene  products 
affect chromatin structure on the viral genome is not entirely understood.   
Finally, several studies have suggested a role for host immunity in suppressing viral 
gene expression in latently infected neurons. Leukocytes, including CD4+ and CD8+ T cells, 
infiltrate  the  TG  during  primary  infection  and  remain  for  prolonged  periods  of  time 
following the establishment of latency (Cantin et al., 1995, Liu et al., 2000). Moreover, 
the tightly regulated production of cytokines, such as gamma interferon (INF-γ), tumour 
necrosis  factor  alpha  (TNF-α)  and  interleukin-6,  in  latently  infected  ganglia  implies  a 
persistent stimulation of the immune system in the absence of full reactivation (Halford et 
al.,  1997,  Shimeld  et  al.,  1997).  This  concept  is  further  supported  by  the  recent 
observations that CD8+ T cells specific for gB are retained in latently infected sensory 
ganglia and are able to block full reactivation in TG cell cultures (Khanna et al., 2003).  
The  precise  mechanisms  governing  the  establishment,  maintenance  of  and 
reactivation from latency and the factors that induce reactivation have been the subject 
of  intense  investigation.  Nevertheless,  the  molecular  mechanisms  controlling  the 
repression  of
  viral  gene  expression  and  reactivation  from  latency  remain  poorly 
understood, which as discussed above may relate to the delicate interactions between HSV 
and its natural human host which may not be fully reflected in other species.  
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1.3.2 Amplicon HSV-1 vectors 
Amplicons are plasmids bearing the expression cassette of interest, the HSV-1 origin of 
replication  and  the  HSV-1  packaging  signal  (Spaete  &  Frenkel,  1982).  Amplicons  are 
packaged  as  concatemers  of  up  to  one  viral  genome  length  into  HSV  virions  in  the 
presence  of  a  helper virus.  Helper  viruses  are  traditionally  replication-defective  HSV-1 
viruses containing mutations or deletions within an essential IE gene, such as ICP4 (Geller 
et al., 1990). Replication of the defective helper virus and packaging of the amplicon are 
performed in a cell line capable of complementing the mutated or deleted gene products 
in trans. The main limitation of this system is that the final preparation contains a mixture 
of  helper  and  amplicon  viruses,  which  has  not  been  possible  to  physically  separate. 
Moreover,  with  each  passage  there  is  the  possibility  of  recombination  between  the 
amplicon,  helper  virus  genome  and  complementing  cell  line,  which  may  result  in 
production  of  replication-competent  virus  (During  et  al.,  1994).  Recently,  it  has  been 
possible to package amplicons free of helper virus by providing a packaging-deficient HSV 
genome via a bacterial artificial chromosome (BAC). The HSV BAC is deleted for ICP27 and 
the addition of ICP0 stuffer sequences render it too large to be packaged into the capsid. 
An  ICP27-complementing  plasmid  is  also  co-transfected  to  allow  the  amplicon  to  be 
replicated and packaged (Saeki et al., 2001). 
Amplicons  can  be  easily  manipulated,  contain  multiple  copies  of  the  cassette  of 
interest,  have  a  large  transgene  capacity  (potentially  up  to  150kb)  and  since  no  viral 
proteins are expressed, they are of low toxicity when packaged without contaminating 
helper  virus.  Moreover,  they  do  not  appear  to  enter  latency  and  thus,  the  choice  of 
promoter  is  not  critical  for  long-term  expression  (discussed  in  the  following  section). 
However,  it  can  be  difficult  to  obtain  reproducible  data,  as  amplicons  may  contain 
different numbers of genome copies. Moreover, although gene expression is maintained for 
extended periods of time in both the central and peripheral nervous system (Federoff et 
al., 1992, Kaplitt et al., 1994, Lawrence et al., 1996), amplicon vectors are eventually 94 
 
degraded. To overcome this limitation, amplicons can be engineered to allow site-specific 
integration of the transgene into the cell genome, mediated by the rep protein of AAV 
(Cortes et al., 2007). Although HSV-1 amplicon vectors have not been so far utilised to 
deliver shRNA to neurons, they have demonstrated effective silencing of tumour-related 
genes in glioma cells and human polyomavirus BK (BKV) T-antigen in BKV-transformed cells 
both in vitro and in vivo (Sabbioni et al., 2006, Saydam et al., 2005, Saydam et al., 2007). 
 
1.3.3 Replication-defective vectors 
The alternative HSV vector system involves the introduction of the cassette of interest 
directly into the HSV-1 genome. This is achieved by insertion of the gene or shRNA into a 
plasmid  that  contains  the  expression  cassette  flanked  by  specific  HSV  sequences. 
Following co-transfection into complementing cells, the cassette is inserted into the HSV 
genome by homologous recombination. The viral vector genome contains a known copy 
number of the cassette and thus, the dose can be controlled. 
Deletion of the essential IE genes ICP4 and/or ICP27 results in replication-defective 
viruses  that  can  be  directly  propagated  to  high  titres  in  appropriate  cell  lines  which 
complement the deleted gene products in trans, without the need for a contaminating 
helper virus. Complementing cell lines for such deletions have been described, including 
E5 that complements ICP4 (DeLuca et al., 1985), B130/2 that complements ICP27 (Howard 
et al., 1998) and E26 that complements both ICP4 and ICP27 (Samaniego et al., 1995). In 
vivo, the temporal cascade of viral gene expression is incapable of proceeding past the IE 
phase, resulting in recombinants that establish a persistent state very similar to latency. 
Furthermore,  replication-defective  vectors  are  unable  to  reactivate  from  latency  and 
therefore persist for long periods of time in both neuronal cells and non-neuronal cells in 
culture.   
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1.3.3.1 Minimising toxicity 
Although deletion of ICP4 is sufficient to create a replication-defective HSV-1 vector, the 
remaining  IE  gene  products,  which  are  highly  toxic  to  cells,  are  abundantly  expressed 
(DeLuca et al., 1985) and thus, ICP4, ICP4/ICP22 or ICP4/ICP47 mutants are still toxic to 
neurons (Johnson et al., 1992). To prevent cytotoxicity, vectors containing multiple IE 
deletions have been engineered. HSV-1 recombinants deleted for all IE genes appear to be 
non-toxic to cells (Samaniego et al., 1997, Samaniego et al., 1998). However, the efficient 
propagation of such viruses is problematic, because it requires that all IE gene products 
are provided in trans by a single complementing cell line, which is difficult to produce due 
to  the  toxicity  of  the  IE  gene  products.  Furthermore,  the  elimination  of  all  IE  genes 
significantly reduces transgene expression (Samaniego et al., 1997). Retention of ICP0, 
which is a promiscuous transactivator of gene expression, allows efficient expression of 
transgenes  and  the  virus  to  be  propagated  to  high  titres.  Moreover,  Johnson  and 
colleagues demonstrated that ICP27 and ICP22 are more likely to contribute to the toxicity 
of  ICP4  deleted  viruses  than  ICP47  and  ICP6  (Johnson  et  al.,  1994).  Indeed, 
ICP4/ICP22/ICP27 mutants were found to be virtually non-toxic to primary cortical and 
DRG neurons and in the brain in vivo (Krisky et al., 1998, Wu et al., 1996). Nevertheless, 
deletion of ICP27 in combination with ICP4 results in large nuclear inclusions caused by 
ICP0 accumulating in the nucleus of infected cells (Zhu et al., 1994, Zhu et al., 1996).  
VP16 cannot be deleted as it encodes an essential structural protein of the virion. 
However, mutations in VP16, which can be to some extent complemented by addition of 
hexamethylbisacetamide (HMBA) to the growth medium, reduce or abolish transactivation 
of IE genes and present an alternative approach to inactivating all IE genes (Ace et al., 
1989, Mossman & Smiley, 1999, Smiley & Duncan, 1997). A 12bp insertion into the VP16 
transactivation domain, termed in1814, disrupts the interaction of VP16 with Oct-1 and 
HCF  and  significantly  reduces  activation  of  IE  gene  transcription,  whilst  VP16  remains 
capable of fulfilling its structural role (Ace et al., 1988). At high MOIs, however, the virus 96 
 
is still capable of replicating and mutations in VP16 need to therefore be accompanied by 
deletion of IE genes such as ICP4 and/or ICP27 (Johnson et al., 1994, Lilley et al., 2001, 
Palmer et al., 2000, Preston et al., 1997). In this case, HMBA is not sufficient for virus 
growth  and  a  complementing  cell  line  providing  the  equine  herpesvirus  1  (EHV-1) 
homologue of VP16, which is not packaged into HSV, together with ICP4 and ICP27, has 
been developed in our laboratory to eliminate the possibility of recombinational repair of 
the VP16 mutation (Thomas et al., 1999b).  
A further block to replication in neurons is the deletion of non-essential genes, such 
as tk that encodes thymidine kinase, ICP6 that encodes the large subunit of ribonucleotide 
reductase, and ICP34.5, which are required for neurovirulence. Deletion of ICP34.5, which 
counteracts the INF-induced PKR-mediated inhibition of viral replication (He et al., 1997), 
provides the greatest degree of neuroattenuation of any single non-essential gene and 
allows  the  virus  to  grow  in  several  cell  types  in  vitro,  without  the  need  for  a 
complementing  cell  line  (Coffin  et  al.,  1996).  HSV  viruses  only  deleted  for  ICP34.5 
transduce neurons of the peripheral and central nervous system with very low efficiency 
(Coffin  et  al.,  1996)  and  have  been  shown  to  cause  severe  inflammation  in  the  brain 
(McMenamin  et  al.,  1998).  They  have  shown,  however,  significant  potential  for  the 
treatment of glioma and other cancers (Harrow et al., 2004, Hu et al., 2006, Walker et 
al., 1999) and one such vector developed in our laboratory is now in a Phase III clinical 
trial in melanoma (Liu et al., 2003).  
Replication-defective HSV-1 vectors with deletions in ICP27, ICP4 and ICP34.5 and an 
inactivating  mutation  in  VP16  (in1814)  have  been  developed  in  our  laboratory.  These 
vectors  are  safe,  non-toxic,  can  be  produced  to  high  titres,  and  allow  efficient  gene 
delivery to neurons in culture and both the peripheral and central nervous system (Lilley 
et al., 2001, Palmer et al., 2000) (figure 1.17).  
 
 97 
 
1.3.3.2 Long-term expression during latency 
The ability of HSV-1 to establish long-term latent infection in neurons has made it  an 
attractive candidate as a vector for the delivery of genes to the nervous system. However, 
obtaining  prolonged  expression  of  a  transgene  in  latently  infected  neurons  proved 
challenging, due to transcriptional silencing of most HSV promoters, such as the tk, ICP0, 
ICP4,  ICP6  and  gC  promoters  (Ho  &  Mocarski,  1988,  Palella  et  al.,  1988),  as  well  as 
exogenous  promoters  introduced  into  the  latent  viral  genome  (Fink  et  al.,  1992, 
Lokensgard et al., 1994). Thus, there was considerable interest in utilising the promoters 
driving  expression  of  the  LATs  to  drive  expression  of  transgenes  in  neurons  of  the 
peripheral and central nervous system.  
Insertion of a gene further downstream of the LAP1 TATA box resulted in 8 weeks of 
expression in the PNS (Ho & Mocarski, 1989) compared to 3 weeks when the gene was 
inserted immediately after the LAP1 TATA box (Dobson et al., 1989, Margolis et al., 1993). 
It therefore appeared that important elements in the sequences downstream of LAP1 were 
required for the promoter to function during latency. LAP2, but not LAP1, was able to 
drive very weak expression for at least 300 days in DRG when inserted at an ectopic locus 
within the HSV genome, such as gC (Goins et al., 1994). When LAP1 linked to LAP2 was 
inserted  into  gC,  efficient  expression  in  the  PNS  was  maintained  for  at  least  28  days 
(Lokensgard et al., 1997). Moreover, an approximately 800bp fragment of LAP1 without 
the TATA box linked to the MoMLV LTR and inserted into the gC locus was able to drive 
stable expression of reporter genes in the PNS for at least 42 days, although this was not 
possible when a number of other promoters were linked to LAP1 (Lokensgard et al., 1994). 
Finally, insertion of an internal ribosome
 entry site (IRES) at a position 1.5
 kb downstream 
of the 5' end of the primary 2kb LAT, which results
 in the maintenance of all cis-acting 
sequence elements for latent expression, allowed expression in the PNS for at least 307 
days (Lachmann & Efstathiou, 1997, Marshall et al., 2000).  98 
 
The  above  findings  suggested  that  although  some  of  the  elements  necessary  for 
expression during latency are present within LAP1, important sequences in LAP2 confer 
long-term expression on LAP1. The MoMLV LTR can substitute for LAP2 to achieve long-
term  expression  in  the  PNS,  further  suggesting  that  the  structure  of  LAP2  and  its 
surrounding regions may be important for the LAT region to remain transcriptionally active 
during latency. Indeed, the LAT region has different dinucleotide content to the rest of 
the  genome,  which  may  reflect  the  chromatin  structure  of  this  region  during  latency 
(Coffin et al., 1995). Based on this hypothesis, elements from the LAT region were utilised 
to  confer  long-term  expression  from  heterologous  promoters.  A  sequence  1.4kb 
downstream of the LAP1 TATA box (referred to as LAT P2), linked to a strong heterologous 
promoter,  such  as  the  cytomegalovirus  (CMV)  IE  promoter,  has  been  shown  to  drive 
efficient expression of reporter genes in DRG for at least 1 month (Palmer et al., 2000). 
Importantly, genes could be expressed in the PNS from two promoters cloned in opposite 
orientations with the LAT P2 sequence centrally located and inserted into the vhs locus 
(UL43).  
Obtaining long-term expression in the CNS has been even more challenging. This may 
be  due  to  the  different  kinetics  of  gene  expression  from  LAP,  resulting  in  a  gradual 
reduction  in  the  number  of  transgene  expressing  neurons,  or  availability  of  different 
neuronal transcription factors. Nonetheless, when the CMV promoter was inserted after 
LAT  P2,  replication-defective  vectors  with  ICP27,  ICP4  and  ICP35.4  deleted  and  an 
inactivating mutation in VP16 (in1814) were able to drive efficient expression of reporter 
genes in the CNS for at least 1 month (Lilley et al., 2001, Perez et al., 2004). These 
vectors were efficiently retrogradely transported, allowing expression not only around the 
injection site, but also at connected sites in the central nervous system (figure  1.17). 
These, and related vector backbones and promoter systems developed in our laboratory, 
have been used as the starting point for the studies reported in this thesis. 
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1.4 DELIVERY OF RNAi TO NEURONS 
Kosik and Krichevsky (2002) were the first to describe the induction of RNAi in primary 
neuronal  cells.  A  growing  number  of  publications  have  since  demonstrated  effective 
silencing in neurons both in vitro and in vivo. Although delivery of siRNA or shRNA has 
achieved silencing of molecular targets in various animal models of neurological disease, 
including  pain  and  neurodegenerative  disorders  (summarised  in  table  1.3),  efficient 
delivery to neurons remains a major hurdle for the successful application of RNAi as an 
experimental tool and for potential therapy.  
For reasons that remain poorly understood, neurons are considerably more difficult 
to transfect  than  many other cell types. Moreover, whilst naked siRNA is taken up by 
endosomes in primary neuronal cells, insufficient amounts reach the cytoplasm (Lingor et 
al., 2004). Cationic lipids, which are amongst the most commonly used siRNA transfection 
reagents, are highly toxic to primary neurons. Nevertheless, they have been used for the 
induction  of  RNAi  when  long-term  survival  of  the  neuronal  culture  is  not  necessary 
(Krichevsky & Kosik, 2002). Novel electroporation methods have emerged as a valuable 
alternative  (Leclere  et  al.,  2005).  Moreover,  Penetratin  and  Transportan  conjugated 
siRNAs have been used to silence genes in primary neuronal cultures with limited toxicity 
(Davidson et al., 2004, Muratovska & Eccles, 2004). Finally, anionic liposomes, termed 
artificial  virus-like  particles  (AVPs),  and  a  cationic  polypeptide  (stearylated  8R)  have 
demonstrated effective and non-toxic delivery of siRNAs to primary hippocampal neurons 
(Tonges et al., 2006).  
Delivery of siRNA to the brain parenchyma presents an even greater obstacle due to 
the  presence  of  the  blood-brain-barrier  (BBB),  which  is  only  permeable  to  lipophilic 
molecules less than 400kDa in size. However, naked siRNA has induced effective silencing 
of target genes following intrathecal delivery to the spinal cord (Dorn et al., 2004) and 
intra-ventricular infusion into the brain (Thakker et al., 2005), which require continuous 
infusion and very high doses of siRNAs that may enhance potential off-target effects and 101 
 
result in oversaturation of the endogenous miRNA pathway. Localised delivery of naked 
siRNAs, such as direct injection into the eye, requires lower doses of siRNAs and has been 
successfully used to protect axotomised retinal ganglion cells from death (Lingor et al., 
2005).  Intravenous  PEG  stabilised  immuno-liposome  delivery  has  shown  efficacy  in 
delivering siRNAs against VEGF across the BBB and into glioma cells (Zhang et al., 2004b). 
In this study, the monoclonal antibody which was conjugated to the liposome targeted a 
transferring receptor expressed in the BBB, and the other antibody targeted an insulin 
receptor expressed in brain cancer. More recently, Kumar et al. demonstrated that RVG 
(rabies virus glycoprotein)-9R complexed with siRNA against fatal Japanese encephalitis 
virus could efficiently cross the BBB following intravenous administration, without inducing 
an immune response (Kumar et al., 2007). RVG interacts specifically with the nicotinic 
acetylcholine receptor expressed on the surface of neurons and enables efficient siRNA 
uptake  into  neuronal  cells.  Moreover,  a  single  intrastriatal  injection  of  cholesterol-
conjugated siRNAs resulted in silencing of huntingtin and delayed disease progression in a 
mouse model of Huntington’s disease (DiFiglia et al., 2007). Finally, intracranial injection 
of siRNAs complexed with the cationic lipid i-FECT protected mice from fatal Japanese 
encephalitis virus and West Nile virus (Kumar et al., 2006).  
In a tissue as highly specialised as the CNS, targeted delivery of siRNA to specific cell 
types is mandatory for many applications. This can be achieved by viral-mediated delivery 
of shRNA or artificial miRNA. To bypass the BBB, viral vectors are stereotaxically injected 
directly into the brain, which results in localised delivery around the injection site, unless 
the virus is capable of retrograde and/or anterograde transport. Although direct injection 
into the brain is more invasive than systemic delivery, it requires considerably lower doses 
of RNAi triggers and a single administration is sufficient to induce long-term silencing. The 
first  in  vivo  demonstration  of  viral-mediated  delivery  of  shRNA  to  the  nervous  system 
made use of a recombinant Ad containing a DsRed expression cassette and a shRNA against 
GFP under the control of a modified version of the CMV pol II promoter (Xia et al., 2002). 102 
 
The authors reported highly effective silencing 5 days post-injection into the striatum of 
GFP transgenic mice.  
Huntington’s disease (HD) and spinocerebellar ataxia type 1 (SCA1) are dominantly 
inherited  disorders  caused  by  polyglutamine  expansions  (CAG  codon)  in  the  proteins 
huntingtin (htt) and ataxin-1, respectively (Gusella & MacDonald, 2000, Orr et al., 1993). 
Xia and colleagues demonstrated that an AAV vector expressing shRNA against the CAG 
repeat region of mutant ataxin-1 under the control of the H1 promoter induced effective 
silencing  in  Purkinje  cells,  reduced  intranuclear  inclusions,  and  improved  motor 
performance in a mouse model of SCA1 (Xia et al., 2004). However, several injections in 
different  sites  were  required  to  achieve  efficient  transduction  of  the  cerebellum.  The 
same group demonstrated improved behavioural and neuropathological abnormalities in a 
mouse model of HD, following striatal injection of an AAV vector expressing U6-shRNA 
against  mutant  htt  (Harper  et  al.,  2005).  Recently,  Boudreau  et  al.  demonstrated 
improved  motor  coordination  and  survival  in  a  HD  mouse  model,  following  striatal 
injection of an AAV vector expressing artificial miRNA against both wild-type and mutant 
htt (Boudreau et al., 2009).  
Amyotrophic  lateral  sclerosis  (ALS)  is  the  most  common  motor  neuron  disease  in 
humans. Dominantly inherited familial ALS is caused by mutations in the gene encoding 
Cu/Zn superoxide dismutase 1 (SOD1) (Bruijn et al., 2004). Three studies have reported 
viral-mediated delivery of shRNA targeting a mutant form of SOD1 to mouse models of 
ALS. Raoul and colleagues injected a VSV-G pseudotyped LV vector, which expressed GFP 
and H1-shSOD1 from separate cassettes, directly into the lumbar spinal cord (Raoul et al., 
2005). Ralph and colleagues used a rabies-G envelope glycoprotein pseudotyped LV vector 
expressing H1-shSOD1 and β-galactosidase from separate cassettes (Ralph et al., 2005). 
Following multiple injections into the muscle, the LV vector was capable of delivery to the 
cell bodies of motor neurons in the spinal cord through retrograde transport mediated by 
the  rabies  G  envelope  glycoprotein.  Both  studies  demonstrated  delayed  onset  of  ALS, 103 
 
improvement of behavioural defects, and protection from neuronal degeneration in the 
spinal cord. Miller and colleagues demonstrated that intramuscular injection of an AAV 
serotype 2 vector expressing H1-shSOD1, which mainly transduces muscle fibres and to a 
lesser  extent,  enters  the  nerve  terminals  of  motor  neurons  and  undergoes  retrograde 
transport  to  the  spinal  cord,  reduced  target  gene  expression  in  the  spinal  cord  and 
delayed loss of hind-limp grip strength in a mouse model of ALS (Miller et al., 2005).  
Parkinson's disease, which is one of the most common neurodegenerative disorders, 
is characterised by selective loss of dopaminergic neurons from the substantia nigra pars 
compacta  and  accumulation  of  intracytoplasmic  protein  inclusions  called  Lewy  bodies, 
which contain α-synuclein (Spillantini et al., 1997). LV-mediated delivery of shRNA against 
a  mutated  form  of  human  α-synuclein,  which  is  associated  with  familial  Parkinson’s 
disease, demonstrated silencing in the human dopaminergic cell line SH-SY5Y in vitro and 
in the rat brain in vivo. However, expression of mutated human α-synuclein in the rat 
striatum  was  achieved  experimentally  from  a  separate  LV  vector  (Sapru  et  al.,  2006). 
Fountaine  and  colleagues  (2007)  demonstrated  that  silencing  of  α-synuclein  by 
transfection of siRNA into SH-SY5Y neuroblastoma dopaminergic cells was able to confer 
resistance to N-methyl-4-phenylpyridinium (MPP+), a potent and selective dopaminergic 
neurotoxin. Furthermore, viral-mediated RNAi has been used for the rapid generation of a 
Parkinson’s disease model. Expression of U6-shRNA against the dopamine synthesis enzyme 
tyrosine hydroxylase, following injection of an AAV vector into the substantia nigra pars 
compacta of mice, resulted in localized silencing and behavioural changes, including a 
performance deficit (Hommel et al., 2003).  
Alzheimer’s disease, which is the most common cause of dementia in the elderly, is 
characterised  by  neuritic  plaques  in  the  hippocampus  and  cortex  and  neurofibrillary 
tangles in the cell bodies of neurons in several regions of the brain. Alterations in the 
processing  and  clearance  of  the  proteolytic  products  of  the  amyloid  precursor  protein 
(APP), such as C-terminal fragments (CTFs) and amyloid-β peptides (Aβ) that accumulate 104 
 
in  neuritic  plaques,  are  believed  to  play  a  key  role  in  the  pathogenesis  of  Alzheimer 
disease  (Selkoe  &  Schenk,  2003).  CTFs  and  Aβ  peptides  are  generated  by  sequential 
cleavage of APP by β-secretase (BACE1) and γ-secretase (Esler & Wolfe, 2001, Sinha et al., 
1999).  LV−mediated  expression  of  shRNA  against  BACE1  reduced  Aβ  deposits  in  the 
hippocampus  and  attenuated  cognitive  deficits  in  two  mouse  models  of  Alzheimer’s 
disease (Laird et al.,  2005, Singer et al.,  2005).  Finally,  a replication-defective HSV-1 
vector expressing H1-shRNA against a mutant form of human APP, which was expressed 
from a co-injected LV, resulted in reduced Aβ accumulation in the mouse hippocampus 
(Hong et al., 2006). However, expression of mutant APP by co-injection of another vector 
is a somewhat artificial situation, and silencing of an endogenous gene using HSV vectors 
had not been demonstrated.   
Induction of RNAi in sensory neurons, which are targeted with the vectors developed 
in this thesis, had only been achieved through delivery of synthetic siRNA. This is despite 
the fact silencing of genes in the cell bodies of these neurons in the dorsal root ganglia 
(DRG) is particularly attractive for both fundamental studies in nociception and neuronal 
regeneration  and  development,  and  for  the  development  of  potential  therapeutic 
approaches. The efforts which have been made to silence genes in various animal models 
of nociception are reviewed in chapter 4. 
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RNAi trigger  Route of 
administration  Target gene  Disease model  Ref 
naked siRNA  Intrathecal  P2X3  Pain 
Dorn et al, 
2004 
naked siRNA  Injection in the 
eye 
c-Jun, Bax, 
Apaf-1  Axotomy 
Lingo et al., 
2005 
PEI siRNA  Intrathecal  NMDA  Pain 
Tan et al., 
2005 
Cationic lipid 
siRNA  Intrathecal  DOR  Pain 
Luo et al., 
2005 
Immunoliposome 
siRNA  Intravenous  VEGF  Glioblastoma 
Zhang et al., 
2004 
RVG-9R-siRNA  Intravenous  JEV  Japanese 
Encephalitis virus 
Kumar et al., 
2007 
Cholesterol-
siRNA  Intrastriatal  htt  Huntington’s 
disease 
DiFiglia et al., 
2007 
i-FECT siRNA  Intracerebral  JEV, WNV 
Japanese 
encephalitis virus 
and West Nile virus 
Kumar et al., 
2006 
AAV-shRNA  Intrastriatal  htt  Huntington’s 
disease 
Harper et al., 
2005 
AAV-miRNA  Intrastriatal  htt  Huntington’s 
disease 
Boudreau et 
al., 2009 
AAV-shRNA  Cerebellum 
injections  Ataxin-1  SCA1 
Xia et al., 
2004 
LV-shRNA  Spinal cord   SOD1  ALS 
Raoul et al., 
2005 
LV-shRNA  Intramuscular 
injections  SOD1  ALS 
Ralph et al., 
2005 
LV-shRNA  Intramuscular  SOD1  ALS 
Miller et al., 
2005 
LV-shRNA  Hippocampal 
injection  BACE1  Alzheimer’s disease 
Singer et al., 
2005; Laird et 
al., 2005 
 
 
Table 1.3 Delivery of siRNA or shRNA to animal models of neurological disease 
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THE AIM OF THIS THESIS 
 
Delivery of synthetic siRNA to sensory neurons in vivo has proven problematic. Moreover, 
there have been no previous reports of delivery of shRNA to DRG, which are inaccessible 
by surgical techniques and thus, not amenable to direct injection with viral or plasmid 
vectors. The replication-defective HSV-1 vectors developed in our laboratory have allowed 
efficient delivery of reporter genes to sensory neurons, through retrograde transport from 
the injection site to the cell bodies in the DRG (Palmer et al., 2000). Nevertheless, HSV 
had not been previously engineered to express shRNA. Thus, the aim of this thesis was to 
develop an efficient method for delivery of shRNA to sensory neurons in vivo to allow 
effective and specific RNAi-mediated silencing of targeted genes. 
The primary aim of the work described in this thesis was to engineer replication-
defective HSV-1 vectors expressing shRNA or artificial miRNA through the development of 
cassettes which would allow effective expression from within the HSV genome by taking 
advantage of regulatory elements derived from the LAT region. Effective expression from 
the HSV genome presents particular challenges, which whilst overcome for the expression 
of  delivered  genes  (Lilley  et  al.,  2001,  Palmer  et  al.,  2000),  had  not  been  previously 
addressed with respect to the expression of shRNA. Silencing from these vectors would be 
optimised by evaluating different approaches of shRNA expression both in vitro and in DRG 
neurons in vivo. Secondly, the work in this thesis aimed to establish proof of concept by 
demonstrating, for the first time, in vivo silencing of an endogenous gene expressed in 
sensory neurons. Finally, the work in this thesis aimed to present potential applications of 
this method in functional genomic studies and target validation by demonstrating silencing 
of a gene involved in nociception and simultaneous silencing of three genes believed to be 
involved in the inhibition of sensory axon regeneration following injury.  
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CHAPTER 2 
MATERIALS & METHODS 
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2.1 MATERIALS 
 
2.1.1 Suppliers 
General laboratory chemicals were of analytical grade and obtained from Sigma-Aldrich 
Company Ltd. or Merck Chemicals Ltd. General disposable plasticware was supplied by 
Sterilin  Ltd.,  Sarstedt  Ltd,  VWR  International  Ltd.,  Eppendorf  Ltd.  and  CLP.  All  tissue 
culture plasticware was obtained from Nunc or Greiner Bio-One Ltd. The suppliers of all 
other materials are stated in the methods.  
Supplier  Address 
Alfa Aesar (Lancaster Synthesis)  Shore Road, Heysham, Lancashire, LA3 2XY, UK 
Alpha Diagnostics International  6203 Woodlake Center, San Antonio, TX 78244 USA 
Ambion (Applied Biosystems)  2130 Woodward St., TX 78744-1832, Austin, USA 
Amersham (GE Healthcare)  The Grove Centre, Amersham, Bucks, HP7 9LL, UK 
BD Biosciences  Edmund Halley Rd, Oxford Science Park, OX4 4DQ, UK 
Bio-Rad Laboratories Ltd.  Maxted Road, Hemel Hempstead, Herts. HP2 7DX, UK 
CLP (Neptune pipettor tips)  6190 Cornerstone Court East, San Diego, CA 92121, USA 
Eppendorf UK Ltd  Endurance House, Histon, Cambridge, CB24 9ZR, UK 
Gibco (Invitrogen)  3 Fountain Drive, Inchinnan Business Park, PA4 9RF, UK 
Greiner Bio-One Ltd.  Brunel Way, Stonehouse, Gloustershire, GL10 3SX , UK 
Hoffmann-La Roche Ltd  6 Falcon Way, Welwyn Garden City, Herts. AL7 1TW, UK 
Insight Biotechnology Ltd.  Wembley, Middlesex, HA9 7YN, UK 
Invitrogen Ltd.   3 Fountain Drive, Inchinnan Business Park, PA4 9RF, UK 
Merck Ltd.  Boulevard Industrial Park, Nottingham NG9 2JR, UK 109 
 
Millipore Ltd.  3-5 The Courtyards, Hatters Lane, Herts. WD18 8YH, UK 
New England Biolabs Ltd.  75/77 Knowl Piece, Wilbury Way, Herts. SG4 0TY, UK 
Nunc (Thermo Fischer Scientific)  Kamstrupvej 90, DK-4000, Roskilde, Denmark 
Promega UK Ltd.  Southampton Science Park, Southampton, SO16 7NS, UK 
Qiagen Ltd.  Fleming Way, Crawley, West Sussex, RH10 9NQ, UK 
Santa Cruz Biotechnology Inc.  2145 Delaware Avenue, Santa Cruz, CA 95060, USA 
Sarstedt Ltd.  68 Boston Road, Beaumont Leys, Leicester LE4 1AW, UK 
Sartorius Ltd.  Longmead Business Centre, Epsom, Surrey, KT19 9QQ, UK 
Sigma-Aldrich Company Ltd.  The Old Brickyard, Gillingham, Dorset, SP8 4XT, UK 
Sterilin Ltd.  Angel Lane, Aberbargoed, Caerphilly, CF81 9FW, UK 
Stratagene (Agilent Technologies)  Cheadle Royal Business Park, Stockport, SK8 3GR, UK 
VWR International Ltd.  Hunter Boulevard, Leicestershire, LE17 4XN, UK 
Whatman International Ltd.  Springfield Mill, Maidstone, ME14 2LE, UK 
 
 
2.1.2 Bacterial Strains 
 
Strain  Genotype  Source 
OmniMAX
TM 2-T1
R 
F’(proAB
+ lacI
q lacZΔM15 Tn10(Tet
R) Δ(ccdAB)} mcrA Δ(mrr-
hsdRMS-mcrBC)φ80(lacZ)ΔM15 Δ(lacZA-argF) U169 endA1 
recA1 supE44 thi-1 gyrA96 relA1 tonA panD 
Invitrogen 
DB3.1
TM  
(CcdB resistant) 
F
- gyr462 endA Δ(sr1-recA) mcrB mrr hsdS20 (rB
-, mB
-) 
supE44 ara14 galK2 lacY1 proA2 rpsL20(Str
R) xyl5 λ
- leu mtl1  Invitrogen 
 E. coli TOP10  F
- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacZX74 recA1 
araD139 Δ(ara-leu)7697 galU galK rpsL (Str
R) endA1 nupG  Invitrogen 
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2.1.3 Plasmids 
 
Plasmid  Antibiotic Resistance  Source 
pR19SYNeGFP  Ampicillin  BioVex 
pR19CMVeGFP  Ampicillin  BioVex 
pR19CMVLacZ  Ampicillin  BioVex 
pR19CMVLacZWCm  Ampicillin  BioVex 
pNOT3.5  Blasticidin  BioVex 
pcDNA3  Ampicillin  Invitrogen 
pENTR
TM/U6  Kanamycin  Invitrogen 
pGEM-T Easy  Ampicillin  Promega 
pSilencer
TM4.1-CMV  Ampicillin  Ambion 
pcDNA
TM6.2-GW/EmGFP-miR  Spectinomycin  Invitrogen 
pDONR
TM221   Kanamycin  Invitrogen 
pSCREEN-iT
TM/LacZ-DEST  Ampicillin  Invitrogen 
pSCREEN-iT
TM/LacZ-GW/CDK2  Ampicillin  Invitrogen 
 
 
2.1.4 Cell Lines 
 
Cell line  Origin  Culture Media  Reference/ Source 
BHK 21 
Clone 13  
Baby Hamster 
Kidney cells 
1 x Dulbecco’s modified 
Eagle’s media (DMEM) 
supplemented with 10%(v/v) 
foetal calf serum (FCS), 
10%(v/v) tryptose phosphate 
broth (TPB) and containing 
100U/ml penicillin and 
100μg/ml streptomycin 
(MacPherson & Stoker, 
1962) 
ATCC CCL 10 
27/12/M:4 
(MAM49) 
BHK cells that 
complement VP16, 
ICP4 and ICP27 
deletions 
As for BHK cells, but also 
containing 750μg/ml Zeocin 
and 800μg/ml G418 to 
maintain selection 
(Thomas et al., 1999b) 111 
 
HEK 293T   Human Embryonic 
Kidney cells  As for BHK cells  (Graham et al., 1977) 
ATCC CRL1573 
9L/LacZ 
Gliosarcoma cell 
line that stably 
expresses LacZ 
As for BHK cells  ATCC CRL2200 
 
ATCC is the registered trademark of the American Type Culture Collection 
 
2.1.5 Primers 
Primers were designed using VNTI and synthesized by Invitrogen: 
Primer  Sequence 5’-3’ 
U6 Forward   GGACTATCATATGCTTACCG 
M13 Reverse  CAGGAAACAGCTATGAC 
AttR1 Forward  CACATTATACGAGCCGGAAGCAT 
AttR2 Reverse  CAGTGTGCCGGTCTCCGTTATCG 
pSilencer F   AGGCGATTAAGTTGGGTA 
pSilencer R  CGGTAGGCGTGTACGGTG 
LAT Forward  CTATGTTCCTGTTTCTGTTCTCC 
LAT Reverse  TCCCCGAAAGCATCCTGCCAC 
miR Forward  TCCCAAGCTGGCTAGTTAAG 
miR Reverse  CTCTAGATCAACCACTTTGT 
CMV Forward  TGACGTCAATGGGTGGACTA 
GFP Forward  GTCCTGCTGGAGTTCGTGACC 
WCm Reverse  GAGATCCGACTCGTCTGAGG 
CMVenh Forward  GTTGACATTGATTATTGACTAG 
CMVenh Reverse  GGCGAGCTCTGCCAAAACAAACTCCCATTG 
 
2.1.6 Double Stranded DNA Oligos 
The shRNA sequences were either supplied by Invitrogen or designed using Invitrogen’s 
RNAi Designer tool (www.invitrogen.com/rnai). The two complementary single-stranded 
DNA  oligonucleotides,  one  of  which  encoding  the  shRNA/miRNA  of  interest,  were 
generated using Invitrogen’s custom primer synthesis service and cloned into appropriate 
expression vectors. 112 
 
Name  Sense Oligo Sequence (5’-3’)  Target Gene 
shLacZ 
CACCGCTACACAAATCAGCGATTTCGAAAAATCGCT
GATTTGTGTAG  β-galactosidase (LacZ) 
miR-LacZ 
TGCTGAAATCGCTGATTTGTGTAGTCGTTTTGGCCA
CTGACTGACGACTACACATCAGCGATTTCAGG  LacZ 
shLacZ  
for pSilencer 
AGCTTCTACACAAATCAGCGATTTTTCGAAATCGCT
GATTTGTGTAGG  LacZ 
shGFP1 
CACCGCAAGCTGACCCTGAAGTTCGAAAACTTCAGG
GTCAGCTTG 
Green fluorescent protein 
(GFP) 
shGFP2 
CACCGCATCAAGGTGAACTTCAAGACGAATCTTGAA
GTTCACCTTGATGC  GFP 
shGFP3 
CACCGCCACAACGTCTATATCATGGCGAACCATGAT
ATAGACGTTGTGGC  GFP 
miR-neg 
TGCTGAAATGTACTGCGCGTGGAGACGTTTTGGCC
ACTGACTGACGTCTCCACGCAGTACATTT  No known target 
shTRPV1 
GCGCATCTTCTACTTCAACTTCAAGAG 
AGTTGAAGTAGAAGATGCGC 
Mouse (and rat) transient 
receptor potential vanilloid 
subtype
 1(trpV1) 
miR-TRPV1 
TGCTGTGTAGTAGCTGTCTGTGTAGCGTTTTGGCC
ACTGACTGACGCTACACACAGCTACTACA  Mouse (and rat) trpV1 
miR-p75#1 
TGCTGTAGACAGGAATGAGGTTGTCAGTTTTGGCC
ACTGACTGACTGACAACCATTCCTGTCTA 
Mouse nerve growth factor 
receptor (p75NTR nt884) 
miR-p75#2 
TGCTGAAAGGAGTCTATATGCTCCGGGTTTTGGCCA
CTGACTGACCCGGAGCATAGACTCCTTT 
 
Mouse p75NTR (nt1239) 
miR-p75#3 
TGCTGTGCACAGGCTCTCCACAATGTGTTTTGGCCA
CTGACTGACACATTGTGGAGCCTGTGCA  Mouse p75NTR (nt1366) 
miR-p75#4 
TGCTGTAGACCTTGTGATCCATCGGCGTTTTGGCCA
CTGACTGACGCCGATGGCACAAGGTCTA 
 
Mouse p75NTR (nt718) 
miR-p75#5 
TGCTGAATATAGGCCACAAGGCCCACGTTTTGGCCA
CTGACTGACGTGGGCCTTGGCCTATATT 
 
Mouse (and rat) p75NTR 
(nt930) 
miR-p75#6 
TGCTGAATGTCAGCTCTCTGGATGCGGTTTTGGCCA
CTGACTGACCGCATCCAGAGCTGACATT 
 
Mouse (and rat) p75NTR 
(nt1350) 113 
 
miR-Lingo1#1 
TGCTGTAGTCTAGCAGGATGACGATCGTTTTGGCCA
CTGACTGACGATCGTCACTGCTAGACTA 
Mouse (and rat) leucine rich 
repeat and Ig domain 
containing 1 (Lingo1 nt855) 
miR-Lingo1#2 
TGCTGTGAAGTAGTTGGGTAGGAGTAGTTTTGGCC
ACTGACTGACTACTCCTACAACTACTTCA 
 
Mouse Lingo1 (nt1631) 
miR-Lingo1#3 
TGCTGATAATGAGCGTCTTGATGTCGGTTTTGGCCA
CTGACTGACCGACATCAACGCTCATTAT 
 
Mouse Lingo1 (nt2049) 
miR-Lingo1#4 
TGCTGTATAGGTCTTGGAACATGTAGGTTTTGGCCA
CTGACTGACCTACATGTCAAGACCTATA  Mouse Lingo1 (nt873) 
miR-Lingo1#5 
TGCTGTACAAACACCTGCTGTGCCTTGTTTTGGCCA
CTGACTGACAAGGCACAAGGTGTTTGTA  Mouse Lingo1 (nt1681) 
miR-NgR2#1 
TGCTGTACAGGTGTAGTGACTGCAGCGTTTTGGCC
ACTGACTGACGCTGCAGTCTACACCTGTA 
Mouse reticulon 4 receptor-
like 2 (Rtn4rl2 or NgR2) 
miR-NgR2#2 
TGCTGTACTGTAGGCTGACCAAGCCTGTTTTGGCCA
CTGACTGACAGGCTTGGAGCCTACAGTA  Mouse NgR2 
miR-NgR2#3 
TGCTGTGAACAGGTAGAGGATGGTGAGTTTTGGCC
ACTGACTGACTCACCATCCTACCTGTTCA  Mouse NgR2 
miR-NgR2#4 
TGCTGAGGTACTGTAGGCTGACCAAGGTTTTGGCC
ACTGACTGACCTTGGTCACTACAGTACCT  Mouse (and rat) NgR2 
miR-NgR2#5 
TGCTGAACAGGTAGAGGATGGTGAGGGTTTTGGCC
ACTGACTGACCCTCACCACTCTACCTGTT  Mouse NgR2 
 
 
2.1.7 Antibodies 
 
Primary  Dilution/Assay  Secondary 
Anti-Lingo1 rabbit polyclonal  
Abcam (ab23631) 
1/500 
Western 
Goat anti-rabbit IgG-HRP 
(Abcam) 1/3000 
Anti-p75 NGFR rabbit polyclonal 
Abcam (ab8874) 
1/500 
Western 
Goat anti-rabbit IgG-HRP 
(Abcam) 1/3000 
Anti-NgR2 rabbit affinity pure 
IgG Alpha Diagnostic (NGR21-A) 
1/100 
Western 
Goat anti-rabbit IgG-HRP 
(Abcam) 1/3000  
Anti-STAT1 rabbit polyclonal  
Abcam (ab31369) 
1/500 
Western 
Goat anti-rabbit IgG-HRP 
(Abcam) 1/3000 114 
 
Anti-alpha tubulin rabbit 
polyclonal Abcam (ab4074) 
1/500 
Western 
Goat anti-rabbit IgG-HRP 
(Abcam) 1/3000 
Anti-TRPA1 rabbit polyclonal 
Abcam (ab31486) 
1/1000 
Western 
Goat anti-rabbit IgG-HRP 
(Abcam) 1/3000 
Anti-TRPV1 rabbit polyclonal  
Santa Cruz (sc-28759) 
1/200 
Western 
Goat anti-rabbit IgG-HRP 
(Abcam) 1/3000 
Anti-TRPV1 rabbit polyclonal 
Abcam (ab31895) 
1/1000 
Immunofluorescence 
Goat anti-rabbit Alexa Fluor 
594 (Invitrogen Molecular 
Probes) 1/200 
Anti-GFP chicken polyclonal  
Abcam (ab13970) 
1/1000 
Immunofluorescence 
Goat anti-chicken 
polyclonal IgY-FITC 
 (Abcam) 1/250 
Anti-GAPDH mouse monoclonal  1/800 
Immunofluorescence 
Goat anti-mouse IgG-FITC 
(Sigma) 1/100 
 
 
2.1.8 Animals 
The  Balb/c  mice  used  in  this  study  were  obtained  from  breeding  colonies  within  the 
Department of Biological Services, UCL. Rosa26 transgenic mice (Gt(ROSA)26Sor), which 
are heterozygous for the ROSA26 retroviral insertion (Friedrich and Soriano,  1991)  and 
express  β-galactosidase  in  most  tissues  of  the  adult  mouse,  were  obtained  from  the 
Jackson Laboratory.  All animal procedures were carried out in accordance to UK Home 
Office Regulations (Home Office project licence no: PPL70/4293).    
 
2.1.9 Standard Solutions 
The following standard solutions were used throughout: 
TE:  10mM Tris-HCl pH 8.0, 1mM EDTA pH 8.0 
TAE:  400mM Tris, 200mM Sodium acetate, 20mM EDTA pH 8.3  
TBE:  89mM Tris Base, 89mM Boric acid, 2mM EDTA pH 8.0 
PBS:  137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4
.7H2O, 1.4mM KH2PO4 
SSC:  150mM NaCl, 15mM Sodium citrate 115 
 
2.2 MOLECULAR BIOLOGY TECHNIQUES 
 
2.2.1 Agarose Gel Electrophoresis 
1% (w/v) agarose gels were prepared using 1xTAE. Ethidium bromide was added to a final 
concentration  of  0.5μg/ml.  Loading  buffer  (10x:  1xTAE,  50%  (v/v)  glycerol,  0.025% 
bromophenol blue) was added to DNA samples prior to loading at a 0.1 volume. 1kb plus 
DNA  ladder  (Gibco)  was  used  in  all  cases  as  a  marker  for  DNA  size.  The  bands  were 
visualized on a UV transilluminator. 
 
2.2.2 Restriction Enzyme Digestions 
Restriction enzyme digests were performed on plasmid DNA for clonal analysis or isolation 
of DNA fragments. Analytical digests were performed in a total volume of 20μl containing 
5μl of mini-prep (approximately 50ng/μl) or 1μl of midi-prep DNA (approximately 1μg/μl), 
1μl  of  each  enzyme  (10units/μl),  2μl  of  the  appropriate  restriction  buffer  (10x)  as 
specified by the manufacturer (Promega) and ddH20. Restriction digests for isolation of 
DNA fragments were performed in a total volume of 100μl containing 5μl of midi-prep 
DNA, 2μl of each enzyme, 10μl of the appropriate restriction buffer (10x) and ddH20. The 
digests were incubated at the appropriate temperature for a minimum of 1 hour and then 
run on 1% agarose gel and visualized on a UV transilluminator.  
 
2.2.3 Blunt End Reactions 
To  create  compatible  ends  for  cloning,  restriction  enzyme  cleaved  overhangs  were 
converted  to  blunt  double-stranded  DNA  ends.  After  restriction  enzyme  digestion  as 
described before, 5μl of a dNTPs (dATP, dTTP, dCTP and dGTP) stock (25mM) and 2μl 116 
 
(7.7units/μl) of T4 DNA polymerase (Promega) were added directly to DNA. The reaction 
was incubated at 37
oC for 1 hour. The digests were heat-deactivated at 80
oC for 20min and 
then cooled on ice for 20min before further restriction enzymes were added. 
 
2.2.4 Phosphatase Treatment  
To decrease the background associated with vector self-ligation, plasmid DNA was treated 
with  calf  intestinal  alkaline  phosphatase  (CIAP,  Promega)  to  remove  5’  phosphates. 
Reactions  were  performed  in  a  total  volume  of  40μl  containing  4μl  CIAP  buffer  (10x), 
1pmol  of  5’  ends  of  DNA,  1μl  of  CIAP  (1unit/μg  DNA)  and  ddH20.  The  reactions  were 
incubated at 37
oC for 15min. The CIAP was heat-deactivated at 65
oC for 15min.   
 
2.2.5 Purification of DNA from Gel Bands 
DNA  was  purified  from  agarose  using  the  GFX  PCR  DNA  and  Gel  Band  Purification  Kit 
(Amersham Biosciences) according to manufacturer’s instructions. The maximum weight of 
gel slice that can be processed is 300mg. Briefly, DNA bands are excised using a clean 
scalpel and transferred to a pre-weighed 1.5ml microcentrifuge tube. The weight of the 
slice is determined and the appropriate volume of capture buffer is added to the gel, 
which is incubated at 60
oC until completely melted. The sample is transferred to a GFX 
column and centrifuged. The column is washed and the DNA is eluted in 35μl of ddH20. The 
concentration of purified DNA is determined using a nanodrop (ND-1000).  
  
2.2.6 DNA Ligation Reactions 
Ligations were performed in a total volume of 20μl containing vector and insert DNA at a 
molar ratio of 1:3 or 1:1, 1μl (3units/μl) of T4 DNA ligase (Promega), 2μl of ligation buffer 
(10x) and ddH20. Molar ratios were converted to mass ratios using the formula: [ng of 117 
 
vector x kb size of insert/ kb size of vector] x molar ratio of insert/ vector = ng of insert. 
Blunt-end ligations were incubated at 16
oC overnight, while sticky ends were ligated at 
room temperature for 3 hours or 4
oC overnight.   
 
2.2.7 The Gateway Technology 
The Gateway
® technology is a universal cloning method that takes advantage of the site-
specific  recombination  properties  of  bacteriophage  lambda  (Landy,  1989)  to  provide  a 
rapid and highly efficient way to move a gene of interest into multiple vector systems. To 
generate an entry clone, a BP recombination reaction is performed between a pDONR
TM 
vector, in this study pDONR
TM221, and an attB expression clone. To generate the desired 
expression clone, an LR recombination reaction is performed between the entry clone and 
a  Gateway
®  destination  vector.  The  Gateway
®  technology  is  schematically  represented 
below: 
 
attB1-gene-attB2  (expression  clone)  x  attP1-ccdB-attP2  (pDONR
TM)  =  attL1-gene-attL2 
(entry clone) x attR1-ccdB-attR2 (destination vector)  
 
CcdB is the F plasmid-encoded gene that inhibits growth in E. coli (Bernard & Couturier, 
1992). The LR and BP recombination reactions were transformed into competent cells, 
which are not E. coli strains containing the F’ episome that contain the ccdA gene and will 
prevent negative selection with the ccdB gene. To select, propagate and maintain the 
pDONR
TM and Gateway
® destination vectors, DB3.1
TM competent cells were used that are 
resistant to ccdB. 
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2.2.8 BP Recombination Reactions 
The attB x attP reaction is mediated by Gateway
® BP Clonase
TM II enzyme mix (Invitrogen), 
which contains the bacteriophage lambda recombination protein Integrase (Int), the E. 
coli-encoded protein Integration Host Factor (IHF), and reaction buffer. To perform the BP 
recombination reaction, 150ng of attB expression clone, 150ng of pDONR
TM and TE buffer 
to 8μl are added to a 1.5ml microcentrifuge tube and mixed. The BP Clonase
TM II enzyme 
mix (5x) is thawed on ice for 2min and 2μl are added to the reaction that is vortexed and 
incubated  at  25
oC  for  a  minimum  1  hour  or  up  to  overnight  to  increase  the  yield  of 
colonies.  Following  this  incubation,  1μl  of  Proteinase  K  (Invitrogen)  is  added  to  the 
reaction, which is vortexed and incubated at 37
oC for 10min. For BP reactions, the most 
efficient substrates are linear attB products and supercoiled attP donor vectors.  
  
2.2.9 LR Recombination Reactions 
The attL x attR reaction is mediated by Gateway
® LR Clonase
TM II enzyme mix (Invitrogen), 
which contains the bacteriophage lambda recombination proteins Int and Excisionase (Xis), 
the E. coli IHF, and reaction buffer. To perform the LR recombination reaction, 150ng of 
entry  clone,  150ng  of  destination  vector  and  TE  buffer  to  8μl  are  added  to  a  1.5ml 
microcentrifuge tube and mixed. The LR Clonase
TM II enzyme mix (5x) is thawed on ice for 
2min and 2μl are added to the reaction, which is vortexed and incubated at 25
oC for a 
minimum  1  hour  or  up  to  overnight  to  increase  the  yield  of  colonies.  Following  this 
incubation, 1μl of Proteinase K is added to the reaction, which is vortexed and incubated 
at 37
oC for 10min. For LR reactions, the most efficient substrates are supercoiled attL 
entry vectors and supercoiled attR destinations vectors. For entry clones <10kb the entry 
clone was linearised. 
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2.2.10 Bacterial Cell Culture 
All  bacteria  were  grown  in  LB  media  (1%  w/v  Bacto
®-trypton,  1%  w/v  NaCl,  0.5  w/v 
Bacto
®-yeast extract) or on plates containing LB and 2% Bacto
®-Agar. LB was autoclaved at 
120
oC for 20min at 10lb/inch
2. Both media contained the appropriate antibiotic selection. 
Ampicillin was used at a final concentration of 100μg/ml. Chloramphenicol was used at a 
final  concentration  of  30μg/ml.  Kanamycin  and  spectinomycin  were  used  at  a  final 
concentration  of  50μg/ml.  LB  cultures  were  incubated  overnight  at  37
oC  in  an  orbital 
incubator at 200rpm. Plates were incubated overnight at 37
oC in a standard incubator.   
 
2.2.11 Preparation of Competent cells 
Competent cells were prepared using the standard CaCl2 technique. A single colony was 
grown overnight in 10ml of LB containing no antibiotics. 100μl of this culture was used to 
inoculate 100ml of LB containing no antibiotics. The cells were allowed to grow for a 
minimum of 2 hours in the orbital incubator at 200rpm (until OD580 = approximately 0.5). 
Cells  were  pelleted  by  centrifugation  at  2000rpm  for  10min  at  4
oC,  excess  LB  was 
discarded and the pellet was resuspended in 10ml of ice-cold CaCl2 (100mM, 0.0218gr/ml). 
Cells were pelleted as before, resuspended in 4ml of ice-cold CaCl2 and kept on ice until 
required. DB3.1
TM (CcdB resistant) and OmniMAX
TM 2-T1
R competent cells were purchased 
by Invitrogen. 
 
2.2.12 Transformation of Bacteria 
Competent cells were transformed by addition of plasmid DNA and subsequent incubation 
on ice for 30min. The cells were heat-shocked for 30sec at 42
oC, incubated on ice for 2min 
and 250μl of LB containing no antibiotics were added. The cells were incubated for 1 hour 
in the orbital incubator at 200rpm. The transformed cells were plated on LB agar plates 
containing  the  appropriate  antibiotic  selection  and  colonies  were  allowed  to  grow 120 
 
overnight at 37
oC. Single colonies were isolated. Each colony was used to inoculate 3ml of 
LB containing antibiotics and incubated in the orbital shaker overnight.      
 
2.2.13 Small Scale Plasmid DNA Purification (Mini-Prep) 
Transformed  cells  from  a  3ml  LB  overnight  culture  were  pelleted  by  centrifugation  at 
7000rpm  for  5min  and  resuspended  in  100μl  suspension  buffer  (50mM  Tris-HCl  pH  7.5, 
10mM EDTA pH 8.0, and 100μg/ml RNase A). The cells were lysed by addition of 200μl of 
lysis buffer (0.2M NaOH, 1% Triton) and neutralized by addition of 150μl of neutralization 
buffer  (3M  potassium  acetate,  pH  4.8).  The  lysate  was  pelleted  by  centrifugation  at 
14,000rpm for 5min and the pelleted precipitate was removed with a bent hypothermic 
needle.  The  plasmid  DNA  was  precipitated  by  addition  of  500μl  of  isopropanol  and 
centrifugation at 14,000rpm for 5min. The pellet was washed with 500μl of 70% ethanol 
and  subsequent  centrifugation  at  14,000rpm  for  5min.  The  supernatant  was  carefully 
discarded and the DNA pellet was allowed to air dry at room temperature for 20min. The 
purified plasmid DNA was resuspended in 50μl ddH20.  
 
Extraction and purification of plasmid DNA from small scale cultures was also performed 
using the illustra plasmidPrep mini spin kit (GE Healthcare) according to manufacturer’s 
instructions.  The  purified  DNA  was  eluted  in  50μl  ddH20  and  stored  at  -20
oC.    The 
concentration of purified DNA was determined using a nanodrop.  
 
2.2.14 High Scale Plasmid DNA Purification (Midi-Prep) 
Transformed  cells  from  a  100ml  overnight  culture  were  pelleted  by  centrifugation  at 
3500rpm  for  10min  at  22
oC.  The  plasmid  DNA  was  extracted  and  purified  using  the 
PureLink  HiPure  Plasmid  Midiprep  kit  (Invitrogen)  according  to  the  manufacturer’s 
protocol. Briefly, the pellet was resuspended in 50mM Tris-HCl (pH 8.0), 10mM EDTA and 121 
 
100μg/ml Rnase A. The cells were lysed in 0.2M NaOH and 1% (v/v) SDS and neutralized in 
3.1M potassium acetate, pH 5.5. The lysate is passed through an ion-exchange column. 
The negatively charged phosphates on the backbone of the DNA interact with the positive 
charges on the surface of the resin. RNA, protein, carbohydrates and other impurities are 
washed away with 0.1M sodium acetate, pH 5.0 and 825mM NaCl. The purified DNA (a 
typical yield is 100μg) is eluted in 200μl of ddH20 and stored at -20
oC. The concentration 
of purified DNA was determined using a nanodrop.  
   
2.2.15 DNA Sequencing 
Plasmid DNA at a concentration of 50ng/μl was sequenced by the Sequencing Facility of 
the Department of Biochemistry at the University of Cambridge. Primers were synthesized 
by  Invitrogen’s  custom  primer  synthesis  service  and  were  used  at  a  concentration  of 
10pmole/μl.   
 
2.2.16 Polymerase Chain Reaction (PCR) 
PCR was performed on plasmid DNA to generate fragments for cloning or on viral DNA to 
confirm that the desired homologous recombination event had occurred. PCR amplification 
was achieved using the methodology described by Saiki and colleagues (Saiki et al., 1985). 
For a standard 50μl reaction, 1μl viral DNA or 1μl plasmid DNA (1-10ng) was added to a 
0.5ml PCR tube containing 5μl (10x) pfu buffer (100mM Tris-HCl pH 8.3, 500mM KCl, 20mM 
MgCl2, Promega), 1μl of a 40mM dNTPs (dATP, dTTP, dCTP and dGTP) mixture, 100ng of 
each primer (10pmoles/μl), 0.5μl Taq DNA polymerase (5units/μl, Promega), and ddH20. 
For cloning, proof reading DNA polymerase (pfu) was used (Promega). Filter pipettes were 
used  to  avoid  contamination  and  all  solutions  were  subjected  to  UV  energy  (999,900 
uJ/cm
2) prior to their use to crosslink any contaminating DNA. The mixture was overlaid 
with 50μl of mineral oil to prevent evaporation and was put through different thermal 122 
 
cycles: 1 cycle at 94
oC for 2min, 30 cycles at 94
oC for 30sec, at 50-60
oC (depending on the 
Tm of the primers used) for 30sec and at 72
oC for 1min (depending on the length of the 
PCR product; ~1min/kb), and 1 cycle at 72
oC for 10min. PCR reactions were performed in 
an Eppendorf Mastercycler. The PCR products were visualized on 1% agarose gel.   
 
2.2.17 Quantitative Reverse Transcriptase (qRT)-PCR 
QRT-PCR experiments were performed by Ronald De Hoogt at Johnson & Johnson R&D in 
Belgium. Total RNA from cultured 293T cells was extracted and DNaseI treated using the 
RNeasy  Mini  kit  (Qiagen)  according  to  the  manufacturer’s  protocol.  Briefly,  cell 
monolayers  were  lysed  in  RLT  buffer  containing  guanidinium  thiocyanate  and  β-
mercaptoethanol. The lysate was DNaseI treated and loaded onto a silica membrane. The 
RNA binds to the silica strongly, contaminants were washed away, and the RNA was eluted 
in water. 3μg of total RNA served as template for cDNA synthesis using Oligo dT primers 
and  Superscript  III  RT  (Invitrogen)  in  a  volume  of  20µl  for  1  hour  at  50°C.  This  was 
followed by inactivation of the enzyme at 70°C for 15min according to the manufacturer’s 
instructions. Quantitative PCR was performed on an
 ABI Prism 7900-HT Sequence Detection 
System  (Applied  Biosystems)
  using  a  qPCR  core  kit  without  dUTP  (Eurogentec).  The 
thermal cycling conditions were 10min at 95°C, followed by 45 cycles of 15sec at 95°C and 
1min  at  60°C.  Validated  pre-designed  Taqman  Gene  Expression  Assays  (Applied 
Biosystems)  corresponding  to  the  housekeeping  genes  ATP5b  (Hs00969569_m1),  B2m 
(Hs99999907_m1),  GAPDH  (Hs99999905_m1),  GUSb  (Hs99999908_m1)  and  an  interferon 
response gene ISGF3G (Hs_00196051_m1) were used to generate standard curves on serial 
dilutions  of  cDNA.  The  relative  standard  curve  method  was  used  to  calculate  the 
expression values. Values were normalized against the values obtained for the B2m gene.  123 
 
 
RNA  from  whole  DRG  was  extracted  using  the  Rneasy  96  kit  (Qiagen)  according  to 
manufacturer’s  instructions.  RNA  was  eluted  in  100µl  H20  and  vacuum  dried  to 
approximately 10µl. The RNA was subsequently amplified using a modified version of the 
two-cycle  amplification  kit  from  Affymetrix.  The  reaction  was  stopped  after  the  first 
amplification step and a DNAseI digestion was performed. The RNA was cleaned in a 96-
well plate, eluted twice in 50µl H20 and vacuum dried to approximately 20µl. First strand 
cDNA synthesis was performed on 1μg of amplified RNA using random hexamer primers and 
Superscript II RT (Invitrogen). Quantitative PCR was performed using the TaqMan PCR kit 
(Applied Biosystems). Serial dilutions of cDNA were used to generate standard curves of 
threshold  cycles  versus  the  logarithms  of  concentration  for  Sart1  (endogenous  control, 
mouse squamous cell carcinoma antigen recognised by T cells) and Trpv1 or GFP. For Sart1 
mRNA levels, the TaqMan Gene Expression Assay (Applied Biosystems) was used. The Trpv1 
primers and probe were designed manually:  
 
Forward primer:   5’-AGAATTCAGTGCTGGAGGTGATC-3’ 
Reverse primer:  5’-GGCTCCACGAGAAGCATGTC-3’ 
Probe sequence:  Carboxyfluorescein-5’-GAGCCAAGGGACCCACCCCATGGAGAGC-3’-
tetramethylrhodamine (Eurogentec).  
 
The GFP primers and probe were also designed manually:   
 
Forward primer:   5’-AGCAAAGACCCCAACGAGAA-3’ 
Reverse primer:  5’-GGCGGCGGTCACGAA-3’ 
Probe sequence:  Carboxyfluorescein-5’-CGCGATCACATGGTCCTGCTGG-3’-
tetramethylrhodamine 
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2.3 TISSUE CULTURE TECHNIQUES 
 
All  tissue  culture  solutions,  media  and  supplements  were  obtained  from  Gibco.  All 
manipulations of cells were carried out under sterile conditions using standard aseptic 
techniques.  
 
2.3.1 Freezing and Recovery of Cells 
Cells were stored in liquid nitrogen suspended in 8% (v/v) dimethyl sulfoxide (DMSO), 30% 
(v/v) FCS and 68% (v/v) of the appropriate full growth medium (FGM) described in section 
2.1.4. The cells from one 175cm
2 flask were trypsinized,  resuspended in 1.8ml of this 
solution  and  aliquoted  in  freezing  vials,  which  were  slowly  cooled  to  -70
oC  and  then 
immersed in liquid nitrogen. DMSO (Sigma) is toxic above 4ºC and thus when recovered, 
cells were rapidly thawed to minimize the toxic effects of the cryoprotectant, transferred 
to a 25cm
2 flask and slowly diluted in pre-warmed media. The media was changed the 
following day. 
 
2.3.2 Routine Cell Passage  
Cells were grown in 175cm
2 flasks in the appropriate media (see section 2.1.4). They were 
incubated at 37
oC/ 5% CO2 and routinely passaged when 85-90% confluent. The medium 
was  carefully  removed  and  the  cell  monolayer  was  washed  with  HANKS  balanced  salt 
solution (HBSS) and incubated with trypsin: versene (1:10) until the cells were detached 
from the surface of the flask. The trypsinized cells were disaggregated, resuspended in a 
small volume of FGM to neutralize trypsin and seeded at a ratio of 1:10 (BHK and MAM49) 
or 1:3 (293T). When cells were grown in roller bottles, the roller bottles were gassed with 
C02 to a final concentration of 5% and placed in a rotary roller apparatus. 
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2.3.3 Transfection of Plasmids for Transient Expression 
293T cells (3x10
5) grown in 24-well plates until 90% confluent were transiently transfected 
with  supercoiled  plasmid  DNA  using  Lipofectamine  (Invitrogen).  For  a  single  well 
transfection, the appropriate amount of plasmid DNA was diluted in 50μl DMEM and mixed 
gently. The appropriate amount of Lipofectamine was also diluted in 50μl DMEM, mixed 
gently and incubated for 5min at room temperature. The Lipofectamine and DNA were 
combined  at  a  ratio  1:1  (v/w)  and  allowed  to  form  complexes  over  30min  at  room 
temperature.  The  cell  media  was  replaced  with  0.5ml  DMEM,  the  Lipofectamine-DNA 
complexes (100μl) were added to the cells and the cells were incubated at 37
oC for 4 
hours. Following this incubation, the cells were overlaid with 0.5ml of FGM. The following 
day the media was replaced. 
 
2.3.4 Construction of Stable Cell Lines 
Stable cell lines based on BHK cells were generated by transfection of linearised plasmid 
DNA using a variation of the standard calcium phosphate transfection method (Stow & 
Wilkie, 1976).  
 
HEBES Transfection Buffer:  
 
 
Filter sterilise with a 0.2μm filter 
Store at 4
oC 
140mM NaCl 
5mM KCl 
0.7mM Na2HPO4 
5.5mM D-glucose 
20mM Hepes 
pH 7.05 with NaOH 
 
BHK cells were grown in a 6-well plate until 70% confluent.  
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The following tubes were set up: 
 
Tube A:  31μl 2M CaCl2 
10μg linearised plasmid DNA 
20μg herring sperm DNA  
 
Tube B:  400ml HEBES 
 
The contents of tube A were gently mixed and added to tube B very slowly whilst the 
contents  of  tube  B  were  continuously  mixed.  The  mixture  was  incubated  at  room 
temperature for 40min to allow the DNA to precipitate. Following this incubation, the 
media was removed from the cells and the mixture was added to the cell monolayer in a 
dropwise manner. The cells were incubated for 40min at 37
oC and after 1ml of FGM was 
added, they were incubated at 37
oC for a further 4 hours. The media was removed and the 
cells were washed twice with 1ml of FGM. 1ml of ice cold 25% (v/v) DMSO in HEBES was 
added and left for 1.5min (no more than 2.5min). The DMSO solution was quickly removed, 
the cells were quickly washed twice with 2ml of FGM and 2ml of FGM without antibiotic 
selection  were  added.  The  following  day,  the  media  was  replaced  with  fresh  FGM 
containing  the  appropriate  antibiotic  selection  at  the  concentration  determined  by  a 
killing curve. In this study, the plasmids transfected for the generation of stable cell lines 
were based on pcDNA3 that expresses the neomycin gene. The concentration of G418 has 
been previously determined at 800μg/ml and no killing curve was therefore necessary. The 
transfection was split into petri dishes (1:10). The selective media was changed every 48-
72 hours until individual colonies were clearly visible. Colonies were selected using an 
inverted microscope and transferred to 96-well plates.  
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2.3.5 Screening and Purification of Cell Lines 
Colonies  grown  in  96-well  plates  were  screened  for  either  GFP  or  β-galactosidase 
expression (see sections 2.3.6 and 2.3.7). The colonies exhibiting the highest expression 
levels were selected and purified under continual selection. Each of the selected clones 
was then grown in a well of a 24-well plate until 85% confluent and infected with disabled 
virus at a multiplicity of infection of 1.0 and 5.0 to ensure that the cell line allows high 
levels  of  transduction.  The  optimal  clones  were  selected  and  amplified  further  under 
continual  selection.  The  cells  from  one  175cm
2  flask  were  frozen  and  stored  in  liquid 
nitrogen. A new vial was defrosted every 4 weeks.     
 
2.3.6 Detection of B-galactosidase Expression 
For cells grown in 6-well plates, the media was removed and the cells were washed twice 
with  2ml  1xPBS  and  fixed  with  1ml  0.05%  glutaraldehyde  in  1xPBS  for  10min  at  room 
temperature. The cells were washed with 2ml 1xPBS and incubated at 37oC with 2ml of 
pre-warmed  x-gal  solution  (1.4μg/ml  potassium  ferrocyanide  [K3Fe(CN)6]  and  1μg/ml 
potassium ferricyanide [K3Fe(CN)6
.6H20] in 1xPBS, 1μl/ml 1M MgCl2, and 2μl/ml 0.015gr X-
gal [5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside] in 100μl DMSO) until stained. The 
x-gal stain was then removed and the cells were washed with 1xPBS. For screening cell 
colonies or purification of viral recombinants expressing β-galactosidase, the cells were 
not  fixed  and  the  x-gal  was  removed  as  soon  as  the  cells  were  stained  to  minimize 
toxicity.     
 
2.3.7 Detection of Green Fluorescent Protein Expression 
Cells expressing GFP or EmGFP were visualised directly using an inverted microscope at a 
wavelength of 500nm. 
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2.4 VIRAL VECTOR CONSTRUCTION AND PROPAGATION 
 
The replication-incompetent virus used in this study was derived from HSV-1 strain 17syn
+ 
and has ICP4 deleted and also an inactivating mutation (in814) in VP16. The virus was 
propagated on the MAM49 cell line, which complements deletions in both ICP4 and ICP27 
and  mutations  in  vwm65.  The  in814  mutation  was
  also  complemented  by  addition  of 
100mM hexamethyl bisacetamide (HMBA) to the
 growth medium.  
 
2.4.1 Transfection for Homologous Recombination  
Insertion  of  expression  cassettes  into  the  HSV-1  genome  was  achieved  by  homologous 
recombination. 80-85% confluent MAM49 cells were co-transfected with plasmid and viral 
DNA, using the standard calcium phosphate technique (Stow & Wilkie, 1976). 0.5-1μg of 
supercoiled or linearised plasmid DNA and 10-20μg of purified viral genomic DNA, together 
with 31μl of 2M CaCl2 and 1μl of phenol-chloroform extracted herring sperm DNA (1μg/μl) 
were added to tube A and gently mixed. The contents of tube A were slowly added to tube 
B containing 400μl of room temperature Hebes transfection buffer (140mM NaCl, 5mM KCl, 
0.7mM Na2HPO4, 5.5mM D-glucose, and 20mM Hepes), whilst tube B was continuously but 
gently mixed. The DNA was allowed to precipitate at room temperature for 30-40 minutes 
and the transfection mixture was added to the cells in a dropwise manner. The cells were 
incubated at 37
oC for 30 minutes, and after 1ml of FGM was added to each well, they were 
incubated at 37
oC for a further 5 hours. Cells were incubated with 1ml of 20% (v/v) DMSO 
in Hebes buffer for no more than 90 seconds and were immediately washed twice with 2ml 
FGM. 2ml FGM containing 3mM HMBA were added and the transfection was incubated at 
37
oC/ 5% CO2 until cytopathic effect (CPE) had occurred. It was then harvested and freeze-
thawed once to disrupt the cells and release the virus.     
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2.4.2 Purification of Viral Recombinants by Plaque Selection 
Serial  10-fold  dilutions  of  the  original  transfection  were  prepared  in  100μl  DMEM.  80% 
confluent MAM49 cells were infected in a total volume of 500μl/well and incubated at 37
oC 
for 40-60 minutes to allow for the virus to be absorbed. Cells were overlaid with 2ml of a 
1:2 (v/v) mixture of 1.6% (w/v) carboxymethyl cellulose (CMC): FGM containing antibiotic 
selection  and  HMBA,  and  incubated  at  37
oC  for  48  hours.  Recombinants  plaques  were 
picked using either GFP fluorescence microscopy or x-gal staining at a volume of 10μl 
using a P20 Gilson micropipette. Each plaque was resuspended in 100μl DMEM, freeze-
thawed and used to infect two wells of a 6-well plate at 10μl and 90μl volumes.  The 
plaque purification process was repeated until a pure population was obtained. Once pure, 
each plaque was used to infect a single well of a 6-well plate. When CPE was observed, 
the wells were harvested, freeze-thawed and half of the virus was used to generate a 
master viral stock,  whereas the rest was kept at  –80
oC.  Virus genome structures were 
confirmed by PCR.  
 
2.4.3 Production of High Titre Viral Stock 
MAM49 cells grown in ten 175cm
2 flasks until 80-90% confluent were seeded in ten 850cm
2 
roller bottles, each containing 50ml FGM, gassed with 5% CO2 and incubated at 37
oC/ 5% 
CO2  until  85-90%  confluent.  Roller  bottles  were  infected  with  virus  master  stock  at  a 
multiplicity of infection (MOI) of 0.01 in a total volume of 500ml FGM supplemented with 
3mM HMBA, and incubated at 37
oC/ 5% CO2 for 24 hours and then at 32
oC/ 5% CO2 until full 
CPE was observed. Cells were detached from the walls of the roller bottles by vigorous 
shaking  and  freeze-thawed.  The  cell  suspension  was  transferred  in  50ml  tubes  and 
centrifuged at 3,500rpm for 45 minutes at 4oC to remove the cell debris. The supernatant 
was filtered using a 5μm/0.45μm filter (SARTOBRAN 300 from sartorius) and centrifuged at 
12,000rpm for 2 hours at 4
oC to pellet the virus. The supernatant was discarded ant the 130 
 
pelleted virus was resuspended in 500μl DMEM by gentle shaking overnight at 4
oC. The 
virus was stored in liquid nitrogen in 25μl aliquots. One aliquot was freeze-thawed and 
used to determine the viral titre of the stock.  
 
2.4.4 Viral Infectivity (Plaque) Assay 
Serial 10-fold dilutions of the virus were prepared in DMEM (10
-1-10
-10) and plated onto 85% 
confluent MAM49 cells. 24-well plates were infected in a volume of 200μl DMEM per well. 
Cells were incubated at 37
oC for 40-60 minutes to allow for the virus to be absorbed, 
overlaid with 1ml of CMC: FGM [1:2] containing 3mM HMBA and incubated at 37
oC for a 
further 48 hours. Plaques were visualized by x-gal staining or GFP fluorescent microscopy. 
The viral titre was calculated as plaque forming units/ml (pfu/ml).  
 
2.4.5 Viral DNA Extraction  
Infected MAM49 cells were harvested from 175cm
2 flasks when full CPE was observed. The 
medium was removed from the flask and 7ml of DNAzol (genomic DNA isolation reagent, 
Helena Biosciences) were added to the monolayer. The lysate was transferred to an empty 
tube and overlaid with an equal volume of absolute ethanol to precipitate the viral DNA. 
The  DNA  was  washed  twice  in  3ml  of  75%  ethanol,  transferred  to  a  clean  tube  and 
centrifuged at 5,000rpm for 1min. Excess ethanol was removed with a hypothermic needle 
and the pellet was allowed to air-dry at room temperature for 20min. The pelleted viral 
DNA was resuspended in 500μl of 8mM NaOH and incubated at 4
oC overnight to allow for 
the viral DNA to dissolve. The following day, 57.5μl of 0.1M Hepes were added to the 
solution  to  neutralize  the  NaOH  and  the  DNA  was  stored  at  –20
oC  until  required.  The 
integrity and approximate amount of the purified viral genomic DNA was determined by 
running 5μl on a 1% agarose gel.   
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2.5 PRIMARY NEURONAL CULTURES 
 
2.5.1 Coating Coverslips  
25mm sterile coverslips were placed into a 12-well plate and covered with poly-D-lysine 
(100μg/ml)  overnight.  The  poly-D-lysine  was  removed  and  the  coverslips  were  washed 
thoroughly  with  sterile  H20  and  were  allowed  to  dry  completely  (for  approximately  2 
hours) at room temperature.  
 
2.5.2 Primary DRG Neuronal Cultures 
A Lewis rat was terminally anesthetised. The head was removed and an incision was made 
along the length of the spinal column to expose the DRG. Each DRG was dissected, rinsed 
in  1xPBS,  and  the  membrane  and  excess  nerve  were  removed  with  fine  forceps  and 
scalpel.  The  ganglia  were  placed  in  1.6ml  DMEM.  400μl  collagenase  (Roche)  and  40μl 
trypsin were added and the ganglia were incubated at 37
oC for 2 hours with agitation 
every  20min.  The  ganglia  were  washed  twice  in  DMEM  containing  10%  horse  serum  to 
inactivate  the  collagenase  and  were  dispersed  using  polished  Pasteur  pipettes  with 
diminishing  diameter.  The  DMEM  was  removed  and  12ml  of  neurobasal  medium 
supplemented with NSF-1, L-glutamine and penicillin-streptomycin was added to the cells 
that were plated on poly-D-lysine coated coverslips and incubated at 37
oC/ 5% CO2. The 
following day, fresh pre-warmed media containing mitotic inhibitors (7.5μg/ml 5-fluoro-
2’deoxyuridine and 17.5μg/ml Ara-C) were added to inhibit proliferation of Schwann cells. 
Neurons were allowed to mature for 9 days prior to being transduced. Half of the media 
was changed with fresh pre-warmed media every 3 days.  
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2.6 IN VIVO DELIVERY 
 
All surgical instruments were obtained form Fine Science Tools (FST) and were sterilized in 
an  autoclave  for  20min  at  120
oC  prior  to  each  surgical  procedure.  Only  one  set  of 
instruments  was  used  per  animal.  Alternatively,  the  instruments  and  needle  were 
autoclaved after each operation to avoid spreading infections between animals. A Zeiss 
operation microscope was used in performing surgical procedures. All animal procedures 
were carried out in accordance to UK Home Office Regulations.    
 
2.6.1 Anaesthesia 
Balb/c mice 6-8 weeks old were anesthetised by delivery of 1.5% oxygen, 3% nitrous oxide 
and 4% halothane in an anaesthetic chamber. Once sedated, the animal was prepared for 
surgery,  transferred  to  the  operating  theatre  and  placed  on  a  heated  pad  where 
anesthesia  was  delivered  via  a  scavenging  nose  cone.  Once  the  animal  was  deeply 
anesthetised, as indicated by the loss of toe-pinch reflex, the level was reduced to 1.5-2% 
to maintain anesthesia during surgery. The breathing pattern of the animal was monitored 
regularly and the anesthesia adjusted accordingly. Post-operatively the animals were kept 
in a clean cage and monitored every hour for the first six hours and then every day until 
stable. 
 
2.6.2 Animal Preparation  
Veterinary clippers were used to shave the appropriate areas prior to surgery. The skin 
was cleaned with 70% ethanol and the animal was covered with a sterile drape exposing 
only the areas of interest. 
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2.6.3 Sciatic Nerve Injection & Conditioning lesion 
A skin incision, parallel and caudal to the femur, was made in the left thigh using a scalpel 
and  the  underlying  muscles  were  exposed.  The  muscles  (biceps  femoris  and 
semitendinosus muscles) were separated by blunt dissection and the left sciatic nerve was 
exposed. Fine forceps were used to separate the two main branches of the sciatic nerve. 
The tibial nerve, which is the larger branch, was injected with 5-7μl of virus over a period 
of 15min using a 10μl Hamilton blunt end syringe connected to a glass needle (Sigma; 50μl 
microcapillary  pipettes)  via  fine  tubing  (SIMS  Portex  Ltd;  Portex  fine  bore  polythene 
tubing). The needle was carefully withdrawn, the nerve was loosely ligated with silk 5/O 
suture  to  prevent  any  outflow  of  virus  and  the  skin  was  closed  with  Michel  clips. 
Conditioning lesion of the sciatic nerve was performed following injection of the virus and 
ligation of the sciatic nerve by crushing both branches using fine forceps.  
 
2.6.4 Transection of the dorsal root (Rhizotomy) 
A left hemilaminectomy was performed at the L2 vertebra and the dura was opened. The 
L3  and  L4  dorsal  roots  were  identified  by  their  large  diameter  and  transected  with 
microsurgical scissors. The cut ends were reanastomosed with a single 10/O suture. The 
dura was closed with 10/O sutures, the musculature was repaired with silk sutures and the 
skin  was  closed  with  Michel  clips.  This  procedure  was  performed  by  Prof.  Patrick 
Anderson.  
 
2.6.5 Transcardial Perfusion    
Animals were placed in a chamber and terminally anesthetised with C02. All animals were 
sacrificed in accordance to Schedule 2 Home Office regulations. The heart was exposed 
and after an incision of the pericardium was made, a blunt end needle was inserted into 134 
 
the left vertical and 4% paraformaldehyde (PFA) in PBS was pumped through the heart 
using a peristaltic pump at a rate of 30rpm.  When the animals were sufficiently perfused, 
the lumbar DRG (L1 to L6) ipsilateral to the inoculated side and/or the spinal cord were 
dissected and post-fixed in ice-cold 4% PFA for 1 hour on ice, after which time the tissue 
was washed twice with 1xPBS and sectioned.  
 
2.6.6 Sectioning of DRG and Spinal Cords 
Lumbar DRG and/or spinal cords were dissected from perfused animals and cryoprotected 
in 30% sucrose in 1xPBS at 4
oC until no longer buoyant. The tissues were embedded in 
Tissue Freezing Medium (Triangle  Biomedical Sciences, Durham, N.C.) and immediately 
frozen. 10-20µm cryosections were cut on a Microm HM 500 M Cryostat and placed on 
Superfrost glass slides (WVR). The sections were stored at –80
oC until either x-gal staining 
or  immunofluorescence  was  performed.  To  assess  GFP  fluorescence,  animals  were  not 
perfused and DRG sections were fixed with 70% ethanol instead of 4% PFA. 
 
2.6.7 Detection of β-galactosidase and GFP in whole DRG 
Animals  were  not  perfused.  The  lumbar  DRG  were  dissected,  post-fixed  in  4%  PFA 
overnight, washed twice with 1xPBS for 15min and stained with x-gal (5mM [K3Fe(CN)6] 
and 5mM [K3Fe(CN)6
.6H20] in 1xPBS, 1mM MgCl2, 0.02% sodium deoxycholate, 0.02% NP-40 
and 40mg/ml x-gal in DMSO) for no more than 3 hours. To assess expression of both GFP 
and β-galactosidase, GFP fluorescence was examined prior to fixation and x-gal staining, 
as this otherwise masks GFP fluorescence. Cell counts were performed in a blinded fashion 
in whole mount DRG preparations at a magnification of x40. 
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2.6.8 Processing Tissue for Protein Extraction 
Animals  were  not  perfused.  The  DRG  were  dissected  on  ice,  rinsed  with  1xPBS  and 
immediately snap-frozen in liquid nitrogen. They were stored at –80
oC until homogenized 
and protein was extracted as described in section 2.7.1. 
 
2.6.9 Processing Tissue for RNA Extraction 
Animals  were  not  perfused.  The  DRG  were  immediately  dissected,  rinsed  with  DEPC-
treated 1xPBS and placed in sterile tubes containing RLT buffer (Qiagen) containing β-
mercaptoethanol. The DRG were immediately homogenized and the RNA was extracted as 
described in section 2.2.17.  
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2.7 PROTEIN ISOLATION & ANALYSIS 
 
2.7.1 Extraction of Protein from DRG 
The frozen DRG were transferred to a pestle and mortar which had been cooled on ice and 
were immediately homogenized in ice-cold RIPA (radio immuno precipitation assay) lysis 
buffer (150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris, pH 8.0) 
containing  a  cocktail  of  protease  inhibitors  (Roche).  The  homogenate  was  first  passed 
through a 21 gauge needle 10 times and then a 25 gauge needle 10 times. It was then 
transferred  to  an  ice-cold  1.5ml  microcentrifuge  tube  and  constant  agitation  was 
maintained for 2 hours at 4
oC. The sample was centrifuged at 12,000rpm for 20min at 4
oC 
and the supernatant was transferred to a clean ice-cold tube and kept on ice. The protein 
concentration  was  determined  using  the  Bradford  assay  (Bio-Rad)  according  to  the 
manufacturer’s protocol and the concentration between samples was equalised in RIPA 
buffer so that 1-5mg/ml protein was loaded onto each gel. The samples were denatured in 
Laemmli standard loading buffer (5% β-mercaptoethanol, 50mM Tris-HCl pH 8.0, 6% (v/v) 
glycerol, 2% (w/v) SDS and 0.005% (w/v) bromophenol blue) at 70
oC for 10min and were 
either loaded onto an SDS-polyacrylamide gel or stored at -20
oC.  
 
2.7.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The  Laemmli  system,  which  is  the  most  widely  used  SDS-PAGE  method  for  separating 
proteins (Laemmli, 1970), operates in a highly alkaline pH and may cause band distortion, 
loss of resolution, or artifact bands. For this reason, the NuPAGE
® system (Invitrogen) was 
used, which operates in neutral pH 7.0 resulting in maximum stability of both proteins and 
gel matrix, thus providing better band resolution. 4-12% NuPAGE
® Bis-Tris pre-cast gels 
were run in the XCell SureLock
TM Mini-Cell vertical gel electrophoresis system (Invitrogen) 
in 1xNuPAGE
® MES [2-(N-morpholino) ethane sulfonic acid] SDS Running Buffer. The upper 
buffer chamber (inner) was filled with running buffer above the level of the wells, the 137 
 
wells  were  rinsed  with  running  buffer,  10μl  of  denatured  sample  and  3μl  of  rainbow 
marker (Amersham) were loaded onto the gel and the lower buffer chamber (outer) was 
filled with 600ml of running buffer. The gels were run for 1 hour at 110/125 mA/gel (start) 
– 70/80 mA/gel (end).   
 
2.7.3 Western Blotting 
Proteins separated on NuPAGE
® Bis-Tris gels were transferred to Hybond C nitrocellulose 
membranes (Amersham) using the wet transfer method (Towbin et al., 1979). Briefly, the 
gel  and  nitrocellulose  membrane  were  pre-soaked  in  1xNuPAGE
®  Transfer  Buffer 
(Invitrogen)  and  sandwiched  between  sheets  of  pre-soaked  Whatman  3MM  paper  and 
Trans-Blot
TM Cell (Bio-Rad). The transfer was performed at 200mA for 2 hours. 
 
2.7.4 Immunodetection of Proteins on Western Blots  
Nitrocellulose membranes were rinsed in 1xPBS with 0.1% Tween-20 (PBST) and blocked in 
5%  (w/v)  skimmed  milk  in  PBST  overnight  at  4
oC  with  constant  shaking.  The  blocked 
membranes were incubated with primary antibody diluted in 5% (w/v) skimmed milk in 
PBST  overnight  at  4
oC  with  constant  shaking  (see  section  2.1.7  for  table  of  primary 
antibodies and dilutions) and washed three times at room temperature for 10min with 
PBST with constant shaking. They were then incubated with an HRP-conjugated secondary 
antibody diluted 5% (w/v) skimmed milk in PBST for 1 hour at room temperature with 
constant shaking (see section 2.1.7 for table of secondary antibodies and dilutions) and 
washed twice with PBST and once with PBS at room temperature for 10min with constant 
shaking.  Immunodetection  was  performed  using  the  ECL+  reagents  (Amersham 
Biosciences).  The  membranes  were  exposed  on  x-ray  film  for  1sec  to  10  minutes 
depending on the strength of the signal. The films were scanned and the pixel count and 
intensity of each band was quantified using the Scion Image software (Scion, Frederick, 138 
 
MD).  Signals  were  normalised  against  α-tubulin  (loading  control)  and  the  result  was 
expressed as a percentage of the negative control signal.  
 
2.7.5 B-galactosidase Activity Assay 
For determining β-galactosidase protein levels, the High Sensitivity β-Galactosidase Assay 
kit (Stratagene) was used according to the manufacturer’s instructions. Cells were lysed 
and  cell  lysates  were  incubated  with  a  reaction  buffer  and  chlorophenol  red-β-D-
galactopyranoside (CPRG) substrate. The activity of β-galactosidase was quantified using a 
microplate reader.  
 
2.7.6 Immunofluorescence 
Sections were defrosted, fixed in 4% PFA for 15min, washed three times with 1xPBS and 
blocked in Image-iT FX Signal Enhancer (Molecular Probes) for 30min at room temperature. 
For Immunodetection of intracellular proteins, the cells were permeabilised by incubation 
with  1xPBS  containing  0.25%  Triton  x-100  (PBST)  for  10min  at  room  temperature  and 
washed three times in 1xPBS for 5min. The sections were then incubated with a mixture of 
primary  antibodies  in  1%  bovine  serum  albumin  (BSA)  in  PBST  for  1  hour  at  room 
temperature in a humidified chamber, washed three times with 1xPBS for 5min and then 
treated with a mixture of secondary antibodies in 1% BSA for 1 hour at room temperature 
in  a  humidified  chamber  (see  section  2.1.7).  Coverslips  were  mounted  with  a  drop  of 
mounting medium, were sealed with nail polish to prevent drying and stored in the dark at 
-20
oC. All photographs were taken using an Axiovert 200M microscope equipped with an 
Axiocam HRc colour camera (Carl Zeiss, Jena, Germany). 
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CHAPTER 3 
 
DEVELOPMENT AND EVALUATION OF REPLICATION-
DEFECTIVE HSV-1 VECTORS EXPRESSING shRNA 
USING DIFFERENT APPROACHES 140 
 
3.1 Introduction 
The choice of promoter driving expression of shRNA is very important in the design of an 
efficient and versatile HSV-based method to deliver RNAi to neurons of the peripheral 
nervous  system.  Optimisation  of  shRNA  expression  will  allow  delivery  of  lower  vector 
doses, thus reducing potential side effects, such as toxicity caused by the virus or off-
target effects caused by shRNA. This chapter describes the development of a number of 
replication-defective HSV-1 vectors expressing shRNA against reporter genes. The aim of 
this  chapter  was  to  compare  different  shRNA  expression  systems  described  in  the 
literature in the context of the HSV genome when combined with LAT-based expression 
systems,  and  evaluate  their  ability  to  silence  target  gene  expression  in  DRG  sensory 
neurons, with a view to developing an optimal system on which to base future work. 
The pol III U6 and H1 promoters had been most commonly used to express shRNA 
from  plasmid  and  viral  vector  systems  (Abbas-Terki  et  al.,  2002,  An  et  al.,  2003, 
Brummelkamp et al., 2002, Huang et al., 2004, Paul et al., 2002, Sui et al., 2002, Yu et 
al., 2002) and thus, were an obvious choice with which to attempt to express shRNA from 
the disabled HSV-1 vectors used in this thesis. However, pol III promoters lack spatial and 
temporal  control,  and  although  inducible  U6  and  H1  promoters  had  been  developed 
(Tiscornia et al., 2004, van de Wetering et al., 2003), in vivo application of such systems 
is  challenging,  as  it  requires  co-delivery  and  expression  of  additional  elements. 
Furthermore,  previous  work  in  our  laboratory  had  demonstrated  that  the  choice  of 
promoter is important in achieving efficient and long-term HSV-mediated gene expression 
in neurons in vivo (Palmer et al., 2000). As discussed in detail in the introduction of this 
thesis, expression from replication-defective HSV-1 vectors poses specific challenges, due 
to  transcriptional  silencing  of  most  HSV  promoters  as  well  as  exogenous  promoters 
introduced into the latent viral genome. It has been suggested that the structure of LAP2 
and  its  surrounding  regions  may  be  important  for  the  LAT  region  to  remain 
transcriptionally active during latency (Coffin et al., 1995). In support of this hypothesis, a 141 
 
sequence  1.4kb  downstream  of  the LAP1  TATA  box  (referred  to  as LATP2)  linked  to  a 
strong heterologous pol II promoter has been shown to drive highly efficient and sustained 
expression of reporter genes during latency in both the peripheral and central nervous 
system (Lilley et al., 2001, Palmer et al., 2000). Palmer et al. however, who investigated 
reporter gene expression in DRG from different promoters, demonstrated that the LATP2 
region  has  the  capability  to  allow  long-term  expression  in  a  relatively  non-promoter 
specific fashion. At the time the objectives of this chapter were conceived, HSV-mediated 
expression  from  pol  III  promoters  had  not  been  investigated  and  thus,  there  was  no 
evidence to suggest that following insertion of the U6 or H1 promoter downstream of the 
LATP2 region, the LAT region would enable these promoters to remain transcriptionally 
active during latency.  
In addition to pol III promoters, a modified pol II CMV promoter (Xia et al., 2004, Xia 
et al., 2002) and a hybrid CMV enhancer-U6 promoter (Xia et al., 2003) had been utilised 
to express shRNA. The modified CMV promoter was found to be more efficient than the H1 
promoter in PC3-6 neural cells, and the CMV enhancer element was shown to significantly 
improve silencing from the U6 promoter in HEK-293 cells. Moreover, an HIV-inducible pol II 
promoter was shown to efficiently express shRNA from a lentiviral vector and silence HIV-1 
Rev protein in culture (Unwalla et al., 2004). Finally, Zeng and colleagues demonstrated 
that shRNA could be efficiently expressed from the CMV promoter when embedded into 
endogenous  miR-30  sequences  and  that  these  artificial  miRNAs  could  induce  specific 
degradation of target mRNAs similar to transfected siRNAs (Zeng & Cullen, 2003, Zeng et 
al., 2002). Silencing of HIV-1 tat in 293 cells was found to be significantly improved when 
shRNA was expressed from a miR-30-based vector under the control of the U6 promoter 
compared  to  shRNA  expressed  from  the  same  promoter  (Boden  et  al.,  2004).  Pol  II 
promoters can be inducible or tissue-specific and the CMV promoter had been previously 
shown to allow efficient and long-term gene expression from the disabled HSV vectors 
developed  in  our  lab  (Lilley  et  al.,  2001,  Palmer  et  al.,  2000).  Moreover,  it  was 142 
 
hypothesised  that  insertion of a hybrid CMV enhancer-U6 promoter downstream of the 
LATP2 region would be less likely to disturb the structure of the region surrounding LAP2, 
as the CMV promoter elements in the proximity of the LATP2 region would be retained.   
At the time work in this chapter begun, silencing in the brain had been achieved 
through vector-mediated expression of shRNA from a lentivirus using the U6 promoter (Van 
den Haute et al., 2003) and an adenovirus or AAV using a modified CMV promoter (Xia et 
al., 2004, Xia et al., 2002). However, expression of shRNA from an HSV-1 vector had not 
been demonstrated, and there were no reports of vector-mediated expression of shRNA in 
peripheral  neurons  in  vivo.  Moreover,  in  vivo  expression  of  shRNA  from  a  miRNA-like 
system or a hybrid CMV enhancer-U6 promoter had not been investigated. Thus, in order 
to identify the most effective system on which to base future work, expression of shRNA 
from the U6 promoter, a hybrid CMVenhancer-U6 promoter, a modified CMV promoter, or 
a miR-like system utilising the CMV promoter were evaluated, when linked to LAT-derived 
sequences,  in  dividing  cells  in  culture  and  both  in  vitro  and  in  DRG  neurons  in  vivo 
following insertion of these cassettes into disabled HSV-1 vectors.  
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3.2 The 1764/4-/27+/RL1+ HSV-1 backbone 
All virus backbones used in this thesis are 1764/4-/27+/RL1+.  They were derived from 
HSV-1 strain 17syn+ (Brown et al., 1973). The term 1764 is used to describe a virus with 
the  in814  mutation  in  the  gene  encoding  VP16  (Ace  et  al.,  1989)  and  with  the  genes 
encoding the neurovirulence factor ICP34.5 and ORF P completely deleted (McLean et al., 
1990).  The  in814  mutation  renders  VP16  capable  of  fulfilling  its  structural  role,  yet 
incapable of transactivating IE gene expression. The term 4- refers to the deletion of ICP4, 
which is necessary for minimal toxicity. The 1764/4-/27- vectors initially developed in our 
lab had ICP27, ICP4 and ICP34.5 deleted and had the inactivating in814 mutation in vmw65 
(Lilley et al., 2001, Palmer et al., 2000). 27+ and RL1+ describe the re-insertion of ICP27 
and ICP34.5 into the HSV genome (Palmer, unpublished). Re-insertion of ICP27 increases 
the ease of the production of the virus without significantly increasing toxicity, and re-
insertion of ICP34.5 increases the expression levels of delivered genes in the context of 
this  vector  backbone  (unpublished  work).  A  schematic  representation  of  the  1764/4-
/27+/RL1+ vector backbone is shown in figure 3.1a.  
  
3.3 The Complementing Cell Line 
The complementing cell line 27/12/M:4 used for the propagation of the 1764/4-/27+/RL1+ 
viruses was previously constructed in our laboratory (Thomas et al., 1999b). It expresses 
the equine herpesvirus 1 (EHV-1) homologue of vmw65, which has minimal similarity to the 
HSV gene to minimise the likelihood of the vmw65 mutation being repaired by homologous 
recombination.  Moreover,  although  the  EHV-1  gene  12  protein  can  functionally 
compensate for mutations in vmw65, it cannot structurally substitute for vmw65. Thus, 
the protein is not packaged in the virions and cannot transactivate IE gene expression 
when the virus produced is used to transduce non-complementing cells. The 27/12/M:4 
cell line also expresses ICP27 from the ICP27 promoter and ICP4 from the MMTV promoter. 
Importantly, in the absence of viral infection, EHV-1 gene 12, ICP27 and ICP4 are only 144 
 
weakly  expressed,  resulting  in  no  observed  toxicity  and  cells  that  can  be  stably 
propagated. Following viral infection and presumably transactivation of ICP0 by the EHV-1 
gene 12 protein, these genes are abundantly expressed allowing efficient propagation of 
disabled viruses.  
 
3.4 The pR19 Expression Cassette 
All viruses in this thesis utilise the pR19 cassette, which has been previously described 
(Wagstaff et al., 1998). To facilitate recombination into the LAT region, the pR19 cassette 
is flanked by sequences derived from the long repeat regions of the HSV-1 genome (nt 
118,441-120,219  and  nt  120,413-122,027).  A  strong  heterologous  promoter  is  inserted 
1.4kb downstream of the LAP1 TATA box, referred to as the LAT P2 region, which allows 
long-term expression during latency in both the peripheral and central nervous system 
(Lilley et al., 2001, Palmer et al., 2000). The gene is placed under the control of a pol II 
promoter, such as the CMV IE gene, EF1α or synapsin promoters, and the bovine growth 
hormone  polyadenylation  sequence  (BGH  polyA).  Expression  from  these  vectors  was 
further improved by insertion of a mutated form of the woodchuck hepatitis virus post-
transcriptional  regulatory  element  (WCm)  between  the  gene  and  BGH  polyA.  WPRE  is 
required for the accumulation of wild-type WHV RNAs (Donello et al., 1998) and has been 
shown to enhance transgene expression in retroviral and lentiviral vector systems both in 
vitro and in vivo (Glover et al., 2003, Klein et al., 2002, Paterna et al., 2000) possibly by 
enhancing mRNA nuclear export (Zufferey et al., 1999). A schematic representation of the 
pR19 cassette is shown in figure 3.1b. 
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3.5 Generation of plasmid vectors expressing shRNA 
In  order  to  identify  the  most  effective  method  of  expressing  shRNA  from  the  1764/4-
/27+/RL1+ vector backbone, a number of different approaches, which are summarised in 
figure  3.2a-d,  were  evaluated.  To  compare  silencing  from  these  expression  systems, 
plasmid vectors were generated to express a well-characterised hairpin sequence designed 
to  target  lacZ,  the  reporter  gene  encoding  β-galactosidase.  Control  plasmids  were 
constructed to mediate expression of shRNA against green fluorescent protein (GFP) or a 
non-target shRNA sequence that is not predicted to target any known vertebrate gene 
(neg). Construction of these vectors is described in the following sections. 
 
3.5.1 Expression of shRNA from a Polymerase III promoter 
The pR19U6shRNA system (figure 3.2a) utilises the U6 pol III type promoter that has been 
widely used to successfully silence genes both in vitro and in vivo. The endogenous U6 
promoter  controls  expression  of  the  U6  RNA,  a  small  nuclear  RNA  (snRNA)  involved  in 
splicing  (Kunkel  et  al.,  1986),  has  been  well  characterised,  and  is  active  in  most 
mammalian cell types. Transcriptional termination by RNA polymerase III provides a means 
of expressing shRNA transcripts with defined ends (Tazi et al., 1993). Moreover, although 
most genes transcribed by RNA polymerase III require cis-acting regulatory elements within 
the  transcribed  regions,  class  III  promoters  such  as  U6  and  H1,  use  exclusively  non-
transcribed promoter sequences (Reddy, 1988).  
Inhibition of gene expression by a shRNA expressed from the U6 promoter has been 
shown to be more effective than inhibition by two siRNA strands expressed from separate 
U6 vectors (Yu et al., 2002). Plasmid vectors allowing efficient expression of shRNA from 
the U6 promoter were commercially available and thus,  the BLOCK-iT
TM U6 RNAi Entry 
Vector from Invitrogen (pENTR-U6) was used. The pENTR-U6 vector allows cloning of an 
approximately  50bp  DNA  oligonucleotide  immediately  downstream  of  the  U6  pol  III 
promoter and upstream the pol III termination sequence that consists of a cluster of 6 148 
 
thymidine (T) residues (figure 3.3). The shRNA sequence consists of a 5’overhang (CACC), 
which allows directional cloning, the 1+-G of the U6 promoter, a 19nt sense sequence, a 
4nt loop (CGAA), and a 19nt antisense sequence. Expression from this cassette results in 
the production of a shRNA, which enters the endogenous miRNA pathway, is transported to 
the cytoplasm and processed by Dicer into a 21nt siRNA. The siRNA guide strand becomes 
incorporated into a RISC, which targets mRNA with perfect complementarity to the siRNA 
for degradation resulting in effective knockdown of target gene expression.  
The pENTR-U6 vector was supplied linearised with 4nt 5’overhangs on each strand to 
facilitate directional cloning of the double stranded DNA oligonucleotide. The validated 
sequence targeting β-galactosidase (shLacZ) and the non-target shRNA sequence that is 
not predicted to target any known vertebrate gene (neg) were supplied by Invitrogen as 
annealed DNA oligonucleotides (sequences available in section 2.1.6) and were cloned into 
pENTR-U6  vectors  (figure  3.3).  The  three  sequences  targeting  GFP  (shGFP1-3)  were 
designed using Invitrogen’s RNAi designer tool (sequences available in section 2.1.6). They 
were  synthesized  as  single  stranded  DNA  oligonucleotides,  annealed  and  cloned  into 
pENTR-U6  vectors.  Each  of  the  pENTR-U6shRNA  vectors  was  sequenced  using  the  U6 
Forward and M13 Reverse primers (described in section 2.1.5) to ensure that the insert 
had  been  cloned  in  the  correct  orientation  and  more  importantly,  that  the  shRNA 
sequence had not been mutated (figure 3.4).  
The pENTR-U6shRNA vectors allow transient expression of shRNA in cells that can be 
efficiently transfected with plasmid DNA and therefore enable rapid screening of shRNA 
sequences. Transfection of post-mitotic neurons is highly inefficient and often toxic. Thus, 
following  initial  screening,  the  U6shRNA  cassette  is  transferred  into  an  appropriate 
destination vector that serves as a shuttle plasmid and allows the cassette to be inserted 
into a disabled HSV vector.  
The  pR19-Gateway  destination  vector  which  was  constructed  contains  flanking 
regions that allow recombination  into  the LAT region of the HSV genome (nt 118,441-149 
 
120,219 and nt 120,413-122,027) and the Gateway cassette (Invitrogen) that allows cloning 
using  the  recombination  properties  of  bacteriophage  lambda  (figure  3.5e).  The  HSV 
flanking regions were derived from the pR19SYNeGFP vector (figure 3.5a), which drives 
expression  of  enhanced  GFP  from  the  synapsin  promoter.  To  remove  the  BGH  polyA 
sequence that is not essential for pol III expression, pR19SYNeGFP was digested with SacI-
EcoNI. This step also removed the 5’end of the HSV nt 120,413-122,027 flanking region, 
which was excised as a BstXI-EcoNI fragment from pNot3.5 and cloned into pR19SYNeGFP 
(SacI-EcoNI)  to  generate  the  pR19SYNeGFP(no  BGH  polyA)  vector  (figure  3.5c).  The 
pNot3.5 plasmid had been previously constructed in our laboratory (figure 3.5b). The LAT 
flanking  regions  were  derived  from  the  NotI  region  of  the  HSV  genome  (nt  118,439-
122,025) and cloned into the unique NotI site of the pGEM5 cloning vector (Promega). The 
pR19SYNeGFP(no BGH polyA) vector was converted into a destination vector by cloning the 
Gateway  cassette  (figure  3.5d)  between  the  ClaI-NsiI  sites  that  had  been  blunted  and 
treated with calf intestinal alkaline phosphatase (as described in sections 2.2.3 and 2.2.4). 
Finally,  the  U6shLacZ,  U6-neg  and  U6shGFP2  (see  section  3.6)  cassettes,  which  were 
flanked  by  attL1-attL2  sequences,  were  inserted  from  pENTR  (figure  3.5f)  into  pR19-
Gateway  by  LR  recombination  (as  described  in  section  2.2.9)  to  generate  the 
pR19U6shLacZ, pR19U6-neg and pR19U6shGFP2 vectors, respectively. The cassettes were 
sequenced  between  the  LAT  flanking  regions  (sequences  not  shown).  A  map  of 
pR19U6shRNA is shown in figure 3.5g. 
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a) pENTR-U6shLacZ sequencing 
 
 
Sequence 1: lcl|1 
Length = 47 (1 .. 47)  shLacZ 
 
Sequence 2: lcl|65536 
Length = 1358 (1 .. 1358)  pENTRU6shLacZ (U6 F primer) 
 
Score = 91.1 bits (47), Expect = 2e-16 
Identities = 47/47 (100%), Gaps = 0/47 (0%) 
Strand=Plus/Plus 
 
Query  1   CACCGCTACACAAATCAGCGATTTCGAAAAATCGCTGATTTGTGTAG  47 
           ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  37  CACCGCTACACAAATCAGCGATTTCGAAAAATCGCTGATTTGTGTAG  83 
 
 
 
The target sequence against β-galactosidase in shLacZ: 
 
gb|FJ440335.1|  Reporter cassette lacTeT, complete sequence 
Length=5870 
 
Score = 38.2 bits (19), Expect = 2.2 
Identities = 19/19 (100%), Gaps = 0/19 (0%) 
Strand=Plus/Minus 
 
Query  29   AAATCGCTGATTTGTGTAG  47 
            ||||||||||||||||||| 
Sbjct  745  AAATCGCTGATTTGTGTAG  727 
 
 
 
b) pENTR-U6shGFP1-3 sequencing 
 
 
Sequence 1: lcl|1 
Length = 45 (1 .. 45) shGFP1  
 
Sequence 2: lcl|65536 
Length = 1434 (1 .. 1434) pENTRU6shGFP1 (M13 R primer) 
 
Score = 87.2 bits (45), Expect = 3e-15 
Identities = 45/45 (100%), Gaps = 0/45 (0%) 
Strand=Plus/Minus 
 
Query  1    CACCGCAAGCTGACCCTGAAGTTCGAAAACTTCAGGGTCAGCTTG  45 
            ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  174  CACCGCAAGCTGACCCTGAAGTTCGAAAACTTCAGGGTCAGCTTG  130 
 
 
 
Sequence 1: lcl|1 
Length = 50 (1 .. 50) shGFP2 
 
Sequence 2: lcl|65536 
Length = 1450 (1 .. 1450) pENTRU6shGFP2 (M13 R primer) 
 
Score = 96.8 bits (50), Expect = 5e-18 
Identities = 50/50 (100%), Gaps = 0/50 (0%) 
Strand=Plus/Minus 
 
Query  1   CACCGCATCAAGGTGAACTTCAAGACGAATCTTGAAGTTCACCTTGATGC  50 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  187 CACCGCATCAAGGTGAACTTCAAGACGAATCTTGAAGTTCACCTTGATGC  138 
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Sequence 1: lcl|1 
Length = 50 (1 .. 50) shGFP3 
 
Sequence 2: lcl|65536 
Length = 1442 (1 .. 1442) pENTRU6shGFP3 (M13 R primer) 
 
Score = 96.8 bits (50), Expect = 5e-18 
Identities = 50/50 (100%), Gaps = 0/50 (0%) 
Strand=Plus/Minus 
 
Query  1  CACCGCCACAACGTCTATATCATGGCGAACCATGATATAGACGTTGTGGC  50 
          |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 185 CACCGCCACAACGTCTATATCATGGCGAACCATGATATAGACGTTGTGGC  136 
 
 
 
 
 
Figure  3.4  Blast  nucleotide  sequence  alignment  between  pENTR-U6shRNA  sequences 
obtained with the U6 Forward or M13 Reverse primers (described in section 2.1.5) and the 
oligonucleotide  sequences  expressing  shRNA  against  a)  β-galactosidase  (shLacZ)  or  b) 
enhanced GFP (shGFP). The target sequence against β-galactosidase in shLacZ is indicated 
in the reporter cassette lacTeT sequence. 
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Figure 3.5 Cloning of pR19U6shRNA plasmids 
 
The  details  of  the  cloning  can  be  found  in  section  3.5.1.  Briefly,  pR19SYNeGFP  was 
converted  into  the  pR19-Gateway  vector  by  removing  the  BGH  polyA  and  cloning  the 
Gateway cassette between ClaI-NsiI. The U6shLacZ, U6-neg and U6shGFP2 cassettes were 
inserted  from  pENTR  (attL1-attL2)  into  pR19-Gateway  vectors  (attR1-attR2)  by  LR 
recombination to generate the pR19U6shLacZ, pR19U6-neg and pR19U6shGFP2 plasmids, 
respectively. 
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3.5.2 Expression of shRNA from a hybrid Pol II-Pol III promoter 
Whilst some snRNAs are synthesized by RNA pol III, others are synthesized by pol II. These 
promoters have been shown to share enhancer elements (Carbon et al., 1987, Kunkel & 
Peterson, 1988) and thus, a pol II enhancer may be able to enhance transcription from a 
pol III promoter. Indeed, various studies have demonstrated that the enhancer element of 
the CMV IE gene pol II promoter can improve the activity of the U6 or H1 pol III promoters 
(Ong et al., 2005, Xia et al., 2003). To test whether shRNA expression could be improved 
in this manner, pR19CMVenhU6shRNA was constructed,  where expression of shRNA was 
placed under the control of a hybrid CMV enhancer-U6 promoter (figure 3.2b).  
In  the  study  by  Xia  et  al.  (2003),  the  authors  evaluated  a  number  of  different 
constructs  containing  various  combinations  of  U6  promoter  and  CMV  enhancer.  They 
demonstrated that the CMV enhancer element increased expression when placed either 
upstream  or  downstream  of  a  full  length  U6  promoter  in  either  forward  or  reverse 
orientation. In this study, a hybrid promoter consisting of the CMV enhancer element in a 
forward orientation inserted upstream of a full length U6 promoter was generated.  
The CMV enhancer comprises nt 619-1024 of the human CMV IE gene promoter. A 
486nt (nt 542-1027) CMV enhancer fragment was generated by PCR (as described in section 
2.2.16) using the CMVenh F and CMVenh R primers (described in section 2.1.5) and the 
pR19CMVLacZWCm  plasmid  as  a  template  (figure  3.6a).  The  CMVenh  R  primer  was 
designed to add a XhoI restriction site to the 3’end of the PCR product to allow the CMV 
enhancer fragment to be cloned into pR19CMVLacZ between the SpeI-XhoI sites, in place 
of the CMV promoter and lacZ gene (figure 3.6b). To remove the BGH polyA sequence, the 
pR19CMVenh plasmid was digested with BstXI-EcoNI (figure 3.6c). This step also removed 
the 5’end of the HSV nt 120,413-122,027 flanking region, which was excised as a BstXI-
EcoNI fragment from pNot3.5 (figure 3.6d) and cloned into pR19CMVenh (BstXI-EcoNI) to 
generate the pR19CMVenh(no BGH polyA) vector (figure 3.6e). The pR19CMVenh(no BGH 
polyA) plasmid was converted into the pR19CMVenh-Gateway destination vector (figure 156 
 
3.6g)  by  cloning  the  Gateway  cassette  (figure  3.6f)  into  the  BstXI  site  that  had  been 
blunted  and  treated  with  calf  intestinal  alkaline  phosphatase.  Finally,  the  U6shLacZ 
cassette (described in the previous section) was inserted from pENTR (figure 3.6h) into 
pR19CMVenh-Gateway by LR recombination. The pR19CMVenhU6shLaZ plasmid (figure 3.6i) 
was sequenced between the LAT flanking regions to ensure that the CMVenh-U6 hybrid 
promoter  had  been  constructed  correctly  and  that  the  shLacZ  sequence  had  not  been 
mutated (figure 3.11a).  
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Figure 3.6 Cloning of the pR19CMVenhU6shLacZ plasmid 
 
The details of the cloning can be found in section 3.5.2. Briefly, the CMV enhancer was 
generated by PCR using the CMVenh F and CMVenh R primers (described in section 2.1.5) 
and the pR19CMVLacZWCm plasmid as a template. A XhoI restriction site was added to the 
3’end  of  the  fragment  during  PCR  to  allow  the  CMV  enhancer  to  be  cloned  into 
pR19CMVLacZ between SpeI-XhoI. The BGH polyA was removed and the pR19CMVenh(no 
BGH polyA) plasmid was converted into the pR19CMVenh-Gateway destination vector by 
cloning the Gateway cassette into BstXI. The U6shLacZ cassette was inserted from pENTR 
into  pR19CMVenh-Gateway  by  LR  recombination  to  generate  the  pR19CMVenhU6shLacZ 
plasmid. 158 
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3.5.3 Expression of shRNA from a miRNA-like system 
Although pol III promoters have so far been most commonly used for expression of shRNA, 
there has been an interest in developing systems using pol II promoters. The miRNA-like 
expression system (pR19CMV/EmGFP-miR) constructed in this thesis takes advantage of 
the  flexibility  and  variety  of  pol  II  promoters,  which  unlike  pol  III  promoters,  can  be 
inducible and tissue-specific (figure 3.2c).   
When  inserted  into  pol  II  mRNA  transcripts  of  irrelevant  sequence,  pre-miRNA 
sequences are readily excised (Zeng et al., 2002). The sequence of the mature miRNA does 
not seem to be important for processing and can be altered to target the chosen gene 
(Zeng & Cullen, 2003). The BLOCK-iT
TM Pol II miR vector obtained from Invitrogen is based 
on pcDNA6.2 and allows directional cloning of a 68bp DNA oligonucleotide encoding an 
engineered pre-miRNA sequence downstream of the pol II CMV promoter (figure 3.7). The 
pre-miRNA  sequence  consists  of  a  5’overhang  (TGCT),  which  is  complementary  to  the 
vector and allows directional cloning, a 5’G followed by the 21nt antisense sequence, a 
19nt  spacer  (GTTTTGGCCACTGACTGAC)  that  forms  the  terminal  loop,  and  the  sense 
sequence with 2nt (AA) removed to form an internal loop. To ensure that the miRNA is 
properly  processed,  the  pre-miRNA  sequence  is  inserted  between  5’  and  3’  flanking 
regions derived from the endogenous miRNA-155 (Chung et al., 2006, Tam & Dahlberg, 
2006).  Expression  from  this  cassette  results  in  the  production  of  a  pri-miRNA  that 
resembles pri-miR-155. The pri-miRNA is processed in the nucleus by Drosha into a pre-
miRNA  that  forms  an  intramolecular  stem-loop  structure  similar  to  the  structure  of 
endogenous pre-miRNA. The pre-miRNA is subsequently transported to the cytoplasm by 
Exportin-5 and processed by Dicer into a 22nt mature miRNA, whose guide is incorporated 
into a miRNP. As described in detail in the introduction of this thesis, endogenous miRNAs 
can  mediate  silencing  of  target  gene  expression  by  mRNA  endonucleolytic  cleavage  or 
translational  repression  and  reducing  mRNA  stability,  depending  upon  the  degree  of 
complementarity  between  the  miRNA  and  its  target  mRNA.  The  engineered  miRNAs 161 
 
expressed from the miRNA-like cassette are designed to have perfect complementarity to 
their target mRNAs and have been shown to mediate silencing by mRNA cleavage in a 
similar manner to siRNAs (Chung et al., 2006, Elbashir et al., 2001, Zeng & Cullen, 2003). 
Extensive base-pairing of a miRNA and its target mRNA is not always sufficient to induce 
mRNA  degradation,  suggesting  that  the  miRNA  produced  from  the  miRNA-like  cassette 
preferentially interacts with a particular Argonaute that is able to direct cleavage. Finally, 
some miRNAs are located within the introns of protein coding genes and are co-expressed 
with  mature  mRNA,  suggesting  that  pre-miRNAs  can  be  excised  from  introns  without 
disrupting  production  of  mRNA  (Baskerville  &  Bartel,  2005).  A  reporter  gene  encoding 
Emerald green fluorescent protein (EmGFP) is expressed from this system co-cistronically 
with  the  pre-miRNA  and  allows  labelling  of  transduced  cells  to  aid  the  monitoring  of 
silencing efficiency.  
The validated pre-miRNA sequence against β-galactosidase (miR-LacZ) and the non-
target  pre-miRNA  sequence  (miR-neg),  which  is  not  predicted  to  target  any  known 
vertebrate gene, were supplied by Invitrogen as annealed DNA oligonucleotides (sequences 
available in section 2.1.6) and were cloned into pcDNA6.2/EmGFP vectors (figure 3.7). The 
21nt target sequence against β-galactosidase in pre-miR-LacZ (figure 3.11b) is identical to 
the  target  sequence  in  shLacZ  (figure  3.4a)  expressed  from  the  U6  or  CMVenh-U6 
promoters  (sections  3.5.1  and  3.5.2).  The  pcDNA6.2/EmGFP-miR-LacZ  plasmid  was 
sequenced using the GFP Forward primer (described in section 2.1.5) to ensure that the 
miRNA-LacZ sequence had not been mutated (figure 3.11b). 
In  pcDNA6.2/EmGFP-miR,  the  EmGFP-miR  cassette  is  flanked  by  attB1-attB2 
sequences  that  allow  recombination  into  a  suitable  donor  vector  (attP1-attP2).  The 
resulting  entry  clone  (attL1-attL2)  allows  the  cassette  to  be  transferred  into  an 
appropriate  destination  vector  (attR1-attR2)  and  ultimately  into  an  HSV  vector.  The 
destination  vector  can  be  engineered  to  drive  expression  of  the  pre-miRNA  from  a 
constitutive, inducible  or tissue specific pol II promoter. The EmGFP-miR  cassette was 162 
 
transferred from pcDNA6.2 (figure 3.8a) into pDONR-221 (figure 3.8b) by BP recombination 
reaction as described in section 2.2.8 (figure 3.8c). The pR19CMVLacZWCm plasmid (figure 
3.8d) was converted into the pR19CMV-Gateway destination vector (figure 3.8f) by cloning 
the Gateway cassette (figure 3.8e) between the HindIII-XhoI sites that had been blunted 
and treated with calf intestinal alkaline phosphatase. Finally, the EmGFP-miR-LacZ and 
EmGFP-miR-neg cassettes were inserted from pDONR221 into pR19CMV-Gateway vectors 
by LR recombination. The pR19CMV/EmGFP-miR vectors were sequenced between the LAT 
flanking regions (sequences not shown) and a map is shown in figure 3.8g.  
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Figure 3.8 Cloning of pR19CMV/EmGFP-miR plasmids 
 
The details of the cloning can be found in section 3.5.3. Briefly, the EmGFP-miR cassette 
was  transferred  from  pcDNA6.2  into  pDONR-221  by  BP  recombination.  The 
pR19CMVLacZWCm plasmid was converted into the pR19CMV-Gateway destination vector 
by cloning the Gateway cassette between HindIII-XhoI. The EmGFP-miR-LacZ and EmGFP-
miR-neg cassettes were inserted from pDONR-221 into pR19CMV-Gateway vectors by LR 
recombination to generate the pR19CMV/EmGFP-miR plasmds.  
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3.5.4 Expression of shRNA from a Polymerase II promoter 
Expression of shRNA from the CMV pol II promoter  results in a capped polyadenylated 
transcript in which the hairpin is extended on both 3’ and 5’ ends by vector sequences and 
polyA. A construct driving expression of shRNA from the CMV promoter and a full length 
polyA cassette failed to silence target gene expression in 293T cells (Paddison et al., 2002, 
Xia et al., 2002). To allow expression of functional shRNA from the CMV promoter, Xia and 
colleagues  (2002)  generated  a  construct  in  which  the  hairpin  was  inserted  almost 
immediately downstream of the CMV transcriptional start site and upstream of a synthetic 
minimal  polyA  cassette.  These  authors  concluded  that  the  spacing  of  the  hairpin 
immediate to the promoter is critically important and together with the minimal polyA, 
they result in the generation of functional siRNA molecules with minimal overhangs. To 
test  whether  shRNA  could  be  expressed  from  a  modified  CMV  promoter,  the 
pR19CMVshRNA vector was generated (figure 3.2d).  
The pSilencer 4.1-CMV vector from Ambion is based on the construct described by Xia 
et  al.  (2002)  and  allows  cloning  of  a  55-60bp  DNA  oligonucleotide  immediately 
downstream of the CMV transcriptional start site and upstream of a minimal SV40 polyA 
(figure  3.9).  The  vector  was  supplied  linearised  with  BamHI  and  HindIII  to  facilitate 
directional cloning. The sequence against β-galactosidase (available in section 2.1.6) was 
synthesized  as  two  complementary  oligonucleotides  with  single  stranded  overhangs 
corresponding to the BamHI and HindIII restriction sites. The target sequence against β-
galactosidase is identical to the target sequence in shLacZ (figure 3.4a) expressed from 
the  U6  or  CMVenh-U6  promoters  (sections  3.5.1  and  3.5.2)  and  thus,  identical  to  the 
target sequence in pre-miR-LacZ (figure 3.11b). The oligonucleotides were annealed and 
ligated into pSilencer, and the pSilencer-shLacZ vector was sequenced using the pSilencer 
Forward and pSilencer Reverse primers (described in section 2.1.5) to ensure that the 
shLacZ sequence had not been mutated (figure 3.11c).  167 
 
The pSilencer-shLacZ vector (figure 3.10a) was digested with EcoRI-PvuI to remove 
the  CMV-shLacZ-SV40  polyA  cassette,  which  was  double  blunted  and  cloned  into 
pR19SYNeGFP  between  the  ClaI-NsiI  sites  (figure  3.10b).  To  remove  the  BGH  polyA 
sequence,  the  resulting  pR19CMVshLacZ  plasmid  was  digested  with  SacI-EcoNI  (figure 
3.10c). This step also removed the 5’end of the HSV nt 120,413-122,027 flanking region, 
which was excised as a BstXI-EcoNI fragment from pNot3.5 (figure 3.10d) and cloned into 
pR19CMVshLacZ (SacI-EcoNI). The pR19CMVshLacZ vector was sequenced between the LAT 
flanking regions (sequences not shown) and a map is shown in figure 3.10e.     
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Figure 3.10 Cloning of the pR19CMVshLacZ plasmid 
 
The details of the cloning can be found in section 3.5.4. Briefly,  pSilencer-shLacZ was 
digested with EcoRI-PvuI to remove the CMV-shLacZ-SV40 polyA cassette. The CMVshLacZ 
cassette  was  cloned  into  pR19SYNeGFP  between  ClaI-NsiI.  Finally,  the  BGH  polyA  was 
removed to generate the pR19CMVshLacZ plasmid.   
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a)  pR19CMVenhU6shLacZ sequencing 
 
 
 
 
Sequence 1: lcl|1 
Length = 47 (1 .. 47) shLacZ 
 
Sequence 2: lcl|65536 
Length = 1421 (1 .. 1421) pR19CMVenhU6shLacZ (CMV Forward primer) 
 
Score = 91.1 bits (47), Expect = 2e-16 
Identities = 47/47 (100%), Gaps = 0/47 (0%) 
Strand=Plus/Plus 
 
Query  1    CACCGCTACACAAATCAGCGATTTCGAAAAATCGCTGATTTGTGTAG  47 
            ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  608  CACCGCTACACAAATCAGCGATTTCGAAAAATCGCTGATTTGTGTAG  654 
 
 
 
 
 
pR19CMVenhU6shLacZ sequenced using the LAT Forward primer: 
 
 
emb|X03922.1|HEHCMVP1  Human cytomegalovirus (HCMV) IE1 gene promoter region 
Length=1848 
 
Score = 898 bits (486),  Expect = 0.0 
Identities = 486/486 (100%), Gaps = 0/486 (0%) 
Strand=Plus/Plus 
 
 
Query  50    TTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAG 109 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  542   TTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAG  601 
 
Query  110   CCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC  169 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  602   CCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC  661 
 
Query  170   CAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGG  229 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  662   CAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGG  721 
 
Query  230   GACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACA  289 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  722   GACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACA  781 
 
Query  290   TCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGC  349 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  782   TCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGC  841 
 
Query  350   CTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT  409 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  842   CTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT  901 
 
Query  410   ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATA  469 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  902   ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATA  961 
 
Query  470   GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTT  529 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  962   GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTT  1021 
 
Query  530   TTGGCA  535 
             |||||| 
Sbjct  1022  TTGGCA  1027 
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pR19CMVenhU6shLacZ sequenced using the CMV Forward primer: 
 
 
gb|AY623053.1|  Homo sapiens clone phU6A U6 small nuclear RNA, promoter region 
Length=485 
 
Score =  492 bits (266),  Expect = 2e-135 
Identities = 266/266 (100%), Gaps = 0/266 (0%) 
Strand=Plus/Plus 
 
Query  346  CCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGAT  405 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  220  CCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGAT  279 
 
Query  406  ACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTAC  465 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  280  ACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTAC  339 
 
Query  466  AAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTT  525 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  340  AAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTT  399 
 
Query  526  TTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT  585 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  400  TTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTAT  459 
 
Query  586  ATATCTTGTGGAAAGGACGAAACACC  611 
            |||||||||||||||||||||||||| 
Sbjct  460  ATATCTTGTGGAAAGGACGAAACACC  485 
 
 
 
 
 
 
b)  pcDNA6.2/EmGFP-miR-LacZ sequencing 
 
 
 
 
Sequence 1: lcl|1 
Length = 68 (1 .. 68) pre-miR-LacZ 
 
Sequence 2: lcl|65536 
Length = 1340 (1 .. 1340) pcDNA6.2/EmGFP-miR-LacZ (GFP Forward primer) 
 
Score =  131 bits (68),  Expect = 3e-28 
Identities = 68/68 (100%), Gaps = 0/68 (0%) 
Strand=Plus/Plus 
 
Query  1    TGCTGAAATCGCTGATTTGTGTAGTCGTTTTGGCCACTGACTGACGACTACACATCAGCG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 105   TGCTGAAATCGCTGATTTGTGTAGTCGTTTTGGCCACTGACTGACGACTACACATCAGCG 164 
 
Query  61   ATTTCAGG  68 
            |||||||| 
Sbjct  165  ATTTCAGG  172 
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The target sequence against β-galactosidase in pre-miR-LacZ: 
 
 
gb|FJ440335.1|  Reporter cassette lacTeT, complete sequence 
Length=5870 
 
Score = 41.0 bits (44),  Expect = 0.40 
Identities = 21/21 (100%), Gaps = 0/21 (0%) 
Strand=Plus/Minus 
 
Query  4    AAATCGCTGATTTGTGTAGTC  26 
            ||||||||||||||||||||| 
Sbjct  745  AAATCGCTGATTTGTGTAGTC  725 
 
 
 
 
 
 
c)  pSilencer-shLacZ sequencing 
 
 
 
 
Sequence 1: lcl|1 
Length = 48 (1 .. 48) shLacZ for pSilencer 
 
Sequence 2: lcl|65536 
Length = 1336 (1 .. 1336) pSilencer-shLacZ (pSilencer Reverse primer) 
 
Score = 93.0 bits (48),  Expect = 7e-17 
Identities = 48/48 (100%), Gaps = 0/48 (0%) 
Strand=Plus/Minus 
 
Query  1   AGCTTCTACACAAATCAGCGATTTTTCGAAATCGCTGATTTGTGTAGG  48 
           |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  72  AGCTTCTACACAAATCAGCGATTTTTCGAAATCGCTGATTTGTGTAGG  25 
 
 
 
 
 
 
 
Figure  3.11  Blast  nucleotide  alignments  between  a)  pR19CMVenhU6shLacZ,  b) 
pcDNA6.2/EmGFP-miR-LacZ or c) pSilencer-shLacZ sequences obtained using appropriate 
sequencing  primers  and  the  oligonucleotide  sequences  against  β-galactosidase.  The 
pR19CMVenhU6shLacZ sequences obtained with the LAT Forward and CMV Reverse primers 
(described  in  section  2.1.5)  were  aligned  against  the  CMV  IE  gene  and  U6  promoter 
sequences  to  ensure  that  the  CMVenh-U6  hybrid  promoter  had  been  successfully 
constructed. The target sequence against β-galactosidase in pre-miR-LacZ is indicated in 
the reporter cassette lacTeT sequence. 
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3.6 Screening of shRNA sequences against GFP 
To identify the most potent shRNA sequence against GFP, 293T cells were co-transfected 
with pR19CMVeGFPWCm (100ng) that expresses enhanced green fluorescent protein and 
either  pENTRU6shLacZ,  pENTRU6shGFP1,  pENTRU6shGFP2,  or  pENTRU6shGFP3  (1μg) 
constructed in section 3.5.1. Transfection was performed using Lipofectamine as described 
in  section  2.3.3.  Fluorescent  microscopy  revealed  highly  effective  knockdown  of  GFP 
expression  as  early  as  12hrs  post-transfection  when  either  shGFP2  or  shGPF3  were 
transfected  (data  not  shown).  Figure  3.12  demonstrates  gfp  silencing  at  48  hrs  post-
transfection.  The  shGFP1  sequence,  which  was  converted  into  shRNA  from  a  validated 
siRNA sequence supplied by Ambion, failed to induce any silencing (figure 3.12b). This 
result is in agreement with numerous other studies that have concluded that a validated 
siRNA sequence is not necessarily effective when converted into a shRNA.  Transfection 
with the pENTRU6shLacZ had no effect on GFP levels indicating that silencing is specific 
(figure  3.12a).  The  U6shGFP2  cassette  that  induced  near  complete  knockdown  of  GFP 
expression (figure 3.12c) was selected and inserted into pR19-Gateway as described in 
section 3.5.1.  
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3.7 Evaluation of plasmid vectors expressing shRNA 
The plasmid vectors constructed in section 3.5 were tested for their ability to express 
shRNA  against  β-galactosidase.  293T  cells  were  co-transfected  with  pR19CMVLacZWCm 
(100ng)  which  expresses  β-galactosidase  and  either  pR19U6-neg,  pR19U6shLacZ, 
pR19CMVenhU6shLacZ,  or  pR19CMVshLacZ  (1μg)  using  Lipofectamine.  In  each  of  these 
conditions, the pR19CMVeGFPWCm plasmid (100ng) that expresses enhanced GFP was also 
co-transfected  to  evaluate  the  transfection  efficiency.  Similarly,  293T  cells  were  co-
transfected  with  pR19CMVLacZWCm  (100ng)  and  either  pR19CMV/EmGFP-miR-neg  or 
pR19CMV/EmGFP-miR-LacZ (1μg). Transfection efficiency was monitored by the presence 
of the EmGFP signal expressed from these constructs.  
X-gal  staining  (as  described  in  section  2.3.6)  at  72  hrs  post-transfection 
demonstrated  that  each  of  the  plasmids  targeting  lacZ  substantially  reduced  β-
galactosidase  levels  (figure  3.13b,  c,  and  f)  except  for  pR19CMVshLacZ  that  failed  to 
induce any silencing (figure 3.13d). GFP levels assessed by fluorescent microscopy prior to 
x-gal staining indicated that the transfection efficiency between different conditions had 
been normalised. Importantly, transfection with the negative controls had no effect on β-
galactosidase levels indicating that silencing is specific (figure 3.13a and d).  
Analysis  of  β-galactosidase  expression  by  enzyme  activity  assay  (as  described  in 
section  2.7.5)  revealed  that  the  pR19U6shLacZ  construct  silenced  lacZ  by  89.0  ±  1.5% 
(n=3,  mean  ±  s.d.),  the  pR19CMVenhU6shLacZ  construct  by  89.4  ±  4.6%  and  the 
pR19CMVGFP-miR-LacZ construct by 93.0 ± 1.7% (figure 3.14). Although these results were 
highly encouraging, the level of sensitivity achieved with this system is greater than that 
achieved with endogenous target gene knockdown, because the constructs expressing lacZ 
and shRNA/pre-miRNA are co-transfected simultaneously and thus, delivery to all cells is 
not required in order to achieve an RNAi response.  
To investigate RNAi specificity further, the mRNA levels of four endogenous genes 
were assessed in 293T cells transfected with each of the above constructs. Induction of 177 
 
the  INF  response  by  shRNA/miRNA  or  any  other  sequences  in  the  expression  cassettes 
would result in non-specific mRNA degradation and significantly reduced mRNA levels of 
housekeeping genes. Quantitative RT-PCR (described in section 2.217) for ATP5b, GAPDH 
and GUSb revealed that there is no significant reduction in the expression levels of any of 
these  housekeeping  genes  72  hrs  following  introduction  of  shRNA  or  pre-miRNA  (figure 
3.15). Moreover, quantitative RT-PCR for ISGF3G, the interferon-stimulated transcription 
factor 3 gamma, confirmed that silencing is not caused by a non-specific effect associated 
with induction of the interferon (INF) response (figure 3.15). The qRT-PCR experiment was 
performed  by  Ronald  De  Hoogt  at  Johnson  &  Johnson  Research  and  Development  in 
Belgium.  
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3.8 Choice of disabled backbone for RNAi delivery to DRG 
Prior to generating viral vectors expressing shRNA, it was important to identify a disabled 
HSV-1 backbone that would make a suitable vector for delivery of RNAi to mouse sensory 
neurons.  The  1764/4-/27+/RL1+  and  1764/4-/27-  backbones  described  in  section  3.2, 
which have different levels of disablement, were both available at the time this project 
began. Previous work in our laboratory had already concluded that expression in the brain 
(Palmer, unpublished) and spinal cord (Groutsi, unpublished) was considerably improved 
by  re-insertion  of  ICP34.5  and  ICP27  into  the  HSV  genome.  These  studies  also 
demonstrated that despite its level of disablement, the 1764/4-/27+/RL1+ vector is not 
appreciably more toxic or immunogenic than the more disabled 1764/4-/27- backbone. 
Although the less disabled 1764/4-/27+/RL1+ backbone was the obvious choice upon which 
to base all the shRNA-expressing viruses constructed in this thesis, its potential to deliver 
high  levels  of  relatively  long-term  expression  to  DRG  sensory  neurons  had  not  been 
properly evaluated.   
The highly disabled 1764/4-/27- viruses had already been tested for gene delivery to 
the rat DRG after footpad inoculation and direct sciatic nerve injection with somewhat 
disappointing results (Palmer et al., 2000). At higher titres (5x10
8 pfu/ml), gene delivery 
was considerably improved following injection into the sciatic nerve, but not following 
footpad inoculation. These results suggested that some level of replication competence 
might be necessary for efficient gene delivery to DRG, especially for the virus to penetrate 
various cell types in the footpad and enter the sciatic nerve. Thus, replication-defective 
viruses allow efficient gene delivery to DRG at high titres when injected directly into the 
sciatic nerve. Consequently, injection into the sciatic nerve was chosen as the route of 
administration to be used throughout this thesis (described in section 2.6.3).  
Based  on  the  above  observations,  the  less  disabled  1764/4-/27+/RL1+  backbone 
might be expected to allow more efficient gene delivery to the DRG than the 1764/4-/27- 
backbone  (Palmer  et  al.,  2000).  To  confirm  this  and  also  compare  expression  from 182 
 
different  promoters,  the  1764/4-/27+/RL1+  pR19CMVLacZWCm  or  pR19EF1αLacZWCm 
vectors were injected into the sciatic nerve of mice (5x10
5 pfu per animal) and the lumbar 
DRG (L3 and L4) were isolated at 3 and 21 days post-injection. X-gal staining in whole 
mount DRG preparations (as described in section 2.6.7) revealed that injection of the virus 
into the tibial branch of the sciatic nerve results in delivery predominantly to the L4 DRG. 
At 3 days post-injection, the 1764/4-/27+/RL1+ backbone allowed highly efficient gene 
delivery to mouse sensory neurons following injection into the sciatic nerve, with the CMV 
promoter driving considerably higher levels of expression in these neurons than the EF1α 
promoter (figure 3.15a).  
Whilst expression in DRG is maintained for at least 21 days, it is considerably reduced 
compared to that at early times post-injection (figure 3.15b). Previous work in our lab has 
shown that in DRG the pR20.9 cassette (which allows expression of two transgenes from a 
MMLV LTR and a LAP1 promoter inserted on either side of the LAT P2 element), when 
inserted  into  UL43  of  a  1764  virus,  maintained  gene  expression  during  latency  as 
efficiently as the endogenous LAT promoters maintained expression of the LATs (Palmer et 
al.,  2000). The same was suggested for the pR19 cassette inserted into a 1764/4-/27- 
virus. It was therefore suggested that reduction in gene expression over time is not due to 
the promoter being transcriptionally inactivated during latency, but may due to the virus 
being cleared by the host immune response. Other work in our laboratory has shown that 
following injection of 1764/4-/27- and 1764/4-/27+/RL1+ pR19CMVLacZ viruses into the 
rat  cervical  spinal  cord,  the  inflammatory  response  appears  to  be  the  same  for  both 
viruses (Groutsi, unpublished). This could be due to ICP34.5 being re-inserted into the 
genome  which  may  have  a  function  in  protecting  against  such  endogenous  responses; 
ICP34.5  has  a  role  in  immune  evasion  by  suppressing  INFα/β  and  MHC  Class  I  and  II 
production from infected cells and the less disabled vectors may therefore suppress the 
local  immune  response.  Moreover,  the  1764  4-/27+/RL1+  pR19CMVeGFPWCm  and 
pR19CMVLacZWcm vectors were found to be non-toxic when used to transduce rat DRG 183 
 
(figure 3.16a) and rat embryonic E14 cortical neuronal cultures (figure 3.16b) respectively, 
at an MOI=5.0. Although this data is sufficient for the purpose of using the vectors as 
target validation tools, a more detailed investigation of the IE gene expression pattern of 
this backbone would be required for the vectors developed in this thesis to be utilized for 
potential long-term therapy.  
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3.9 Generation of disabled HSV-1 vectors expressing shRNA  
Following evaluation of shRNA expression from the plasmid vectors constructed in section 
2.5 and selection of the disabled backbone that would make a suitable vector for delivery 
of  RNAi  to  mouse  DRG  (section  3.8),  the  cassettes  that  successfully  reduced  β-
galactosidase  levels  (section  3.7)  were  inserted  into  1764  4-/27+/RL1+  HSV-1  by 
homologous recombination. The pR19CMVshLacZ system that failed to induce any silencing 
was abandoned. The pR19 cassette is flanked by sequences that allow recombination into 
the LAT region of the HSV genome and thus, following recombination with viral DNA, each 
cassette was inserted immediately 3’ of the LAT P2 region and was present in two copies 
per genome.  
The pR19U6shLacZ, pR19U6-neg and pR19CMVenhU6shLacZ plasmids constructed in 
sections 3.5.1 and 3.5.2 were each co-transfected with 1764 4-/27+/RL1+ pR19CMVeGFP 
WCm viral DNA (prepared as described in section 2.4.5) into complementing MAM49 cells 
as  described  in  section  2.4.1.  Viral  recombinants  were  identified  by  their  inability  to 
express GFP (white plaques)  using fluorescent microscopy and were plaque purified as 
described in section 2.4.2. The pR19U6shGFP2 plasmid constructed in section 3.5.1 was 
co-transfected with 1764 4-/27+/RL1+ pR19CMVLacZWCm viral DNA. White plaques were 
identified following x-gal staining for β-galactosidase. White plaques may arise from a 
mutation in the reporter gene or the promoter and thus, during negative selection, i.e. 
when white plaques are selected from a coloured background, there is an increased risk of 
selecting  recombinants  that  may  not  be  of  the  desired  structure.  It  was  therefore 
particularly  important  to  confirm  that  the  cassette  expressing  GFP  or  LacZ  had  been 
replaced by the cassette expressing shRNA and that the shRNA sequence had not been 
mutated. This was achieved by performing PCR on viral DNA extracted from each plaque 
(figure  3.18)  followed  by  sequencing  of  the  PCR  products.  One  plaque  from  each 
recombinant virus was selected and grown to a high titre as described in section 2.4.3. 187 
 
The pR19CMV/EmGFP-miR-LacZ and pR19CMV/EmGFP-miR-neg plasmids described in 
section 3.5.3 were linearised using a unique XmnI site in the plasmid backbone. 1764 4-
/27+/RL1+  pR19CMVLacZWCm  viral  DNA  was  co-transfected  with  linearised  pR19CMV/ 
EmGFP-miR-neg. The pR19CMV/EmGFP-miR-LacZ plasmid was not transfected with viral 
DNA expressing β-galactosidase, as the lacZ would be silenced by the virus expressing miR-
LacZ making it impossible to select the correct recombinants. Instead, pR19CMV/EmGFP-
miR-LacZ  was  co-transfected  with  1764  4-/27+/RL1+  pR19U6shLacZ  viral  DNA.  Viral 
recombinants  were  identified  by  their  ability  to  express  GFP  (green  plaques)  using 
fluorescent  microscopy.  Two  recombinant  populations  arose  from  these  transfections 
represented by faint green and bright green plaques. As two copies of the LAT region are 
present  in  the  genome,  they  were  believed  to  be  a  consequence  of  the  miR  cassette 
having been inserted in the genome once and then twice, respectively. The bright green 
plaques  were  preferentially  selected  and  purified.  When  a  pure  green  population  was 
obtained, the purity of the pR19CMV/EmGFP-miR-neg plaques was confirmed further by x-
gal staining. Expression of GFP from the pR19CMV/EmGFP-miR-LacZ and pR19CMV/EmGFP-
miR-neg  recombinants  indicated  that  the  desired  homologous  recombination  event  had 
occurred. However, to confirm that the pre-miRNA sequence had not been mutated, PCR 
was performed on viral DNA extracted from each plaque using the GFP Forward and WCm 
Reverse  primers  described  in  section  2.1.5  (figure  3.19)  and  the  PCR  products  were 
sequenced. One plaque from each recombinant virus was selected and grown to a high 
titre.  
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3.10 Construction of a cell line expressing β-galactosidase 
Evaluation of plasmid vectors expressing shRNA against β-galactosidase revealed that the 
systems  which  were  effective  induced  approximately  90%  silencing  of  lacZ  when  the 
reporter  gene  and  shRNA  were  co-delivered  simultaneously  (section  3.7).  The  level  of 
sensitivity achieved with this system is greater than that achieved with endogenous gene 
silencing,  because  delivery  to  all  cells  is  not  required  in  order  to  achieve  an  RNAi 
response. To evaluate the efficiency of HSV-mediated silencing in vitro, a cell line that 
expresses β-galactosidase would be more appropriate, as it would alleviate the need to 
deliver lacZ together with the RNAi viruses and would allow assessment of silencing in a 
system closer to endogenous gene expression.  
The  only  available  cell  line  expressing  β-galactosidase  was  the  9L/LacZ  rat 
gliosarcoma cell line. 9L cells have been reported to be highly susceptible to infection 
with replication-defective ICP4- HSV-1 mutants (Krisky et al., 1998, Moriuchi et al., 2000). 
However, when 9L/LacZ cells were transduced with 1764 4-/27+/RL1+ pR19CMVeGFPWCm 
(MOI=10.0), the number of GFP positive cells at 72 hrs post-transduction was very low 
(data not shown). Thus, 9L/LacZ cells do not allow efficient gene expression from the 
disabled vectors used in this thesis and are not an appropriate cell line to evaluate HSV-
mediated  silencing.  BHK  cells  are  routinely  used  to  assess  expression  levels  from  the 
vectors developed in our lab and therefore, a BHK cell line that constitutively expresses 
high levels of β-galactosidase was constructed for the purpose of evaluating the vectors 
generated in section 3.10. 
The β-galactosidase coding sequence without the polyadenylation signal was excised 
from  pR19CMVLacZWCm  as  a  HindIII-XhoI  restriction  fragment  and  subcloned  into  the 
pcDNA3 multiple cloning site between HindIII-XhoI (figure 3.20). The pcDNA3-LacZ plasmid 
was linearised with SpeI and transfected into BHK cells as described in section 2.3.4. 100 
neomycin (G418) resistant colonies were selected and screened for their ability to express 
β-galactosidase. The colony expressing the highest levels was selected and the BHK-LacZ 191 
 
the  cell  line  was  generated  as  detailed  in  section  2.3.5.  Finally,  BHK-LacZ  cells  were 
transduced  with  1764  4-/27+/RL1+  pR19CMVeGFPWCm  at  an  MOI=5.0.  Fluorescent 
microscopy for GFP followed by x-gal staining at 48 hrs post-transduction demonstrated 
that the BHK-LacZ cell line uniformly expresses high levels of β-galactosidase and allows 
high levels of HSV-mediated expression (figure 3.21). 
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3.11 Evaluation of disabled vectors targeting lacZ in culture 
To compare silencing from the HSV vectors expressing shRNA using different approaches 
(constructed in section 3.9), BHK-LacZ cells were transduced with each vector targeting 
lacZ (HSV-U6shLacZ, HSV-CMVenhU6shLacZ or HSV-CMV/EmGFP-miR-LacZ) or the negative 
control vectors (HSV-U6shGFP or HSV-CMV/EmGFP-miR-neg) at an MOI=10.0 (figure 3.22a). 
The expression of functional shRNA from the HSV-U6shGFP negative control (MOI=5.0) was 
confirmed by the reduction of GFP levels in BHK cells co-transduced with the 1764 4-
/27+/RL1+ pR19CMVeGFPWCm virus expressing enhanced GFP (MOI=1.0)  (figure 3.22b). 
Expression  of  miRNA  from  the  HSV-CMV/EmGFP-miR-neg  control  was  confirmed  by  the 
presence of the EmGFP signal (figure 3.22a-iv). Silencing was assessed by x-gal staining at 
72hrs  post-transduction.  Transduction  with  the  HSV-U6shGFP  (figure  3.22a-i)  or  HSV-
CMV/EmGFP-miR-neg  (figure  3.22a-iv)  control vectors  had  no  effect on  β-galactosidase 
expression levels. Transduction with HSV-U6shLacZ (figure 3.22-ii), HSV-CMVenhU6shLacZ 
(figure 3.22a-iii) or HSV-CMV/EmGFP-miR-LacZ (figure 3.22a-v) resulted in a significant 
reduction  in  β-galactosidase  levels.  Importantly,  GFP  expression  in  BHK-LacZ  cells 
transduced with HSV-CMV/EmGFP-miR vectors was not affected by expression of miR-LacZ 
as  evaluated  by  fluorescent  microscopy  (figure  3.22a-iv  and  v).  It  can  be  therefore 
concluded that silencing is not caused by a non-specific effect mediated by the HSV vector 
backbone.  Unlike off-target effects, this would most likely be a non-sequence specific 
effect caused by induction of the INF response or toxicity from the virus and thus affect 
the expression levels of both lacZ and gfp. 
B-galactosidase  activity  assay  performed  in  BHK-LacZ  cells  at  various  times  post-
transduction  with  HSV-U6shLacZ,  HSV-CMVenhU6shLacZ  or  HSV-CMV/EmGFP-miR-LacZ 
revealed reduced protein levels by up to 84.0 ± 8.0% (n = 6, mean ± s.d.), 91.0 ± 7.0% and 
86.0  ±  7.0%,  respectively  (figure  3.23a).  B-galactosidase  levels  were  calculated  as  a 
percentage  of  the  expression  in  the  cells  transduced  with  the  negative  controls  (HSV-
U6shGFP or HSV-CMV/EmGFP-miR-neg). HSV-CMV/EmGFP-miR-LacZ is most effective at 48 195 
 
hrs,  HSV-CMVenhU6shLacZ  at  72  hrs  and  HSV-U6shLacZ  at  4  days  post-transduction, 
reflecting the different kinetics of expression from the promoters used. B-galactosidase 
activity assay performed at 72 hrs post-transduction at MOI=1.0, 5.0 and 10.0 revealed 
that silencing is dose-dependent (figure 3.23b). Transduction of BHK-LacZ cells with these 
vectors at an MOI higher that 10.0 resulted in no further improvement of silencing, whilst 
cell viability was considerably reduced, indicating that the endogenous miRNA pathway 
may be saturated (data not shown). 
 
3.12 HSV-mediated silencing in primary DRG neurons 
To determine whether HSV-mediated delivery of shRNA could induce silencing in primary 
neuronal cells, rat DRG neuronal cultures (prepared as described in section 2.5.2) were co-
transduced  with  1764  4-/27+/RL1+  pR19CMVeGFPWCm  (MOI=1.0),  and  either  HSV-
U6shLacZ or HSV-U6shGFP (MOI=5.0). High transduction efficiencies were achieved with 
over  90%  of  neurons  being  positive  for  GFP.  Fluorescent  microscopy  at  48  hrs  post-
transduction  revealed  that  transduction  with  HSV-U6shLacZ  had  no  effect  on  GFP 
expression  levels,  whereas  transduction  with  HSV-U6shGFP  resulted  in  near  complete 
inhibition of GFP expression (figure 3.24). This data indicates highly effective silencing in 
neurons in vitro induced by HSV-mediated RNAi.     
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3.13 Evaluation of disabled vectors targeting lacZ in DRG in vivo 
To  compare  the  efficiency  of  HSV-mediated  silencing  in  sensory  neurons  in  vivo,  β-
galactosidase was overexpressed in the DRG of BALB/c mice using a disabled HSV-1 vector. 
A single injection into the sciatic nerve was performed as described in section 2.6.3 to co-
deliver 1764 4-/27+RL1+ pR19CMVLacZWCm  expressing β-galactosidase  and each of the 
HSV-U6shLacZ,  HSV-CMVenhU6shLacZ  and  HSV-CMV/EmGFP-miR-LacZ  vectors  targeting 
lacZ or each of the HSV-U6-neg and HSV-CMV/EmGFP-miR-neg negative controls, at a ratio 
1:5.  In  animals  injected  with  HSV-U6-neg,  HSV-U6shLacZ  or  HSV-CMVenhU6shLacZ,  the 
1764  4-/27+/RL1+  pR19CMVeGFPWCm  vector  was  also  co-injected  to  normalise 
transduction  efficiency  (figure  3.25a).  In  animals  injected  with  HSV-CMV/EmGFP-miR 
vectors,  transduction  efficiency  was  monitored  by  the  presence  of  the  EmGFP  signal 
expressed from these vectors (figure 3.25b). 
7 days post-injection, the lumbar DRG (L4/L5) from the injected side of the animals 
were isolated and analysed as described in section 2.6.7. High transduction efficiencies 
were achieved in all injections (n=15) mainly to the L4 DRG, with the majority of neurons 
being  positive  for  GFP  as  assessed  by  fluorescent  microscopy.  Figures  3.25a  and  b 
demonstrate representative L4 DRG from these animals. X-gal staining in whole mount 
DRG  preparations  revealed  a  dramatic  reduction  in  β-galactosidase  levels  in  animals 
injected  with  HSV-U6shLacZ  (figure  3.25a-ii), HSV-CMVenhU6shLacZ  (figure  3.25a-iii)  or 
HSV-CMV/EmGFP-miR-LacZ  (figure  3.25b-ii)  compared  to  control  groups  injected  with 
either HSV-U6-neg (figure 3.25a-i) or HSV-CM/EmGFP-miR-neg (figure 3.25b-i).  
In  the  experiments  described  in  this  section,  silencing  can  only  be  achieved  in 
neurons  that  have  been  transduced  with  both  β-galactosidase-  and  shRNA-expressing 
vectors. In animals also injected with the GFP-expressing vector (figure 3.25a), expression 
of GFP allows monitoring of transduction efficiency, but not direct labelling of neurons 
expressing shRNA. Previous work in our lab has demonstrated that co-injection of viruses 
expressing different reporter genes from the same backbone results in highly overlapping 200 
 
transduction patterns in DRG (S.Martins, unpublished data). This is also demonstrated by 
the  high  degree  of  β-galactosidase  and  GFP  co-localisation  evident  in  figure  3.25a-i. 
Nevertheless, the high levels of β-galactosidase displayed in some neurons when the β-
galactosidase-expressing  and  HSV-U6shLacZ  or  HSV-CMVenhU6shLacZ  vectors  were  co-
injected may be due to incomplete transduction overlap (figure 3.25a-ii and iii). In the 
DRG  of  animals  injected  with  HSV-CMV/EmGFP-miR-LacZ  (figure  3.5b-ii),  EmGFP 
expression allows identification of transduced neurons and >90% of GFP-positive neurons 
display markedly reduced or abolished β-galactosidase expression.  
Silencing  was  quantified  by  directly  counting  the  number  of  LacZ-positive  versus 
GFP-positive neurons in whole mount DRG preparations. Thus, transduction efficacy was 
normalised  between  different  conditions  and  silencing  was  assessed  in  relation  to  the 
transduced population of neurons rather than the total number of neurons in the DRG. We 
found that HSV-U6shLacZ reduces β-galactosidase levels by 78.0 ± 6.8% (p = 0.001) (n = 3, 
mean ± s.d.), HSV-CMVenhU6shLacZ by 62.1 ± 20.9% (p = 0.02) and HSV-GFP-miR-LacZ by 
92.0  ±  3.0%  (p  =  0.0002)  (figure  3.26).  B-galactosidase  levels  were  calculated  as  a 
percentage of the expression in DRG injected with the negative controls. Whereas the 
number of GFP-positive neurons remained essentially stable at 170 ± 53 cells (n = 15, 
mean  ±  s.d.)  in  each  of  the  different  conditions,  the  level  of  lacZ-positive  neurons 
dropped  from  464  ±  68  cells  (n  =  6,  mean  ±  s.d.)  in  DRG  injected  with  the  negative 
controls to 122 ± 68, 148 ± 60 and 63 ± 15 cells (n = 3, mean ± s.d.) in DRG injected with 
HSV-U6shLacZ, HSV-CMVenhU6shLacZ or HSV-GFP-miR-LacZ, respectively. The number of 
GFP-positive  neurons  was  found  to  be  much  lower  than  the  number  of  LacZ-positive 
neurons in DRG injected with the negative controls. This is mainly due to the fact that x-
gal  staining  used  to  visualise  LacZ-positive  cells  is  more  sensitive  than  fluorescence 
microscopy  used  to  visualise  GFP-positive  cells.  Moreover,  in  the  HSV-miRNA  vectors, 
EmGFP is co-cistronically expressed with the pre-miRNA and this may result in inefficient 
GFP mRNA processing.  201 
 
The above data confirm robust silencing in peripheral neurons in vivo induced by 
HSV-mediated RNAi. Importantly, injection with the negative controls had no effect on β-
galactosidase levels and injection with the vectors targeting lacZ does not seem to have 
an effect on the levels of GFP indicating silencing specificity.  
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3.14 HSV-mediated silencing of lacZ in a transgenic mouse model 
The results described in the previous section demonstrate silencing in a system where a 
marker gene has been delivered coincidentally with silencing. It was therefore important 
to determine whether lacZ could be effectively silenced in a transgenic mouse model, 
where  β-galactosidase  expression  resembles  endogenous  gene  expression.  The  HSV-
CMV/EmGFP-miR-LacZ vector, which was shown in the previous section to be the most 
effective at silencing in vivo, was selected for further testing. Moreover, co-expression of 
EmGFP from these vectors allows direct labelling of transduced neurons.  
Rosa26  transgenic  mice  (supplied  by  Johnson  &  Johnson)  were  injected  into  the 
sciatic nerve with HSV-CMV/EmGFP-miR-neg or HSV-CMV/EmGFP-miR-LacZ (as described in 
section  2.6.3).  7  days  post-injection,  the  lumbar  DRG  from  the  injected  side  of  the 
animals were isolated and sectioned (as described in section 2.6.6). Rosa26 mice express 
high levels of β-galactosidase in the majority of their tissues, including neuronal and non-
neuronal cells of the DRG. Quantification of β-galactosidase expression in the whole DRG 
would measure silencing not only in sensory neurons, which is the target cell population, 
but also in non-neuronal cells not transduced by the vector. The DRG were, therefore, 
sectioned to clearly demonstrate silencing in individual neurons transduced by the virus.  
Fluorescence microscopy for GFP demonstrated high transduction efficiencies with 
the  vectors  throughout  all  sections  taken  from  injected  animals.  Figure  3.27  shows 
representative  sections  from  L4  DRG.  In  all  4  independent  experiments,  neurons 
transduced  with  HSV-CMV/EmGFP-miR-LacZ  (figure  3.27-ii),  whilst  also  GFP-positive, 
displayed  significantly  reduced  x-gal  staining  compared  to  animals  injected  with  the 
negative  control  (figure  3.27-i).  B-galactosidase  expression  in  these  sections  was  also 
markedly reduced compared to sections taken from the DRG of the non-injected side of 
the same animals (data not shown).   
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3.15 Discussion 
RNAi has become a powerful tool for modulating gene expression. Delivery to neurons 
however  poses  specific  challenges.  Whereas  delivery  of  siRNAs  to  primary  neuronal 
cultures has been achieved with relatively high efficiency (Davidson et al., 2004), in vivo 
delivery of RNAi to neurons and DRG neurons in particular, has been problematic. The 
development of an efficient method for in vivo delivery of RNAi to peripheral neurons 
would allow a better understanding of gene function, enable the validation of novel gene 
targets  in  drug  discovery,  and  potentially  allow  the  development  of  RNAi-based 
treatments.  
The  replication-defective  HSV-1  vectors  developed  in  our  laboratory  allow  highly 
efficient gene delivery to neurons of the central and peripheral nervous system both in 
vitro and in vivo (Lilley et al., 2001, Palmer et al., 2000) and are particularly efficient at 
targeting  DRG  neurons  in  both  mice  and  rats  through  retrograde  transport  following 
injection into the sciatic nerve. Whilst work in our laboratory had previously identified 
regulatory elements in the HSV genome that allow efficient expression of exogenous genes 
from heterologous promoters in a relatively non-promoter specific fashion, expression of 
shRNA from these vectors had not been previously investigated.  
The work described in this chapter demonstrates that replication-defective HSV-1 
vectors can express shRNA and induce highly effective and specific silencing in dividing 
cells  in  culture,  primary  neuronal  cells  and  DRG  neurons  in  vivo.  Silencing  in  sensory 
neurons  in  vivo  was  assessed  in  an  overexpression  system  and  more  importantly  in  a 
transgenic mouse model. Moreover, it was established that expression of shRNA from the 
disabled 1764/4-/27+/RL1+ HSV-1 vector backbone can be achieved using either pol II or 
pol III promoters linked to the LATP2 region.  
With the exception of the modified CMV promoter that failed to induce any silencing, 
the shRNA expression systems tested in this thesis demonstrated similar levels of highly 
effective silencing in  dividing cells in culture. However, when these promoter systems 207 
 
were tested in DRG neurons in vivo, the miRNA-like system was found to be considerably 
more effective. These results are in agreement with the more recent findings by Hassani 
et al., who have demonstrated that when plasmid vectors expressing shRNA from the H1 
promoter or a hybrid CMV enhancer-H1 promoter were tested in vitro on two different cell 
lines,  silencing  efficacy  was  independent  of  the  promoter  used.  However,  when  these 
vectors  were  tested  in  vivo  in  either  the  developing  or  the  adult  mouse  brain,  the 
efficiency of the shRNA depended markedly on the promoter used (Hassani et al., 2007). 
There is now general consensus that the choice of promoter for expression of shRNA varies 
in  different  in  vitro  and  in  vivo  situations  and  thus,  the  conclusions  drawn  from  the 
evaluation performed in this thesis apply only to the cell types and conditions tested.  
The  reasons  behind  the  disappointing  results  obtained  with  the  modified  CMV 
promoter  were  not  investigated  further.  The  highly  promising  data  obtained  with  the 
other shRNA expression systems evaluated in this chapter was sufficient for this work to 
progress  to  the  in  vivo  evaluation  phase,  which  was  the  main  focus  of  this  thesis. 
Nevertheless, the failure to produce any obvious reduction in the levels of β-galactosidase 
can only be attributed to the lack of functional shRNA being expressed from this system, 
as the target sequence against β-galactosidase was identical in all the cassettes tested, 
which  were  also  fully  sequenced  to  confirm  that  the  shRNA  sequence  had  not  been 
mutated.  This  result  was  highly  surprising  especially  since  silencing  was  investigated 
following transfection into 293T cells and identical shRNA expression cassettes have been 
shown to induce effective silencing of gfp or ataxin-1 following transfection into HEK-293 
cells. These cassettes also induced effective silencing of β-glucuronidase and ataxin-1 in 
the mouse brain, when inserted into adenoviral and AAV vectors, respectively (Xia et al., 
2004,  Xia et al.,  2002).  Moreover, two independent studies have since confirmed that 
efficient expression of shRNA can be achieved from tissue-specific pol II promoters using 
cassettes similar to the one described by Xia and colleagues (Giering et al., 2008, Gou et 
al., 2004).         208 
 
The enhancer element of the CMV promoter failed to improve silencing from the U6 
promoter when transfected into 293T cells, it demonstrated marginally improved silencing 
in BHK-LacZ cells when expressed from an HSV vector, and this system was identified as 
the least effective at silencing in vivo. These findings contradict a previous study that 
demonstrated approximately 50% enhanced silencing in 293T cells when the same system 
was  expressed  from  a plasmid  (Xia  et  al.,  2003).  However,  in  the  study  by  Xia  et  al. 
silencing achieved from the U6 promoter was relatively modest. It has been suggested that 
expression from the U6 promoter may be regulated by a mechanism that aims to prevent 
accumulation of U6 RNAs (Noonberg et al., 1996). Thus, improving silencing from the U6 
promoter  may  only  be  feasible  in  situations  where  the  activity  of  the  U6  promoter  is 
relatively  weak.  Studies  in  the  mouse  brain  have  demonstrated  that  although  the  U6 
promoter is more effective that the H1 promoter when inserted into a lentivirus (Mäkinen 
et al., 2006), the CMV enhancer significantly improves silencing from the H1 promoter 
(Hassani et al., 2007). It remains to be established whether a hybrid CMV enhancer-H1 
promoter is more efficient than the CMV enhancer-U6.  
Although the miRNA-based vector demonstrated the most effective silencing in DRG 
neurons in vivo, a more systematic comparison is required in order to identify whether 
expressing shRNA from a miRNA-like system is superior to expressing shRNA from pol III 
promoters. Boden et al. demonstrated that shRNA embedded into miR-30 sequences and 
expressed from the U6 promoter was 80% more effective in reducing HIV-1
 p24 antigen 
production  in  293  cells  than  shRNA  expressed  from  the  same  promoter  (Boden  et  al., 
2004). Northern
 blot analysis revealed that shRNA expressed from a miRNA-like system is 
more efficiently processed into siRNA. Similar results were obtained by Silva et al., who 
demonstrated  that  HEK-293  cells  transfected  with  miR-30-based  plasmids  contained 
approximately 12 times more siRNA than cells transfected with plasmids expressing shRNA 
(Silva  et  al.,  2005).  Expression  of  shRNA  from  miRNA-like  plasmids  resulted  in  more 
effective and consistent knockdown of target gene expression. In contrast to the above 209 
 
studies  in  which  shRNAs  with  21nt  stem  /  9nt  loop  and  29nt  stem  /  4nt  loop  were 
evaluated respectively, Li et al. demonstrated that shRNAs with a 19nt stem and 9nt loop 
expressed from the U6 promoter were considerably more effective than synthetic miRNAs 
expressed from miR-30-based vectors under the control of either the CMV or U6 promoter 
(Li et al., 2007). Boudreau et al. argued that the shRNAs tested by Boden et al. and Silva 
et al. had sub-optimal 5’overhangs (5’ XbaI site and a 27nt leader sequence respectively), 
which are important substrates for Exportin 5 and Dicer, and that none of the previous 
comparison  studies  had  assessed  strand  biasing,  i.e.  which  strand  of  the  siRNA  duplex 
enters  the  RISC  and  mediates  gene  silencing  (Boudreau  et  al.,  2008b).  The  authors 
demonstrated that when variability between shRNA and miRNA-like vectors is minimised 
by taking into account the transcribed product, processing sites and strand bias, shRNAs 
expressed from the U6 promoter are more effective that synthetic miRNAs expressed from 
the same promoter both in vitro and in mice in vivo. In the experiments described in this 
thesis,  the  shRNA  sequences  were  designed  to  have  3′  overhangs  resulting  from  pol  III 
termination, which provide optimal substrates for Exportin 5 and Dicer. Moreover, they 
were selected to account for the +1-G nucleotide of the U6 promoter and to contain AU-
rich 3′ ends, both of which promote loading of the antisense strand. However, although 
the  target  sequence  against  β-galactosidase  was  identical  in  pre-miRNA  and  shRNA 
sequences, the stem length and loop structure were different. Moreover, expression of 
shRNA and synthetic miRNA was driven by different promoters and thus, it can be argued 
that a fair comparison of shRNA and miRNA-like vectors was not provided.  
Nevertheless,  expression  of  a  marker  gene  together  with  miRNA  from  a  single 
transcription unit and the potential to use inducible or tissue-specific pol II promoters hold 
clear  advantages  for  the  use  of  miRNA-like  expression  vectors.  The  latter  may  be  a 
requirement in the design of safe vectors, as there is evidence to suggest that shRNAs 
compete with endogenous miRNAs for limiting cellular factors required for processing of 
small RNAs, such as Exportin 5 and RISC (Castanotto et al., 2007, Hutvágner, 2004, Yi et 210 
 
al.,  2005).  This  can  result  in  oversaturation  of  the  endogenous  miRNA  pathway, 
downregulation of endogenous miRNA production, toxicity and even death (Grimm et al., 
2006).  The  risk  of  oversaturation  can  be  minimised  by  optimising  the  shRNA  dose  and 
sequence,  as  well  as  expressing  shRNA  from  inducible  or  tissue-specific  promoters. 
However, expression of shRNA from miRNA-based vectors requires the additional step of 
excision from the longer pri-miRNA sequence by the Drosha-DGCR8 complex (Han et al., 
2006).  This  additional  step  may  add  another  point  of  competition  with  endogenous 
miRNAs, thereby increasing the risk of saturation. Nevertheless, it has been demonstrated 
that unlike siRNAs and shRNAs, synthetic miRNAs do not compete with the endogenous 
miRNAs pathway (Castanotto et al., 2007). Moreover, synthetic miRNAs were shown to 
have improved safety profiles compared to shRNAs both in vitro and the mouse cerebella 
in vivo when expressed from an AAV vector (Boudreau et al., 2008a). Although synthetic 
miRNAs  were  found  to  be  less  potent  than  shRNAs,  shRNAs  generate  an  abundance  of 
unprocessed  precursors,  whereas  synthetic  miRNAs  are  processed  more  efficiently 
(Boudreau  et  al.,  2008b).  It  was  subsequently  revealed  that  shRNAs  disrupt  miRNA 
biogenesis  and  function,  whereas  synthetic  miRNAs  have  negligible  effects  even  when 
dosed  to  silence  as  effectively  as  shRNAs.  Moreover,  shRNAs  caused  Purkinje  cell 
neurotoxicity, whereas synthetic miRNA expression was well tolerated and sufficient to 
silence ataxin-1 in SCA1 mice. Finally,  whilst shRNA has been shown to induce an INF 
response  in  neurons  (Alvarez  et  al.,  2006,  Cao  et  al.,  2005),  neurotoxicity  in  cortical 
cultures and the mouse striatum was attenuated when shRNA sequences were inserted in 
miRNA-based lentiviral and AAV vectors, respectively (Bauer et al., 2008, McBride et al., 
2008). Collectively, the above findings suggest that miRNA-based vectors are better suited 
for silencing in the mammalian nervous system.  
Additionally, pol III promoters can only allow expression of a single shRNA and thus, 
inhibition  of  multiple  genes  requires  expression  from  multiple  promoters  or  different 
vectors, resulting in variable levels of shRNA expression. The miRNA-like system allows 211 
 
expression of multiple miRNA cassettes from a single transcript and it is therefore possible 
to simultaneously silence multiple gene targets (Chung et al., 2006, Zeng & Cullen, 2003). 
Alternatively, delivery of RNAi can be combined with expression of a biologically active 
protein in place of the reporter gene. These properties of the miRNA-like vectors may 
prove particularly useful in the study or treatment of complex conditions that are likely to 
be  caused  by  a  combination  of  factors  (an  example  is  described  in  Chapter  5  of  this 
thesis). Finally, a single miRNA cassette may be multimerised in tandem, up to at least 
eight  copies,  resulting in  increased  inhibition  of  target  gene  expression  (Chung  et  al., 
2006).  It  has  to  be  noted  that  vectors  based  on  miR-30  expressing  multiple  copies  of 
miRNA in tandem have yielded conflicting results. Zhou et al. reported reduced silencing 
from a plasmid vector expressing two copies of miRNA in tandem compared to a plasmid 
expressing a single copy (Zhou et al., 2005), whilst Sun et al. reported improved silencing 
efficacy in 293 cells when two copies of the same miRNA were expressed in tandem from a 
lentiviral vector, but addition of a third copy yielded a disproportionally smaller increase 
(Sun et al., 2006). Factors such as copy number and positioning, and intervening spacer 
length and composition are all likely to affect miRNA processing.  Although, during the 
course of this thesis, another study was published to describe expression of shRNA from a 
replication-defective HSV-1 (Hong et al., 2006), this is the only demonstration of HSV-
mediated expression of artificial miRNA.   
Specificity has become a major concern in the use of RNAi. Non-specific silencing 
may result from a non-sequence-specific effect caused by the virus, sequence-specific off-
target effects, or induction of the INF response. Throughout this study, negative control 
vectors had no effect on target gene expression. Moreover, the levels of GFP were not 
affected by expression of shRNA or miRNA targeting lacZ, and vice versa, thus excluding 
any  potential  non-specific  effects  induced  by  the  HSV  vector  backbone.  Furthermore, 
expression of shRNA/miRNA against β-galactosidase in 293T cells had no effect on the 
expression levels of four unrelated endogenous genes, including a gene involved in the 212 
 
induction of an INF response, indicating that silencing is not caused by a general non-
specific shutdown of protein synthesis. Nevertheless, a microarray analysis is required in 
order to identify any potential off-target effects caused by the hairpin sequence against 
lacZ. Moreover, although expression of shRNA from a pol III-based system or a miRNA-
based vector resulted in no obvious toxicity in primary neurons in vitro or DRG neurons in 
vivo,  a  more  detailed  investigation  is  required  to  exclude  neurotoxicity  caused  by 
induction of an INF response or competition with the endogenous miRNA pathway.         
In conclusion, the present chapter has developed replication-defective HSV-1 vectors 
that can be used to efficiently deliver RNAi to peripheral neurons both in vitro and in vivo. 
These highly promising results provided the basis for the work described in the following 
two chapters of this thesis, which aimed to provide proof of concept that endogenous 
genes  can  be  silenced  in  sensory  neurons  in  vivo  using  the  vectors  developed  in  this 
chapter and also demonstrate potential applications of this method in target validation 
and functional studies. 
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CHAPTER 4 
 
HSV-MEDIATED SILENCING OF AN ENDOGENOUS 
GENE INVOLVED IN NOCICEPTION –  
SILENCING OF TRPV1  
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4.1 Introduction 
The  recent  discovery  that  RNAi  operates  in  mammalian  neurons  has  generated  great 
excitement, not only with respect to potential applications in functional genomic studies 
and  target  validation,  but  also  harnessing  RNAi  as  a  therapeutic  strategy  to  silence 
disease-causing genes. Although delivery of synthetic siRNAs to the nervous system has 
achieved silencing of molecular targets in various models of neurological disease including 
pain  (summarised  in  section  4.1.3),  silencing  requires  frequent  administration  and 
relatively high doses of siRNAs. As a more efficient alternative, targeted delivery of RNAi 
to neurons can be achieved using viral vectors. At the time the objectives of this chapter 
were conceived, lentiviruses, adenoviruses and AAV had been engineered to deliver shRNA 
to the central nervous system (Harper et al., 2005, Ralph et al., 2005, Raoul et al., 2005, 
Singer et al., 2005, Xia et al., 2004). There were no reports, however, of vector-mediated 
delivery of shRNA to DRG neurons in vivo, the main target site for studying nociceptive 
processes and for the development of new analgesics.  
This chapter investigates the potential of the disabled HSV vectors developed in the 
previous chapter to silence the endogenous trpv1 gene, which is thought to be involved in 
nociceptive  processes,  in  sensory  neurons  in  vivo.  The  following  introductory  sections 
provide a brief overview of the neuroanatomy of the structures involved in nociception, 
chronic pain and the role of TrpV1, and review the efforts being made to validate pain-
related genes using synthetic siRNAs.  
 
4.1.1 Nociception  
Nociception  is  the  term  commonly  used  to  refer  to  the  perception  of  pain.  Acute 
nociceptive pain serves a crucial physiological function, warning the body of impending or 
actual tissue damage,  preventing further damage,  and aiding  the healing process. The 
peripheral
 terminals of primary afferent fibres respond to a variety of
 stimuli and translate 
this information into the dorsal horn
 of the spinal cord (grey matter), where the central 215 
 
ends of these fibres terminate. This information is conveyed by spinal projection neurons 
to higher
 centres in the brain, including the reticular formation, thalamus and ultimately 
the  cerebral  cortex,  where  non-noxious  and  noxious  signals
  can  be  perceived.  Sensory 
fibres  arise  from  cell  bodies  in  the  trigeminal  and  dorsal  root  ganglia,  and  can  be 
categorised into Aβ-fibres, Aδ-fibres, and
 C-fibres. Aβ-fibres are large in diameter, are 
highly myelinated and detect innocuous stimuli applied to skin, muscle and joints. Aδ-
fibres are smaller in diameter, are thinly myelinated and respond
 to both thermal and 
mechanical stimuli. C-fibres are the smallest
 type of primary afferents, are unmyelinated 
and  detect  selectively  nociceptive  stimuli.  Collectively,  Aδ-  and
  C-fibres  are  termed 
nociceptors and respond to noxious stimuli. Efforts to determine how these neurons detect 
pain-producing stimuli of a thermal, mechanical or chemical nature have revealed new 
signalling  mechanisms  and  improved  our  understanding  of  the  molecular  events  that 
facilitate transitions from acute to persistent pain. 
  
4.1.2 Chronic pain, animal models & the role of TrpV1 
Chronic  pain  is  a  major  socio-economic  burden  with  more  than  320  million  sufferers 
worldwide. Despite great progress being made in elucidating the molecular mechanisms 
underlying nociception, pain remains poorly treated due to the analgesic drugs currently 
available resulting in only partial and transient relief and severe side effects. There are 
two types of chronic pain, inflammatory and neuropathic. Inflammatory pain is associated 
with tissue damage and the resulting inflammatory process. Neuropathic pain is caused by 
damage to the neurons mainly in the peripheral, but also central nervous system, and is 
generally associated with hyperalgesia (hypersensitivity to noxious stimuli) and allodynia 
(hypersensitivity to normally non-noxious stimuli).  
Mechanistic and molecular-based understanding of chronic pain has relied heavily on 
animal  studies.  There  are  three  widely  used  animal  models  of  neuropathic  pain:  the 
chronic  constriction  injury  model  (Bennett  &  Xie,  1988),  partial  ligation  of  the  sciatic 216 
 
nerve (Seltzer et al., 1990), and spinal nerve ligation (Kim & Chung, 1992). One common 
feature of these models is that only a proportion of sciatic nerve fibres are damaged and 
the  undamaged  axons  still  innervating  the  hind  paw  allow  assessment  of  altered  pain 
responses  after  nerve  injury.  In  the  capsaicin  model,  intradermal  administration  of 
capsaicin  induces  hypersensitivity  to  mechanical  and  thermal  stimulation,  as  well  as 
spontaneous  pain  (Gilchrist  et  al.,  1996).  Other  experimental  animal  models,  such  as 
injection of formalin, Complete Freund’s Adjuvant or Carrageenan, mimic inflammatory 
pain and have been widely used in assessing the efficacy of analgesic compounds.  
Hyperexcitability  in  peripheral  sensory  nerves  acts  as  an  important  driving 
mechanism for neuropathic pain
 and can account for the initiation and maintenance of 
central
  hyperexcitability.  Amongst  the  proposed  molecular  drivers  of  peripheral 
hyperexcitability is
 the transient receptor potential vanilloid subtype 1 (TrpV1) receptor, 
which is predominantly expressed in nociceptive afferent fibres of the DRG, trigeminal 
ganglia and nodose ganglia. TrpV1 is a ligand-gated cation channel activated by capsaicin, 
noxious  heat  (>45
oC)  and  protons  (Caterina  et  al.,  1997,  Tominaga  et  al.,  1998)  and 
regulated by a variety of intracellular pathways and molecules, including inflammatory 
mediators  and  neuroregulators  (Cortright  &  Szallasi,  2004,  Zhang  et  al.,  2005).  TrpV1 
knockout mice exhibit diminished sensitivity to heat and lack of capsaicin-induced pain 
behaviour, but show normal responses to noxious mechanical stimuli after partial nerve 
ligation  (Caterina  et  al.,  2000,  Davis  et  al.,  2000).  In  contrast,  selective  TrpV1 
antagonists,  which  aim  to  inhibit  peripheral  nerve  fibre  activity  by  blocking  TrpV1 
transduction, have shown attenuated mechanical hyperalgesia and allodynia in various rat 
models of neuropathic pain (Christoph et al., 2006a, Honore et al., 2005, Kanai Y, 2005, 
Pomonis et al., 2003). Thus, TrpV1 appears to be a central molecular integrator of noxious 
stimuli and although it is believed to play a key role
 in neural sensitization caused by 
inflammation and nerve injury, its specific role in neuropathic pain has been controversial. 
 217 
 
4.1.3 Delivery of siRNAs to animal models of nociception 
The pain-related RNAi approaches published to date involve delivery of synthetic siRNAs by 
repeated  injections  or  continuous  infusion.  Silencing  of  several  pain-related  genes  has 
been achieved in various animal models of nociception using this experimental design. 
However, knockdown is transient lasting only up to several days, requires high doses of 
siRNAs and lacks specificity in the sense that uptake of siRNAs cannot be restricted to 
neurons or a specific subset of neurons.  
Dorn et al. achieved silencing of the P2X3 receptor, whose role in inflammatory and 
neuropathic pain had already been established (Honore et al., 2002, Jarvis et al., 2002), 
by  intrathecal  delivery  of  naked  siRNAs  infused  via  a  mini  pump  (Dorn  et  al.,  2004). 
Silencing of P2X3 in the DRG and dorsal horn of the spinal cord inhibited hyperalgesia and 
allodynia and provided pain relief in a rat model of neuropathic pain. Luo et al. achieved 
silencing of the delta opioid receptor (DOR) by daily intrathecal injections of siRNAs mixed 
with a cationic lipid (i-Fect
TM) (Luo et al., 2005). Transfection resulted in more efficient 
delivery of siRNAs to the lumbar DRG and spinal cord and thus, a lower dose was required 
to induce effective silencing of DOR, which inhibited antinociception induced by a DOR 
selective agonist. Tan et al. achieved silencing of the NR2B subunit of the N-methyl-D-
aspartate (NMDA) receptor that had been suggested to play a role in chronic pain (Coderre 
& Melzack, 1992) by intrathecal injection of siRNAs complexed with polyethyleimine (Tan 
et al., 2004a). Reduced mRNA and protein levels of NR2B in the spinal cord abolished 
formalin-induced  pain  behaviours  in  rats.  Furthermore,  Guo  et  al.  demonstrated  that 
injection  of  siRNAs  against  TrkB,  the  receptor  for  BDNF,  into  the  rostral  ventromedial 
medulla,  followed  by  electroporesion,  prevented  the  upregulation  of  TrkB  expression 
induced by inflammation caused by injection of Freund’s adjuvant (Guo et al., 2006). More 
recently, silencing of the P2X7 receptor in satellite cells of the lumbar DRG by intrathecal 
delivery of siRNAs elicited up-regulation of the P2X3 receptor, increased the activity of 218 
 
sensory neurons responding to painful stimuli and evoked abnormal nociceptive behaviours 
in rats (Chen et al., 2008).  
Finally, inhibition of TrpV1 expression has been achieved by delivery of antisense 
oligonucleotides (Christoph et al., 2007) or siRNAs (Christoph et al., 2006b). Intrathecal 
injection of naked siRNAs against trpV1 reduced cold allodynia by more than 50% over a 
time period of approximately 5 days in rats with chronic constriction injury and diminished 
spontaneous visceral pain behaviour induced by capsaicin in mice. Moreover,  Christoph 
and colleagues have recently published the generation of a transgenic mouse expressing 
shRNA  against  trpV1,  which  develops  mechanical  allodynia  and  hyperalgesia,  thus 
providing further evidence for the relevance of TrpV1 in neuropathic pain (Christoph et 
al., 2008).  
 
4.1.4 Rationale 
The  primary  aim  of  this  chapter  was  to  provide  proof  of  concept  that  an  endogenous 
neuronally expressed gene could be silenced using the replication-defective HSV-1 vectors 
developed in the previous chapter. Trpv1 is an ideal target for testing the efficacy of HSV-
mediated silencing in vivo, as it is predominantly expressed in DRG sensory neurons that 
can  be  efficiently  targeted  following  injection  of  the  virus  into  the  sciatic  nerve. 
Furthermore, TrpV1 has been shown to play a key role in inflammatory and neuropathic 
pain and is considered to be an attractive target for new analgesic drugs. Thus, effective 
and specific silencing of trpV1 in DRG neurons in vivo would demonstrate the potential of 
the  vectors  developed  in  this  thesis  as  a  valuable  tool  for  the  study  of  nociceptive 
processes and the validation of potential novel targets for pain therapy. 
The work described in this chapter was performed in parallel to the second half of 
the  work  described  in  chapter  3.  It  followed  evaluation  of  different  shRNA  expression 
systems in BHK-LacZ cells, which revealed that similar levels of specific silencing could be 
achieved with all three vectors tested (section 3.11). Thus, two vectors were constructed 219 
 
to express shRNA against trpV1 from the U6 pol III promoter or pre-miRNA against trpV1 
from the CMV pol II promoter. Work in this chapter was performed in collaboration with 
Johnson & Johnson Research and Development in Belgium.  
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4.2 Screening of shRNA / pre-miRNA sequences against trpV1 
In preliminary experiments performed by Ines Royaux at Johnson & Johnson Research and 
Development in Belgium, several plasmid vectors expressing shRNA sequences under the 
control  of  the  U6  promoter  or  pre-miRNA  sequences  under  the  control  of  the  CMV 
promoter  were  evaluated  for  their  ability  to  knockdown  mouse  trpv1  by  at  least  80% 
following transfection into 293T cells (data not shown). Screening of sequences against 
TrpV1 was performed by cloning the mouse trpV1 cDNA sequence (GI:49616384) into the 
pSCREEN-iT/LacZ-DEST  vector  (Invitrogen),  which  allows  generation  of  a  screening 
construct  containing  the  target  gene  fused  to  the  lacZ  reporter  gene.  The  pSCREEN-
iT/LacZ-trpV1  plasmid  was  co-transfected  into  293T  cells  with  each  of  the  plasmids 
expressing shTRPV1 or pre-miR-TRPV1 using Lipofectamine. Target gene knockdown was 
assessed by measuring β-galactosidase levels. This system allows rapid screening of target 
genes without the need for an antibody or prior knowledge of the knockdown phenotype 
and is particularly useful when screening sequences targeting neuronally expressed genes, 
as transfection of neuronal cell lines with plasmid DNA is highly inefficient. 
 
4.3 Generation of plasmid vectors targeting trpV1 
The most effective shRNA sequence against TrpV1, which targeted the region containing 
nucleotides 1296-1316 of the mouse trpv1 gene, was used to generate the pR19U6shTRPV1 
vector (figure 4.1a). The shTRPV1 sequence (available in section 2.1.6) was synthesized as 
single stranded DNA oligonucleotides, annealed and cloned into pENTR-U6 (described in 
figure 3.3). The U6shTRPV1 cassette was then inserted from pENTR-U6 into pR19-Gateway 
(constructed  in  section  3.5.1)  by  LR  recombination.  The  pR19U6shTRPV1  plasmid  was 
sequenced between the LAT flanking regions to ensure that the shTRPV1 sequence had not 
been mutated (figure 4.2a). Figure 4.2a also demonstrates that the shTRPV1 sequence is 
predicted to target the rat and human trpV1 gene, in addition to the mouse gene. 221 
 
The most effective pre-miRNA sequence against TrpV1, which targeted the region 
containing  nucleotides  581-601  of  the  mouse  trpv1  gene,  was  used  to  generate  the 
pR19CMV/EmGFP-miR-TRPV1 vector (figure 4.1b). The pre-miR-TRPV1 sequence (available 
in section 2.1.6) was synthesized as single stranded DNA oligonucleotides, annealed and 
cloned  into  pcDNA6.2/EmGFP-miR  (described  in  figure  3.7).  The  EmGFP-miR-TRPV1 
cassette  was  inserted  into  pDONR-221  by  BP  recombination  and  then  into  pR19CMV-
Gateway (constructed in section 3.5.3) by LR recombination. The pR19CMV/EmGFP-miR-
TRPV1 plasmid was sequenced between the LAT flanking regions to ensure that the pre-
miR-TRPV1 sequence had not been mutated (figure 4.2b). Figure 4.2b also demonstrates 
that the pre-miR-TRPV1 sequence is predicted to target the rat trpV1 gene, in addition to 
the mouse gene. 
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Figure 4.1 Cloning of pR19U6shTRPV1 and pR19CMV/EmGFP-miR-TRPV1 
 
a)  The  U6shTRPV1  cassette  was  inserted  from  pENTR-U6  into  pR19-Gateway  by  LR 
recombination. 
 
b)  The EmGFP-miR-TRPV1 cassette was inserted from pcDNA6.2 into pDONR-221 by BP 
recombination and then into pR19CMV-Gateway by LR recombination.  
 
The details of the cloning can be found in section 4.3. The details of the cloning of the 
pR19-Gateway plasmid can be found in section 3.5.1 and the details of the cloning of the 
pR19CMV-Gateway can be found in section 3.5.3.  The LR and BP recombination reactions 
are described in section 2.2.9 of the materials and methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 223 
 
 224 
 
a)  pR19U6shTRPV1 sequencing 
 
 
 
Sequence 1: lcl|1 
Length = 47 (1 .. 47) shTRPV1 
 
Sequence 2: lcl|65536 
Length = 1205 (1 .. 1205) pR19U6shTRPV1 (U6 Forward primer) 
 
Score = 91.1 bits (47),  Expect = 2e-16 
Identities = 47/47 (100%), Gaps = 0/47 (0%) 
Strand=Plus/Plus 
 
Query  1    GCGCATCTTCTACTTCAACTTCAAGAGAGTTGAAGTAGAAGATGCGC  47 
            ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  223  GCGCATCTTCTACTTCAACTTCAAGAGAGTTGAAGTAGAAGATGCGC  269 
 
 
 
 
The target sequence against mouse, human and rat TrpV1 in shTRPV1: 
 
 
gb|AY445519.1| Mus musculus transient receptor potential cation channel V1 (Trpv1) 
mRNA, complete cds 
Length=2520 
 
Score = 44.1 bits (22), Expect = 0.036 
Identities = 22/22 (100%), Gaps = 0/22 (0%) 
Strand=Plus/Plus 
 
Query  1     GCGCATCTTCTACTTCAACTTC  22 
             |||||||||||||||||||||| 
Sbjct  1296  GCGCATCTTCTACTTCAACTTC  1317 
 
 
gb|BC136633.1| Homo sapiens transient receptor potential cation channel, subfamily 
V, member 1, mRNA, complete cds 
Length=4021 
 
Score = 44.1 bits (22), Expect = 0.036 
Identities = 22/22 (100%), Gaps = 0/22 (0%) 
Strand=Plus/Plus 
 
Query  1     GCGCATCTTCTACTTCAACTTC  22 
             |||||||||||||||||||||| 
Sbjct  1775  GCGCATCTTCTACTTCAACTTC  1796 
 
 
gb|AF029310.1|AF029310 Rattus norvegicus transient receptor potential cation 
channel, subfamily V, member 1 (Trpv1), mRNA 
Length=2847 
 
Score = 44.1 bits (22), Expect = 0.036 
Identities = 22/22 (100%), Gaps = 0/22 (0%) 
Strand=Plus/Plus 
 
Query  1     GCGCATCTTCTACTTCAACTTC  22 
             |||||||||||||||||||||| 
Sbjct  1373  GCGCATCTTCTACTTCAACTTC  1394 
 
 
 
 
 225 
 
b)  pR19CMV/EmGFP-miR-TRPV1 sequencing 
 
 
 
Sequence 1: lcl|1 
Length = 64 (1 .. 64) pre-miR-TRPV1 
 
Sequence 2: lcl|65536 
Length = 1397 (1 .. 1397) pR19CMV/EmGFP-miR-TRPV1 (GFP Forward primer) 
 
Score =  123 bits (64),  Expect = 6e-26 
Identities = 64/64 (100%), Gaps = 0/64 (0%) 
Strand=Plus/Plus 
 
Query  1    TGCTGTGTAGTAGCTGTCTGTGTAGCGTTTTGGCCACTGACTGACGCTACACACAGCTAC  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 122   TGCTGTGTAGTAGCTGTCTGTGTAGCGTTTTGGCCACTGACTGACGCTACACACAGCTAC  181 
 
Query  61   TACA  64 
            |||| 
Sbjct  182  TACA  185 
 
 
 
The target sequence against mouse and rat TrpV1 in pre-miRNA-TRPV1: 
 
 
gb|AY445519.1| Mus musculus transient receptor potential cation channel V1 (Trpv1) 
mRNA, complete cds 
Length=2520 
 
Score = 39.2 bits (42), Expect = 1.4 
Identities = 21/21 (100%), Gaps = 0/21 (0%) 
Strand=Plus/Minus 
 
Query  6    TGTAGTAGCTGTCTGTGTAGC  26 
            ||||||||||||||||||||| 
Sbjct  601  TGTAGTAGCTGTCTGTGTAGC  581 
 
 
gb|AF029310.1|AF029310 Rattus norvegicus transient receptor potential cation 
channel, subfamily V, member 1 (Trpv1), mRNA 
Length=2847 
 
Score = 39.2 bits (42), Expect = 1.4 
Identities = 21/21 (100%), Gaps = 0/21 (0%) 
Strand=Plus/Minus 
 
Query  6    TGTAGTAGCTGTCTGTGTAGC  26 
            ||||||||||||||||||||| 
Sbjct  678  TGTAGTAGCTGTCTGTGTAGC  658 
 
 
 
Figure  4.2  Blast  nucleotide  sequence  alignment  of  a)  the  pR19U6shTRPV1  sequence 
obtained with the U6 Forward primer and b) the pR19CMV/EmGFP-miR-TRPV1 sequence 
obtained with the GFP Forward primer against the oligonucleotide sequences expressing 
shRNA and pre-miRNA against TrpV1, respectively. The primer sequences are described in 
section 2.1.5. The target sequence in shTRPV1 is indicated in the mouse, rat and human 
trpV1 gene sequences. The target sequence in pre-miR-TRPV1 is indicated in the mouse 
and rat trpV1 gene sequences 226 
 
4.4 Generation of disabled HSV-1 vectors targeting trpV1 
The U6shTRPV1 and EmGFP/miR-TRPV1 cassettes were inserted into the LAT region of the 
replication-defective  1764/4-/27+/RL1+  HSV-1  genome  immediately  3’  to  the  LATP2 
region, which allows long term expression during latency. 
The  pR19U6shTRPV1  plasmid  was  co-transfected  with  1764  4-/27+/RL1+ 
pR19CMVeGFPWCm viral DNA (prepared as described in section 2.4.5) into complementing 
MAM49 cells as described in section 2.4.1. Viral recombinants were identified by their 
inability to express GFP (white plaques) using fluorescent microscopy and were plaque 
purified as described in section 2.4.2. To confirm that the cassette expressing GFP had 
been replaced by the cassette expressing shRNA and that the shTRPV1 sequence had not 
been mutated, PCR was performed on viral DNA extracted from each plaque using the U6 
Forward  and  LAT  Reverse  primers  described  in  section  2.1.5  (figure  4.3a).  This  was 
followed by sequencing of the PCR products. One recombinant plaque was selected and 
grown to a high titre as described in section 2.4.3. 
The pR19CMV/EmGFP-miR-TRPV1 plasmid was linearised using a unique XmnI site in 
the plasmid backbone and was co-transfected with 1764 4-/27+/RL1+ pR19CMVLacZWCm 
viral  DNA.  Viral  recombinants  were  identified  by  their  ability  to  express  GFP  (green 
plaques) using fluorescent microscopy. Bright green plaques were selected and purified. 
When a pure green population was obtained, the purity of the plaques was confirmed 
further by x-gal staining. Expression of GFP from these recombinants indicated that the 
desired homologous recombination event had occurred. However, to confirm that the pre-
miR-TRPV1 sequence had not been mutated, PCR was performed on viral DNA extracted 
from each plaque using the GFP Forward and WCm Reverse primers described in section 
2.1.5 (figure 4.3b). The PCR products were sequenced and one recombinant plaque was 
selected and grown to a high titre. 
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4.5 Evaluation of disabled vectors targeting trpV1 in culture 
Prior  to  testing  the  HSV-U6shTRPV1  and  HSV-CMV/EmGFP-miR-TRPV1  vectors  in  DRG 
neurons in vivo, the viruses were evaluated for their ability to silence trpV1 in 293T cells 
transfected with the pSCREEN-iT/LacZ-trpV1 plasmid (supplied by Ines Royaux). The HSV-
U6shGFP and HSV-CMV/EMGFP-miR-neg vectors constructed in section 3.9 were used as 
negative controls.  
293T cells were transfected with 100ng pSCREEN-iT/LacZ-trpV1 using Lipofectamine 
(as  described  in  section  2.3.3)  and  were  allowed  to  recover  overnight  prior  to  being 
transduced with viruses at an MOI = 5.0. B-galactosidase activity assay at 48 hrs post-
transduction revealed highly effective knockdown of TrpV1 fused to β-galactosidase, when 
either HSV-U6shTRPV1 or HSV-CMV/EmGFP-miR-TRPV1 were transduced compared to the 
negative controls. The HSV-miR-TRPV1 vector induced 88.5 ± 6.8% silencing (n=3, mean ± 
s.d.) and was found to be more effective than the HSV-U6shTRPV1, which resulted in a 
74.5 ± 5.0% in silencing (figure 4.4). This result is in agreement with the data obtained in 
BHK-LacZ  cells  transduced  with  vectors  targeting  β-galactosidase  from  different 
promoters, which revealed marginally improved silencing of lacZ at 48 hrs with the vector 
expressing pre-miR-LacZ compared to the vectors expressing shLacZ. However, bearing in 
mind that the pre-miR-TRPV1 and shTRPV1 sequences target different regions of the trpV1 
gene  (figure  4.2),  this  may  also  be  due  to  the  pre-miR-TRPV1  sequence  being  more 
effective than the shTRPV1 sequence.  
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4.6 HSV-mediated silencing of trpV1 in DRG neurons in vivo 
This section describes silencing of trpV1 in DRG neurons in vivo following injection of HSV-
U6shTRPV1 or HSV-CMV/EMGFP-miR-TRPV1 into the sciatic nerve of mice. Silencing was 
assessed at the mRNA and protein levels. As explained in section 4.1.4, following injection 
of the HSV-U6shTRPV1 vector and assessment of TrpV1 mRNA levels, evaluation of disabled 
vectors expressing shRNA using different approaches (described in section 3.13) revealed 
that expression of shRNA from a miRNA-like system was more effective at silencing lacZ in 
DRG  neurons  in  vivo  than  expression  of  shRNA  from  the  U6  promoter.  Thus,  the  HSV-
U6shTRPV1 vector was abandoned and silencing was further assessed at the protein level 
using  the  HSV-CMV/EmGFP-miR-TRPV1  vector,  which  had  also  been  found  to  be  more 
effective  at  silencing  trpV1  in  293T  cells  transfected  with  pSCREEN-iT/LacZ-trpV1  and 
allows direct labelling of transduced cells through expression of EmGFP together with the 
pre-miRNA. 
 
4.6.1 Silencing of trpV1 – assessment of TrpV1 mRNA levels 
The HSV-U6shTRPV1 vector was injected into the sciatic nerve of BALB/c mice (n=4). Mice 
injected with HSV-U6shLacZ were used as negative controls (n=2). The 1764 4-/27+/RL1+ 
pR19CMVeGFPWCm vector expressing GFP was also co-injected to monitor transduction 
efficiency. At day 8, the left DRG (injected side) and right DRG (non-injected side) were 
isolated and analysed for GFP and Trpv1 levels. GFP expression assessed by quantitative 
RT-PCR confirmed delivery to all injected animals, predominantly to the L4 DRG (data not 
shown).  Quantitative  RT-PCR  for  Trpv1  revealed  markedly  reduced  mRNA  levels  in  all 
animals injected  with  HSV-U6shTRPV1 compared to animals injected with  the negative 
control (figure 4.5). Trpv1 mRNA in the left DRG isolated from these animals was reduced 
by  53.6  ±  11.2%  (one-way  t-test,  p=0.01)  (n  =  4,  mean  ±  s.d.)  compared  to  the  DRG 
isolated from the non-injected side of the same animals. Silencing was assessed between 
the L4 DRG of the same animals to avoid variation in TrpV1 expression between different 231 
 
animals. Importantly, HSV-U6shLacZ does not seem to have an effect on the levels of the 
endogenous  trpV1  gene  further  indicating  the specificity  of  this  method.  The  qRT-PCR 
experiment was performed by Johnson & Johnson Research and Development in Belgium as 
described in section 2.2.17.  
 
4.6.2 Silencing of trpV1 – assessment of TrpV1 protein levels 
In the previous chapter, it was demonstrated that the HSV-CMV/EmGFP-miR vector is more 
effective at silencing in vivo than the HSV-U6shRNA system. Subsequent experiments were 
therefore performed using the vector expressing pre-miRNA against trpV1. Detection of 
mRNA degradation by RT-PCR is often used to assess RNAi effects. However, it has been 
reported that in some cases the RISC could merely inhibit mRNA translation without mRNA 
degradation  by  a  mechanism  similar  to  the  miRNA  translation  inhibition.  To  evaluate 
silencing at the protein level, BALB/c mice were injected directly into the sciatic nerve 
with HSV-CMV/EmGFP-miR-neg (n=10) or HSV-CMV/EmGFP-miR-TRPV1 (n=10). 8 days post-
injection  the  DRG  from  injected  animals  were  isolated  as  described  in  section  2.6.8. 
Delivery was assessed by fluorescent microscopy for GFP, which confirmed delivery to all 
injected animals mainly to the L4 DRG. Western blot analysis (as described in sections 
2.7.2-2.7.4)  for  TrpV1,  TrpA1  and  Stat1  (antibodies  described  in  section  2.17)  was 
performed on protein extracted from the L4 DRG isolated from each group (as described in 
section 2.7.1) (figure 4.6). Quantification of band density using the Scion Image software 
revealed  an  average  59%  reduction  in  the  levels  of  TrpV1  protein  compared  to  the 
negative  control  (figure  4.7).  The  levels  of  Stat1  remained  essentially  unchanged 
indicating  that  silencing  is  specific  and  not  caused  by  induction  of  the  INF  response. 
However,  protein  extracted  from  the  DRG  of  non-injected  animals  should  have  been 
included as a negative control to exclude the possibility that the miR-neg induces the INF 
response.  Finally,  although  TrpA1  was  not  downregulated,  this  is  not  enough  data  to 
conclude that the miR-TRPV1 sequence does not cause any off-target effects.  232 
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4.7 Transduction efficacy of TrpV1-expressing neurons 
The in vivo data obtained with both vectors targeting trpV1 is particularly promising as it 
represents overall mRNA and protein levels in both transduced and non-transduced sensory 
neurons expressing TrpV1. It should be noted that the 92% knockdown of β-galactosidase 
expression described in section 3.13 was calculated by counting LacZ-positive vs. GFP-
positive neurons and therefore reflects the proportion of transduced neurons in which lacZ 
was completely silenced. 
The DRG is comprised of a heterologous population of neurons and TrpV1 is almost 
exclusively expressed in small- and medium- diameter sensory fibres. Thus, to provide an 
explanation  as  to  why  complete  trpV1  silencing  was  not  achieved  with  the  vectors 
constructed in this chapter, the efficiency TrpV1-expressing neurons are transduced by the 
vector following injection into the sciatic nerve was investigated. BALB/c mice (n=2) were 
injected with HSV-CMV/EmGFP-miR-neg and immunofluorescence (as described in section 
2.7.6) was performed on L4 DRG sections isolated from these animals to investigate the 
degree of co-localization between EmGFP expressed by the vector and TrpV1 (antibodies 
described in section 2.17). Figure 4.8 shows representative sections from DRG isolated 4 
days  post-injection.  Immunofluorescence  confirmed  that  the  vector  transduces  a 
heterologous population of neurons, including an estimated 80% of neurons that express 
TrpV1 (neurons not counted). However, 20% of such neurons were not transduced. This 
provides  one  explanation  for  the  53.6%  reduction  in  TrpV1  mRNA  using  the  U6  vector 
expressing  shTRPV1  (figure  4.5)  and  59%  reduction  of  TrpV1  protein  using  the  miRNA 
version (figure 4.6).  
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4.8 Discussion 
Although replication-defective HSV-1 vectors have been extensively used to deliver genes 
to peripheral neurons, including in animal models of neuropathic and inflammatory pain 
(Goss  et  al.,  2001,  Hao  et  al.,  2003a,  Hao  et  al.,  2003b),  HSV  vectors  had  not  been 
previously developed to provide silencing of an endogenously expressed gene in sensory 
neurons in vivo. The previous chapter  of this thesis  demonstrated that disabled HSV-1 
vectors can induce highly effective and specific silencing of reporter genes in dividing cells 
in culture, primary neuronal cells and DRG neurons in vivo. This chapter demonstrates 
that in addition to the silencing of transgenically expressed reporter genes, HSV-mediated 
expression of shRNA or artificial miRNA to DRG neurons in vivo results in effective and 
specific  silencing  of  the  endogenous  trpv1  gene,  which  is  involved  in  nociceptive 
processing and therefore is a potential target for therapeutic pain relief.  
Both vectors constructed in this chapter were effective at silencing trpV1 in DRG 
following  injection  into  the  sciatic  nerve.  Trpv1  mRNA  levels  were  reduced  by  54%  in 
sensory  neurons  from  mice  injected  with  the  vector  expressing  shTRPV1.  This 
downregulation is highly promising as intrathecal delivery of siRNAs against other pain-
related genes has achieved a maximum 40% mRNA reduction in DRG neurons in vivo (Dorn 
et al., 2004, Luo et al., 2005). Previous studies have shown that partial injury of the 
sciatic nerve results in downregulation of TrpV1 in the L4 and L5 DRG (Hudson et al., 
2001, Michael & Priestley, 1999). Quantitative RT-PCR revealed no significant difference in 
TrpV1 mRNA levels between L4 DRG taken from the injected and non-injected side of the 
same  animals.  This  result  demonstrates  that  the  disabled  HSV  backbone  and/or 
introduction  of  shRNA  do  not  induce  the  INF  response,  but  also  suggests  that  the 
procedure used to inject the virus into the sciatic nerve does not alter TrpV1 expression 
levels by injuring the nerve fibres. In addition to reduced mRNA levels,  TrpV1 protein 
levels  were  reduced  by  59%  in  sensory  neurons  from  mice  injected  with  the  vector 
expressing  miR-TRPV1.  Protein  levels  were  assessed  by  western  blot,  because  using 238 
 
immunocytochemistry to detect a partial reduction of TrpV1 expression against the large 
TrpV1  pool  existing  prior  to  delivery  of  shRNA  would  be  challenging.  To  investigate 
silencing  specificity  further,  western  blot  analysis  demonstrated  that  the  pre-miRNA 
sequence against trpV1 had no effect on the expression levels of Stat-1, which would be 
significantly upregulated in the event of an induction of the INF response. Furthermore, 
the pre-miRNA sequence against trpV1 had no effect on the expression levels of TrpA1, 
although it has to be noted, that trpV1 has limited homology to trpA1. 
Incomplete  knockdown  of  TrpV1  may  be  due  to  residual  protein  in  DRG  neurons 
expressed prior to expression of shRNA. Thus, silencing will depend on the half-life of the 
protein  expressed  from  the  target  gene.  Moreover,  the  RNAi  efficacy  of  the  method 
described  in  this  thesis  will  critically  depend  upon  the  efficiency  at  which  the  vector 
transduces  the  specific  subset  of  neurons  expressing  the  target  gene.  TrpV1  is  almost 
exclusively expressed by unmyelinated small- and medium-diameter DRG neurons, mainly 
C-fibers  (Michael  &  Priestley,  1999).  Further  investigation  into  the  reasons  complete 
silencing of trpV1 was not achieved revealed that injection of the vector into the sciatic 
nerve results in incomplete transduction of the subset of DRG neurons expressing TrpV1. 
Additional  experiments  are  required  to  determine  the  subpopulation  of  DRG  neurons 
transduced with disabled HSV following injection of the sciatic nerve and thus, predict the 
potency of this approach against future targets.  
TrpV1,  whose  role  in  inflammatory  and  neuropathic  pain  has  already  been 
established (Christoph et al., 2006, 2007 and 2008), has been used here as a proof of 
concept that an endogenous gene can be specifically silenced in DRG using the vector 
system  developed.  Since  the  primary  aim  was  to  evaluate  a  means  of  effective  and 
specific RNAi delivery to DRG neurons in vivo rather that to validate the role of trpV1 
itself,  the  assessment  of  any  behavioural  effects  was  beyond  the  scope  of  this  thesis, 
although Johnson & Johnson are separately undertaking this work. Previous studies suggest 
that  only  a  small  number  of  TrpV1-expressing  neurons  have  to  be  reached  by  siRNA 239 
 
treatment  to  evoke  an  analgesic  response  and  that  knockdown  of  TrpV1  protein  by 
antisense oligonucleotides, despite being too subtle to detect in the DRG or spinal cord, 
was sufficient to reduce neuropathic pain behaviour (Christoph et al., 2006 and 2007). 
Thus, 59% knockdown of TrpV1 protein demonstrated here would be expected to confer a 
biological  effect,  which  it  is  hoped  will  be  confirmed  in  a  capsaicin  mouse  model  by 
Johnson & Johnson in the coming months.  
In  conclusion,  the  results  described  in  this  chapter  highlight  the  potential  of  the 
disabled HSV-1 vectors developed in this thesis, which can theoretically be engineered to 
target  any  gene,  as  a  valuable  tool  for  the  study  of  nociceptive  processes  and  the 
development  of  new  analgesic  drugs.  Furthermore,  these  vectors  could  ultimately  be 
applicable to the development of an HSV vector-based approach to pain control. Such an 
approach may be particularly relevant in the case of TrpV1 silencing. Current analgesic 
strategies are aimed at developing TrpV1 agonists or antagonists to attenuate excitability
 
in sensory fibres, and several antagonists are in various stages of clinical development for 
the treatment of pain. Although TrpV1 is most strongly expressed in sensory neurons, it is 
functionally expressed in many other tissues throughout the body, including the central 
nervous system (Szallasi et al., 2007), where it has been suggested to play an important 
role  in  hippocampal  synaptic  plasticity  (Gibson  et  al.,  2008).  Thus,  systemic  TrpV1 
antagonists or non-targeted delivery of siRNAs against trpV1 may interfere with processes 
such as learning and memory, and adversely affect cognitive function. Administration of 
the vectors developed in this thesis, via the relatively non-invasive route of sciatic nerve 
injection, allows targeted delivery of shRNA to the cell bodies of sensory neurons in the 
DRG  and  α-motor  neurons  in  the  ventral  horn  of  the  spinal  cord  though  retrograde 
transport. However, disabled HSV vectors are incapable of trans-synaptic transport and 
thus, unable to spread to the central nervous system to induce any adverse side effects 
that might result from knockdown of TrpV1 at that site. 240 
 
Shortly  after  the  work  described  in  this  chapter  was  completed,  a  replication-
defective HSV-1 vector was shown to express shRNA in the mouse brain to suppress mutant 
APP exogenously expressed from a co-injected LV vector (Hong et al., 2006). Furthermore, 
HSV amplicon vectors have demonstrated silencing of genes in tumour cells in vitro and in 
vivo (Sabbioni et al., 2006, Saydam et al., 2005, Saydam et al., 2007). Nevertheless, the 
work  described  in  chapters  3  and  4  of  this  thesis  represents  the  first  and  so  far  only 
demonstration  of  endogenous  gene  silencing  in  neurons  in  vivo  using  HSV  and  of  gene 
silencing  in  sensory  neurons  in  vivo  by  vector-mediated  delivery  of  shRNA  or  artificial 
miRNA and (Anesti et al., 2008).  
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CHAPTER 5 
 
HSV-MEDIATED SILENCING TO PROMOTE 
REGENERATION OF SENSORY AXONS INTO THE SPINAL 
CORD 
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5.1 Introduction 
The regenerative capacity of the injured adult mammalian CNS is extremely limited. There 
is now widespread agreement that the failure of axonal regeneration is multifactorial. A 
combination  of  inhibitory  molecules,  attenuated  cell  body  responses  to  axotomy  and 
inadequate  neurotrophic  support  are  all  believed  to  play  some  part  in  preventing  CNS 
axonal regeneration. Effective regeneration will therefore depend on strategies directed 
at blocking multiple inhibitors simultaneously, whilst boosting the intrinsic capacity of CNS 
neurons  to  regenerate.  To  effectively  restore  function,  such  approaches  should  be 
combined with strategies aimed at directing regenerating axons to reconnect with their 
target neurons and reconstituting neuronal circuits.  
This  chapter  investigated  the  potential  of  a  disabled  HSV-1  vector  to  induce 
regeneration of sensory axons into the spinal cord by silencing a combination of genes 
suggested  to  be  involved  in  the  inhibition  of  axonal  regeneration.  The  following 
introductory sections provide a brief overview of the degenerative processes following CNS 
injury, cell body responses to axotomy and inhibitory molecules that contribute to the 
failure of axonal regeneration, with special focus on the inhibitors that are targeted by 
the vector constructed in this chapter. 
 
5.1.1 Spinal cord injury 
An estimated 2.5 million people worldwide live with spinal cord injury (SCI), with more 
than  130,000  new  injuries  reported  each  year.  Injury  to  the  spinal  cord  can  result  in 
dramatic  disability.  Although  many  patients  show  some  spontaneous  recovery,  most 
patients with significant damage to the spinal cord have permanent symptoms, such as 
loss of voluntary movement and chronic pain. SCI cannot yet be repaired by any therapy. 
During the past 50 years, however, improvements in medical and surgical care, the advent 
of rehabilitation programmes and new devices have drastically changed the prognosis of 243 
 
serious SCI from utter hopelessness, great suffering and early death to the expectation of 
long-term survival and a significantly improved quality of life.   
 
5.1.2 Degenerative processes following spinal cord injury 
Traumatic injury to the spinal cord causes immediate death of cells in the vicinity of the 
injury  site,  including  neurons,  oligodendrocytes,  astrocytes  and  endothelial  cells,  and 
although  injury  can  directly  damage  the  cell  bodies  of  neurons  with  typically  modest 
functional  consequences,  this  often  results  in  substantial  axonal  damage.  Following 
axotomy,  the  axon  proximal  segment  survives,  but  unlike  axotomised  neurons  of  the 
peripheral  or  embryonic  nervous  system,  the  damaged  fails  to  regenerate  beyond  the 
lesion site. The distal axon segment retracts from post-synaptic neurons and undergoes 
progressive degeneration, a process known as Wallerian degeneration. Myelin sheaths are 
wrapped around axons to ensure rapid propagation of action potentials. Peripheral myelin 
is produced by Schwann cells, whereas central myelin is produced by oligodendrocytes. 
Axonal  loss  leads  to  the  damage  of  myelin,  death  of  oligodendrocytes  and  the 
accumulation of cellular debris rich in degenerating myelin. In the PNS, myelin debris is 
phagocytosed by Schwann cells and macrophages. In the CNS, Wallerian degeneration is 
relatively  slow  and  degenerating  myelin  can  persist  for  years  due  to  delayed  and 
inefficient  macrophage  responses  (George  &  Griffin,  1994).  Moreover,  resident  and 
invading  inflammatory  cells,  such  as  microglia  and  macrophages,  can  mediate  various 
destructive  processes,  such  as  further  cell  death,  membrane  damage  and  apoptosis. 
Finally, within hours of injury, recruitment of inflammatory cells and reactive astrocytes 
leads to the formation of a glial scar often accompanied by a fluid-filled cyst, which act as 
an additional barrier to axonal growth.  
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5.1.3 Inhibitors of axonal regeneration 
Despite early claims that adult CNS axons are incapable of regeneration (Ie Gross Clark, 
1943), sprouting within the lesion site (Guth et al., 1985, Liu & Chambers, 1958) and even 
short  distance  sprouting  from  surviving  axons  have  been  observed  in  several  different 
experimental  models  (Freund  et  al.,  2006,  Li  &  Raisman,  1994,  Taylor  et  al.,  2006). 
Ramon  and  Cajal  (1928),  who  were  the  first  to  describe  the  anatomical  responses  to 
nervous  system  injury,  reported  that  the  ends  of  lesioned  axons  become  swollen  into 
dystrophic endballs. Recent studies have revealed that these dystrophic growth cones are 
highly active structures stalled in an inhibitory environment (Kerschensteiner et al., 2005, 
Tom et al., 2004). Moreover, DRG neurons that have axons in both the CNS and PNS can 
only regenerate their peripheral processes, and some injured CNS axons can regenerate 
over long distances in the permissive environment of a peripheral nerve graft (David & 
Aguayo, 1981, Richardson et al., 1980). These observations suggested that adult CNS axons 
have an intrinsic capacity for regeneration, which is severely limited by the inhibitory and 
nonpermissive nature of the injured mammalian CNS.   
An  increasing  number  of  CNS  inhibitory  cues  have  been  identified,  including  the 
prototypic  myelin  inhibitors  Nogo-A,  myelin-associated  glycoprotein  (MAG),  and 
oligodendrocyte  myelin  glycoprotein  (OMgp),  as  well  as  several  types  of  chondroitin 
sulfate proteoglycans (CSPGs), which are upregulated following injury particularly near 
the  site  of  the  glial  scar  formation  (discussed  in  section  5.1.8).  In  addition,  recent 
evidence  suggests  that  developmental  axon  guidance  molecules  belonging  to  the 
semaphorin, ephrin and netrin families, which are also upregulated following injury, may 
repel  regenerating  axons  and  inhibit  axonal  regrowth  (Yiu  &  He,  2006).  Although 
interfering  with  signaling  from  axon  guidance  molecules  has  been  suggested  to  be  as 
effective  in  promoting  functional  recovery  following  SCI  as  interfering  with  myelin-
associated inhibitors (Bolsover et al., 2008), this is beyond the scope of this thesis. The 245 
 
following sections focus on myelin-associated inhibitors and their role in the failure of 
axonal regeneration.    
 
5.1.4 Myelin-associated inhibitors 
In  the  late  1980s,  pioneering  work  in  the  lab  of  Martin  Schwab  demonstrated  that 
oligodendrocytes and myelin membranes are major inhibitors of axonal growth within the 
CNS (Schwab & Caroni, 1988). Recent evidence suggests that myelin inhibition is complex, 
involving multiple and distinct receptor systems that may operate in a redundant manner. 
Furthermore,  the  relative  contribution  of  different  ligand-receptor  systems  to  myelin 
inhibition may vary amongst different neuronal cell types. Whilst great progress has been 
made in identifying myelin-associated inhibitors, defining their mechanism of action and 
their  relative  contribution  to  the  failure  of  axonal  regeneration  is  of  fundamental 
importance for the rational design of therapies to promote functional recovery following 
CNS injury.  
 
5.1.5 Nogo, MAG and OMgp 
Nogo is a member of the reticulon (RTN) family of membrane-associated proteins. At least 
three isoforms (Nogo-A, -B and -C) are generated by alternative splicing and promoter 
usage.  Amongst  them,  Nogo-A  is  highly  expressed  in  developing  and  mature 
oligodendrocytes and in some subpopulations of neurons, but is absent from peripheral 
myelin (Huber et al., 2002). Nogo-A contains two distinct inhibitory domains that have 
both been shown to inhibit neurite outgrowth and growth cone collapse (Caroni & Schwab, 
1988, GrandPre et al., 2000, Oertle et al., 2003). The unique N-terminal domain (amino-
Nogo) is not shared by Nogo-B and Nogo-C, whereas the 66 amino acid hydrophilic loop 
(Nogo-66), which is flanked by two transmembrane domains and is part of the C-terminal 
RTN homology domain, is common to all three isoforms. The topology of Nogo-A remains 
controversial. Although initial evidence places Nogo-66 on the cell surface and amino-Nogo 246 
 
in the cytoplasm, amino-Nogo can also be detected on the cell surface (Oertle et al., 
2003). It has been hypothesized that a large part of Nogo-A may be exposed following 
oligodendrocyte membrane damage, further contributing to growth inhibition after injury. 
A  monoclonal  antibody  against  amino-Nogo  (IN-1)  has  been  shown  to  promote  axonal 
regeneration and functional recovery following SCI (Bregman et al., 1995, Brosamle et al., 
2000, Liebscher, 2005, Schnell & Schwab, 1990). However, ascending sensory fibres do not 
exhibit enhanced regeneration into  the rat spinal cord when treated with an antibody 
against amino-Nogo (NI-35/250), suggesting that the relative contribution of Nogo-A to the 
failure  of  regeneration  varies  between  different  fibre  systems  (Oudega  et  al.,  2000). 
Furthermore,  studies  with  Nogo  null  mice  have  failed  to  demonstrate  any  signiﬁcant 
regeneration of corticospinal ﬁbers following dorsal hemisection (Simonen et al., 2003, 
Zheng  et  al.,  2003)  and  only  one  study  has  reported  robust  regeneration  (Kim  et  al., 
2003),  raising  questions  about  whether  blocking  Nogo  alone  is  sufficient  to  promoter 
axonal regeneration following SCI. Due to the lack of reproducibility of these transgenic 
studies, the role of Nogo in axonal regeneration remains controversial.  
MAG  is  comprised  of  five  extracellular  immunoglobulin  (Ig)-like  domains,  a  single 
transmembrane  domain  and  a  cytoplasmic  domain.  It  is  expressed  in  both 
oligodendrocytes in the CNS and Schwann cells in the PNS, and has been implicated in 
myelin  formation  and  maintenance  (Schachner,  2000).  Interestingly,  MAG  promotes 
embryonic and neonatal neurite outgrowth (Hasegawa et al., 2004, Johnson et al., 1989). 
The molecular basis underlying the transition from promotion to inhibition of growth is not 
fully  understood  and  depending  on  the  neuronal  cell  type,  it  occurs  at  different 
developmental  stages.  Following  postnatal  day  6,  however,  all  neuronal  cell  types 
examined to date, including DRG neurons, are strongly inhibited by MAG (Cai et al., 2001, 
Mukhopadhyay et al., 1994). Whilst MAG has been shown to be a potent inhibitor of axonal 
growth in vitro (Wong et al., 2003), MAG null mice do not demonstrate improved axonal 
growth following SCI (Bartsch et al., 1995). Moreover, MAG null mice exhibit defects in 247 
 
myelin stability (Li et al., 1994, Montag et al., 1994), late-onset progressive PNS axonal 
atrophy, increased Wallerian regeneration, and CNS axon degeneration (Loers et al., 2004, 
Pan et al., 2005).  
Finally,  OMgp is a GPI-anchored protein that contains a leucine-rich repeat (LRR) 
domain  (Mikol  et  al.,  1990).  Similar  to  Nogo-A,  OMgp  is  expressed  by  neurons  and 
oligodendrocytes in the developing and adult CNS (Habib et al., 1998). Recent evidence 
suggests that it is present at Nodes of Ranvier and may act to prevent collateral sprouting 
(Huang et al., 2005). It remains to be determined whether blocking OMgp function in vivo 
leads to enhanced axonal regeneration after SCI. 
 
5.1.6 NgR1 and NgR2  
The Nogo receptor gene family consists of three members NgR1, NgR2 and NgR3. Nogo 
receptors are GPI-anchored proteins containing a LRR cluster flanked by cysteine–rich N-
terminal and C-terminal LRR capping domains. NgR1 is expressed in many types of CNS 
neurons, including a subpopulation of adult DRG neurons (Hunt et al., 2002). The NgR1 
LRR cluster can bind with high affinity to the Nogo-66 domain of Nogo-A (Fournier et al., 
2001), as well as MAG (Domeniconi et al., 2002) and OMgp (Wang et al., 2002) that are 
structurally different to Nogo. The finding that all three myelin inhibitors, which seem to 
be redundant for axonal growth, signal through a single receptor, made NgR1 an attractive 
candidate to block in order to promote axonal regeneration.  
Administration  of  a  function-blocking  NgR1  ectodomain  resulted  in  sprouting  of 
corticospinal and raphespinal ﬁbres, which correlated with improved spinal cord electrical 
conduction and improved locomotion (Li et al., 2004a). Moreover, some of the most robust 
regeneration  following  SCI  has  been  observed  in  animals  treated  with  the  NgR1 
antagonistic peptide NEP1-40 (Li & Strittmatter, 2003). This study, however, could not be 
reproduced  by  Steward  and  colleagues  (Steward  et  al.,  2008).  Furthermore, NgR1  null 
mice failed to show enhanced regeneration of corticospinal ﬁbres (Kim et al., 2004, Zheng 248 
 
et al., 2005), although some regeneration of raphespinal and rubrospinal descending fibres 
was observed after complete transection, suggesting that the effect of blocking NgR1 may 
vary between  different populations  of spinal  cord fibres (Kim et al.,  2004).  Moreover, 
although DRG neurons isolated from wild-type mice demonstrated a significant increase in 
growth cone collapse in response to soluble myelin inhibitors compared to DRG neurons 
from  NgR1  null  mice  (Kim  et  al.,  2004),  it  was  later  shown  that  neurite  outgrowth 
inhibition  in  DRG  neurons  grown  on  substrate  bound  Nogo-66,  MAG  and  OMgp  is  NgR1 
independent (Chivatakarn et al., 2007, Zheng et al., 2005). These results suggest that 
growth cone collapse and growth inhibition may be separate activities of myelin inhibitors. 
Finally,  RNAi-mediated  knockdown  of  NgR1  further  confirmed  that  blocking  NgR1 
expression  does  not  result  in  enhanced  neurite  outgrowth  on  membrane  bound  MAG 
(Chivatakarn et al., 2007). Collectively, recent studies have challenged the oversimplified 
scenario that all three inhibitors converge on NgR1 to mediate their effects and imply the 
existence of redundancy at the receptor level. Thus, great interest has been focused on 
defining the mechanism of action and relative contribution of NgR2 to myelin inhibition.  
NgR2 is predominantly expressed in neurons of the embryonic and adult central and 
peripheral nervous systems, including a subpopulation of DRG neurons, and has a distinct 
though largely overlapping expression pattern to NgR1 (Barrette et al., 2007, Funahashi et 
al., 2008, Hunt et al., 2002). NgR2 binds MAG with an approximately five-fold greater 
affinity than NgR1, but does not support binding of Nogo-66 or OMgp (Venkatesh et al., 
2005)  and  thus,  NgR2  has  been  suggested  to  substitute  for  NgR1  in  mediating  MAG 
inhibition. NgR1 and NgR2 double mutant mice are not yet available and therefore, the 
relative contribution of NgR1 and NgR2 to myelin inhibition remains to be established.  
Finally, Nogo receptor independent mechanisms to MAG inhibition may also exist, as 
neurons treated with an enzyme that cleaves all GPI-linked proteins can still respond to 
MAG  (Niederost  et  al.,  2002).  Some  evidence  has  implicated  ganglioside  GT1b  in  MAG 
inhibition  (Vyas  et  al.,  2002).  Combined  pharmacological  inhibition  of  gangliosides 249 
 
biosynthesis and NgR1 resulted in increased neuronal growth of DRG neurons cultured on 
substrate  bound  MAG  than  either  treatment  alone,  further  suggesting  that  combined 
blockage of multiple binding molecules may be necessary to overcome myelin inhibition 
(Mehta et al., 2007). 
  
5.1.7 Lingo, p75 and TROY 
NgR1 lacks an intracellular domain and has been shown to interact with p75 or TROY, 
which are members of the tumour necrosis factor receptor family, and Lingo1, which is a 
nervous system specific type-1 membrane protein, to mediate transduction across the cell 
membrane. Early studies suggested that neurite outgrowth inhibition by Nogo-66, MAG and 
OMgp  is  mediated  by  an  NgR1/p75/Lingo1  receptor  complex.  Lingo1  and  NgR1  show 
distinct  but  largely  overlapping  neuronal  expression  patterns  (Barrette  et  al.,  2007, 
Llorens et al., 2008). Lingo1 is an essential component of the NgR1 complex in culture (Mi 
et al., 2004) and a Lingo1 antagonist has been shown to promote axonal sprouting and 
functional recovery following SCI (Ji et al., 2006). Moreover, neurons from p75 null mice 
showed  dramatically  reduced  responses  to  Nogo-66,  MAG  and  OMgp  (Yamashita  et  al., 
2002). Subsequently, p75 that was originally identified as a neurotrophin receptor was 
shown  to  associate  with  NgR1  (Wang  et  al.,  2002,  Wong  et  al.,  2002)  and  undergo 
intramembrane proteolysis by α- and γ-secretase, which is important for RhoA activation 
and subsequent inhibition of neurite outgrowth (Domeniconi et al., 2005). RNAi-mediated 
knockdown of p75 in cultured DRG neurons resulted in enhanced neurite outgrowth in the 
presence of MAG and CNS myelin (Ahmed et al., 2005, Higuchi et al., 2003). However, 
similar  to  studies  with  Nogo-A  knockout  mice,  p75  null  mice  failed  to  regenerate 
corticospinal  fibres  following  SCI  injury  (Song  et  al.,  2004b).  Moreover,  p75  is  not 
expressed in most populations of mature neurons and thus, many types of CNS neurons 
that are inhibited by myelin do not express p75.  250 
 
NgR1 was subsequently found to interact with TROY with eight-fold higher affinity 
than  with  p75.  Functional  studies  demonstrated  that  ectopic  expression  of  dominant 
negative TROY in DRG neurons attenuates Nogo-66 inhibition (Park et al., 2005). Moreover, 
DRG neurons isolated from TROY null mice are significantly more resistant to Nogo-66, 
OMgp and CNS myelin inhibition of neurite outgrowth in vitro (Shao et al., 2005). Thus, 
TROY  has  been  suggested  to  substitute  for  p75  in  neurons  that  do  not  express  p75. 
However, whilst TROY has been reported to be expressed in DRG neurons amongst other 
neurons (Park et al., 2005), these findings have not been confirmed by subsequent studies 
(Hisaoka et al., 2006), suggesting that additional signal-transducing co-receptors exist. 
 
5.1.8 RhoA activation 
Expression of NgR1, p75 or TROY, and Lingo1 is sufficient to confer responsiveness of non-
neuronal  cells  to  myelin  inhibition  by  activating  the  downstream  signal  RhoA  and  its 
effector  RhoA-associated  kinase  (ROCK)  (Park  et  al.,  2005,  Shao  et  al.,  2005).  RhoA 
belongs  to  the  Rho  family  of  small  intercellular  GTPases  that  signal  modulation  of 
polymerization of the actin cytoskeleton. RhoA is directly activated in response to myelin-
associated inhibitors and this activation correlates with signals that induce growth cone 
collapse  (Winton  et  al.,  2002).  Inhibition  of  RhoA  using  C3  transferase  or  dominant 
negative  RhoA  and  inhibition  of  ROCK  resulted  in  enhanced  neuronal  outgrowth  on 
inhibitory substrates (Fournier et al., 2003, Lehmann et al., 1999, Niederost et al., 2002). 
Furthermore,  silencing  of  RhoA  in  DRG  cultures  resulted  in  more  enhanced  neurite 
outgrowth in the presence of CNS myelin than when p75 or NgR1 were silenced (Ahmed et 
al., 2005). More importantly, inhibition of RhoA promoted sprouting of corticospinal fibres 
following dorsal hemisection, and inhibition of ROCK promoted significant regeneration of 
corticospinal fibres and functional recovery (Dergham et al., 2002, Fournier et al., 2003, 
Lehmann  et  al.,  1999).  Ephrins,  semaphorins  and  CSPGs  have  also  been  suggested  to 
converge on the RhoA pathway (Hunt et al., 2002, Sandvig et al., 2004). Thus, the RhoA-251 
 
ROCK  pathway  is  an  attractive  candidate  to  block  in  order  to  promote  axonal 
regeneration.     
 
5.1.9 Glial scar 
In addition to degenerating myelin, another important source of inhibition is the glial scar, 
which is composed predominantly of reactive astrocytes that extend their hypertrophied 
processes to form both a physical and chemical barrier (Berry et al., 1983, Fitch & Silver, 
1997).  The  glial  scar  has  traditionally  been  regarded  inhibitory  to  axonal  regeneration 
mainly  due  to  indirect  evidence,  such  as  labeled  axons  stopping  at  the  region  of 
astrogliosis (Davies et al., 1997) and detection of inhibitory CSPGs (Davies et al., 1999, 
Levine, 1994). Breakdown of CSPGs using the enzyme chodroitinase ABC (ChABC) has been 
shown to promote regeneration of sensory and corticospinal axons, and improve functional 
recovery after SCI (Barritt et al., 2006, Bradbury et al., 2002, Caggiano et al., 2005). 
Studies with transgenic animals, however, have clearly demonstrated that although the 
glial scar may be a source of inhibitory molecules, its formation plays a critical role in 
limiting the extent of the injury (Faulkner et al., 2004, Okada et al., 2006). Moreover, a 
transgenic mouse that overexpresses ChABC demonstrated sensory axon regeneration and 
behavioural recovery following dorsal rhizotomy, and regeneration of corticospinal axons 
but  no  significant  recovery  after  dorsal  hemisection  (Cafferty  et  al.,  2007).  Thus, 
neutralizing specific components of the glial scar that inhibit axon regeneration without 
significantly  altering  its  wound  healing  properties  in  combination  to  blocking  myelin-
associated inhibitors may be a promising strategy to promote functional recovery following 
CNS injury.  
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5.1.10 Cell body responses to axotomy 
The central axons of DRG neurons have been shown to regenerate into peripheral nerve 
transplants inserted into the dorsal column of the spinal cord, when their peripheral axons 
have been previously transected (Richardson & Issa, 1984). More recently, Neumann and 
Woolf  observed  sprouting  of  central  DRG  axons  across  the  non-permissive  spinal  cord 
injury site, when DRG neurons were conditioned by sciatic nerve transection (Neumann & 
Woolf,  1999).  Conditioning  lesion  of  the  peripheral  DRG  axon  triggers  upregulated 
expression of a number of genes, collectively referred to as regeneration-associated genes 
or RAGs (Broude et al., 1997, Schreyer & Skene, 1993), which include genes expressing 
transcription  factors,  cytoskeletal  proteins,  cell  adhesion  molecules,  axonal  guidance 
molecules and neurotrophic factors (Befort et al., 2003, Boeshore et al., 2004, Tanabe et 
al., 2003).  
Upregulation of RAGs in the CNS is weaker and more transient than in the PNS, and in 
some  systems,  altogether  absent  (Mason  et  al.,  2003,  Tetzlaff  et  al.,  1991).  Thus, 
although some transected axons may sprout, grow collaterals and even new functional 
connections, RAGs are downregulated soon after injury and injured axons eventually form 
dystrophic growth cones. Moreover, although axotomy induces the expression of RAGs in 
both  central  and  peripheral  neurons,  adult  CNS  neurons  may  lack  the  downstream 
effectors, such as ATF3/c-jun (Hunt et al., 2004, Mason et al., 2003), to translate these 
signals into long-distance regeneration. Thus, enhancing the expression of developmental 
genes  associated  with  axonal  growth  in  combination  to  blocking  myelin-associated 
inhibitors may be necessary to promote meaningful axonal regeneration.  
cAMP has been identified as an important intrinsic  determinant of axonal growth 
(Neumann et al., 2002, Qiu et al., 2002) and has been suggested to mediate some of its 
effects  by  regulating  cAMP-responsive  binding  protein  (CREB)  and  CRE-mediated 
transcription of genes required for regeneration (Gao et al., 2004). The endogenous levels 
of cAMP decline dramatically with development and this spontaneous decline coincides 254 
 
with the switch to the inhibition of regeneration by MAG (Cai et al., 2001). Moreover, it 
has been suggested that priming neurons with particular neurotrophins elevates cAMP and 
prevents subsequent inhibition of regeneration by MAG through activation of PKA (Cai et 
al.,  1999).  Indeed,  in  vivo  treatment  with  nerve  growth  factor  (NGF),  neurotrophin-3 
(NT3)  or  glial-derived  neurotrophic  factor  (GDNF)  promoted  regeneration  of  sensory 
neurons  across  the  dorsal  root  entry  zone  and  into  the  spinal  cord  and  demonstrated 
functional recovery in rats with injured dorsal roots (Ramer et al., 2000). 
 
5.1.11 Rationale 
Genetic deletions of individual myelin components or individual components of the NgR1 
complex have produced conflicting results. It is clear from the studies described in this 
introduction that no single component is solely responsible for the failure of regeneration 
in  the  adult  mammalian  CNS.  A  reasonable  next  step  would  therefore  be  to  use 
approaches  to  simultaneously  target  multiple  and  potentially  compensatory  inhibitory 
pathways. Moreover, treatments to enhance the intrinsic regenerative capacity of injured 
neurons may also be required for successful regeneration.  
As described in chapter 3, the miRNA-like disabled HSV-1 vector developed in this 
thesis  has  the  potential  to  allow  silencing  of  multiple  genes  simultaneously  through 
expression of multiple miRNA cassettes from a single transcript. The primary aim of this 
chapter was to investigate whether silencing of multiple genes could be achieved cells in 
culture  and  sensory  neurons  in  vivo  using  the  miRNA-like  vector  system.  Furthermore, 
preliminary experiments were performed to test the novel hypothesis that silencing p75, 
Lingo1 and NgR2 in combination to a conditioning lesion of the sciatic nerve can promote 
regeneration of sensory axons  into the spinal  cord following injury of the dorsal roots 
(rhizotomy). This hypothesis is substantiated by previous studies suggesting that 1) p75, 
which is highly expressed in sensory neurons, is important for Nogo-66, MAG and OMgp 
neurite outgrowth inhibition in these neurons (Yamashita et al., 2002), 2) Lingo1 is an 255 
 
essential component of the NgR1 complex (Mi et al., 2004), 3) Nogo-A is redundant for 
outgrowth inhibition in sensory neurons and thus, MAG inhibition may play an important 
role (Oudega et al., 2000), and 4) NgR2, which does not signal through p75 or Lingo and is 
highly  expressed  in  sensory  neurons,  may  substitute  for  NgR1  to  mediate  MAG-specific 
inhibitory effects (Venkatesh et al., 2005). At the time the objectives of this chapter were 
conceived, there were no reports of silencing multiple genes simultaneously using vector-
mediated delivery of shRNA, or silencing receptors for myelin-associated inhibitors in vivo. 
Work in this chapter was performed in collaboration with Prof. Patrick Anderson at the 
Department of Anatomy, UCL.  
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5.2 Screening of pre-miRNA sequences against p75, Lingo1 & NgR2  
Six  pre-miRNA  sequences  against  mouse  p75  (GI:23468246),  five  pre-miRNA  sequences 
against mouse Lingo1 (GI:41351214) and five pre-miRNA sequences against mouse NgR2 
(GI:124376089) were designed using Invitrogen’s RNAi designer tool (sequences available in 
section 2.1.6). Figure 5.2 shows the 21-22nt regions within each gene that are targeted by 
these  sequences.  The  sixteen  pre-miRNAs  were  synthesized  as  single  stranded  DNA 
oligonucleotides,  annealed  and  cloned  into  pcDNA6.2/EmGFP  vectors  (shown  in  figure 
3.7). The pcDNA6.2/EmGFP-miR plasmids were sequenced using the GFP Forward primer 
(described  in  section  2.1.5)  to  ensure  that  the  pre-miRNA  sequences  had  not  been 
mutated (data not shown).  
 To screen the pre-miRNA sequences in 293T cells, the mouse p75 (IMAGE:5367638), 
Lingo1  (IMAGE:5685897)  and  NgR2  (IMAGE:40130800)  cDNA  sequences  were  cloned  into 
pSCREEN-iT/LacZ-DEST  vectors  (Invitrogen),  which  allow  generation  of  screening 
constructs containing each target gene fused to the lacZ reporter gene (figure 5.3a). The 
mouse p75 cDNA sequence (Geneservice) was supplied cloned into the pCMVSPORT6 vector 
between the SalI-NotI sites and was subcloned into pENTR4 (Invitrogen) between SalI-NotI. 
The  mouse  Lingo1  cDNA  sequence  (Geneservice)  was  supplied  cloned  into  the  pYX-Asc 
vector between the EcoR1-NotI sites and was subcloned into pENTR4 between EcoRI-NotI. 
A map of pENTR4 is shown in figure 5.3b. The mouse NgR2 cDNA sequence, which was a 
gift to Prof. Anderson, was supplied cloned into pFLAG-CMV-1 between the HindIII-XbaI 
sites (figure 5.3c) and was subcloned into pENTR-U6shLacZ between BamHI-XbaI in place 
of the U6 promoter, shLacZ and pol III termination signal (figure 5.3d). The resulting entry 
clones (attL1-attL2) allowed the p75, Lingo1 and NgR2 cDNA sequences to be transferred 
into pSCREEN-iT/LacZ-DEST destination vectors (attR1-attR2).  
The  pSCREEN-iT/LacZ-p75,  pSCREEN-iT/LacZ-Lingo1  and  pSCREEN-iT/LacZ-NgR2 
vectors  (100ng)  were  then  co-transfected  into  293T  cells  with  each  of  the  plasmids 
expressing  pre-miR-p75(1-6),  pre-miR-Lingo1(1-5)  and  pre-miR-NgR2(1-5)  (1μg) 257 
 
respectively, using Lipofectamine (as described in section 2.3.3). The pcDNA6.2/EmGFP-
miR-neg plasmid constructed in section 3.5.3 was used as a negative control. Target gene 
knockdown  was  assessed  by  measuring  β-galactosidase  levels  (as  described  in  section 
2.7.5) at 48 hrs post-transfection. EmGFP levels expressed from the pre-miRNA constructs 
were  assessed  by  fluorescent  microscopy  prior  to  assessing  β-galactosidase  levels,  to 
ensure that differences in knockdown were not due  to variable transfection efficiency 
between the different conditions (data not shown). Ideally, sequences would be selected 
for their ability to knockdown target gene expression by over 80%. However, the most 
effective  pre-miRNA  sequences  against  p75,  Lingo1  and  NgR2  were  found  to  induce 
silencing at somewhat lower levels of up to 65% (figure 5.4). Nevertheless, as the pre-
miRNA sequences tested were predicted by Invitrogen’s RNAi designer tool to be the most 
potent, no additional sequences were screened. The pre-miR-p75-1, pre-miR-Lingo1-1 and 
pre-miR-NgR2-1 sequences, found to silence p75 by 63±4.0%, Lingo1 by 65±9.0% and NgR2 
by 57±2.0% respectively (n=4, mean ± s.d.), were selected for further testing.  
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pcDNA6.2/EmGFP-miR-p75 sequences 
 
 
gb|BC038365.1| Mus musculus nerve growth factor receptor (TNFR superfamily, member 
16), mRNA (cDNA clone MGC:35588 IMAGE:5367638), complete cds, Length=3441 
 
The target sequence in pre-miR-p75-1: 
 
Score = 41.0 bits (44), Expect = 0.40 
Identities = 22/22 (100%), Gaps = 0/22 
(0%) Strand=Plus/Minus 
 
Query  5    GAAATCGCTGATTTGTGTAGTC  26 
            |||||||||||||||||||||| 
Sbjct 746   GAAATCGCTGATTTGTGTAGTC 725 
 
 
The target sequence in pre-miR-p75-2: 
 
Score = 39.2 bits (42), Expect = 1.4 
Identities = 21/21 (100%), Gaps = 0/21 
(0%) Strand=Plus/Minus 
 
Query  6     AAAGGAGTCTATATGCTCCGG  26 
             ||||||||||||||||||||| 
Sbjct  1259  AAAGGAGTCTATATGCTCCGG  1239 
 
 
The target sequence in pre-miR-p75-3: 
 
Score = 39.2 bits (42), Expect = 1.4 
Identities = 21/21 (100%), Gaps = 0/21 
(0%)Strand=Plus/Minus 
 
Query  6     TGCACAGGCTCTCCACAATGT  26 
             ||||||||||||||||||||| 
Sbjct  1386  TGCACAGGCTCTCCACAATGT  1366 
 
 
The target sequence in pre-miR-p75-4: 
 
Score = 41.0 bits (44), Expect = 0.39 
Identities = 22/22 (100%), Gaps = 0/22 
(0%) Strand=Plus/Minus 
 
Query  5    GTAGACCTTGTGATCCATCGGC  26 
            |||||||||||||||||||||| 
Sbjct  739  GTAGACCTTGTGATCCATCGGC  718 
 
 
The target sequence in pre-miR-p75-5: 
 
Score = 39.2 bits (42), Expect = 1.4 
Identities = 21/21 (100%), Gaps = 0/21 
(0%)Strand=Plus/Minus 
 
Query  6    AATATAGGCCACAAGGCCCAC  26 
            ||||||||||||||||||||| 
Sbjct  950  AATATAGGCCACAAGGCCCAC  930 
 
The target sequence in pre-miR-p75-6: 
 
Score = 39.2 bits (42), Expect = 1.4 
Identities = 21/21 (100%), Gaps = 0/21 
(0%)Strand=Plus/Minus 
 
Query  6     AATGTCAGCTCTCTGGATGCG  26 
             ||||||||||||||||||||| 
Sbjct  1370  AATGTCAGCTCTCTGGATGCG  1350 
 
 
 
pcDNA6.2/EmGFP-miR-Lingo sequences 
 
 
gb|BC052384.1| Mus musculus leucine rich repeat and Ig domain containing 1,  
mRNA (cDNA clone MGC:57943 IMAGE:5703857), complete cds Length=3321 
 
The target sequence in pre-miR-Lingo1-1: 
 
Score = 42.8 bits (46), Expect = 0.11 
Identities = 23/23 (100%), Gaps = 0/23 
(0%) Strand=Plus/Minus 
 
Query  4    TGTAGTCTAGCAGGATGACGATC  26 
            ||||||||||||||||||||||| 
Sbjct  932  TGTAGTCTAGCAGGATGACGATC  910 
 
 
The target sequence in pre-miR-Lingo1-2: 
 
Score = 41.0 bits (44), Expect = 0.39 
Identities = 22/22 (100%), Gaps = 0/22 
(0%)Strand=Plus/Minus 
 
Query  5     GTGAAGTAGTTGGGTAGGAGTA  26 
             |||||||||||||||||||||| 
Sbjct  1707  GTGAAGTAGTTGGGTAGGAGTA  1686 
 
 
The target sequence in pre-miR-Lingo1-3: 
 
Score = 41.0 bits (44), Expect = 0.39 
Identities = 22/22 (100%), Gaps = 0/22 
(0%)Strand=Plus/Minus 
 
Query  5     GATAATGAGCGTCTTGATGTCG  26 
             |||||||||||||||||||||| 
Sbjct  2125  GATAATGAGCGTCTTGATGTCG  2104 
 
The target sequence in pre-miR-Lingo1-4: 
 
Score = 42.8 bits (46), Expect = 0.11 
Identities = 23/23 (100%), Gaps = 0/23 
(0%)Strand=Plus/Minus 
 
Query  4    TGTATAGGTCTTGGAACATGTAG  26 
            ||||||||||||||||||||||| 
Sbjct  950  TGTATAGGTCTTGGAACATGTAG  928 259 
 
The target sequence in pre-miR-Lingo1-5: 
 
Score = 41.0 bits (44), Expect = 0.39 
Identities = 22/22 (100%), Gaps = 0/22 
(0%)Strand=Plus/Minus 
 
Query  6     TACAAACACCTGCTGTGCCTTG  27 
             |||||||||||||||||||||| 
Sbjct  1756  TACAAACACCTGCTGTGCCTTG  1735 
 
 
 
 
 
 
 
pcDNA6.2/EmGFP-miR-NgR2 sequences 
 
 
gb|BC138154.1| Mus musculus reticulon 4 receptor-like 2, mRNA (cDNA clone MGC:169778, 
IMAGE:8861173), complete cds Length=1401 
 
The target sequence in pre-miR-NgR2-1: 
 
Score = 39.2 bits (42), Expect = 1.4 
Identities = 21/21 (100%), Gaps = 0/21 
(0%)Strand=Plus/Minus 
 
Query  6    TACAGGTGTAGTGACTGCAGC  26 
            ||||||||||||||||||||| 
Sbjct  480  TACAGGTGTAGTGACTGCAGC  460 
 
 
 
The target sequence in pre-miR-NgR2-2: 
 
Score = 41.0 bits (44), Expect = 0.39 
Identities = 22/22 (100%), Gaps = 0/22 
(0%)Strand=Plus/Minus 
 
Query  5    GTACTGTAGGCTGACCAAGCCT  26 
            |||||||||||||||||||||| 
Sbjct  541  GTACTGTAGGCTGACCAAGCCT  520 
 
The target sequence in pre-miR-NgR2-3: 
 
Score = 41.0 bits (44), Expect = 0.39 
Identities = 22/22 (100%), Gaps = 0/22 
(0%)Strand=Plus/Minus 
 
Query  6    TGAACAGGTAGAGGATGGTGAG  27 
            |||||||||||||||||||||| 
Sbjct  770  TGAACAGGTAGAGGATGGTGAG  749 
 
 
The target sequence in pre-miR-NgR2-4: 
 
Score = 41.0 bits (44), Expect = 0.39 
Identities = 22/22 (100%), Gaps = 0/22 
(0%)Strand=Plus/Minus 
 
Query  5    GAGGTACTGTAGGCTGACCAAG  26 
            |||||||||||||||||||||| 
Sbjct  544  GAGGTACTGTAGGCTGACCAAG  523 
 
The target sequence in pre-miR-NgR2-5: 
 
Score = 39.2 bits (42), Expect = 1.3 
Identities = 21/21 (100%), Gaps = 0/21 
(0%)Strand=Plus/Minus 
 
Query  5    AACAGGTAGAGGATGGTGAGG  25 
            ||||||||||||||||||||| 
Sbjct  768  AACAGGTAGAGGATGGTGAGG  748 
 
 
 
 
 
 
Figure  5.2  Blast  nucleotide  alignments  between  the  oligonucleotides  expressing  pre-
miRNA sequences and the p75, Lingo1 and NgR2 cDNA sequences. 
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5.3 Assessment of silencing specificity   
There is no significant sequence similarity between p75, Lingo1 and NgR2. Nevertheless, 
prior to expressing the three pre-miRNA sequences from a single vector, it was necessary 
to exclude any potential off-target effects arising from a miRNA against one gene non-
specifically silencing any of the genes that it is not predicted to target. 293T cells were 
therefore  co-transfected  with  pSCREEN-iT/LacZ-p75,  pSCREEN-iT/LacZ-Lingo1,  or 
pSCREEN-iT/LacZ-NgR2 (100ng) and each of the plasmids expressing pre-miR-neg, pre-miR-
p75-1,  pre-miR-Lingo1-1,  or  pre-miR-NgR2-1  (1μg)  using  Lipofectamine.  Transfection 
efficiency was monitored by the presence of the EmGFP signal expressed from the pre-
miRNA constructs. B-galactosidase activity assay at 48 hrs post-transfection confirmed that 
each  miRNA  silences  its  intended  target  gene  only  with  comparable  potency  to  that 
demonstrated in the previous section, indicating that silencing is specific. However, p75, 
Lingo and NgR2 expression levels were found to be lower in cells transfected with the 
pcDNA6.2/EmGFP-miR-neg  plasmid  than  in  cells  co-transfected  with  the  plasmids 
expressing pre-miR-p75, pre-miR-Lingo1 or pre-miR-NgR2 and the genes that they are not 
predicted to target (figure 5.5). The downregulation of Lingo1 by the negative control 
miRNA appears to be statistically significant. Thus, miR-neg represses Lingo1 expression by 
a non-specific effect, which may be due to an off-target effect or induction of the INF 
response. The quantitative  RT-PCR performed in chapter 3 demonstrated that miR-neg 
does not induce the INF response in 293T cells (section 3.7). Moreover, miR-neg is not 
predicted to target any known vertebrate gene. The reasons behind this result were not 
further investigated, but as a result miR-neg was not used as a negative control in any 
further experiments performed in this chapter.    
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5.4 Tandem expression of pre-miRNAs against p75, Lingo1 & NgR2  
Endogenous miRNAs are often expressed in clusters by RNA pol II (He et al., 2005, Suh et 
al., 2004). Cloning of pre-miRNA sequences in tandem may potentially allow co-cistronic 
expression  of  multiple  pre-miRNAs  and  thus,  silencing  of  multiple  genes  from  a  single 
transcript.  The  most  potent  pre-miRNA  sequences  against  p75,  Lingo1  and  NgR2  were 
cloned in tandem and transferred into a pR19 vector, which allows the cassette expressing 
all three pre-miRNAs in series to be inserted into a disabled HSV vector.  
The pcDNA6.2/EmGFP-miR-Lingo1 plasmid was digested with BamHI-XhoI to release 
the pre-miR-Lingo1 sequence together with the miR-155 flanking regions. This fragment 
was  inserted  into  pcDNA6.2/EmGFP-miR-p75  between  BglII-XhoI.  The  resulting 
pcDNA6.2/EmGFP-miR-p75/Lingo1 plasmid was digested with BglII-XhoI and was used as a 
backbone to insert the pre-miR-NgR2 and miR-155 flanking regions, which were excised 
from  pcDNA6.2/EmGFP-miR-NgR2  using  BamHI-XhoI  (figure  5.6).  The  resulting 
pcDNA6.2/EmGFP-miR-p75/Lingo1/NgR2  plasmid  was  sequenced  using  the  GFP  Forward 
primer (described in section 2.1.5) to ensure that the three pre-miRNA sequences had 
been chained correctly. The pre-miR-p75/ Lingo1/NgR2 cassette was inserted into pDONR-
221 by BP recombination and then into pR19CMV-Gateway (constructed in section 3.5.3) 
by LR recombination. The pR19CMV/EmGFP-miR-p75/Lingo1/NgR2 plasmid was sequenced 
between the LAT flanking regions (figure 5.7). 
To  investigate  whether  tandem  expression  of  pre-miRNA  sequences  targeting 
different  genes  results  in  knockdown  of  each  individual  gene,  293T  cells  were  co-
transfected  with  pSCREEN-iT/LacZ-p75,  pSCREEN-iT/LacZ-Lingo1,  or  pSCREEN-iT/LacZ-
NgR2  (100ng)  and  either  pR19CMV/EmGFP-miR-TRPV1  or  pR19CMV/EmGFP-miR-p75/ 
Lingo1/NgR2  (1μg)  using  Lipofectamine.  The  pR19CMV/EmGFP-miR-TRPV1  plasmid 
(constructed  in  section  4.3)  was  used  as  negative  control  to  avoid  using  the  plasmid 
expressing pre-miR-neg or the pR19CMV/EmGFP-miR-LacZ plasmid (constructed in section 
3.5.3), which would silence the lacZ gene that is fused to the target genes. Transfection 265 
 
efficiency was monitored by the presence of the EmGFP signal expressed from the pre-
miRNA constructs. B-galactosidase activity assay at 48 hrs post-transfection revealed that 
pR19CMV/EmGFP-miR-p75/Lingo1/NgR2  silences  p75  by  74±14%,  Lingo1  by  75±11%  and 
NgR2 by 63±10% (n=4, mean ± s.d.), suggesting that tandem expression of   pre-miRNA 
sequences has no effect on the processing of individual pre-miRNAs into functional miRNAs 
(figure 5.8). Silencing from these miRNAs seems to be considerably improved indicating 
that the miR-TRPV1, which is used as a negative control, does not reduce expression of 
the targeted genes.  
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Sequence 1: lcl|1 
Length = 1431 (1 .. 1431) pre-miR-p75-1 
 
Sequence 2: lcl|65536 
Length = 64 (1 .. 64) pR19CMV/EmGFP-miR-p75/Lingo1/NgR2 (GFP F Primer) 
 
Score = 123 bits (64), Expect = 2e-24 
Identities = 64/64 (100%), Gaps = 0/64 (0%) 
Strand=Plus/Plus 
 
Query  145  TGCTGTAGACAGGAATGAGGTTGTCAGTTTTGGCCACTGACTGACTGACAACCATTCCTG  204 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    TGCTGTAGACAGGAATGAGGTTGTCAGTTTTGGCCACTGACTGACTGACAACCATTCCTG  60 
 
Query  205  TCTA  208 
            |||| 
Sbjct  61   TCTA  64 
 
 
 
Sequence 1: lcl|1 
Length = 1431 (1 .. 1431) pre-miR-Lingo1-1 
 
Sequence 2: lcl|65536 
Length = 64 (1 .. 64) pR19CMV/EmGFP-miR-p75/Lingo1/NgR2 (GFP F Primer) 
 
Score = 123 bits (64), Expect = 2e-24 
Identities = 64/64 (100%), Gaps = 0/64 (0%) 
Strand=Plus/Plus 
 
Query  283  TGCTGTAGTCTAGCAGGATGACGATCGTTTTGGCCACTGACTGACGATCGTCACTGCTAG  342 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    TGCTGTAGTCTAGCAGGATGACGATCGTTTTGGCCACTGACTGACGATCGTCACTGCTAG  60 
 
Query  343  ACTA  346 
            |||| 
Sbjct  61   ACTA  64 
 
 
 
Sequence 1: lcl|1 
Length = 1431 (1 .. 1431) pre-miR-NgR2-1 
 
Sequence 2: lcl|65536 
Length = 64 (1 .. 64) pR19CMV/EmGFP-miR-p75/Lingo1/NgR2 (GFP F Primer) 
 
Score = 123 bits (64),  Expect = 2e-24 
Identities = 64/64 (100%), Gaps = 0/64 (0%) 
Strand=Plus/Plus 
 
Query  421  TGCTGTACAGGTGTAGTGACTGCAGCGTTTTGGCCACTGACTGACGCTGCAGTCTACACC  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    TGCTGTACAGGTGTAGTGACTGCAGCGTTTTGGCCACTGACTGACGCTGCAGTCTACACC  60 
 
Query  481  TGTA  484 
            |||| 
Sbjct  61   TGTA  64 
 
 
 
Figure  5.7  Blast  nucleotide  sequence  alignment  between  the  pR19CMV/EmGFP-miR-
p75/Lingo1/NgR2 sequence obtained with the GFP Forward primer and the oligonucleotide 
sequences expressing pre-miRNA against p75, Lingo1 and NgR2. The pre-miRNA sequences 
were cloned in the right order and were not mutated.  
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5.5 Generation of a disabled HSV-1 vector against p75/Lingo1/NgR2 
The  EmGFP/miR-p75/Lingo1/NgR2  cassette  was  inserted  into  the  LAT  region  of  the 
replication-defective  1764/4-/27+/RL1+  HSV-1  genome  immediately  3’  to  the  LATP2 
region,  which  allows  long  term  expression  during  latency.  The  pR19CMV/  EmGFP-miR-
p75/Lingo1/NgR2 plasmid was linearised using a unique XmnI site in the plasmid backbone 
and  was  co-transfected  into  MAM49  complementing  cells  with  1764  4-/27+/RL1+ 
pR19CMVLacZWCm  viral  DNA  (as  described  in  section  2.4.2).  Viral  recombinants  were 
identified by their ability to express GFP (green plaques) using fluorescent microscopy. 
Bright  green  plaques  were  selected  and  purified.  When  a  pure  green  population  was 
obtained, the purity of the plaques was confirmed further by x-gal staining. Expression of 
GFP from these recombinants indicated that the desired homologous recombination event 
had occurred. However, to confirm that the pre-miR-p75/Lingo1/NgR2 sequence had not 
been mutated, PCR was performed on viral DNA extracted from each plaque using the GFP 
Forward  and  WCm  Reverse  primers  described  in  section  2.1.5  (figure  5.9).  The  PCR 
products were sequenced (data not shown) and one recombinant plaque was selected and 
grown to a high titre as described is section 2.4.3. 
293T cells were transfected with pSCREEN-iT/LacZ-p75, pSCREEN-iT/LacZ-Lingo1, or 
pSCREEN-iT/LacZ-NgR2  (100ng)  and  were  allowed  to  recover  for  24hrs  prior  to  being 
transduced with HSV-CMV/EmGFP-miR-TRPV1 (negative control) or HSV-CMV/EmGFP-miR-
p75/  Lingo1/NgR2  at  an  MOI=10.0.  B-galactosidase  activity  assay  at  72  hrs  post-
transfection  (figure  5.10)  revealed  that  HSV-CMV/EmGFP-miR-p75/Lingo1/NgR2  silences 
p75  by  94±0.9%,  Lingo1  by  94±0.8%  and  NgR2  by  96±0.5%  (n=3,  mean  ±  s.d.).  Thus, 
knockdown was significantly improved when the pre-miRNA cassette was expressed from a 
disabled HSV vector as compared to when it was expressed from a plasmid vector (figure 
5.8),  presumably  due  to  the  more  efficient  delivery  by  the  viral  rather  than  plasmid 
vector. 
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5.6 HSV-mediated silencing of p75/Lingo1/NgR2 in DRG in vivo 
To  evaluate  HSV-mediated  silencing  of  p75,  Lingo1  and  NgR2  in  DRG  neurons  in  vivo, 
BALB/c mice were injected directly into the sciatic nerve with HSV-CMV/EmGFP-miR-LacZ 
(n=10) or HSV-CMV/EmGFP-miR-p75/Lingo1/NgR2 (n=10).  7 days post-injection the DRG 
were isolated as described in section 2.6.8. Fluorescent microscopy for EmGFP confirmed 
high levels of delivery to all injected animals, mainly to the L4 DRG. Western blot analysis 
for p75, Lingo1 and NgR2 (antibodies described in section 2.17) was performed on protein 
extracted from the L4 DRG isolated from each group as described in sections 2.7.1-2.7.4 
(figure 5.11). Quantification of band density using the Scion Image software revealed an 
average 85% reduction in the levels of p75, 40% reduction in the levels of Lingo1, but only 
20%  reduction  in  the  levels  of  NgR2  compared  to  the  negative  control  (figure  5.12). 
Protein levels were normalized against α-tubulin.  
The experiment described in the previous section that investigated the efficiency at 
which the tandem pre-miRNAs are expressed and processed when inserted into a single 
HSV vector, revealed highly effective silencing of all target genes in 293T cells (section 
5.5).  However,  HSV-mediated  delivery  of  these  pre-miRNAs  expressed  from  a  single 
transcript resulted in highly effective silencing of p75, modest silencing of Lingo1 and poor 
silencing of NgR2 in DRG neurons in vivo. In the DRG, p75, Lingo1 and NgR2 proteins have 
distinct  though  largely  overlapping  expression  patterns.  HSV-1  has  been  shown  to 
transduce a heterologous population of DRG neurons following injection into the sciatic 
nerve (section 4.7; figure 4.8). Thus, although the potency of the pre-miRNA sequence 
against each target gene is important, the relative efficiency at which the virus transduces 
the specific subpopulations of DRG neurons expressing p75, Lingo1 and NgR2 may be a 
major limiting factor for silencing all three individual target genes in target tissue in vivo.    
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5.7 Labelling of sensory axons following sciatic nerve injection 
Sensory axons enter the spinal cord from the dorsal root and terminate at distinct laminae 
in the spinal cord grey matter (figure 5.13). Different subtypes of sensory axons show 
prominent lamina-specific connectivity. Calcitonin gene-related peptide (CGRP)-positive 
and substance P (SP)-positive nociceptors, terminate in lamina I and the outer aspect of 
lamina  II  (IIo),  isolectin  B4  (IB4)-positive  nociceptors  terminate  in  the  inner  aspect  of 
lamina  II  (IIi),  and  TrkC-positive  proprioceptors  terminate  in  Clark’s  column  and  the 
ventral horn. C-fibres are CGRP-positive, SP-positive, or bind to IB4 and thus terminate in 
laminae I and II. 
To identify which types of sensory axons projecting into the spinal cord are most 
efficiently transduced by the virus, BALB/c mice were injected directly into the sciatic 
nerve  with  HSV-CMV/EmGFP-miR-LacZ  (n=3).  3  days  post-injection,  the  lumbar  spinal 
cords were removed and sectioned (as described in section 2.6.6). Immunofluorescence 
for EmGFP (antibodies described in section 2.17) performed as described in section 2.7.6 
revealed strong labelling of sensory axons terminating in laminae I and II of the dorsal 
horn (figure 5.14 and figure 5.15b). Thus, following injection into the sciatic nerve, the 
virus preferentially enters the peripheral axons of nociceptive afferents, which are mainly 
C-fibers, and gets retrogradely transported along the dorsal root to the DRG, where it 
expresses EmGFP together with pre-miRNA (figure 5.13). The EmGFP expressed in the cell 
bodies of these neurons diffuses along the axons to label laminae I and II of the dorsal 
horn, where their central axons terminate. Moreover, following sciatic nerve injection, 
the virus enters the axons of motor neurons and gets retrogradely transported along the 
ventral  root  resulting  in  highly  efficient  delivery  to  the  cell  bodies  of  motor  neurons, 
which are located in the ventral horn of the spinal cord grey matter (figure 5.13), as 
shown in figure 5.15a.      
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5.8 Assessment of sensory axon regeneration into the spinal cord 
The regenerative capacity of the central axons of DRG neurons is considerably weaker 
than their peripheral axons. Although sensory axons can regenerate through the dorsal 
root after dorsal root injury (rhizotomy), they are unable to cross the dorsal root entry 
zone (DREZ) to reconnect with their target neurons in the dorsal horn of the spinal cord. 
The DREZ, which is a distinct interface between peripheral and central nerve tissues, is 
permissive to the regeneration of adult sensory axons under normal circumstances, but 
becomes  inhibitory  after  dorsal  root  axons  have  been  injured  (McPhail  et  al.,  2005). 
Following  injury,  the  DREZ  is  believed  to  form  a  physical  and  chemical  barrier  to 
regenerating sensory axons by reactive astrocytes and factors produced by them, including 
various  proteoglycans  (Beggah  et  al.,  2005).  Astrogliosis  that  begins  within  days  after 
dorsal rhizotomy is followed by Wallerian degeneration, which does not begin until 1 week 
later and results in the breakdown and accumulation of inhibitory myelin (Li Liu, 1998, 
Ramer et al., 2001). Thus, although rhizotomy is a suitable and simplified model to study 
axonal  regeneration,  there  is  no  evidence  to  suggest  that  blocking  myelin-associated 
proteins or their receptors is sufficient to overcome inhibition by the DREZ, which spatially 
and  temporally  precedes  myelin  inhibition.  Moreover,  even  when  the  regenerative 
capacity of DRG axons is enhanced by a conditioning lesion of the sciatic nerve, vigorously 
regenerating  axons  usually  fail  to  penetrate  the  DREZ  (Chong  et  al.,  1999).  The 
preliminary experiments performed in this section were aimed at investigating whether 
HSV-mediated silencing of p75, Lingo1 and NgR2 in combination to a conditioning lesion of 
the sciatic nerve are sufficient to promote regeneration of sensory axons across the DREZ, 
overcome myelin inhibition in the white matter and allow regenerating axons to reconnect 
with their targets in the dorsal horn.  
BALB/c mice (n=6) received complete transection of the left L4 and L5 dorsal roots 
as described in section 2.6.4. 3 days after rhizotomy, these mice were injected directly 
into the sciatic nerve with either HSV-CMV/EmGFP-miR-LacZ (n=3) or HSV-CMV/EmGFP-280 
 
miR-p75/Lingo1/NgR2 (n=3) and also received a conditioning lesion of the sciatic nerve (as 
described in section 2.6.3). 4 weeks after rhizotomy, the lumbar spinal cords, dorsal roots 
and DRG were removed and sectioned. Immunofluorescence for EmGFP was performed to 
identify axons transduced by the virus. Figure 5.16 shows a representative longitudinal 
(horizontal)  section  from  animals  injected  with  HSV-CMV/EmGFP-miR-p75/Lingo1/NgR2. 
The dorsal column (DC) and dorsal roots (DR) are shown, and dashed lines outline the 
borders of the DREZ and dorsal roots. Although many axons in the dorsal roots are strongly 
labelled, EmGFP could not be detected in the DRG (not shown), indicating that the virus 
has ceased expression in the cell bodies 4 weeks post-injection. Labelled axons in the 
dorsal root, which was accidentally folded, extend beyond the DREZ and into the dorsal 
horn of the spinal cord (figure 5.16a,  indicated by arrows). This is  most likely due to 
incomplete transection of the dorsal root. Strongly labelled sensory axons from injured 
dorsal roots regenerate through the dorsal root injury site and towards the DREZ. When 
they  reach  the  DREZ,  however,  they  exhibit  typical  behaviour  associated  with  DREZ 
inhibition  (figure  5.16b,  indicated  by  arrows  with  stars).  Axons  inhibited  by  astrocytes 
form endbulb structures (Carlstedt, 1985) or are re-directed around the DREZ (Zhang et 
al., 2001), and axons encountering repulsive cues at or near the DREZ are repelled and 
turn  back  into  the  dorsal  roots  (Reier  et  al.,  1983).  Some  axons,  however,  seem  to 
penetrate the DREZ (figure 5.16b, indicated by arrows). This may be due to effective 
silencing of p75, Lingo1 and NgR2, the conditioning lesion, incomplete transection of the 
dorsal  root,  or  a  combination  of  the  above.  Nevertheless,  these  axons  fail  to  extend 
beyond the DREZ and into the dorsal horn (figure 5.16a).  
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5.9 Discussion 
The weak regenerative capacity of the injured adult mammalian CNS is partially attributed 
to various inhibitory components present in CNS myelin. As discussed in the introduction of 
this chapter, studies with transgenic mice have revealed that blocking the expression of 
individual  myelin-associated  inhibitors  and  receptors  has  limited  effects  on  axonal 
regeneration  in  vivo.  Moreover,  different  types  of  CNS  neurons  possess  very  different 
regenerative capacities and respond differently to experimental treatment strategies in 
vivo.  Thus,  depending  on  the  fibre  tract  injured,  different  combinations  of  myelin 
inhibitors may need to be targeted in order to promote meaningful regeneration. The miR-
like disabled HSV-1 vector developed in this thesis has the potential to silence multiple 
genes  simultaneously  through  expression  of  multiple  miRNA  cassettes  from  a  single 
transcript  and  can  be  engineered  to  theoretically  target  any  combination  of  genes 
appropriate to the fibre tract injured. This was clearly demonstrated in vitro where very 
high  level  vector-mediated  silencing  of  three  genes  in  parallel  was  demonstrated. 
Furthermore, the use of transgenic animals with germline mutations, which often lead to 
compensatory processes and/or developmental defects, has been a major drawback in the 
field of regeneration.  HSV-mediated delivery  of RNAi to validate genes believed to be 
involved  in  the  failure  of  axonal  regeneration  offers  control  over  the  duration  of 
knockdown and may overcome these limitations.  
In addition to numerous inhibitory molecules present in the environment of injured 
axons, the failure of axonal regeneration is also attributed to the poor intrinsic capacity of 
CNS axons to regenerate following injury. Although many experimental approaches have 
been  developed  to  overcome  these  obstacles  individually,  there  is  now  a  general 
consensus that combinatorial approaches will be needed to elicit sustained and effective 
regenerative responses. The miR-like disabled HSV-1 vector developed in this thesis allows 
expression  of  a  biologically  active  protein,  in place  of  EmGFP,  together  with  the  pre-
miRNA. Thus, it may be possible, in combination to silencing multiple inhibitors of axonal 283 
 
regeneration, to overexpress developmental axonal guidance molecules in an attempt to 
boost the intrinsic capacity of CNS neurons to regenerate. Although such an approach was 
not investigated in this thesis, it represents a highly attractive strategy to promote axonal 
regeneration following SCI injury. In the present study, a conditioning lesion of the sciatic 
nerve  was  performed  in  order  to  increase  cAMP  levels  and  enhance  the  regenerative 
capacity of the central axons of DRG neurons. In studies demonstrating regeneration of 
DRG axons into the spinal cord, cAMP was administered to DRG either 2 days (Neumann et 
al., 2002) or 7 days (Qiu et al., 2002) before the spinal cord injury was induced. The 
conditioning lesion in the experiments described in this chapter was performed 3 days 
following injury. Within the context of  translating any positive results into a clinically 
relevant strategy for spinal cord repair, the beneficial effects of manipulating cAMP levels 
would have to be demonstrated after injury. However, there is no evidence to suggest 
that a conditioning lesion performed after injury has the same positive effect in promoting 
regeneration as when it is performed before injury. 
In the present study, a disabled HSV-1 vector was engineered to silence p75, Lingo1 
and  NgR2  in  an  attempt  to  target  distinct  and  potentially  compensatory  pathways  of 
myelin  inhibition.  Prior  to  investigating  the  potential  of  this  vector  to  promote 
regeneration of sensory axons into the spinal cord, its ability to simultaneously silence 
these genes in DRG neurons in vivo was investigated. Western blot analysis revealed highly 
effective silencing of p75, modest silencing of Lingo1 and inefficient silencing of NgR2, 
when the virus was injected into the sciatic nerve. This result raised numerous concerns. 
The 85% silencing of p75 is not predicted on its own to be sufficient in blocking myelin 
inhibition  through  NgR1,  as  TROY  or  other  unidentified  co-receptors  are  likely  to 
substitute  for  p75.  The  40%  silencing  of  Lingo1  on  its  own  or  in  combination  to  the 
silencing of p75 may be sufficient to block inhibition by Nogo-A and OMgp in a subset of 
neurons. However, NgR2 that is only silenced by 20% may substitute for NgR1 to mediate 
MAG-specific inhibitory effects. Nogo-A has been shown to be redundant for outgrowth 284 
 
inhibition in sensory neurons and thus, blocking inhibition by MAG may be essential to 
promote regeneration of sensory axons (Oudega et al., 2000). Nevertheless, the majority 
of neurons expressing p75 have been shown to also express NgR2 and Lingo1 (Venkatesh et 
al., 2005). Thus, it cannot be excluded that in a subset of DRG neurons transduced by the 
vector, all target genes may be sufficiently silenced. This remains to be established using 
immunocytochemistry  on  DRG  sections  taken  from  animals  injected  with  the  vector, 
rather than western blot that measures total protein levels in the whole DRG. Thus while 
proof of principle that the expression of multiple genes can be simultaneously repressed in 
DRGs in vivo was achieved, further work, outside of the scope of this thesis, is required. 
Immunocytochemistry for EmGFP, which is expressed co-cistronically with the pre-
miRNA,  demonstrated axonal labelling of  nociceptive neurons, when the disabled virus 
expressing pre-miR-LacZ was injected into the sciatic nerve. This is in agreement with the 
results obtained in the previous chapter, which demonstrated that the virus expressing 
pre-miR-neg transduces a heterologous population of DRG neurons, including an estimated 
80% of TrpV1-positive neurons, which are mainly C-fibers (section 4.7). Approximately half 
of  all  sensory  neurons  of  different  sizes  express  high  levels  of  p75  (Schecterson  & 
Bothwell, 1992, Wright & Snider, 1995). Moreover, NgR2 has been shown to be expressed 
in a heterologous population of DRG neurons, the majority of which also express p75 and 
Lingo1 (Venkatesh et al., 2005). Thus, the 20% silencing of NgR2 in DRG neurons in vivo 
cannot  be  entirely  attributed  to  the  efficiency  at  which  NgR2-positive  neurons  are 
transduced by the virus. It is possible that effective silencing of p75 may have triggered a 
compensatory response resulting in upregulation of the levels of NgR2. Moreover, it cannot 
be excluded that processing of tandem pre-miRNAs into functional miRNAs may not be as 
efficient in neurons as in 293T cells. This could be investigated by transducing primary 
DRG neurons and assessing expression of pre-miRNAs or miRNAs against each target using 
northern blots, or assessing silencing of target genes when the pre-miRNAs are chained in 
a different sequence. 285 
 
Despite the incomplete silencing observed by western blot analysis in DRG in vivo, 
the  disabled  vector  targeting  p75,  Lingo1  and  NgR2  was  in  any  case  evaluated  for  its 
ability  to  promote  regeneration  of  sensory  axons  into  the  spinal  cord  following  dorsal 
rhizotomy in combination with a conditioning lesion of the sciatic nerve. This was thought 
worthwhile not least because a subset of cells may well have had all three target genes 
effectively  silenced,  which  it  was  not  possible  to  determine  by  western  blot.  Dorsal 
rhizotomy disconnects primary sensory neurons from their spinal targets and DRG neurons 
fail to regenerate their central axons across the DREZ, often even when their regenerative 
capacity is enhanced by a conditional lesion of the sciatic nerve. Clinically, lack of primary 
afferent regeneration across the DREZ results in loss of sensation and the development of 
severe pain. Numerous strategies have been employed to promote regeneration of sensory 
axons across the DREZ, including viral vector-mediated delivery of polysialic acid, which 
acts as a permissive agent for cell migration (Zhang et al., 2007), viral vector-mediated 
delivery or intrathecal infusion of neurotrophins (Ramer et al., 2002, Zhang et al., 1998), 
transplantation  of  olfactory  ensheathing  cells  (Li  et  al.,  2004b),  and  degradation  of 
proteoglycans  (Steinmetz  et  al.,  2005).  These  strategies  have  produced  some  level  of 
regeneration across the DREZ. However, both astrocytic and myelin-derived inhibitors are 
present following dorsal rhizotomy. Regenerating DRG axons first come into contact with 
the DREZ and then with degenerating myelin. Whilst axons treated with NT-3 have been 
shown to cross the DREZ (Ramer et al., 2002, Zhang et al., 1998), following the onset of 
myelin degeneration, they fail to elongate and remain within the CNS compartment of the 
dorsal  root.  Although,  degenerating  myelin  represents  a  substantial  barrier,  blocking 
myelin-associated inhibitors or their receptors to promote regeneration of sensory axons 
into the spinal cord had not been previously investigated.  
Following  injection  of  the  HSV-CMV/EmGFP-miR-p75/Lingo1/NgR2  vector  into  the 
sciatic  nerve  of  mice  that  had  received  complete  transection  of  the  dorsal  roots,  the 
majority of labelled axons either stopped at the DREZ or were re-directed around the 286 
 
DREZ, whilst some axons were repelled back into the dorsal root. A few labelled axons 
seemed to have penetrated the DREZ, but failed to regenerate into the dorsal horn. Thus, 
despite a conditioning lesion of the sciatic nerve and possibly some degree of resistance to 
myelin inhibition achieved by the vector, axons failed to regenerate across the DREZ and 
into the dorsal horn of the spinal cord. There is no evidence to suggest that overcoming 
myelin inhibition  is sufficient to overcome inhibition by the  DREZ,  which spatially and 
temporally precedes myelin inhibition. Thus, it is not possible to formally conclude that 
the levels of p75, Lingo1 and NgR2 were sufficiently reduced by vector-mediated RNAi to 
confer  resistance  of  injured  neurons  to  myelin  inhibition,  or  that  the  failure  of 
regeneration across the DREZ was due to insufficiently effective silencing of p75, Lingo1 
and NgR2. Further work may contemplate HSV-mediated delivery of NT3 or a cocktail of 
neurotrophic factors to the spinal cord, as has otherwise been previously achieved in our 
laboratory (unpublished), to attempt to overcome inhibition by the DREZ prior to silencing 
p75, Lingo1 and NgR2. Moreover, the conditioning lesion may have been more effective 
when received prior to dorsal rhizotomy. Finally, dorsal rhizotomy may not be a suitable 
model to investigate the potential of the HSV-CMV/EmGFP-miR-p75/Lingo1/NgR2 vector to 
promote axonal regeneration following injury. Disabled HSV-1 vectors have been shown to 
efficiently transduce corticospinal neurons following direct injection into the spinal cord 
(Groutsi et al., 2008). Future experiments may therefore be directed at investigating the 
potential of this vector to promote regeneration of descending fibres following SCI. NgR2 
and Lingo1 are strongly expressed in several neuronal populations of the adult mouse brain 
projecting into the spinal cord, including corticospinal, rubrospinal, reticulospinal, and 
raphespinal tracts. Expression of p75 is restricted to neuronal descending pathways from 
the brainstem that also express NgR2 and Lingo1 (Barrette et al., 2007). Thus, silencing 
p75,  Lingo1  and  NgR2  in  these  fibre  systems  may  be  a  promising  strategy  to  promote 
axonal  regeneration  following  SCI,  indeed  potentially  more  so  than  in  the  model 
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In conclusion, while multiple genes can be clearly silenced simultaneously in vitro 
and in vivo using the vectors developed, in vivo the situation is more complex and likely 
dependent upon the genes targeted, their expression patterns as compared to the cells 
which are transduced by the vector, and the largely unknown functional consequences 
which  may  result  from  silencing.  The  in  vitro  experiments  performed  in  this  chapter 
provide the first demonstration of silencing of multiple genes using HSV-mediated RNAi, 
and indeed while complete silencing was not achieved for all genes in parallel in vivo, 
even  partial  silencing  of  multiple  genes  in  DRGs  has  not  been  previously  achieved. 
Unfortunately,  however,  due  to  severe  time  constraints,  the  preliminary  regeneration 
experiments  presented  here  could  not  be  further  expanded  such  that  conclusive 
phenotypic effects were not observed and thus, the potential of miR-based HSV-1 vectors 
for unequivocally promoting regeneration remained unproven. This could of course be a 
consequence  of  the  combination  of  gene  targets  chosen  as,  as  yet,  it  is  not  known 
knockdown  of  which  if  any  gene  combination  may  result  in  a  regenerative  effect.  It 
remains to be established, therefore, whether simultaneous silencing of p75, Lingo1 and 
NgR2 is sufficient to promote axonal regeneration following PNS injury, future experiments 
in models of CNS injury also being justified.  
Another important question that remains to be answered is whether and to what 
extent the RNAi machinery remains functional in axotomised neurons. Protein synthesis in 
neurons occurs in the cell body, as well as in axons and nerve terminals (Brittis et al., 
2002, Zheng et al., 2001). The axons of adult and developing DRG neurons have been 
shown  to  contain  components  of  RISCs/miRNPs,  including  Argonaute  proteins,  which 
assemble and function independently of the cell body (Hengst et al., 2006, Murashov et 
al., 2007). The mechanism by which miRNAs, which are expressed in the cell body, are 
transported along the axons to regulate the expression of axonally localised transcripts 
remains  unknown.  Thus,  disruption  of  the  RNAi  machinery  in  axons  or  shRNA/miRNA 
transport  along  axons,  following  axotomy,  may  prevent  effective  silencing  of  axonally 288 
 
localised mRNAs, such as RhoA (Wu et al., 2005). Considerable further work is therefore 
clearly  required  in  the  field  of  using  miRNAs  to  suppress  gene  expression  in  neurons, 
particularly of proteins which are usually present in axons or axonal terminals, the work in 
this chapter providing a potential starting point from which such work using HSV vectors 
might proceed.  
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RNA  interference  is  a  fascinating  cellular  gene  regulation  machinery  that  has  rapidly 
emerged  as  a  powerful  experimental  and  target  validation  tool.  Moreover,  RNAi  holds 
considerable  promise  as  a  therapeutic  strategy  to  silence  disease-causing  genes, 
particularly those that encode non-druggable targets, i.e. those which are not amenable 
to conventional therapeutics such as small molecules, proteins, or monoclonal antibodies. 
Despite great progress being made in elucidating the cellular processes involved in the 
RNAi/miRNA pathway, delivery and specificity have remained the main limitations for the 
effective  use  of  RNAi  in  vivo.  Advances  in  our  understanding  of  esiRNA  and  miRNA 
biogenesis and functions are expected to result in the improved design and specificity of 
silencing triggers. In recent years, considerable effort has also been focused on developing 
methods to improve delivery of RNAi to target tissues in vivo, which is the main focus of 
this thesis.  
This thesis aimed to develop an efficient method for delivery of RNAi to specific 
target tissues, sensory neurons, in vivo. Delivery to sensory neurons has been problematic 
using non-viral systems, and had not been feasible using the vector systems previously 
tested. It was anticipated that efficient expression of shRNA or artificial miRNA in sensory 
neurons  would  improve  the  understanding  of  sensory  neuronal  pathways,  allow  the 
generation of transgenic knockdown animals, enable the validation of novel gene targets 
in  drug  discovery,  and  may  assist  in  the  development  of  RNAi-based  therapeutics  for 
peripheral neuropathies, such as chronic pain. The results obtained during the course of 
this thesis, recently published in Nucleic Acids Research (Anesti et al., 2008), demonstrate 
that the novel replication-defective HSV-1 vectors developed in the thesis can express 
shRNA, artificial miRNA and multiple miRNAs in tandem, and induce effective and specific 
silencing of targeted genes in dividing cells in culture, in primary neurons in vitro and DRG 
neurons in vivo.   
Chapter 3 of this thesis evaluated various approaches to RNAi expression from within 
the  HSV  genome  by  utilising  regulatory  elements  derived  from  the  LAT  region. 291 
 
Optimisation of RNAi strategies remains essential due to potential side effects caused by 
siRNAs or shRNAs competing with the endogenous miRNA machinery, stimulating cellular 
responses to dsRNA, or silencing unintended target mRNAs due to partial complementarity. 
These side effects can result in severe cellular toxicity and even death. Improved gene 
silencing strategies would be expected to allow the use of lower doses of the silencing 
trigger, thus reducing the likelihood of RNAi-induced side effects. With the exception of 
the modified CMV promoter, which failed to induce any silencing for reasons that were not 
elucidated,  the  RNAi  expression  systems  evaluated  in  this  thesis  each  demonstrated 
similar levels of highly effective silencing in dividing cells in culture. However, the miRNA-
based system was found to clearly be the most effective at providing silencing in DRG 
neurons  in  vivo.  At  the  time  the  disabled  HSV-1  vectors  described  in  this  thesis  were 
developed, it was unclear in the field as to whether expression of artificial miRNA was 
superior to expressing shRNA, and so both were tested. Recent publications have clearly 
demonstrated that expression of shRNA embedded into endogenous miRNA sequences does 
not saturate the endogenous miRNA pathway and prevents induction of the INF response. 
Thus, miRNA-based vectors are currently considered more suitable than all other available 
systems for gene silencing in the mammalian nervous system. The miRNA-based vector 
developed  in  this  thesis  represents  the  first  and  so  far  only  demonstration  of  HSV-
mediated silencing by expression of artificial miRNA and currently is the only available 
method allowing expression of artificial miRNA in sensory neurons in vivo. 
Chapter 4 of this thesis provided proof of concept that an endogenous gene can be 
effectively and specifically silenced in DRG using the vectors developed. Assessment of 
both protein and mRNA levels revealed that HSV-mediated expression of shRNA or artificial 
miRNA  reduces  the  levels  of  the  neuronally  expressed  TrpV1  gene  by  half,  and  thus 
demonstrated the potential of this technology as a gene target validation tool for genes 
involved in nociception. Indeed, the vector expressing miRNA against trpV1 is currently 
under evaluation by a number of biotechnology and pharmaceutical companies with a view 292 
 
to utilizing this technology as a routine gene target validation tool in the development of 
novel analgesics.     
Chapter 5 of this thesis demonstrated that it is possible to simultaneously silence 
multiple gene targets through expression of multiple artificial miRNAs in tandem using the 
miRNA-based vector system developed in this thesis. Whilst expression of multiple miRNAs 
in culture resulted in highly effective silencing of each targeted gene, silencing in DRG 
neurons in vivo was found to decrease in potency the further away the miRNA in question 
was  inserted  from  the  promoter.  The  reasons  behind  this  result  were  not  clear. 
Furthermore, it remains to be determined whether simultaneous silencing of p75, Lingo1 
and NgR2, the genes targeted, is sufficient to promote regeneration of sensory axons into 
the  spinal  cord  following  rhizotomy.  Nevertheless,  the  experiments  performed  in  this 
thesis provide the first demonstration of silencing of multiple genes using HSV, and the 
first example of silencing multiple genes in peripheral neurons in vivo, even though this 
silencing  was  not  complete.  Although  the  potential  of  the  vector  expressing  artificial 
miRNA against p75, Lingo1 and NgR2 to promote axonal regeneration following PNS injury 
was not fully investigated, this vector is under evaluation by others at UCL for its ability to 
promote regeneration of corticospinal fibres following SCI.      
Silencing with the disabled HSV vectors developed in this thesis was sustained for 
at least 1 week in DRG. Furthermore, EmGFP could be detected in the axons and nerve 
terminals of transduced DRG neurons at 4 weeks post-injection of the 1764 4-/27+/RL1+ 
pR19CMV/EmGFP-miR-p75/Lingo1/NgR2 vector. However, expression of miRNA in the cell 
bodies of these neurons, assessed by expression of EmGFP in the DRG, was reduced to 
below detectable levels by this time. Thus, this vector is potentially ideal for targeting 
inhibitors of axonal regeneration, as induction of RNAi is only required for sufficiently long 
periods  of  time  to  promote  regeneration,  and  expression  of  these  genes  should  be 
eventually allowed to return to normal levels. Furthermore, although complete silencing 
of  targeted  genes  was  not  achieved,  complete  silencing  of  targeted  genes  is  neither 293 
 
necessary nor desirable for many applications. TrpV1, for example, plays an important 
role in nociception and thus, complete silencing of this gene may result in undesirable side 
effects. Furthermore, a reduction in TrpV1 expression by half is predicted to be sufficient 
in alleviating pain. This is currently being assessed by a pharmaceutical company who are 
performing behavioural studies in animal models of pain.  
Finally, although this thesis has focused on delivery of RNAi to peripheral neurons, 
it has formed the basis of a project funded by the Michael J. Fox Foundation (which the 
thesis author is conducting and which is currently underway) to investigate the potential 
of the miRNA-based system developed to simultaneously silence α-synuclein and Lingo-1 in 
the brain of Parkinson’s disease animal models. A vector produced on this project has 
already demonstrated highly efficient silencing of both α-synuclein and Lingo-1 in 293T 
cells  transfected  with  plasmids  expressing  each  target  gene.  Furthermore,  preliminary 
experiments in primary ventral midbrain neurons indicate that silencing of α-synuclein and 
Lingo-1 is sufficient to protect neurons against toxicity caused by MTPT treatment. This 
result has also provided evidence that processing of tandem pre-miRNAs into functional 
miRNAs  can  be  efficiently  achieved  in  neurons.  Evaluation  of  silencing  in  the  brain, 
following  injection  of  the  virus  into  the  striatum  and  retrograde  transport  to  the 
substantia nigra, is currently underway. These results will demonstrate the general utility 
of  the  technology  developed  during  the  course  of  the  thesis  and  particularly  that 
knockdown of genes in central as well as peripheral neurons in vivo is feasible using a 
replication-defective HSV-1 vector.                  
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